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1.1  The origin of residues in food 
 1.1.1  Introduction 
Antimicrobials were first used in veterinary medicine for the treatment of mastitis in dairy cows 
shortly after they were developed.1 Veterinary medicinal agents are generally used in veterinary 
medicine for three purposes:2 
 
 1. Therapeutic treatment of active infection or prophylactic treatment in situations 
 that induce high susceptibility using antibiotics and parasiticides 
 2. Vaccination of prophylactic medication to prevent or to minimise infection 
 3.  Production enhancement, growth promotion and improvement of feed 
 efficiency with antibiotic drugs and hormones 
 
According to these purposes, approximately 42% of all veterinary pharmaceuticals used 
worldwide are used as feed additives, 19% are used as anti-infectives (e.g. antibacterials, 
antifungals and antivirals), 13% as parasiticides (e.g. anthelmintics), 11% are used as 
biologicals and 15% represent other pharmaceuticals.1 
According to their chemical structure, the most commonly used antimicrobials in food-producing 
animals can be grouped into five major classes. These include the β-lactams (e.g. penicillins 
and cephalosporins), tetracyclines (e.g. oxytetracycline, tetracycline and chlortetracycline), 
aminoglycosides (e.g. streptomycin, neomycin and gentamicin), macrolides (e.g. erythromycin) 
and sulfonamides (e.g. sulfamethazine).  
The most frequently used anthelmintics can be divided into two major classes. These are the 
benzimidazoles (e.g. oxibendazole, flubendazole and mebendazole) including the tetra-hydro-
imidazole levamisole and the macrocyclic lactones (e.g. avermectines as eprinomectine and 
milbecynes). 
 
1.1.2  Improper or illegal use of veterinary drugs 
The administration of any pharmacologically active chemical to a food-producing animal can 
lead to the occurence of residues in food. Violations can occur as a result of improper use of 
licensed products or through the illegal use of unlicensed substances.3 Several factors have 
contributed to the residue problem such as poor treatment records or failure to identify treated 
animals, but most violations result from the use of a drug in an inconsistent manner with the 
product label. This occurs mainly by neglecting withdrawal periods before putting the milk and 
the eggs on the market or before slaughtering of the animal. Treatments involving any other 
application than stated on the product label (e.g. different species, increased dosage, different 
route of administration, different frequency of treatment) are classified as off-label usage, in 
which case withdrawal times are difficult or impossible to determine.1 
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Providing that a licensed drug is used in accordance with its product licence and providing that 
the drug withdrawal periods are respected by the farmers, drug residues should not occur in 
human food in harmful concentration. However, some contamination processes have to be 
taken into account. 
 
 1.1.3  Contamination of feed 
Cross-contamination in feed mills is a recognised problem.3 Residual quantities of medicated 
feed may be retained at various points along the production line, contaminating subsequent 
batches of feed as they are processed. The electrostatic properties of some drugs, particularly 
those in powder form, aggravate the problem, making it more difficult to purge the equipment 
between batches. Manufacturers have responded to the problem by producing granular 
preparations with reduced electrostatic properties. It has been reported that the carry-over of 
sulfamethazine (SMT) in feed was four times higher with powdered water-soluble preparations 
than with granular forms of the drug. The preparation of nicarbazin-free withdrawal diets can be 
hindered since nicarbazin (NCB) powder is strongly electrostatic.4 NCB is a widely used 
anticoccidial drug, which is licensed in Belgium as a feed additive for broiler chickens, but not 
for laying hens. There is a problem in many countries world-wide with the occurrence of NCB 
residues in poultry tissues and eggs. Cannavan et al.4  have reported a proportional relationship 
between the concentration of 4,4’-dinitrocarbanilide (DNC) and 4,6-dimethyl-2-
hydroxypyrimidine (DHP) in eggs, the two marker residues for nicarbazin, and the feed levels. 
Feed contaminated with NCB at concentrations higher than about 2 mg/kg gave rise to residue 
concentrations of DNC in eggs higher than 100 µg/kg. Cannavan and Kennedy5 have reported 
the occurrence of violative residue concentrations for DNC, as marker residue for nicarbazin, in 
tissues of broiler chickens due to feed contamination. No maximum residue limit (MRL) has yet 
been established by the EU for nicarbazin in tissues. Residue concentrations above 200 µg/kg 
may occur in muscle tissue of broiler chickens not exposed to nicarbazin during rearing, but fed 
with withdrawal rations accidently contaminated at at least 2.4 mg/kg.  
 
 1.1.4  Environmental contamination 
Potential environmental contamination may arise e.g. from commercial fish farming where 
veterinary drugs, given as feed additives, accumulate in sediments and may be ingested by 
marine species in the vicinity of farms.3 A large portion of the medicated feed is not eaten or not 
digested by the farm fish. It is spoiled and falls through the holding cages on the seabed. 
Relatively large quantities of veterinary drugs can contaminate the surrounding environment 
and can be absorbed by other marine animals and fauna. The presence of drug residues may 
pose a risk to health, if these wild species are harvested for human consumption. 
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 1.1.5  Animal-to-animal transfer 
Recycling of drugs as a result of ingestion of faeces and/or urine significantly contributes to the 
concentration and persistence of residues in porcine tissues, poultry tissues and eggs.3,5,6 Brief 
exposure of unmedicated animals to the excretions of medicated animals in improperly cleaned 
housing, perhaps during transport or in the lairage of a slaughter house can result in violative 
residues. With banned compounds, having zero tolerance, it is obvious that severe problems 
can arise. 
Cannavan and Kennedy5 have observed a tenfold higher DNC concentration in liver of broiler 
chickens treated with NCB and housed on litter compared with those housed on wire flooring. 
Kennedy et al.3 have studied the faecal recycling of NCB in laying hens. DNC concentrations 
above 2.0 µg/kg in the eggs were obtained up to 16 and even up tot 60 days after withdrawal of 
NCB medication at feed contamination levels (2.3 mg/kg) of caged hens and of hens kept on a 
deep litter, respectively. Complete exchange of the litter was the only way to prevent recycling.  
 
1.2  The risks to human health and drawbacks 
 1.2.1  Toxicity and allergenicity 
Quite a large number of antibiotic and anthelmintic drugs administered in therapeutic and 
subtherapeutic form to domestic animals are also approved for human use. These drugs have 
been shown to be relatively safe. Acute and chronic toxicities have been evaluated and are well 
documented.2 In most cases, the amount ingested by an individual who consumes the drugs as 
residue in animal foodstuffs will be considerably less than that consumed as a primary drug. 
The likelihood of acute toxicity from veterinary drugs or their metabolites originating from animal 
tissues is extremely low. However, the possibility of chronic toxicity expressed in longterm, 
cumulative allergenic, mutagenic, teratogenic or carcinogenic effects, which are difficult to 
assess, may occur. 
Veterinary drugs with high potential to cause one or more of these toxic effects for human 
health were banned by the EC for veterinary use. Chloramphenicol produces toxic aplastic 
anemia that is not related to dosage. Chloramphenicol has been implicated as the causative 
agent in several cases of fatal aplastic anemia after its use as an ophthalmic drug at an 
estimated total dose of 82 mg only. Nitrofurans and nitroimidazoles require restrictions as 
carcinogens, mutagens or inducers of DNA synthesis. But the inherent hazards of their 
genotoxicity could be overcome by appropriate drug use and by application of a two- or three-
fold increased conservative withdrawal time. Sulfonamides have been used widely at 
subtherapeutic and therapeutic concentrations in food-animal production, but increasing 
concern over their carcinogenic and mutagenic potential and their thyroid toxicity has led to 
decreased use, longer withdrawal times and more intensive residue monitoring. 
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Carry-over of tetracycline residues can reversibly slow down the growth of the skeleton and 
irreversibly discolor the teeth of children younger than 8 years since tetracyclines are deposited 
in bones and teeth. The extractable residues of benzimidazole anthelmintics have a defined 
toxic potential.7 Some benzimidazoles are mutagenic, but the effect is limited or low in 
mammals even at high doses. Teratogenicity may be considered as a general property of this 
drug group. Teratogenic metabolites have been identified and quantified in animal products as 
milk, eggs and meat. Long and Rupp8 have reported limb effects associated with teratogenic 
activity in rats fed albendazole. For levamisole, the most important of the observed adverse 
effects, which are rare, were agranulocytosis and neutropenia.9  
To safeguard human health, the EU has established safe maximum residue limits (MRLs) for 
residues of licensed veterinary drugs in animal tissues entering the human food chain. The term 
MRL may be defined as the maximum concentration of marker residue (e.g. parent compound, 
metabolites, etc.) resulting from the use of a veterinary drug, expressed in µg/kg, that is legally 
permitted or recognised as acceptable in or on food.1 The MRL is based on the acceptable daily 
intake (ADI). The ADI is the result of a scientific risk assessment following pharmacological and 
toxicological studies. The ADI is determined by the no-observable-effect level (NOEL) taking 
into account a safety factor of usually 100.10 The maximum acceptable total residue level (TRL) 
is calculated from the ADI considering the consumption pattern. The MRL is the detectable 
proportion of the marker residue that corresponds to the TRL value. The MRL value refers to the 
permissible level for the marker residue. 
In addition to conventional toxicological effects, other effects such as the effects of drugs on the 
immune system and pharmacological effects including specific effects of residues of veterinary 
antibiotics on the human gut flora, should be taken into account considering safe residue 
levels.11 
Besides the toxicological problems, hypersensitive reactions in humans from ingesting 
antibiotic-contaminated foods of animal origin can occur. Most reactions result from β-lactam 
(e.g. penicillin) antibiotic residues in milk and meat1,2,12 in sensitive individuals. Many people that 
went through prior medical treatment were hypersensitised to such a degree that following oral 
exposure a response was evoked. 
Nevertheless, the risk to human health due to residues of veterinary drugs in foodstuffs have to 
be relativated. Microbial contamination of food is a major health problem worldwide.13 Infections 
of poultry products with Salmonella and Campylobacter are greater risks for public health than 
are residues of veterinary drugs in food.14 Nevertheless, the public health risks of antibiotics and 
their metabolites in food are difficult to define, and the presence of violative levels of residues in 
food is illegal and therefore subjected to financial penalties in many countries. The consumer 
does not like food with veterinary drug residues, unlike the residue concentration is below the 
published human safety MRL level. 
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 1.2.2  Antibiotic resistance 
Antibiotic resistance is a well documented major health threat around the world that has been 
given high priority by many health agencies.1,2,12,14 The potential for animal-to-human transfer of 
resistance is existing. Clearly, the use of antibiotics in lifestock production has been associated 
with the development of human antibiotic resistance. Animals fed with low (prophylactic) levels 
of antibiotics may develop bacteria evolving resistance to these and/or other drugs. Humans 
may be exposed to these bacteria during the preparation or consumption of food. It has been 
documented that humans developed drug resistant salmonellosis from food of animal origin.15 
Examples of drugs which have been shown to cause the growth of resistant bacteria in food 
animals are fluoroquinolones and avoparcin. 
The resistance of microorganisms arising from subtherapeutic use of penicillin, tetracyclines and 
sulfa drugs in agriculture is suggested by the WHO to be a high priority issue.2 Curbing the use 
of antibiotics in subtherapeutic disease prevention and growth promotion might offer the 
greatest opportunity to reduce the amount of antibiotics used in food-producing animals. The 
concept of the integrated control where an optimal animal treatment starts with an optimal 
housing and hygiene has to be promoted.12 
 
 1.2.3  Technological problems 
The initial concerns with regard to antimicrobial residues in food were not expressed by 
consumers but by dairy processors who found that contaminated milk was inhibiting the starter 
cultures used in the production of fermented milk products as well as the influence on the 
results of the dye reduction tests used for milk quality.1 The sensitivity of thermophilic and 
mesophilic starter cultures for manufacturing high-value fermented products as yoghurt, cheese, 
butter or raw sausages, needs biotechnological safe raw materials.15 
 
 1.2.4  Effect of processing on residues 
Although most food of animal origin is heated before consumption, none of the required studies 
for licensing drugs include the effect of processing on residues. Information about this influence 
is required to obtain more accurate estimates of consumer exposure to residues or possible 
breakdown products. The fate of several drug residues during normal cooking and processing 
procedures is described by Rose et al.17 Oxytetracycline was not stable but showed no apparent 
major breakdown products measurable by UV detection. Ellis18 reported that tetracyclines are 
relatively labile to mild heating in acid solutions, which destroys the tetracycline ring structure. 
Residues of levamisole were found to be stable to heating, but a fraction was lost from the meat 
into the juice.17 Some evidence of oxfendazole instability in boiling water was found after            
3 hours. Heating of samples with incurred residues of oxfendazole nevertheless destroys the 
drug residues. Moats19 reported that ordinary heating procedures for meat, even to “well-done”, 
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can not be relied on to inactivate even the more heat sensitive compounds such as penicillins 
and tetracyclines. More severe heating as for canning or prolonged cooking with moist heat will 
inactivate the more heat sensitive compounds. The relevance to food safety is uncertain since 
the nature of the degradation products is unknown in most cases. The identity of these 
degradation products should be established and their toxicity assessed. 
The use of data generated from surveillance of raw tissue for dietary intake calculations and 
consumer exposure estimates has to be considered in the light of the effect of cooking on these 
residues. 
 
1.3  Legislative aspects 
 1.3.1  Overview of EC Decisions, Council regulations and 
guidelines 
The occurrence of residues of veterinary drugs is a world-wide problem. Food-producing 
animals and animal products are transported between the different EU countries and between 
EU countries and third countries. A lot of energy is spent by the EU to harmonise the European 
legislation to control the residue problems. This European legislation and the reference methods 
to analyse the animal products are summarised by Heitzman.20 European legislation aspects 
are published in the Official Journal of the European Communities. The European Commission 
had regulated the inspection of animals and of fresh meat for the presence of residues of 
veterinary drugs and specific contaminants by Council Directive 86/469/EEC.21 The current 
monitoring (paragraph 1.7) is governed by national surveillance schemes, established under 
Council Directive 96/23/EC22 on measures to monitor certain substances and residues thereof in 
animal products and under Commission Decision 97/747/EC,23 laying down levels and 
frequences of sampling in order to monitoring some substances and residues thereof in certain 
animal products. This EU Decision establishes numbers of samples to be tested for each 
compound group. 
Quality criteria for the analysis of residues are described in Commission Decision 89/610/EEC24 
laying down the reference methods and the list of national reference laboratories for detecting 
residues. Quality criteria for residue analyses are also described in Commission Decision 
93/256/EEC25 laying down the methods to be used for detecting residues of substances having 
a hormonal or a thyreostatic action. Commission Decision 93/257/EEC26 lays down the 
reference methods and the list of national reference laboratories for detecting residues. The two 
Decisions are revised regularly in order to take into account the current scientific knowledge and 
the latest technical improvements. The revised version was submitted by the Directorate 
General for Agriculture as draft Commission Decision SANCO/1805/200027 laying down 
performance criteria for the analytical methods to be used for certain substances and residues 
thereof in live animals and animal products according to Council Directive 96/23/EC.22 This draft 
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document was revised and published as Commission Decision 2002/657/EC28 implementing 
Council Directive 96/23/EC22 concerning the performance of analytical methods and the 
interpretation of results. The validation of analytical methods is discussed in paragraph 1.6. 
The establishment of MRLs in the EU is governed by Council Regulation EEC/2377/90,29 
amended by several EC-Regulations. This regulation establishes lists of compounds that have a 
fixed MRL (Annex I), that need no MRL (Annex II), or that have a provisional MRL (Annex III).30 
Certain compounds, including some antibiotics, are listed in Annex IV of this Regulation, 
prohibiting their use in livestock production. Annex V provides information and data needed to 
determine the MRL values. Since 1 January 2000, the administration to food-producing animals 
of veterinary medicinal products containing pharmacologically active substances which are not 
listed in Annex I to III is prohibited. Tables 1.1 and 1.2 present the pharmacologically active 
substances, involved in this thesis, for food-producing animals including the established MRL 
values. The current status of 25 November 2002 (fixed or provisional) of the MRL values are 
indicated. 
In addition to the protection of consumers from the potential risk of harmful residues, MRLs are 
also essential to facilitate international trade. However, the introduction of the MRL concept has 
a severe impact on the availability of veterinary medicinal products. The risks of the occurence 
of residues in food when food-producing animals are treated with unlicensed products or with 
products used in an off-label manner, has potentially increased.31 
 
 1.3.2  Belgian legislation 
For the residue control of slaughtered animals, the kidney of the slaughtered animal is used. 
The Ministerial Decision32 of 19 June 1995 describes the new Belgian kidney test which is a 
microbial inhibition test. The quality criteria including limits for residues of anti-infection and 
antiparasitic substances for consumption milk and milk products are stipulated in the Royal 
Decision33 of 14 September 1995. The Ministerial Decision34 of 6 October 2000 describes the 
official determination of the quality and the composition of milk delivered to buyers. This 
Decision refers to Council Regulation EEC/2377/90.29 
The financial penalties imposed on producers who violate residue regulations are increasing. 
After successive violations a R-statute (R of residue) can be imposed, excluding the producer 
from the market for a certain time. 
 
1.4  Pharmacokinetics of veterinary drugs 
 1.4.1  Introduction 
Pharmacokinetics may be defined as the mathematical description of drug concentration 
changes in the body.35 Pharmacokinetics in veterinary medicine has been used to describe the 
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processes of drug absorption, drug distribution and drug elimination (metabolism and excretion) 
in animals, factors influencing the amount of residue remaining in consumable products. The 
complex processes that determine duration of drug action and circulation of drugs through the 
body, are schematically outlined in Figure 1.1. These processes are influenced by many 
different factors, a number of which arising from the physiology of the subject receiving the drug. 
In addition, pathologic processes can alter drug disposition by modifying the physiological 
functions that influence the circulation of drugs in the body. The variety of animal species 
influences the different processes. The variations in drug response can be attributed to species 
differences. For the majority of therapeutic agents, the species variations in response are due to 
differences in disposition kinetics of the drugs. If a drug is administered extravascularly, the 
accessibility of the drug to the systemic circulation, or systemic availability, will also influence 
the clinical outcome. This process is especially complex when the extravascular route is oral, as 
the drug must gain access to the portal circulation from the enteric environment and survive 
passage through the gut wall and liver with their respective ability to metabolise and inactivate 
drugs.  
Absorption and distribution of a drug influence the concentration obtained in the immediate 
vicinity of its receptor sites (biophasic concentration), while biotransformation (metabolism) and 
excretion are responsible for determining the action of the drug. Either directly or indirectly, all 
processes shown in Figure 1.1 involve passage of drugs across membranes. Both nonpolar 
lipid-soluble compounds and polar water-soluble substances that possess sufficient lipid 
solubility can cross the predominantly lipoid plasma membrane by passive diffusion. Most drugs 
are weak organic acids or bases and exist in solution as both nonionised and ionised forms. 
The nonionised form is usually lipid-soluble and can readily diffuse across the cell membrane to 
achieve the same equilibrium concentration on either side. In contrast, the ionised moiety is 
often virtually excluded from transmembrane diffusion because of its low lipid solubility. 
 
 1.4.2  Drug administration 
Most veterinary drugs, mainly as prepared form, are administered to animals by intramuscular, 
intravenous or subcutaneous injection, orally in the feed or the water, topically on the skin or by 
intramammary or intra-uterine infusions.1 
Parenteral administration where the gastrointestinal tract is bypassed, is mainly performed as 
intravenous, intramuscular or subcutaneous injection when systemic effects are desired.35 
Injection of a drug solution directly into the bloodstream gives a predictable concentration of the 
drug in plasma and, in most cases, produces an immediate pharmacologic response.  
Topical application and intramammary and intra-uterine infusions are mostly employed when 
local effects are desired. 
Although some oral administration procedures either aqueous or under the form of elixirs or 
suspensions are available, other oral dosage forms are solids and include tablets, bolusses for 
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 Figure 1.1  Diagram of the interrelationships of the processes that determine the 
  disposition of a drug in the body and the extent and duration of drug action36 
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large animals, pellets, capsules, or a variety of specialised sustained-release products for 
ruminant animals. 
 
 1.4.3  Drug absorption and bioavailability 
Drug absorption is the rate at which the drug enters the general circulation and is generally 
defined as the passage of the drug from its site of administration into the bloodstream. The 
absorption process is governed by the solubility of the dosage form, the route of administration 
and certain physicochemical properties of the drug substance.35 A low degree of ionisation and 
a high lipid solubility favour absorption. 
Absorption of most drugs from intramuscular and subcutaneous injection sites is rapid when it is 
administered as aqueous solutions. 
The ability of a drug, applied topically as a dermatologic preparation, to be absorbed through 
the skin depends on two consecutive events. It must first dissolve and be released from the 
vehicle and then penetrate the keratin layer and cells of the epidermis. Since absorption takes 
place by passive diffusion, lipid solubility is the most important physicochemical property of the 
drug. 
Before entering the systemic circulation, a drug administered as a solid form must undergo 
three events: release from the dosage form, be transported across the gastrointestinal mucosal 
barrier and passage through the liver. Dissolution is the rate-limiting step that determines 
release of the drug from a solid dosage form and can be enhanced by administering the drug in 
salt form, by micronisation or by decreasing the particle size. A drug that is stable in 
gastrointestinal fluids and that is not completely ionised and lipid-soluble, would be expected to 
be well absorbed. The rate of gastric emptying is the most important physiologic factor 
controlling the drug absorption rate, since the small intestine is the principal site of absorption. 
Bioavailability is defined as the rate and extent to which a drug administered as a particular 
dosage form enters the systemic circulation intact. This pharmacokinetic parameter determines 
the relationship between drug dosage and intensity of action. 
 
 1.4.4  Drug distribution 
Drugs are conveyed through-out the body in the circulating blood and reach tissues of each 
organ in an amount determined by blood flow to the organs. The distribution, i.e. the drug 
concentration in various tissues at a given time after administration, is dependent on the drug’s 
polarity, molecular size and structure and the amount of protein binding that occurs.15 Binding of 
a drug to plasma proteins, mainly albumin, restricts its distribution, thereby limiting its biophasic 
availability, and can influence elimination of the drug from the body.35 Protein binding is a 
reversible interaction, which implies that the drug-protein complex serves as a circulating 
reservoir of potentially active drugs. 
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Rapid administration of a high dose of drugs that slowly distributes to body tissues poses a risk 
of toxic predistribution plasma concentrations.37 
 
 1.4.5  Drug elimination 
Mechanisms of drug elimination, i.e. the processes responsible for removal of the drug from the 
body, are biotransformation (hepatic metabolism) and renal excretion.35 The rate of elimination 
may be influenced by extensive (> 80%) binding to plasma proteins, degree of perfusion of the 
eliminating organ(s), activity of drug-metabolising enzymes and the efficiency of renal excretion. 
The rate of elimination of a drug is usually an important determinant of duration of 
pharmacologic effect. The fate of a drug is largely determined by some of its physicochemical 
properties, specifically the lipid solubility and the degree of ionisation. Lipid solubility appears to 
be a prerequisite for biotransformation of drugs by the hepatic microsomal enzyme system.  
Drugs undergo metabolic changes in the body that are primarily directed toward formation of 
metabolites which have physicochemical properties favorable to their excretion. Products of 
biotransformation are generally less lipid-soluble and are polar in nature. Biotransformation of 
the parent drug can also occur during metabolism which may serve to activate or deactivate the 
drug. Apart from the liver, metabolism of drugs takes place in blood plasma and lumen of the 
gut, where hydrolytic and reductive reactions may occur, as well as in other tissues. The general 
pattern of drug metabolism is usually biphasic.15 Common “phase I” biotransformation reactions 
include oxidation, reduction or hydroxylation. Although metabolic reactions usually yield 
products with decreased activity, some may give rise to products with similar or even greater 
activity. “Phase II” reactions involve synthetic reactions as conjugations or combinations with 
endogenous substances as glucuronic acid, glycine, cysteine, methionine, acetyl and sulphate. 
The resulting conjugates are water-soluble, often polar and facilitate the elimination of the drug 
from the body. 
Available evidence suggests minimal metabolism for tetracycline, chlortetracycline and 
doxycycline. Benzimidazole anthelmintics are extensively metabolised by mammals following 
oral administration.7 The parent drug is usually short-lived. The free, primary metabolites are 
usually the products of normal oxidative or hydrolytic processes and are more soluble than the 
parent drug. A small amount of benzimidazole metabolites becomes bound to endogenous 
macromolecules in a relatively non-extractable form. 
Polar drugs and compounds with low lipid solubility are mainly eliminated by excretion. Although 
the kidney is by far the most important organ of excretion, the liver, salivary, sweat, mammary 
glands and lungs constitute nonrenal routes of excretion. Renal excretion is the principal 
process of elimination for drugs that are predominantly ionised at physiologic pH and for 
compounds with limited solubility in lipid. 
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Drugs excreted unchanged (not altered by a metabolic reaction), mainly in urine, include many 
antibiotics such as penicillin (except nafcillin), cephalosporines, aminoglycosides and 
oxytetracycline.  
Some compounds with a relative molecular mass (Mr) greater than 300 and with polar groups, 
are excreted mainly by the liver into bile. Conjugation with glucuronic acid, which takes place in 
the hepatocytes, may be the determining factor for excretion of a drug or metabolites and 
certain endogenous substances in bile. Compounds excreted in bile enter the small intestine. 
Depending on their lipid solubility, some drugs (e.g. tetracyclines) are reabsorbed. 
 
 1.4.6  Withdrawal times 
The time when the residue content of the edible tissues of 99% of the total projected population 
of animals does not exceed the required MRL is the withdrawal time or the minimal period of 
time between the last recommended treatment and the time of slaughter or the time of collection 
of animal products as milk and eggs.1 This time allows the veterinary drug and its residues to 
decrease to levels below the established MRL. 
Data on the depletion of the marker residues in the target tissue are used to estimate this 
withdrawal time. Characterisation of the elimination times for drugs from edible tissue or animal 
products is an important part of the drug approval process so that appropriate withdrawal times 
can be set to minimise the incidence of drug residues.  
One of the obvious limitations of tissue residue studies is the lack of sufficient tissue samples 
per individual test animal to characterise individual tissue depletion kinetics. Although there is 
great potential for the population approach to address drug tissue disposition and residue 
avoidance, adequate strategies for its implementation still have to be explored.36 Knownledge of 
the pharmacokinetic characteristics of a drug reduces the number of animals required by 
conventional residue testing.38 
The primary pharmacologic determinant of a withdrawal time is the administered dose and the 
rate of depletion of the drug in the tissue.39 The kinetics of drug depletion are often reported in 
the literature when a pharmacokinetic study has been conducted. Withdrawal times after        
off-label use of a drug increasing the dose for a disease covered by the label or using a normal 
dose for a disease not covered on the label, can be estimated. When a higher dose is used, the 
concept of half-life, which is the time required for 50% of a drug to be eliminated from an animal 
or tissue, can be used. Application of extrapolation of drug disposition parameters across 
species are not appropriate to determine withdrawal times. The best rule of thumb to follow is 
that, in general, half-lives are shorter in a smaller species. 
The Committee for Veterinary Medicinal Products (CVMP) approved an approach towards 
harmonisation of withdrawal periods which was published by the European Agency for the 
Evaluation of Medicinal Products (EMEA) and which is in operation since January 1997.40 The 
calculation is based on a regression approach so that it can be assured with a 95% confidence 
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that in at least 99% of the animals, levels will have declined to below the MRL within the 
specified time. There is a need for harmonisation of the calculation of withdrawal periods. No 
specific recommendations exist in the current EU regulations for the setting of withdrawal times 
for veterinary drugs in tissues. 
Several other approaches are described in the literature. Concordet and Toutain41 have 
presented a non-parametric method. Fisch42 has proposed a set of models with varying 
assumptions. 
 
1.5  Determination of veterinary drug residues  
 1.5.1  Introduction 
Analytical methods can include screening, determinative and confirmatory procedures. 
Screening methods are designed to be rapid, easy to use and to give a positive or negative 
respons for a drug at a specified concentration level in a matrix.15 Traditionally, microbial 
inhibition tests have been used to screen large numbers of samples for antibiotics and these 
tests are still widely used today.  
In addition, new rapid test kits as microbial receptor, receptor binding, radio- or enzyme immuno 
assays are being used to screen samples for specific drugs. These screening tests, however, 
are not always accurate at or below the test threshold, are often drug class but not compound 
specific and do not give quantitative information. Therefore, additional analytical tests may be 
needed to determine if a sample is actually violative for an animal drug residue. Some tests as 
e.g. immuno assays, provide semi-quantitative results. 
Determinative methods are designed to separate and to quantify and provide some qualitative 
information on the analyte of interest. Most gas and liquid chromatographic methods would fall 
into this category. Qualitative assays classify samples as positive or negative relative to a 
specific drug concentration.  
Confirmatory methods are meant to provide unambiguous identification of the drug residue in 
question. Because of its sensitivity and specificity, mass spectrometry is the preferred method 
for confirmation. 
 
 1.5.2  Screening assays 
The screening assays make a distinction between non-violative and suspected samples. The 
most important requisite for a screening assay is that the β-error (possibility of false negative 
result or a risk for the consumer) is lower then 5%.43 
The earliest methods used for detection of antimicrobial residues in food were based on the 
detection of growth inhibition of various sensitive bacterial strains.1 The major disadvantages of 
these assays are that they are not very specific for antibiotic identification purposes, that they 
are not quantitative and that they have limited detection levels for many antibiotics. Moreover, 
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they are time consuming requiring several hours before results are available. However they are 
inexpensive, easy to perform, adaptable to screen large numbers of samples and they have a 
reasonable broad antimicrobial detection spectrum. 
The CHARM I and II tests are qualitative microbial receptor assays for rapid detection of β-
lactams, macrolides, aminoglycosides, tetracyclines, chloramphenicol and sulfonamides in milk 
and tissues. The tests use two types of bacterial cells containing either the natural receptor sites 
for antibiotics or an antibody coating and a radiolabelled antibiotic. Any unbound receptor site 
on the bacterial cell will bind with the radiolabelled antibiotic. Binding is measured with a 
scintillation counter and compared to control samples.  
The Penzyme test is a qualitative enzymatic method for the rapid detection of β-lactam antibiotic 
in milk. The antibiotics will specifically bind with an enzyme and inactivate it. The end products 
are measured by use of a redox colour indicator and the final colour is compared with a colour 
chart. 
The SNAP and Delvo-X-Press tests for β-lactam antibiotics in milk are qualitative enzyme linked 
receptor binding assays in which β-lactams are captured by a penicillin binding protein 
conjugated to an enzyme. The absence of β-lactams in a sample results in all of the enzyme 
conjugate remaining unbound and available for binding to the immobilised β-lactam, while the 
presence of β-lactams results in a portion of the enzyme conjugate being bound and unavailable 
to bind with the immobilised β-lactam. Samples are declared positive or negative on the basis of 
a visual comparison of the intensity of colour development.  
The specificity of the immune system is demonstrated by its ability to distinguish subtile 
differences between antigens. Examples of immunoassays are radioimmunoassay (RIA) and 
enzyme-linked immunosorbent assay (ELISA). Lactek tests are examples of commercial test 
kits commonly used for drug residue testing in milk. On the basis of the relationship between 
colour development and concentration, it is possible to design qualitative, quantitative or     
semi-quantitative ELISA’s. 
Jackman44 described class specific enzyme immunoassays (EIA’s) for the detection of 
tetracyclines and most benzimidazole drugs. For the structural very different thiabendazole, a 
compound specific EIA had to be developed. 
Elliott et al.45 described a biosensor immunoassay (BIA), an automatical variant of RIA. The bulk 
of the work relied upon the use of a commercially available surface plasmon resonance 
biosensor instrument. A positive sample can be detected by a reduction in the level of antibody 
binding to a chip due to binding of drugs of the sample. Results are generated in real time 
without the need of time consuming sample preparation. These techniques have the possibility 
to perform high throughput analysis where animals raised for meat are slaughtered. Also the 
feasibility to perform milk residue analysis for antimicrobial compounds is investigated. 
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 1.5.3  Confirmatory methods 
 1.5.3.1  Introduction 
Suspected samples have to be further analysed by a confirmatory analytical method. 
Chromatographic techniques play an important role in the confirmatory tests for residues of 
veterinary drugs. There are several types of chromatographic methods currently in use for 
residue analysis. These include thin layer chromatography (TLC), gas chromatography (GC) 
and high performance liquid chromatography (HPLC). TLC has found some use, generally for 
screening or qualitative analysis only. Most veterinary drugs are to polar, non-volatile              
(Mr > 1500), heat sensitive and/or difficult to derivatise for GC.46 Therefore, HPLC is the most 
commonly used analytical technique for residue analysis. Mass spectrometry (MS) is the 
preferred detection method for confirmation. Hyphenated techniques as gas chromatography-
mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) are the 
most powerful analytical tools in the analytical laboratory.43 
 
 1.5.3.2  HPLC 
1.5.3.2.1  Extraction techniques 
One aspect of residue analysis that has received comparatively little attention is the initial 
extraction of the analyte from the sample matrix. Some applications of high-speed 
homogenisation for the solvent extraction of drug residues are used. McCracken et al.47 have 
compared four different techniques. The use of a high speed mixer/emulsifier, an ultrasonic 
bath, a Stomacher and an end-over-end mixer were used to extract both incurred and fortified 
residues from chicken muscle sample. Comparable analytical recoveries from fortified muscle 
samples were obtained using each of the extraction techniques. However, for each analyte the 
highest drug concentration detected in incurred samples was obtained using a mixer/emulsifier 
extraction. 
The total drug residue content of a tissue comprises all free residues (parent compound plus all 
low molecular weight metabolites) plus all residues covalently bound to endogenous 
macromolecules. A residue is designated as bound if it is not released from the macromolecular 
fractions after mild but exhaustive extraction procedures. Extraction of bound residues needs 
hydrolysis by chemical or enzymatic means.48 
 
1.5.3.2.2  Clean-up procedures 
In the past, liquid-liquid extraction (LLE) was the most used clean-up procedure. Moats and 
Harik-Khan49 described this procedure for the determination of tetracycline antibiotics in milk. 
The tetracyclines were recovered in the water layer formed by liquid-liquid partitioning of the 
acetonitrile extract with hexane and methylene chloride as purification agents. This clean-up 
procedure requires more organic solvent. Matrix solid phase dispersion (MSPD) is a technique 
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where the sample is directly blended with chromatographic material such as bonded silica. Long 
et al.50 have used this clean-up technique for the determination of tetracyclines in milk. After 
washing the column material with hexane, the tetracyclines were eluted with a mixture of ethyl 
acetate and acetonitrile. Solid phase extraction (SPE) is the most frequently used clean-up 
procedure for the determination of residues of veterinary drugs. Österdahl et al.51 have 
described a SPE procedure for the determination of levamisole in milk. The sample extract was 
transferred to the prepacked SPE cartridge. After washing with hexane, levamisole was eluted 
from the cartridge with methylene chloride. 
 
1.5.3.2.3  Ion-pair chromatography  
Ion-pair chromatography (IPC) allows acidic, basic or amphoteric compounds to be separated 
simultaneously with neutral analytes on column.52 IPC is most popular in the reversed-phase 
mode. The mobile phase consists of an aqueous buffer (plus an added organic co-solvent such 
as methanol or acetonitrile for bonded-phase separations) and an added anionic or cationic 
counter-ion of opposite charge to the analyte molecule. Alkylsulphonate and tetrabutyl 
ammonium salts are the most commonly used ion-pair reagents.  
The principle of ion-pair chromatography is explained by using the ion-pair model shown in 
Figure 1.2. 
 
Analyte Ion-pair reagent A Neutral molecule 
R-COO-aq        +        N(C4H9)4+ aq                                                  [R-COO-+N(C4H9)4]org 
 Ion-pair 
 
Analyte Ion-pair reagent B Neutral molecule 
R-NH3+aq          +       R’-SO3- aq                                     [R- NH3+- SO3-R’]org 
 Ion-pair 
 
Figure 1.2  The ion-pair model 
 
Ionic analytes, acids or bases, do not easily adsorb into the hydrophobic layer of reversed-
phase columns due to the charge on the analyte molecule. The analyte and the ion-pair reagent 
form a neutral ion pair that will readily partition into the reversed-phase packing. In the simplist 
case of ion-pair chromatography, it can be assumed that the analyte and counter ions are 
soluble only in the aqueous mobile phase, and that the ion-pair formed from these ions is 
soluble only in the organic stationary phase. The subscripts “aq” and “org” in Figure 1.2 refer to 
aqueous and organic phases, respectively. Ion-pair reagents of the same charge as the analyte 
may decrease retention while those of opposite charge may increase retention on reversed-
phase columns, presumably by forming a complex which is less polar than the original analyte.53 
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Retentions can be further increased by adding ionic compounds with hydrocarbon tails. 
Retention is then related to the length of the hydrocarbon tail. An octanesulphonic acid (C8)   
ion-pair reagent will cause basic compounds to be retained longer than a hexanesulphonic acid 
(C6) ion-pair reagent. The hydrophobic portion of the ion-pair reagent contributes to the overall 
hydrophobicity. The more hydrophobic the ion-pair reagent, the greather the retention of the ion-
pairs. Retention of non-ionic sample components is not influenced. The pH of the mobile phase 
and the type and concentration of buffer can both be used to control ion-pair separations. 
By using IPC, residues can be separated effectively from interferences without further clean-up. 
Tetracyclines are very polar bases and can be effectively separated from endogenous 
interferences in milk extracts by adding an alkylsulphonate as ion-pair reagent.49 Fletournis et 
al.54 have succesfulIy applied IPC with octanesulphonate as ion-pair reagent for the 
determination of fenbendazole in milk. In the absence of the octanesulphonate, fenbendazole, 
which in highly acidic conditions exists in its protonated form, shows severe peak tailing. This 
indicates that a relatively strong adsorptive interaction between the protonated fenbendazole 
and the silica-based reversed-phase packing material had occurred. The negatively charged 
octanesulphonate ions were used in order to form hydrophobic ion-pairs with the analyte. This 
addition eliminated peak tailing, increased the retention time slightly and a two-fold higher peak 
height was obtained. A stable and increased column temperature (30 to 50°C) is important for 
IPC determinations. The better mass transfer of the analyte between the stationary and mobile 
phase can improve the peak shape. 
IPC in the reversed-phase mode was used for the determination of tetracyclines in eggs and 
broiler chicken muscle and of anthelmintics in milk described in Chapters 2 and 3, respectively. 
In the other analytical methods using liquid chromatography-mass spectrometry (Chapters 4, 5 
and 6), reversed-phase chromatography was applied with mobile phases containing non-volatile 
buffers or aqueous solvent mixtures. 
 
 1.5.3.2.4  Detection techniques 
For screening purposes, universal variable wavelength ultra violet (UV) detectors could be 
used.55 However, for the confirmation of suspected samples, more analytical data than just a 
retention time and a detector response are expected. With a fluorescence detector more 
specific analyses at lower detection limits could be performed and spectral data for each time 
point are generated. In most cases some kind of derivatisation of the analyte (pre- or post 
column) is needed. Analytical evidence for each time point with spectral data and not only signal 
strength could also be gathered by using a diode array detector (DAD). The DAD is a special 
UV detector that continuously takes a UV spectrum of the eluent throughout the complete HPLC 
run. The DAD (Figure 1.3) utilises a deuterium or xenon lamp that emits light over the UV 
spectrum range.56 Light from the lamp is focused by means of an achromatic lens through the 
sample cell and onto a holographic grating. The dispersed light from the grating is arranged to 
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fall on a linear diode array. The resolution of the detector will depend on the number of diodes in 
the array and on the range of wavelengths covered. A chromatogram can be reconstructed by 
monitoring at a specific wavelength depicting only those substances that adsorb UV light at the 
chosen wavelength and that have unique absorbance characteristics. 
The determinations of tetracyclines in eggs and broiler chicken muscle and of anthelmintics in 
milk described in Chapters 2 and 3, respectively, were performed with a DAD. The mass 
spectrometric detector, using the principles of mass spectrometry and generating mass spectral 
data is very important in residue analysis. The principles of a mass spectrometer detector are 
described in next paragraph. 
 
 
 
Figure 1.3  Schematic view of a UV photo diode array detector56 
 
 1.5.3.3  Liquid chromatography-mass spectrometry 
 1.5.3.3.1  Introduction 
The liquid chromatography-mass spectrometry (LC-MS) technique should be regarded as a 
complementary analytical tool compared with GC-MS that particularly enables the determination 
of compounds with high molecular masses and polar, non-volatile or thermolabile analytes 
without derivatisation, which makes this technique particularly interesting for residue analysis of 
veterinary drugs. 57 Mass spectrometers generate mass spectral data that can provide valuable 
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information about the identity, the molecular mass and the structure of an analyte. A mass 
spectrometer is more sensitive and far more specific than all other HPLC detectors.  
The three primary processes associated with mass spectrometer analysis are ion production 
(source), ion separation (analyser) and ion collection (detector). The movement of ions is 
controlled by applying electric fields and vacuum. Ions are separated and identified according to 
their mass-to-charge (m/z) ratios. 
 
 1.5.3.3.2  Ionisation modes 
The elimination of the mobile phase needs an interface. The most currently used interface is the 
atmospheric pressure interface. The ionisation of the analytes takes place at atmospheric 
pressure and afterwards the analyte ions are mechanically and electrostatically separated from 
neutral molecules and transferred into the mass spectrometer through a series of chambers with 
decreasing pressure. The two types of ionisation most common in use are electrospray 
ionisation (ESI) and atmospheric pressure chemical ionisation (APCI). 
A schematic view of a mass spectrometer with electrospray interface is presented in Figure 1.4. 
 
 
 Figure 1.4  Schematic diagram of a mass spectrometer with electrospray interface58 
 
The ESI operates by the process of ion evaporation where ions are emitted from a droplet into 
the gas phase.57 The eluent from the LC is pumped through a stainless steel capillary which 
carries a high potential, typically 2 to 5 kV.50 The strong electric field generated by this potential 
causes the liquid to be sprayed from the end of the capillary and highly charged droplets are 
produced (Figure 1.5). As the droplets evaporate, ions are emitted from the droplets into the gas 
phase. This process is supported by a flow of nitrogen used as drying and as nebuliser gas. 
Basic compounds can form a protonated molecule ([M+H]+) which can be analysed in the 
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positive operating mode. Acidic compounds can form a deprotonated molecule ([M-H]-) which 
can be analysed in the negative mode. 
As ESI is a very soft ionisation technique, there is usually little or no fragmentation and the 
mass spectrum contains only the quasi-molecular ion. Some in-source fragmentation can be 
induced by adjusting the source parameters.60 The cone voltage assisted fragmentation delivers 
fragments which are very useful structural information tools. The energies involved in the 
collisions are such that usually only weaker bonds such as C-N and C-O bonds are broken. 
 
  
 
 
 
 
 
 
 
 
 Figure 1.5  Ion evaporation mechanism of the electrospray ionisation process59 
 
APCI tends to give better sensitivity for less polar compounds. In APCI operation, the eluent 
from the LC is carried through a probe heated at 350 to 600°C and elutes into the APCI source 
which is also heated.57 A heated probe and coaxially introduced nitrogen cause the liquid to 
form an aerosol which is evaporated and passes a corona pin held at a voltage of 2 to 3.5 kV. 
The resulting discharge that is formed ionises solvent molecules. 
 
 1.5.3.3.3  Mass spectrometer analysers 
Quadrupole and ion trap mass analysers are used most often in mass spectrometers for residue 
analysis. The quadrupole mass analyser actually is a mass filter.58 It consists of four hyperbolic 
or circular rods (poles) equally spaced around a central axis in a square. A mass selector is 
created by applying precisely controlled voltages to opposing sets of poles. Ions of different m/z 
value are transmitted by the quadrupole filter by ramping the voltages on each set of poles. 
An ion trap mass analyser can be imagined as a quadrupole bent on itself which consists of a 
circular ring electrode as outer rod plus two end caps that together form a chamber.58 The inner 
rod is reduced to a point. Ions entering the chamber are trapped there by electromagnetic fields. 
By raising the potential, the trajectories of ions of successive m/z values are made unstable and 
these ions are ejected out of the trap. Ion traps are able to perform multiple stage mass 
Chapter 1: General introduction - Residues of veterinary drugs in food 
_________________________________________________________________________________________________________________________________ 
 
26
spectrometry generating a lot of successive fragments delivering structural information which is 
very useful in mass spectrum research for qualitative residue analysis. 
Most mass spectrometers are equipped with a photomultiplier for the detection of the ions. 
 
  1.5.3.3.4  Determination modes 
Quadrupole mass analysers can operate in the scan mode or in the selected ion monitoring 
(SIM) mode, where only a few m/z ratios are monitored. This last mode is significantly more 
sensitive and is used for quantification and monitoring of target compounds. The highest 
sensitivity and selectivity with the quadrupole technique for target residue analysis is obtained 
by means of tandem mass spectrometry (MS/MS) using a triple quadrupole LC-MS/MS system 
operating in the multiple reaction monitoring (MRM) mode. The first quadrupole is used to select 
the precursor ions.59 Fragmentation or collision induced dissociation (CID) of the precursor ions 
takes place in the second stage (octopole or quadrupole), which is called the collision cell. A low 
argon gas flow enhances these CID. The selected fragment ions are monitored in the third 
stage or quadrupole. Because of the high selectivity, specificity and resulted sensitivity, 
thorough sample preparation, clean-up steps and sufficient chromatographic separation for   
LC-MS/MS methods seem no longer necessary. Although this may hold true to a certain extent 
for clean samples, complex matrices, such as liver, kidney or muscle which have to be analysed 
in laboratories involved in residue control, require an appropriate sample preparation combined 
with effective chromatography in order to avoid quantitative errors associated with matrix effects 
of the final extract.57 
 
 1.5.3.3.5  Mobile phase limitations 
The transformation of a HPLC method to a LC-MS method may sometimes be hindered 
because for LC-MS only volatile components for the mobile phase can be used.55 Non-volatile 
salts as ion-pair reagents and phosphate crystallise in the source of the mass spectrometer and 
have to be substituted by e.g. ammonium acetate. 
A triple quadrupole LC-MS/MS system operating with electrospray ionisation was used for the 
multiresidue determinations of anthelmintics in milk (Chapter 4), of flubendazole and its 
metabolites in eggs and poultry tissues (Chapter 5) and of mebendazole and its metabolites in 
sheep tissues (Chapter 6). 
 
1.6  Validation of quantitative confirmatory methods 
 1.6.1  Introduction 
Confirmatory methods that provide full or complementary information enable the analyte to be 
identified unequivocally at the level of interest.61 These methods are specifically designed to 
provide unequivocal identification of unauthorised substances and substances with an 
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established MRL and for quantification of analytes. For quantitative methods, the degree of 
precision and trueness must be specified. According to Council Directive 96/23/EC,22 reference 
methods have to be used for the confirmation of all samples suspected for unauthorised 
substances. These methods must be based on molecular spectrometry providing direct 
information on the molecular structure of the analyte under examination. On behalf of the EC, 
Heitzman20 published a lot of analytical methods for veterinary drug residues. However, most of 
these methods are very laborious and time consuming and are not suitable for routine analysis. 
Therefore, surveillance laboratories are developing their own methods. These have to be 
validated to demonstrate their reliability. Validation parameters to be evaluated for quantitative 
confirmatory methods and described in the Draft Commission Decision SANCO/1805/200027 
are: specificity, linearity, trueness, precision, recovery, analytical limits, stability and 
applicability/ruggedness. These parameters are the same as those described in the definitive 
Commission Decision 2002/657/EC.28 However, the Draft is cited as reference because this 
Draft was followed during the validation procedures in this thesis. 
 
 1.6.2  Validation parameters27 
 1.6.2.1  Specificity 
The specificity describes the ability of the method to measure unequivocally the analyte of 
interest in the presence of all other components as interfering analytes, metabolites, 
endogenous material and matrix constituents in a complex matrix.62 
 
 1.6.2.2  Linearity 
The mathematical relationship between the measured response and the concentration of the 
analyte in the matrix has to be established. Whenever possible, a suitable internal standard (IS), 
preferably deuterated and certified reference material (CRM) should be used for the quality 
control of the calibration curves. De Wasch et al.63 advised to make a five-point calibration curve 
based on 10 datapoints grouped as 3 at the lowest and highest concentration, 2 in the middle 
and 1 in between. Removal of some outliers at the edges of the curve will not have a major 
impact then on the slope of the curve. 
 
 1.6.2.3  Trueness 
Trueness is a component of accuracy and is defined as the difference between the mean value 
measured for an analyte in a CRM and its certified value, expressed as a percentage of this 
value. If no CRM is available, relevant parameters may be evaluated by analysing fortified 
sample material. 
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 1.6.2.4  Precision 
The precision, another accuracy component, is the closeness of agreement between the results 
obtained by applying the experimental procedure several times under prescribed conditions and 
covers repeatability, within-laboratory reproducibility and inter-laboratory reproducibility. 
 
 1.6.2.5  Recovery 
Matrix effects in biological samples, e.g. lipids in plasma or residual protein, can cause loss of 
analyte during the analytical procedure and can affect the recovery or extraction efficiency.64 If 
there is no CRM available to calculate the trueness, the recovery has to be determined by 
experiments using fortified blank matrix material. Whenever possible, incurred residue matrix 
material has to be used to optimise the method to recover as much incurred material as 
possible.47 
 
 1.6.2.6  Analytical limits 
The analytical limits comprise the limit of detection (LOD), the limit of quantification (LOQ), the 
detection capability (CCβ) and the decision limit (CCα). The LOD is the lowest concentration of 
analyte that can be detected in a sample after applying the appropriate identification criteria. 
The LOQ is the lowest concentration of the identified analyte in a sample that can be quantified 
with a specified degree of accuracy and within-laboratory reproducibility.  
Two new analytical limits are introduced on revision of Commission Decision 93/256/EEC.25 The 
definition of these analytical limits are based on CCβ and on CCα.65 The detection capability is 
the smallest content of the substance that may be detected, identified and/or quantified in a 
sample with an error probability of β. The β-error, defined as the probability that the tested 
sample is truly violative, even though a non-violative measurement has been obtained (false 
negative decision), should be less than or equal to 5%. In case of banned substances, CCβ is 
the lowest concentration at which a method is able to detect truly residues in samples with a 
statistical certainty of 1-β. For substances with an established MRL, CCβ is the concentration at 
which the method is able to detect MRL concentrations with a statistical certainty of 1-β. 
The decision limit is the limit from which on it can be decided that a sample is truly violative with 
an error probability of α. The α-error, which is the probability that the tested sample is not truly 
violative, even though a violative measurement has been obtained (false positive decision), 
shall be 1% or lower and 5% or lower for banned and MRL substances, respectively. In the 
case of banned substances, CCα is the lowest concentration level at which a method can 
discriminate with a statistical certainty of 1-α whether the identified analyte is present. For 
substances with an established MRL, CCα is the concentration above which it can be decided 
with a statistical certainty of 1-α that the identified analyte content is truly above the MRL. 
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 1.6.2.7  Stability 
The validation protocol should always include an investigation of the stability of the analyte or 
matrix constituents in the sample matrix as well as the stability of the standard analyte in 
solution.62 Whenever possible, incurred samples should be used to check the stability in matrix 
material. 
 
 1.6.2.8  Applicability/ruggedness 
Pre-investigation studies have to be carried out by selecting factors of the sample pretreatment, 
clean-up, instrument and analysis, which may influence the measurement results. Such factors 
may include the operator, the reagents and the laboratory circumstances. The determination of 
the within-laboratory reproducibility during the real validation is covering some of these factors 
contributing to the ruggedness/applicability of the method. 
 
 1.6.3  Validation criteria 
The validation procedures, the quality and the validation criteria for the analytical methods for 
residues were previously described in Commission Decisions 89/610/EEC24 and 93/256/EC.25 
The decisions have to be updated systematically in order to take into account the scientific 
knowledge and the technical improvements. The updated criteria27 of Commision Decision 
93/256/EC have introduced a number of new concepts for the confirmation of veterinary drug 
residues described in detail by De Brabander et al.65 A system of identification points (IPs) has 
been introduced to define the number of ions and their corresponding ratios that must be 
measured for both authorised and unauthorised substances when mass spectrometric analysis 
is employed. An identifier, e.g. UV absorption or MS ions, is described by Stefany61 as the part 
of the total information needed to unambiguously identify the structure of an analyte as being 
identical with an assumed structure or with the known structure of the compound tested for. For 
LC-MS/MS analysis, the precursor ion accounts for 1 IP and each fragment ion (transition 
product) earns 1.5 IPs. According to the criteria, for the positive confirmation of substances 
listed in group A (banned substances) of Annex I of Council Directive 96/23/EC,22 at least four 
IPs must be acquired. This means that at least 2 diagnostic fragment ions from 1 precursor ion 
has to be measured. For substances listed in group B (authorised substances), a minimum of   
3 IPs is required. The main advantage of the IP system is that new techniques are very easily 
introduced in a system of quality criteria. 
In the Draft Commission Decision SANCO/1805/2000,27 some words have also been changed. 
A “positive” and “negative” result is replaced by “violative” and “non-violative”, respectively. For 
unauthorised substances, the result of the analysis is considered as violative if all relevant 
identification criteria for the analyte are met and if the CCα is exceeded. For MRL substances, 
the result of the analysis is considered as violative if the determined content of the identified 
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analyte in the sample is greater than the appropriate CCα. For substances with a zero 
tolerance, a non-violative result is obtained if the identity of the analyte has not been proven and 
the criteria are not fulfilled, or if the CCα is not exceeded. For MRL substances, the result is 
non-violative if the measured content of the identified analyte is below the CCα. 
In addition, a new regulatory limit, the minimum required performance limit (MRPL), has been 
introduced in order to establish more officially the level at which European control has to be 
made for banned substances.65 
Recently, the Draft Commission Decision SANCO/1805/200027 has been approved and has 
been published as definitive Commission Decision 2002/657/EC28 after some minor revisions. 
The Decision is valid since 1 September 2002. The responsibility of the surveillance laboratories 
is very high now, because the obtained decision limit is determining the interpretation of results 
according to this Decision. The result of a residue determination has to be considered          
non-compliant if the decision limit of the confirmatory method for the analyte is exceeded. 
 
 1.6.4  Validation of methods for depletion studies 
Producers of veterinary drugs require residue methods for use in depletion studies, which are 
part of the evaluation dossier of new veterinary medicinal products. Depletion studies are 
carried out under completely controlled conditions and in compliance with the requirements of 
good laboratory practise (GLP) and quality assurance. Van Leemput and Clayton66 described 
the validation of analytical methods for residue analysis in depletion studies. The validation has 
to be done for the selected marker residue, which is not necessarily identical to the parent 
substance. It can be a metabolite or a combination of analytes. The validation must be 
performed in the edible matrices of concern in depletion experiments. These matrices usually 
include liver, kidney, muscle and fat, and where appropriate skin with fat in natural proportions, 
milk or eggs. The method must be specific in the conditions of the depletion experiment. 
Linearity, accuracy and precision are determined in the working range of the depletion studies 
by spiking of blank matrices obtained from animals of the same type as used in the 
experiments. There is no need to explore the LOD, because the MRL is the reference. One and 
half the MRL can be considered as the LOQ. The repeatability must be determined, but 
practicability and applicability are no issues. 
 
1.7  Monitoring and surveillance 
 1.7.1  Introduction 
MRLs are only of value if backed up with good residue control programmes. The EU requires 
from each member state to have in place surveillance and monitoring programmes according to 
Council Directive 96/23/EC22 and Commission Decision 97/747/EC.23 These programmes have 
to ensure safe food from animal origin controlling that the MRLs are not violated and that no 
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residues of banned substances are found. Residue analyses are not only related to public 
health, but international trade or environmental aspects are also involved. 
 
 1.7.2  Integrated systems 
Residue monitoring or surveillance programmes require the analysis of a large number of 
samples. Traditionally screening techniques, such as microbiological assays and 
immunoassays are commonly used in residue laboratories.67 Multiresidue screening methods 
are needed. Screening methods reduce the number of samples requiring more detailed 
analysis, but care must be taken to ensure whether the number of false negatives is kept to a 
minimum. Screening assays are an important part of the integrated approach to residues 
monitoring. It is necessary to combine different methods in an integrated system in which a 
number of different tests are applied consecutively depending on the targets or objectives of the 
analysis. For regulatory purposes such a strategy should include at least two or more 
independent methods:1 
 
1.  Screening with a method optimised to prevent false negative results and with an 
acceptable number of false positive results at low cost (e.g. microbial growth 
inhibition tests) 
2.  Intermediate tests to identify the residue type (e.g. microbial receptor assays, 
receptor binding assays) 
3.  Quantitative confirmation with an independent method optimised to prevent false 
positive results  
 
Heeschen and Suhren16 have described an integrated system for the detection of antimicrobials 
in milk ensuring toxicological and technological safety. The dominating residues in milk in most 
countries are β-lactam antibiotica and sulfa drugs including dapsone. Tetracyclines, 
aminoglycosides, chloramphenicol and some others may occur. An integrated detection system 
for antimicrobials and inhibitors in raw and heat-treated milk has to distinguish between aspects 
of the method applied and the responsibilities of milk producers, treatment/processing plant and 
food inspection within this system. Positive results with microbiological inhibitor tests or with 
starter cultures are indicative for a technologically unsafe product. These tests could be used as 
MRL screening tests to select highly suspicious samples for the presence of antimicrobials 
exceeding the MRL. Additional tests have to be used, which can detect specific groups of 
antimicrobials (e.g. tetracyclines, aminoglycosides and chloramphenicol) which are often not 
sufficiently detected by microbiological inhibitor tests. 
A modern strategy to avoid residues of veterinary drugs must involve producers, 
processors/manufacturers and regulators. The farmer/producer has to respect the withdrawal 
period which is the most important critical control point in the prevention of unwanted residues. 
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Products from the farm (e.g. milk or the slaughter animals) should regularly and randomly be 
tested for inhibitors, using appropriate tests. The food processing plant must check the incoming 
raw material by using rapid test kits (e.g. receptor tests) as MRL screening tests. Under 
regulatory aspects, food inspection authorities have to identify residues of antimicrobials 
qualitatively and quantitatively applying appropriate methods including MRL screening tests and 
physicochemical tests for final identification. 
 
 1.7.3  Drug residue laboratories 
The EU has gradually created an extensive network of laboratories entrusted with the 
surveillance of residues in animal products.68 A hierarchical system is installed. Routine or field 
laboratories (RFLs) involved in the annual residue monitoring programmes are coordinated and 
controlled in each EU member state by at least one national reference laboratory (NRL) 
designated by the national government. The NRLs are supported, advised and controlled by 
four EU community reference laboratories (CRLs) designated by the EU in 1991. Besides these 
official laboratories, many other laboratories are involved in residue analysis. 
Good laboratory quality assurance (QA) practises are required for the analytical procedures for 
detection, identification and/or quantification of drugs in food of animal origin.69 Quality standard 
regulations require a formally established and documented QA program to ensure the validity of 
results from analytical laboratories. Accreditation of the QA programme by an independent 
organisation will provide customers confidence in the analytical results. Additional residue 
measures concerning the official control of food require official control laboratories to be 
accredited according to ISO 17025 from January 2002 on.28 The quality of results of monitoring 
tests shall also be ensured by a QA system accredited according to this regulation. 
A database, accessible on Internet, provides a carefully judged inventory of analytical methods 
available for the determination of residues of veterinary drugs.70 The monitoring programme 
subdatabase provides useful qualitative and quantitative data obtained from monitoring of 
Belgian animal food products. The Federal Agency for Food Safety belonging to the Belgian 
Federal Ministry of Social Affairs, Public Health and Environment coordinates all monitoring 
programmes and is responsible for surveillance and compliant actions. 
 
 1.7.4  Interpretation of results 
Sometimes, a different way of interpretation of analytical results exists between inspection 
services and laboratories.71 Inspection services are mainly interested in a yes/no answer 
concerning the violation of a sample. In Belgium, a contradiction between a first and a second 
analysis automatically starts up a quality assurance procedure. The remnants of both samples 
are analysed by the NRL. The NRL has to investigate the methods used and has to find out on 
which quality criteria the laboratory results are based. 
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Qualitative methods may be used for illegal drugs having a so called zero tolerance. If the 
analyte is detected, the concentration can be determined or estimated and an action limit (AL) is 
used to convert the results in yes (violative) or no (non-violative) answers. The AL is an 
agreement between inspection services and laboratories. The AL is based on the analytical 
possibilities of the moment taking into account a safety factor to protect the producers of food of 
animal origin. This limit should be the basis to take compliant actions. Quantitative analysis is 
necessary especially for drug residues with a MRL. Anyway, qualitative criteria must be fulfilled 
before quantification. 
Today’s consumers require the safest possible food in sufficient quantities and at a reasonable 
price. Therefore, the precautionary principle has also been implemented in a systematic way 
(already included in the veterinary medicines approval system) as an approach of risk 
management.31 This is applied to circumstances of scientific uncertainty, reflecting the need to 
take action in the face of a potentially serious risk without awaiting the results of scientific 
research. 
Surveillance with analytical methods of independent authorities could increase consumer 
confidence in safe food, certainly when the obtained results would be published.66 Setting 
unreachable objectives and promising those to the consumers can only reduce the consumer 
confidence. Residue control without publication of the results will not improve consumers 
confidence. Residue control with publication of violative tests only and with their definitions of 
residues reduces consumer confidence, as consumers assume that residues have been found 
accidently.31 Systematic publication of well-established results of residues is highly desired, as 
the consumer can be convinced that, despite large efforts to detect residues, only a small part 
of food contains some residues. 
The surveillance and monitoring programmes must be harmonised in all EU member states and 
the publication of results must be made uniform, so that only those in excess of the MRL and 
confirmed by validated confirmatory methods, are published. 
 
1.8  Research objectives and relevance of the presented 
  research work 
 1.8.1  Introduction 
The two main objectives of the research work described in two separate parts in this doctoral 
thesis are: 
 
1. The development of chromatographic confirmatory methods for the 
quantitative determination of residues of tetracyclines and anthelmintics 
including metabolites in the following animal products: milk, eggs, poultry and 
sheep tissues 
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2. Measuring of disposition, distribution and depletion of residues of 
tetracyclines and anthelmintics including metabolites in milk, eggs, poultry 
and sheep tissues 
 
Because of the objective to apply the methods in routine analysis, simple, reliable, accurate, 
relatively sensitive and flexible methods which are relatively fast have to been developed. 
Before the analytical methods were applied in depletion studies or were proposed for analysis in 
monitoring programmes, a reliable and comprehensive validation according to European 
requirements was performed. 
Throughout this thesis, there has been an evolution in analytical technology. In the two first 
described methods, HPLC with DAD detection was used. Later on, only LC-MS/MS methods 
were developed. 
 
 1.8.2  Monitoring of residues in food 
The laboratory involved in screening of samples for veterinary drug residues of the Department 
of Animal Product Quality and Transformation Technology was looking for analytical tools for 
confirmation of the violative screened samples of Belgian monitoring programmes. Firstly, a 
method for tetracyclines in milk had to be developed and had to be optimised later for analysis 
of eggs and poultry muscle tissue. Most of the available methods were not practical for routine 
analysis because of their time consuming and laborious sample clean-up. Ion-pair 
chromatography reduces sample clean-up to a minimum. In Chapter 2, a HPLC method using 
ion-pair chromatography and DAD detection for the determination of tetracyclines in eggs and 
broiler chicken muscle is described. 
Besides the tetracycline antibiotics, all other research work presented is dealing with 
anthelmintic veterinary drug residues. Because until then, there was no control on anthelmintic 
residues, it took a long time before the farmers were convinced that anthelmintic veterinary 
drugs also could give rise to residues in animal products of treated animals. Anthelmintic 
residues can not be screened efficiently by conventional screening methods due to the lack of 
antimicrobial activity of the anthelmintics and due to the lack of commercially available test kits. 
Therefore, in order to be able to propose the monitoring of Belgian milk, a confirmatory method 
for anthelmintics in milk had to be developed. The determination of anthelmintic residues in milk 
was performed with two HPLC methods using ion-pair chromatography and DAD detection 
(Chapter 3) which were simpler and faster than the existing methods.  
More sensitivity, specificity, selectivity and confidence for surveillance purposes is obtained with 
mass spectrometry, certainly when an LC-MS/MS system operating in the MRM mode is used. 
The LC-MS/MS multiresidue method for anthelmintics in milk, used actually in the Belgian 
monitoring programme, is presented in Chapter 4. Compared to available, published methods, 
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the advantage of the developed method, is the ability to determine simultaneously 
benzimidazoles and levamisole using electrospray tandem quadrupole mass spectrometry. 
The new approach of supplementary measurement of metabolite compounds was introduced. 
The tissue residue concentrations of metabolites of flubendazole and mebendazole, widely 
used in anthelmintic treatments of poultry and sheep, respectively, can be very high. Very 
sensitive LC-MS/MS procedures for the simultaneous determination of flubendazole and its 
metabolites in eggs and poultry muscle tissue are described in Chapter 5. The methods for 
mebendazole and its metabolites in some sheep tissues are discussed in Chapter 6. 
 
 1.8.3  Disposition of residues in food-producing animals 
The determination of some validation parameters has to be performed, if possible, on incurred 
samples obtained after treatment of animals with veterinary products containing the target drug 
analyte. The applicability of the developed methods could be intensively tested on the 
numerous real animal product samples containing residues, which were analysed to study the 
disposition and distribution of residues in food-producing animals. Potential human health risks 
were indicated by off-label use of drugs including higher dosage levels and application to 
related, nonlabeled species.  
Because no recent depletion data of tetracyclines in eggs and broiler chickens after oral 
administration and of levamisole in milk after topical administration were available, depletion 
studies were performed (Chapters 7 and 8, respectively). 
The disposition and distribution of flubendazole and its metabolites in tissues of turkeys and 
guinea fowls and species differences between both avian species are described in Chapter 9. 
The disposition of mebendazole and its metabolites in sheep tissues is presented in Chapter 10. 
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Abstract: 
 
HPLC with ion-pair chromatography and UV diode array detection at 355 nm was used to 
determine residues of tetracycline antibiotics in eggs and chicken muscle tissue. 
The samples were deproteinised with hydrochloric acid and the tetracycline antibiotics 
were extracted with acetonitrile. The extracts were purified by liquid-liquid extraction with 
methylene chloride and petroleum ether and were concentrated by evaporation using 
vacuum. 
The analytical methods were optimised and validated. The mean recovery values for 
oxytetracycline in eggs and for tetracycline in breast muscle tissue were 76%. The 
within-day precision ranged from 8.0 to 11.8% for oxytetracycline in eggs and from 6.1 to 
15.5% for tetracycline in breast muscle tissue. The between-day precision was 4.8% and 
5.0% respectively for oxytetracycline in eggs and tetracycline in breast meat. The limit of 
detection and the limit of quantification for oxytetracycline in eggs were 2.2 and 13.0 
µg/kg, respectively. These limit values for tetracycline in breast muscle tissue were 10.5 
and 20.9 µg/kg, respectively. 
 
Keywords: tetracycline residues, eggs, chicken muscle tissue, HPLC 
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2  Introduction 
.1.1 Description of tetracycline antibiotic compounds 
T cycline antibiotics (TCA’s) are broad-spectrum antibacterial drugs active against a number 
o am-positive and gram-negative bacteria.1 These group of substances are widely used as 
v inary drugs for food-producing animals because of their broad-spectrum activity and cost 
e tiveness. The commonly used TCA drugs in veterinary medicine are tetracycline (TC), 
o tracycline (OTC), chlortetracycline (CTC) and doxycycline (DC). TC, OTC and CTC are 
n al TCA’s obtained through fermentation with tetracycline-producing Streptomycetes 
b ria. Doxycycline is a modified, semisynthetic derivative prepared by chemical conversion 
o C via methacycline. 
T CA compounds have the basic “2-naphthacenecarboxamide” structure, which is hydroxy 
s tituted at the 5-position.2 The chemical structure of the molecules is presented in        
F e 2.1. 
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   Figure 2.1  Molecular structures of tetracycline antibiotics2 
he various TCA compounds are relatively good soluble in water, but are insoluble in non-polar 
rganic solvents. The TCA’s are ionised in the pH range between 3 and 8. The molecules exist 
s cations at a pH around 3 and lower, as zwitter-ion between a pH of 3.5 and 7.5 and as 
nions at a pH above 7.5. Tetracyclines form highly fluorescent complexes with metallic ions. 
he chelate formation is pH dependent. The emitted fluorescence from the chelate complex 
ormed with a zirconium cation (Zr4+), is optimal at a pH of 2.0.3 Epimerisation and isomerisation 
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of the tetracycline, the oxytetracycline and the chlortetracycline molecules can occur during the 
sample pretreatment and during the determination. However, the formation of the C4-epimer of 
the TCA’s can be minimised using a mobile phase at a pH of 2.0.4 Zurhelle et al.5 have 
observed that the formation of 4-epi-chlortetracycline (4-epi-CTC), 6-iso-chlortetracycline        
(6-iso-CTC) and 4-epi-tetracycline (4-epi-TC) in eggs depends on temperature and time. No 
epimerisation or isomerisation occurred in spiked egg yolk and egg white samples kept 
refrigerated at 8°C. Neither could these chemical reactions be observed during the analytical 
procedure performed at ambient temperature. The epimerisation of OTC probably needs a 
temperature above 37°C or reaction times longer then 25 h. 
 
 2.1.2  Objectives 
There are many HPLC methods available for the determination of residues of TCA’s in eggs and 
muscle tissue. However, most of them are impractical for routine applications because of their 
time consuming and laborious sample clean-up.6,7,8,9,10 More-over, several analytical methods 
are using fluorescence detection, which needs a supplementary derivatisation procedure.7,8,9,11 
The objective of this study was to optimise a fast and quantitative multiresidue HPLC method for 
the routine determination of residues of TC, OTC, CTC and DC in eggs and chicken muscle 
tissue. Tissue samples of breast meat obtained from broiler chickens were used for the 
optimisation and validation of the analytical procedure. 
The MRLs, set in the EU according to Council Regulation EEC/2377/9012 and amendments, are    
200 µg/kg for OTC, TC and CTC in eggs. Doxycycline is not licensed for treatment of laying 
hens. The MRL level for OTC, TC, CTC and DC in chicken muscle tissue was established at a 
concentration of 100 µg/kg. 
The optimised method had to be used in depletion studies of oxytetracycline in laying hens and 
of tetracycline in broiler chickens, which are described in Chapter 7. 
 
2.2  Materials and methods 
 2.2.1  Reagents 
OTC-dehydrate, TC, CTC-hydrochloride and DC-hydrochloride, used to prepare standard 
solutions of the drug analytes, were obtained from Sigma (St. Louis, MO, USA). Methanol 
(Panreac, Barcelona, Spain), acetonitrile (Panreac for sample preparation and column flushing 
and Merck (Darmstadt, Germany) for mobile phase) and methylene chloride (Sigma) were of 
HPLC grade. Petroleum ether (b.p. 40-60°C, Panreac), 2-methyl-2-propanol (Aldrich, 
Milwaukee, WI, USA), phosphoric acid (Aldrich), hydrochloric acid (Panreac), trifluoroacetic acid 
(Pierce, Rockford, IL, USA) and sodium 1-decanesulphonate (Sigma) were of analytical grade. 
Water of HPLC grade was obtained by a Maxima LC 113 Ultra-pure water purification system 
(Elga, Bucks, UK). 
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2.2.2  Standard solutions 
TCA analyte stock solutions (1 mg/ml) were prepared in methanol and stored at -20°C. The 
solutions were replaced by fresh solutions every month. The working standard solutions, 
prepared immediately before use, were made by dilution of the stock solution in 0.01 N 
hydrochloric acid (HCl). 
 
 2.2.3  Apparatus 
The breast meat samples were minced and grinded with a Knifetec sample mill (Tecator, 
Höganäs, Sweden). The egg samples and the ground tissue samples were homogenised with 
an Unimix homogeniser (Haagen and Rinau, Bremen, Germany). The HPLC system       
(Perkin-Elmer, Norwalk, CT, USA) consisted of a Sec-4 Solvent Environmental Control delivery 
system with helium degassing, a Series 410 quaternary pump system, an ISS 200 autosampler 
and a 235 UV diode array detector. A reversed-phase polymeric column type PLRP-S, 100 Å,   
5 µm, 150 X 4.6 mm i.d. was used in combination with a PLRP-S guard cartridge of 5 X 3.0 mm 
(Polymer Laboratories, Church Stretton, UK). 
 
 2.2.4  Sample preparation and clean-up 
 2.2.4.1  Eggs 
Two ml of 1 N HCl was added as deproteinisation reagent to 10 g of homogenised whole egg in 
a beaker. To fortify samples, homogenised egg was spiked before the addition of HCl. After 
swirling, 50 ml of acetonitrile were added as extraction solvent and the sample liquid was 
homogenised. After standing for 10 min, the mixture was filtered through a plug of glass wool in 
the stem of a funnel. The extraction beaker was rinsed with 30 ml of acetonitrile. Fifty ml of 
filtrate was collected, which was purified in a separatory funnel by liquid-liquid extraction with  
45 ml of methylene chloride and 45 ml of petroleum ether. The mixture was shaken vigorously. 
After standing for 5 min, the lower water layer was collected in a side-arm flask. This fraction 
was evaporated to 1-2 ml in a water bath at 45°C using vacuum. The remaining phase was 
transferred into a graduated tube. The flask was rinsed with 1 ml of 0.01 N HCl. The combined 
liquids were evaporated to about 0.8 ml under a stream of nitrogen. The concentrate was made 
up to 1 ml with 0.01 N HCl. Finally, the drug residue concentrate was filtered through a 0.2 µm 
regenerated cellulose (RC) filter cartridge (Alltech, Deerfield, IL, USA) in an autosampler vial. 
 
 2.2.4.2  Muscle tissue 
A 10 g sample of ground breast muscle tissue was homogenised in 30 ml of water. To prevent 
foaming, five drops of 2-methyl-2-propanol were added. To fortify samples, muscle tissue was 
spiked before adding water. After standing for 5 min, 2.5 ml of 1 N HCl and 80 ml of acetonitrile 
were added to 20 ml of the homogenised mixture, while swirling. After standing for 10 min, the 
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liquid was filtered through a plug of glass wool in the stem of a funnel. Eighty ml of filtrate was 
purified in a separatory funnel by liquid-liquid extraction with 80 ml of methylene chloride and  
80 ml of petroleum ether. The mixture was shaken vigorously. After standing for 10 min, the 
concentration phase was performed as described for eggs in paragraph 2.2.4.1. 
 
 2.2.5  Liquid chromatography 
The separation of the tetracycline analytes while minimising endogenous interferences on the 
column, was performed by ion-pair chromatography with 1-decanesulphonate as ion-pair 
reagent. The mobile phase consisted of a buffer solution containing 0.02 M phosphoric acid with 
0.01 M sodium 1-decanesulphonate (A), filtered through a 0.45 µm hydrophilised polypropylene 
filter disc (Millipore, Bedford, MA, USA), and pure acetonitrile (B). Gradient elution was applied 
and the gradient programme consisted of 75A:25B (0 min), 75A:25B to 63A:37B (1-22 min), 
63A:37B (23-26 min), 63A:37B to 100B (27-28 min), 100B (29-43 min), 100B to 75A:25B      
(44-46 min) and 75A:25B (47-56 min). The flow rate was 1.0 ml/min, the injection volume was 
150 µl and the detection wavelength of the diode array detector was set at 355 nm. The column 
was flushed daily with 120 ml of a solvent mixture consisting of 87.5% acetonitrile and 12.5% 
water. The column was back-flushed weekly with 960 ml of a solvent mixture consisting of 50% 
acetonitrile and 50% water containing 0.1% trifluoroacetic acid. 
 
 2.2.6  Method validation 
  2.2.6.1  Calibration curves 
The linearity of the HPLC detection was checked by analysing a series of OTC, TC, CTC and 
DC standard solutions on four different days, in the concentration range of 50 to 5000 µg/l. The 
calibration curves were obtained using the linear least squares regression procedure of the 
peak area versus concentration ratios. The accuracy is expressed as the relative standard 
deviation (sr) of the slope of the curves. 
 
  2.2.6.2  Extraction recoveries 
The recovery of the four tetracyclines was determined by analysing blank egg and blank breast 
meat samples spiked with a standard mixture solution. The samples were fortified on three 
different days at two concentrations of respectively 100 and 200 µg/kg for eggs and 50 and   
100 µg/kg for breast meat. The obtained mean recovery values were used for calculations of the 
residue concentrations and the precision data. 
 
  2.2.6.3  Precision 
The precision of the assays was checked by repeatedly analysing blank egg and blank breast 
meat samples spiked at the respective MRL concentrations. The within-day precision 
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(repeatability), the between-day precision and the overall precision were determined during 
three different days and are expressed as sr value. 
 
  2.2.6.4  Limit of detection and limit of quantification 
The detection limits (LODs) and quantification limits (LOQs) were estimated as those analyte 
concentrations which yield a signal-to-noise (S/N) ratio of at least 3/1 and 5/1, respectively. 
These analytical limits were determined by extrapolating the five-point matrix calibration curves 
made with blank samples spiked at 0, 100, 200, 300 and 400 µg/kg for eggs and at 0, 50, 100, 
150 and 200 µg/kg for breast meat, respectively. 
 
2.3  Results and discussion 
 2.3.1  Analytical method 
In this study, a relatively simple, fast and accurate method, suitable for routine analysis, was 
developed. The discussed analytical method was an optimisation of available procedures 
described by Moats,13 Moats and Harik-Khan,14 Moats and Harik-Khan15 and White et al.16 
Some previous investigation had indicated a higher stability of TCA analytes in standard 
solutions and even in spiked sample extracts when using methanol as solvent. The TCA’s are 
slightly unstable in highly acidic (1N HCL) conditions.6  
Moats and Harik-Khan15 obtained better results when the tissue samples were first 
homogenised in water before the tetracycline residues were extracted. TCA’s are polar, 
ionisable compounds which do not generally partition effectively into organic solvents.13,17 The 
analytes could be concentrated in the water layer by adding equal volumes of petroleum ether 
and of methylene chloride to the acetonitrile filtrate. 
Careful selection of pH and of ionic strength and the addition of ion-pair reagents improve the 
partitioning of TCA’s into organic solvents.17 The application of ion-pair chromatography reduces 
the sample clean-up to a minimum. Moats and Harik-Khan14  have reported that tetracyclines 
could be effectively separated from endogenous interferences in milk extracts by ion-pair 
chromatography without further clean-up. 
A polymeric analytical column was chosen, to minimise possible chromatographic problems 
which can be expected with silica-based bonded columns.18 With a bonded column, interactions 
between analytes and the residual silanol groups present in the silica-based support materials 
may occur. A polymeric column type is widely used in the residue analysis of TCA’s to obtain 
higher recoveries and lower peak tailing.4,7,9,11 
For multiresidue analysis, gradient elution is advantageous because sharp peak shapes can be 
maintained throughout the elution and early eluting peaks are not excessively co-eluted.16 An 
acceptable analyte separation with relatively sharp peaks was obtained applying a elution 
programme with linear gradients. Representative chromatograms of a blank egg sample and an 
Chapter 2:  High performance liquid chromatographic method for the determination 
 of tetracycline residues in eggs and chicken muscle tissue 
 
54
 
C
ha
pt
er
 2
:  
H
ig
h 
pe
rfo
rm
an
ce
 li
qu
id
 c
hr
om
at
og
ra
ph
ic
 m
et
ho
d 
fo
r t
he
 d
et
er
m
in
at
io
n 
 
of
 te
tra
cy
cl
in
e 
re
si
du
es
 in
 e
gg
s 
an
d 
ch
ic
ke
n 
m
us
cl
e 
tis
su
e 
  
5 5
 
Fi
gu
re
 2
.4
 U
V 
sp
ec
tra
 o
f t
et
ra
cy
cl
in
e 
(T
C
), 
ox
yt
et
ra
cy
cl
in
e 
(O
TC
), 
ch
lo
rte
tra
cy
cl
in
e 
(C
TC
) a
nd
 d
ox
yc
yc
lin
e 
(D
C
) 
 
 
at
 a
 c
on
ce
nt
ra
tio
n 
of
 1
0 
g/
l 
Chapter 2:  High performance liquid chromatographic method for the determination 
 of tetracycline residues in eggs and chicken muscle tissue 
 
 
55
egg sample fortified at MRL concentration are illustrated in Figure 2.2. Figure 2.3 shows 
chromatograms of blank breast meat sample and a breast meat sample spiked at                 
MRL concentration. 
The UV detection by the DAD was carried out at a wavelength of 355 nm. This wavelength was 
chosen as mean optimum value for the four tetracycline substances. As shown in the 
representative UV spectra in Figure 2.4, the UV absorption values were much higher at 268 nm. 
However, in preliminary research more interference and non-specific absorption was obtained at 
this wavelength. With the specific UV spectra, supplementary analyte confirmation was 
obtained. 
 
 2.3.2  Validation of the analytical method 
 2.3.2.1  Calibration curves 
The regression parameters of the external calibration curves obtained with six calibration points 
(50, 100, 200, 500, 1000, 5000 µg/l) with standard solutions made with mixtures of the TCA’s 
are summarised in Table 2.1. The curves are described by the equation Y = aX + b                
(“Y” represents peak area, “a” represents slope, “X” represents concentration in µg/l and “b” 
represents intercept). The HPLC respons was linear in the concentration range of 50 to       
5000 µg/l. The sr values on the slope of the calibration curves obtained on four different days 
were below 9%. 
 
 2.3.2.2  Recovery studies 
Table 2.2 presents the recoveries obtained for egg and breast meat samples fortified at two 
concentrations with a TCA analyte mixture. The mean recovery values for OTC, TC, CTC and 
DC in eggs and in breast meat were 76, 78, 62 and 58% and 78, 76, 76 and 68%, respectively. 
The sr values on the mean recovery were 8.4% and 10.4% for OTC in eggs and for TC in breast 
meat, respectively. These analytes were intensively measured in the depletion studies. The 
recovery of the analytical procedure can probably be increased by replacing acetonitrile for  
ethyl acetate as extractant. Cooper et al.17 have observed a highest recovery of 90% for OTC in 
spiked cattle kidney tissue after extraction with ethyl acetate. They also investigated the effect 
of spiking procedures (spike contact time, spike solvent and tissue state) on the recovery. The 
increase of the spike contact time caused a small but statistical significant reduction in recovery 
due to a slight degradation of OTC. 
The obtained recoveries for breast meat were slightly lower than those reported by Moats and 
Harik-Khan15 for beef muscle tissue. McCracken et al.8 have obtained comparable results for 
the residue determination in muscle tissues of pigs, cattle and poultry. Much lower recovery 
values for pork muscle tissue and eggs were measured by Croubels et al.,9 probably due to the 
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extensive sample clean-up. The selection of the SPE cartridges, applied for sample clean-up, is 
critical.10 Only cartridges providing high and consistent recoveries should be used. 
 
 
  Table 2.1  Regression analysis of calibration curves obtained on four different days 
     Analyte Day Slope (a)     Intercept (b)               r 
1  1166.4       -14104.5 0.9999
2 1141.6       -17854.0 0.9999
3 1142.4       -23437.7 0.9999
OTC 
4 1183.2       -19024.9 0.9999
  sr = 1.7%  
1 1133.7       -46188.1 0.9998
2 1034.9         -3850.0 0.9999
3 1067.1         -9725.6 0.9999
TC 
4 1111.7       -14337.9 0.9999
  sr = 4.1%  
1 567.7        13368.2 0.9999
2 586.2       -10758.4 0.9999
3 631.7       -29740.4 0.9996
CTC 
4 539.9       -12821.9 0.9999
  sr = 4.5%  
1 588.1         4176.9 0.9999
2 606.6      -25925.0 0.9998
3 702.0      -54513.6 0.9992
DC 
4 607.8      -22152.2 0.9999
  sr = 8.2%  
 OTC: oxytetracycline     TC: tetracycline     CTC: chlortetracycline     DC: doxycycline  
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  2.3.2.3  Precision of the assay 
The mean concentrations and the precision values, expressed as sr values, obtained for the 
repetitive analyses are summarised in Table 2.3. The repeatability or within-day precision 
ranged from 8.0 to 11.8% for OTC in eggs and from 6.1 to 15.5% for TC in breast meat. The 
between-day precision was 4.8% for OTC in eggs and 5.0% for TC in breast meat, respectively. 
The overall precision values for these analytes and these matrices were 9.4 and 12.6%, 
respectively. 
 
  2.3.2.4  Limit of detection and limit of quantification 
The linearity data of the determination assay and the analytical limit values obtained with spiked 
egg and breast meat samples are shown in Table 2.4. The LOD and the LOQ values calculated 
for OTC in eggs were 2.2 and 13.0 µg/kg, respectively. These limit values obtained for TC in 
breast meat were 10.5 and 20.9 µg/kg, respectively. 
 
Table 2.4  LOD (µg/kg) and LOQ(µg/kg) values for tetracycline determinations 
 Eggs Breast muscle tissue 
 r LOD LOQ r LOD LOQ 
OTC 0.9986        2.2 13.0 0.9999        8.4 17.6 
TC 0.9994        4.7 16.1 0.9999      10.5 20.9 
CTC 0.9996      28.6 51.6 0.9999      18.2 37.4 
DC 0.9977      27.3 47.3 0.9996      18.6 34.5 
  OTC: oxytetracycline     TC: tetracycline     CTC: chlortetracycline     DC: doxycycline 
 
The calculated values for OTC and TC in breast meat were comparable with those reported by 
Moats and Harik-Khan.15 The obtained values for CTC were somewhat lower. McCracken et al.8 
and Blanchflower et al.7 have obtained comparable results for the analysis of meat samples 
using more elaborate equipment and fluorescence detection. Much lower detection limits can be 
obtained when a more intensive or a more selective sample clean-up is performed. Also, low 
detection limits can be obtained measuring the analytes by more specific fluorescence 
detection. Agasoster11 has described an automated method for control of OTC residues in milk, 
eggs and several animal tissues. Tissue homogenate, skimmed milk or whole egg solution was 
dialysed and the dialysate was enriched on a small polystyrene column on-line to HPLC. The 
analytes were eluted by ion-pair chromatography and were measured by a fluorescence 
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spectrophotometer. Oxytetracycline could be detected (S/N of 3/1) at concentrations between 1 
and 8 µg/kg depending on the matrix. 
Croubels et al.9 have proposed an appropriate method for trace residue analysis of TCA’s in 
animal tissues and egg. The sample clean-up was performed by metal chelate affinity 
chromatography based on the chelate complex formation of zirconium with the tetracycline 
compounds. To enable low detection limits, further concentration on an extraction membrane 
with cation-exchange properties was carried out. The TCA’s were measured by fluorescence 
detection after post-column derivatisation. The LOD values (S/N of 4/1) ranged from 0.4 to     
5.0 µg/kg, depending on tissue and compound. The described procedure was successfully used 
in other applications. De Wasch et al.19 have reported the detection of residues of TC, OTC, 
CTC and DC in pork and chicken meat. The detection limits (S/N of 4/1) were estimated at 
concentrations between 0.4 and 1.4 µg/kg depending on the compound. In a tissue depletion 
study in turkeys, doxycycline could be detected at an estimated LOD (S/N of 3/1) of 1.0 and   
1.2 µg/kg in muscle and liver tissue, respectively.20 
 
2.4  Conclusions 
The optimised chromatographic method for the simultaneous determination of tetracycline, 
oxytetracycline, chlortetracycline and doxycycline in eggs and in chicken muscle tissue was 
proven to be reliable and suitable for routine analysis. The sample preparation could be kept 
minimal to be able to perform the procedure in a relatively short time. An acceptable separation 
of the analytes could be obtained using ion-pair chromatography. Supplementary analyte 
confirmation was obtained with the specific UV spectra of the diode array detector. 
The optimised method is used in depletion studies of oxytetracycline in laying hens and of 
tetracycline in broiler chickens, which are described in Chapter 7. 
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Abstract: 
 
The optimisation of two HPLC methods for the determination of residues of anthelmintic drugs 
in milk is described. Satisfactory analytical separations and detection limits were obtained 
with ion-pair liquid chromatography and UV diode array detection at 225 nm for levamisole 
and at 295 nm for fenbendazole, thiabendazole, albendazole and oxibendazole. 
Levamisole was extracted with chloroform after the milk sample was made alkaline. The 
analyte extract was concentrated by evaporation using vacuum. For the determination of the 
benzimidazoles, the milk sample was deproteinised with acetonitrile and the analytes were 
extracted with ethyl acetate. After centrifugation, the supernatant was defatted with            
iso-octane. The extract was further purified by liquid-liquid extraction with methylene chloride. 
The remaining organic phase was washed with di-sodium hydrogen phosphate and was 
concentrated by evaporation using vacuum. 
The mean extraction recoveries ranged from 68 to 85%. The limits of detection for 
fenbendazole, thiabendazole, albendazole, oxibendazole and levamisole were 3.1, 3.4, 3.8, 
1.3 and 0.5 µg/l, respectively. The limits of quantification for these anthelmintics were 6.8, 4.3, 
6.9, 2.7 and 1.4 µg/l, respectively. The overall precision data, based on within-day and 
between-day variations during three different days were 11.9, 3.9, 8.2, 7.4 and 12.7%, 
respectively. 
 
Keywords: anthelmintic drug residues, milk, HPLC-DAD 
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3.1  Introduction 
 3.1.1  Description of anthelmintic compounds 
Anthelmintic veterinary drugs are widely used prophylactically as well as curatively in           
food-producing animals against endoparasitic worm infections. The anthelmintic drug 
substances involved in the analytical procedure described in this chapter are fenbendazole 
(FB), thiabendazole (TB), albendazole (AB), oxibendazole (OB) and levamisole (LE). These 
synthesised compounds have a broad-spectrum activity and are very suitable for the control of 
most gastrointestinal nematodes and lungworms in cattle, sheep, pigs and poultry species.1,2 
FB, TB, AB and OB belong to the benzimidazole (BZ) group of antiparasitic drug substances. 
Benzimidazole anthelmintic compounds have as common central chemical structure a          
“1,2-diaminobenzene” moiety (Figure 3.1) which gives rise to the “benzimidazole” nucleus.1 
Levamisole is defined as the L-isomer of tetramisole, an imiothiazole (imidazothiazole) 
anthelmintic substance consisting of a racemic mixture of D- and L-isomers.2,3,4 
The molecular structures of the anthelmintic drug compounds are illustrated in Figure 3.1. 
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Figure 3.1  Chemical structures of the examined anthelmintics1,2 
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In general, benzimidazoles are insoluble or only slightly soluble in water.1 The BZs are generally 
soluble in dimethyl sulphoxide and dimethyl formamide. Levamisole is very soluble in water and 
in polar organic solvents.2 Benzimidazoles intensively absorb UV light.1 Thiabendazole shows 
fluorescence properties. The examined BZs are weakly basic compounds due to their 
secondary amino group. 
The heat stability of levamisole was investigated by Rose et al.5 Levamisole was found to be 
stable in cooking water, but unstable in cooking oil at 260°C, with a half-life of about 5 min. 
Levamisole was stable in incurred and fortified samples under heating conditions during 
microwaving, boiling, grilling or frying. However, some migration of levamisole from the tissue 
into the meat juices does occur. Roasting was the only heating process where a loss of 
levamisole was observed. Levamisole intake from contaminated meat can be reduced by 
discarding the liquids used for cooking or by discarding the meat juices. 
 
3.1.2  Toxicity 
Benzimidazole anthelmintic residues are of little human health concern. Toxicological data 
include studies on metabolism, carcinogenicity, genotoxicity, effects on reproduction and 
teratogenicity.1 Short term studies suggest that this group of compounds is efficacious for 
parasitic control while demonstrating a great margin of safety in mammals, including humans. 
The most sensitive indicators of developmental toxicity associated with BZs appear to be limb 
defects associated with teratogenic activity in rats fed with AB. Armour3 also reported that many 
BZs including oxibendazole, fenbendazole, albendazole and other analogues, are characterised 
by a very low toxicity for mammalian hosts, in general. It was virtually impossible to find a 
median lethal dose (LD50) for fenbendazole. Albendazole, known to be teratogenic, should not 
be used in early pregnancy at higher than therapeutic dose. Delatour and Parish6 have reported 
teratogenicity for albendazole in sheep. The malformations observed were predominantly 
skeletal. 
The mammalian toxicity of levamisole is greater than with the benzimidazoles although, in 
normal usage, toxic effects are seldom seen and adverse effects are rare.2,3 Levamisol is also 
used in human medicine as an anthelmintic, as an immunomodulator and as an adjuvant in the 
treatment of colorectal cancer.2 
 
 3.1.3  Objectives 
Residue concentrations of anthelmintic drugs in milk can be very high if farmers do not respect 
the recommended withdrawal times after treatment of dairy cows. Adequate safety margins 
(MRLs) should be established to prevent consumer health problems since in many cases 
teratogenic metabolites have been identified in animal products such as milk, eggs and meat.6 
The MRL values in milk are 10 µg/kg for FB, 100 µg/kg for TB and for AB and 50 µg/kg for OB.7  
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The MRL value for OB is provisional and still under consideration. Levamisole is not more 
allowed for lactating dairy cows. 
Several analytical methods are described in the literature. De Baere et al.8 described a     
HPLC-UV method for the determination of levamisole in animal plasma. A liquid-liquid extraction 
procedure in alkaline medium, using hexane-isoamyl alcohol as extraction solvent, was 
performed to clean-up the plasma samples. Chromatographic separation was achieved by 
gradient elution with a mobile phase containing ammonium acetate buffer and pure acetonitrile. 
However, the method is not sensitive. A LOD of 77 µg/l was obtained. 
Chappell et al.4 presented a method for the determination of levamisole in milk at low 
concentrations with a hyphenated multidimensional technique consisting of a coupled HPLC-GC 
system. The HPLC system was used to provide a sample clean-up phase prior to on-line GC 
analysis. A solid phase extraction (SPE) sample clean-up procedure was applied. Detection 
limits of 0.4 and 2.2 µg/l could be obtained by flame ionisation and nitrogen-phosphorus GC 
detection, respectively. 
A multiresidue HPLC procedure with diode array detection for the determination of eight 
benzimidazole anthelmintics in foodstuffs of animal origin was reported by Neri et al.9 The 
sample was extracted with acetonitrile using an ultrasonic bath. The organic layer was 
evaporated and the residue was dissolved in hydrochloric acid. After an initial washing with 
hexane to remove fats, the aqueous layer was purified by SPE. The concentrated and cleaned 
sample extract was analysed by gradient elution with a mobile phase consisting of phosphate 
buffer and acetonitrile. Limits of detection lower than 10 µg/kg were reported.  
In another procedure, matrix solid phase dispersion (MSPD) was compared with SPE for the 
determination of fenbendazole and metabolites in milk. The MSPD method showed some 
advantages such as shorter times of analysis and smaller amounts of reagents. However, lower 
LODs were obtained with the more laborious and expensive SPE procedure. 
For monitoring purposes, an analytical method for anthelmintics in milk had to be developed. 
This Chapter reports an analytical study dealing with the optimisation of sensitive and 
quantitative HPLC methods with UV diode array detection for routine analysis of cow’s milk on 
residues of the benzimidazoles fenbendazole, thiabendazole, albendazole, oxibendazole and of 
the imidazothiazole levamisole. The method had to be suitable for quantification of LE residues 
in milk during a depletion study with dairy cows. The excretion study of levamisole in milk of 
treated dairy cows is reported in Chapter 8. 
 
3.2  Materials and methods 
 3.2.1  Reagents 
FB, TB, AB, OB and LE-hydrochloride, obtained from Sigma (St. Louis, MO, USA), were used to 
prepare the standard solutions. Dimethyl sulphoxide (Panreac, Barcelona, Spain), acetonitrile 
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(BDH (Poole, UK) for sample preparation and column flushing and Merck (Darmstadt, Germany) 
for mobile phase), methanol (Merck), methylene chloride (Panreac), iso-octane (Panreac) and 
chloroform (Panreac) were of HPLC grade. Ethyl acetate (Sigma), di-sodium hydrogen 
phosphate (Merck), sodium 1-octanesulphonate (Sigma), ortho-phosphoric acid (> 85%, UCB, 
Ghent, Belgium) and sodium hydroxide (1 N, Panreac) were of analytical grade. Water was of 
HPLC grade and was obtained from a Maxima LC 113 Ultra-pure water purification system 
(Elga, Bucks, UK). 
 
 3.2.2  Standard solutions 
The benzimidazole stock solutions (0.4 mg/ml) were prepared in a mixture of 40% dimethyl 
sulphoxide and 60% acetonitrile. These stock solutions were stored refrigerated at 5°C and 
were replaced every three weeks. The working standard solutions were prepared by mixing one 
part of acetonitrile with one part of 0.01 M sodium 1-octanesulphonate which was adjusted to a 
pH of 3.5 with ortho-phosphoric acid. These working solutions were prepared immediately 
before use. 
The LE stock solution (0.4 mg/ml) was prepared in a mixture of 40% dimethyl sulphoxide and 
60% methanol. This stock solution was also stored refrigerated at 5°C and replaced every three 
weeks. The working standard solutions were made in a mixture of one part of methanol and one 
part of 0.01 M sodium 1-octanesulphonate. The solutions were adjusted to a pH of 3.0 with 
ortho-phosphoric acid. These solutions were also prepared immediately before use. 
 
 3.2.3  Apparatus 
A RC-5B Sorvall centrifuge (DuPont Instruments, Wilmington, DE, USA) was used during 
sample preparation. The HPLC system11 described in Chapter 2, was used. During this 
analytical study, the reversed-phase column was an Alltima C18 column (Alltech, Deerfield, IL, 
USA) 100 Å, 5 µm, 150 X 3.2 mm i.d. protected with an Alltima C18 guard cartridge of 7.5 X 3.2 
mm i.d. The column was thermostated at 35°C using a Column Heater Model 7971 (Jones 
Chromatography, Hengoed, Mid Glamorgan, UK). 
 
 3.2.4  Sample preparation and clean-up 
  3.2.4.1  Procedure for benzimidazoles 
Twenty five ml of acetonitrile and 5 ml of ethyl acetate as deproteinisation reagent and as 
extraction solvent, respectively, were added to 10 ml of milk sample in a centrifuge tube. After 
shaking vigorously during 30 s, the sample extract was centrifuged for 5 min at 5000 rpm. The 
clear supernatant was defatted with 30 ml of iso-octane in a separatory funnel. After mixing, the 
lower aqueous layer was purified by liquid-liquid extraction with 60 ml of methylene chloride in a 
second separatory funnel and the upper iso-octane layer was discarded. The mixture was 
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shaken vigorously during 30 s. After standing for 5 min, the lower organic layer was transferred 
into another separatory funnel and the upper layer was discarded. The remaining organic phase 
was washed with 20 ml of 0.1 M di-sodium hydrogen phosphate adjusted to a pH of 10.0 with 
sodium hydroxide. The mixture was shaken for 30 s. After standing for 5 min, the bottom 
organic layer was transferred into a side-arm flask and was evaporated to 4-5 ml using vacuum 
in a water bath heated at 50°C. The remaining fraction was transferred into a graduated tube. 
The flask was rinsed with 1 ml of a mixture of one part acetonitrile and of one part 0.01 M 
sodium 1-octanesulphonate adjusted to a pH of 3.5 with ortho-phosphoric acid. The combined 
liquids were evaporated to dryness under a stream of nitrogen. The residue was made up to     
1 ml with the above mentioned mobile phase mixture. This cleaned and concentrated sample 
extract was finally filtered through a 0.2 µm regenerated cellulose (RC) filter cartridge (Alltech, 
Deerfield, IL, USA) in an autosampler vial. 
 
  3.2.4.2  Procedure for levamisole 
Sixty ml of chloroform as extraction solvent and 20 ml of 0.1 N sodium hydroxide were added to 
10 ml of milk sample in a separatory funnel. This sample mixture was shaken for 1 min. After 
standing for 5 min, the lower organic layer was collected in a side-arm flask and the 
concentration of this fraction was performed as previously described in the procedure for BZs 
(paragraph 3.2.4.1). However, the flask was rinsed with 1 ml of chloroform and the volume 
correction was performed with a mixture of one part methanol and one part 0.01 M sodium       
1-octanesulphonate adjusted to a pH of 3.0 with ortho-phosphoric acid. 
 
 3.2.5  Liquid chromatography 
The separation of the anthelmintic analytes was performed by ion-pair chromatography with     
1-octanesulphonate as ion-pair reagent. The analytes were detected by a diode array detector 
(DAD). The benzimidazoles and levamisole were determined by separate HPLC methods. 
 
  3.2.5.1  Multiresidue method for benzimidazoles 
The mobile phase consisted of a buffer solution (A), acetonitrile (B) and water (C). The buffer 
solution contained 0.01 M sodium 1-octanesulphonate adjusted to a pH of 3.5 with ortho-
phosphoric acid, and was filtered through a 0.45 µm hydrophilised polypropylene filter disc 
(Millipore, Bedford, MA, USA). Gradient elution was applied and the gradient programme 
consisted of 80A:20B (0 min), 80A:20B to 50A:50B (1-2 min), 50A:50B (3-13 min), 50A:50B to 
50C:50B (14-15 min), 50C:50B (16-35 min), 50C:50B to 80A:20B (36-37 min) and 80A:20B  
(38-57 min). The mobile phase flow rate was 0.5 ml/min and a volume of 50 µl was injected by 
the autosampler. The analytes were detected by the diode array detector at a wavelength of 
295 nm. The column was flushed daily with 150 ml of a solvent mixture consisting of 50% 
acetonitrile and 50% water. 
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 3.2.5.2  Method for levamisole 
The mobile phase consisted of a filtered buffer solution (A), methanol (B) and water (C). The 
buffer solution contained 0.01 M of the ion-pair reagent and was adjusted to a pH of 3.0 with 
ortho-phosphoric acid. Isocratic elution was applied with a mobile phase containing 48A:52B. 
The complete HPLC run consisted of 48A:52B (0-8 min), 48A:52B to 48C:52B (9-10 min), 
48C:52B (11-33 min), 48C:52B to 48A:52B (34-35 min) and 48A:52B (36-58 min). The flow rate 
for the mobile phase was 0.5 ml/min. A sample extract volume of 150 µl was injected and the 
analytes were measured at a wavelength of 225 nm by the DAD. The same column flushing 
procedure was applied as described in the method for benzimidazoles (paragraph 3.2.5.1). 
 
3.2.6 Validation of the HPLC assays 
 3.2.6.1  Standard curves 
The linearity of the HPLC respons was studied by analysing a series of mixed benzimidazole 
and levamisole standard solutions in the concentration range 20-5000 µg/l. The analyses were 
performed on three different days. The standard curves were obtained using the linear least 
squares regression procedure of the peak area versus concentration ratios. The between-day 
variation is expressed as the relative standard deviation (sr) of the slope of the curves. 
 
 3.2.6.2  Recovery 
The extraction efficiency for the five examined anthelmintic compounds was determined by 
analysing spiked blank milk samples. The samples were fortified at two concentration levels, 10 
and 100 µg/l. For the benzimidazoles, milk samples were fortified with a mixture of standard 
solutions. The recoveries were calculated by extrapolating of standard curves taking into 
account the concentration factor of 10. The accuracy of the recovery determinations is given by 
the sr values. 
 
 3.2.6.3  Linearity, limit of detection and limit of quantification 
The linearity of the complete analytical assay including sample preparation, was checked by 
analysing blank milk samples fortified separately with a mixture of the examined benzimidazoles 
and with levamisole. The analyses were performed on three different days on samples spiked at 
concentrations between 0 and 1000 µg/l (seven calibration points). The matrix calibration curves 
were calculated using the linear least squares regression analyses of the peak area to 
concentration ratios. The sr value of the slope of the curves represents the between-day 
variation. The limit of detection (LOD) and the limit of quantification (LOQ) were estimated as 
those concentrations of analyte which yield a signal-to-noise (S/N) ratio of at least 3/1 and 5/1, 
respectively. These analytical limits were determined by extrapolating of linear matrix calibration 
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curves, which were obtained by plotting peak height versus concentration with data obtained 
from the linearity study. 
 
 3.2.6.4  Trueness 
This accuracy parameter was studied by analysing blank milk samples spiked with anthelmintic 
standard solutions at a concentration of 100 µg/l. The four benzimidazole substances were 
spiked with a mixed spiking solution. The trueness was determined by comparing the measured 
concentration, calculated with matrix calibration curves, to the fortified concentration. 
 
 3.2.6.5  Precision 
The precision of the assays was studied by repeatedly analysing milk samples, fortified at the 
respective MRL concentration for the various benzimidazole compounds and at 10 µg/l for 
levamisole. The drug concentrations were calculated by extrapolating of matrix calibration 
curves. The within-day precision (repeatability), the between-day precision and the overall 
precision were determined on three different days and were expressed as sr value.  
 
3.3  Results and discussion 
 3.3.1  Analytical methods 
In this study, an easy, relatively fast and reliable method for the routine determination of 
anthelmintic residues in milk had to be developed. Due to the great difference in chemical 
properties of benzimidazole compounds and levamisole, the optimisation of a multiresidue 
procedure for the analysis of milk samples on the five anthelmintic analytes, was not successful. 
The BZ analytes were determined with a optimised multiresidue method based on a procedure 
for fenbendazole described by Fletournis et al.12 
Preliminary experiments indicated that a slightly higher recovery for the BZs was obtained by 
addition of ethyl acetate to the acetonitrile deproteinisation and extraction reagent. The BZs are 
weakly basic hydrophobic compounds with appreciable solubility in polar organic solvents.12 
Ethyl acetate has a high solvating power for weakly basic compounds and is able to form 
emulsion-free interfaces.13 Other research workers14,15 also used ethyl acetate for the extraction 
of anthelmintic residues in animal product samples. 
As co-extracted lipids can interfere in the analysis, especially when sample extracts were 
concentrated to a small volume, a defatting phase is recommended. Washing of the extracts 
with iso-octane could efficiently remove lipids.12 Some clean-up of the milk extract could be 
affected by addition of methylene chloride. By this addition, most of the water of the extract was 
separated, which favours removal of highly basic and acidic hydrophilic interfering compounds. 
Interfering weakly acidic compounds could effectively be removed by further purification by 
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washing the remaining organic extract with phosphate buffer. The formed emulsion-free 
interface greatly facilitates the quantitative separation of the organic phase. A very satisfactory 
HPLC separation of the benzimidazole analytes was obtained by ion-pair chromatography and 
gradient elution. An optimum separation with sodium 1-octanesulphonate as ion-pair reagent 
was obtained by adjusting the pH of the mobile phase buffer solution at 3.5. A relatively strong 
adsorptive interaction between the protonated analytes and the silica-based reversed-phase 
packing material may occur. The negatively charged octanesulphonate ions were used in order 
to form hydrophobic ion-pairs with the analytes. Peak tailing was avoided, the retention times 
increased slightly and a considerable increase in peak height was obtained. Representative 
chromatograms of a blank milk sample and a milk sample spiked at 100 µg/l with the examined 
BZs are presented in Figure 3.2. 
The maximum UV absorption values for FB, TB, AB and OB (Figure 3.3) were obtained with the 
DAD at wavelengths of 294, 300, 297 and 292 nm, respectively. In the optimised multiresidue 
method, the eluted analytes were detected with a mean wavelength of 295 nm. 
Levamisole was determined with an optimised procedure based on the method applied by 
Archambault et al.16 The assay is easy and fast and is very suitable for routine analysis. After 
extraction with chloroform, only a concentration step has to be carried out. A clean-up of the 
sample extract can be omitted. This method is easier and faster than the method described by 
Österdahl et al.17 They prefer a more laborious sample pretreatment with a clean-up by SPE on 
an Extrelut column. The HPLC-DAD method published by De Baere et al.8 is also relatively fast 
to perform. After liquid-liquid extraction with hexane/iso-amylalcohol, a separation of the extract 
was performed by centrifugation. A concentration phase evaporating the extract was followed. 
However, the method was not fully optimised to obtain a high sensitivity (LOD = 77 µg/l). For 
their HPLC-UV determination method for animal tissues, Dreassi et al.18 also proposed the use 
of chloroform for the extraction of LE. A SPE sample clean-up was applied. Recovery values up 
to 89% for muscle samples were obtained. A LOQ value of 4 µg/kg was reported. 
Maximum UV absorption for levamisole was obtained at a wavelength of 211 nm (Figure 3.3). 
However, more endogenous interference due to non-specific absorption at this wavelength was 
observed in previous research work. The HPLC eluate was analysed by the diode array detector 
at an optimised wavelength of 225 nm.  
A satisfactory separation of the LE analyte from endogenous interfering material was obtained 
with the described sample preparation procedure. Figure 3.4 shows representative 
chromatograms of a blank milk sample and a milk sample fortified with levamisole at a 
concentration of 100 µg/l. 
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Potential additional analyte characterising data could be obtained by DAD detection. The DAD 
can assist in the screening of suspected peaks, allowing immediate comparison of the UV 
spectra of the sample with the specific UV spectra of standard compounds. 
Preliminary experiments on the HPLC separation of anthelmintic analytes were performed with 
a polymeric column with i.d. of 4.6 mm. Changing this type of column for an Alltima C18 with an 
i.d. of 3.2 mm was very advantageous. Significant higher peak heights resulting in more 
sensitive analysis could be obtained and the mobile phase consumption could be halved. 
 
 3.3.2  Validation of the analytical methods 
 3.3.2.1  Standard curves  
The linearity of the HPLC response was verified by running a mixed BZ standard solution and a 
LE standard solution in a series at seven different concentrations of 20, 100, 200, 500, 1000, 
2000 and 5000 µg/l. These analyses were repeated on three successive days. Regression 
analysis of the analytical data showed a linear response between drug concentration and peak 
area in the examined range between 20 and 5000 µg/l. The between-day variation, expressed 
as sr value of the slope of the curves obtained on the three days, was below 3% for each of the 
five anthelmintic compounds. 
The average standard curves (“Y” represents peak area, “X” represents concentration in µg/l) 
calculated with the mean regression parameters are given below: 
FB:  Y = 1253.2 X - 9550.9 r = 0.9999 
TB:  Y = 3335.0 X + 840.7 r = 0.9999 
AB : Y = 1060.5 X - 2610.0 r = 0.9999 
OB:  Y = 1618.0 X - 4699.0 r = 0.9999 
LE:  Y = 4752.6 X + 97793.3 r = 0.9998 
 
 3.3.2.2  Recovery study 
Table 3.1 summarises the mean extraction recovery values obtained for milk samples spiked 
separately with a mixture of the four benzimidazole substances and levamisole. The recovery 
values ranged from 68 to 85% and are comparable with those obtained by Long et al.19 These 
authors have also described a multiresidue HPLC-DAD method for BZs in milk using a more 
laborious sample pretreatment including matrix solid phase dispersion. In spite of their more 
intensive sample preparation, Macri et al.20 reported for their multiresidue method also 
comparable recovery values ranging from 73 to 83% for the same analytes. The extraction of 
the analytes was performed with ethyl acetate/methylene chloride on milk samples which were 
previously made alkaline. A liquid-liquid extraction clean-up and a back extraction was 
performed. Diethylamine was used to form a counter ion in the ion-pair chromatographic 
separation of the analytes. The extraction recovery for fenbendazole obtained in the presented 
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Table 3.1  Extraction recoveries obtained for milk samples fortified at concentrations  
 of 10 and 100 µg/l with anthelmintic compounds [mean value (%) (sr (%))] 
     Analyte  10 µg/l 100 µg/l 
  Fenbendazole 71 (9.5)a 68 (9.0)b 
  Thiabendazole 80 (4.9)a 77 (5.1)b 
  Albendazole 74 (10.5)a 73 (7.4)b 
  Oxibendazole 85 (8.6)a 73 (6.4)b 
  Levamisole 72 (7.1)c 72 (5.9)d 
a n = 10     b n = 9     c n = 12     d n = 11 
 
method was significantly lower than that published by Fletournis et al.12 They reported recovery 
values near 100%. However, these researchers have optimised their method only for 
fenbendazole. 
The extraction efficiency for LE obtained in the proposed procedure was somewhat lower than 
that obtained by Archambault et al.16 (80%). 
 
 3.3.2.3  Linearity and analytical limits 
The results of the regression analysis of the data, obtained by analysing the spiked milk 
samples, are summarised in Table 3.2. The linearity of the matrix calibration curves, obtained 
with seven different concentrations (0, 5, 10, 100, 200, 500 and 1000 µg/l), was demonstrated in 
the concentration range of 0-1000 µg/l. The curves are described by the equation Y = aX + b 
(“Y” represents peak area, “a” represents slope, “X” represents concentration in µg/l and “b” 
represents intercept). The between-day variation expressed as sr values of the slope of the 
calibration curves obtained on three different days, was below 10%. 
The LODs and LOQs for the anthelmintic residue determinations are summarised in Table 3.3. 
Acceptable sensitivity was obtained and all LOD values for the BZs were below the respective 
MRL values. The obtained analytical limit values for the BZ anthelmintics are comparable or 
somewhat lower than those obtained by Fletournis et al.12,13,21 Macri et al.20 reported a LOQ 
value of 10 µg/kg for the various BZ compounds. 
As wanted, the presented procedure for the unauthorised substance levamisole was very 
sensitive. The efficiency of the chromatographic procedure and the effectiveness of the sample 
preparation procedure permitted quantification of LE residue values in milk samples as low as 
1.4 µg/l. The calculated LOD was 0.5 µg/l. The detection limit was much lower than those 
published by Österdahl et al.,17,22 Archambault et al.16 and Simkins et al.,23 which were 20, 40, 
50 and 10 µg/l, respectively. 
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Table 3.2  Regression analysis of calibration curves of anthelmintics obtained on three days 
    Analyte Day Slope (a) Intercept (b)          r 
 
Fenbendazole 
1 
2 
3 
 
8805.6 
8329.0 
8151.2 
sr = 4.0% 
           -9263.8 
          85319.4 
        100357.3 
          0.9936 
          0.9964 
          0.9985 
 
Thiabendazole 
1 
2 
3 
 
30284.5 
30864.6 
28252.9 
sr = 4.6% 
       -122121.2 
         -82184.6 
          24215.7 
          0.9995 
          0.9998 
          0.9979 
 
Albendazole 
1 
2 
3 
 
8424.0 
7654.2 
8188.2 
sr = 4.9% 
       -101813.0 
          54225.2 
          48465.9 
          0.9975 
          0.9972 
          0.9994 
 
 
Oxibendazole 
1 
2 
3 
 
14768.3 
13118.0 
15936.2 
sr = 9.7% 
         -58279.4 
        129299.3 
          70596.8 
          0.9994 
          0.9970 
          0.9993 
 
Levamisole 
1 
2 
3 
 
33916.0 
32985.1 
33811.6 
sr = 1.5% 
          50692.9 
         -90191.8 
        123028.9 
 
          0.9999 
          0.9993 
          0.9998 
 
 
Table 3.3  Analytical limit values for the anthelmintic determinations 
     Analyte LOD (µg/l) MRL (µg/kg) LOQ (µg/l) 
Fenbendazole 3.1                  10 6.8 
Thiabendazole 3.4                100 4.3 
Albendazole 3.8                100 6.9 
Oxibendazole 1.3                  50 2.7 
Levamisole 0.5 Not allowed 1.4 
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 3.3.2.4  Trueness 
This accuracy parameter was found to be within acceptable limits. The mean calculated 
concentrations and sr values (%) in milk samples spiked at 100 µg/l for the BZ compounds       
(n = 13) FB, TB, AB, OB and LE (n = 9) were 105.4 (9.1), 102.1 (6.4), 106.3 (6.4), 106.0 (5.2) 
and 96.5 (6.8) µg/l, respectively. The allowed range for trueness recommended by the EU24 for 
the analysis of an analyte content > 10 µg/l is between - 20% and + 10%. The mean 
concentrations of all examined anthelmintic drugs fell within the range of 80 to 110 µg/l. 
 
 3.3.2.5  Precision of the assays 
The mean measured concentrations and the precision data of the anthelmintic determinations, 
expressed as sr values, are given in Table 3.4. The BZ samples were spiked at respective MRL 
concentrations and the LE samples were fortified at 10 µg/l. These precision data fell within the 
allowed ranges stipulated by the EU for analysis of drug residues by confirmation methods. The 
sr values of the repeatability (within-day precision) of the different anthelmintic compounds are 
lower than one-half of the values calculated according to the Horwitz equation (sr = 2(1-0.5logC), 
where “C” represents the residue concentration expressed as a power of 10).24 These maximum 
allowed values for a residue concentration of 10 and of 100 µg/kg are 32 and 23%, respectively. 
The overall precision values for the determinations of FB, TB, AB, OB and LE were 11.9, 3.9, 
8.2, 7.4 and 12.7%, respectively. 
 
Table 3.4   Precision of anthelmintic determinations at respective MRL concentration for 
fenbendazole, thiabendazole, albendazole, oxibendazole and at 10 µg/l for 
levamisole [sr (%) (mean value (µg/l))] 
 Fenbendazole Thiabendazole Albendazole Oxibendazole Levamisole 
Within-day   
Day 1     9.6 (8.9)a    2.9 (97.9)a    7.1 (94.2)a 3.6 (45.2)a   13.1 (11.7)b 
Day 2   11.6 (10.3)c    3.4 (102.2)c    6.3 (105.7)c 4.7 (52.0)c     7.6 (10.1)d 
Day 3     9.0 (9.3)e    4.1 (97.9)e    7.4 (99.3)e 5.8 (48.6)e   10.1 (9.9)f 
Between 
daysg 
    7.3 (9.2)    3.7 (98.5)    8.1 (97.6) 9.6 (48.3)     7.6 (9.9) 
Overall   11.9 (9.5)    3.9 (99.3)    8.2 (99.8) 7.4 (48.6)   12.7 (10.5) 
a n = 10     b n = 10     c n = 10     d n = 12     e n = 10     f n = 8     g n = 3 
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3.4  Conclusions 
Two easy, relatively fast and reliable chromatographic analytical methods for the quantitative 
determination of the benzimidazole substances fenbendazole, thiabendazole, albendazole, 
oxibendazole and the imiothiazole levamisole in milk at low residue concentrations, were 
optimised. The benzimidazole compounds and levamisole have to be determined by two 
separate HPLC assays. The methods have shown satisfactory validation characteristics with 
respect to recovery, sensitivity, selectivity, trueness and precision. The detection limits are much 
lower than the respective MRL concentrations. Additional analyte identification was obtained 
with the specific UV spectra recorded by the diode array detector. 
The methods are suitable as tests assays for routine screening of anthelmintic residues in milk. 
The HPLC-DAD methods were used several years for the monitoring of Belgian farm milk.  
The HPLC assay for levamisole was suitable for quantitative determination of residue values in 
a depletion study with dairy cows administered with levamisole, which is described in Chapter 8. 
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Abstract: 
 
A liquid chromatographic-tandem mass spectrometric multiresidue method for the 
simultaneous quantitative determination of levamisole and the benzimidazoles thiabendazole, 
oxfendazole, oxibendazole, albendazole, fenbendazole, febantel and triclabendazole in milk 
has been developed. The anthelmintic residues were extracted with ethyl acetate after the 
milk sample was made alkaline. The extract was centrifuged and the supernatant was 
concentrated by evaporation using a stream of nitrogen. The liquid chromatographic 
separation was performed on a reversed-phase C18 column with gradient elution. The 
analytes were detected by tandem quadrupole mass spectrometry after positive electrospray 
ionisation by multiple reaction monitoring. The confirmatory method has low detection limits 
and each component can be detected at a residue concentration lower than 1 µg/l. The 
method is validated according to the revised European Union requirements and all 
determined parameters were found conform the criteria. The evaluated parameters were 
linearity, specificity, stability, recovery, precision (repeatability and within-laboratory 
reproducibility) and analytical limits (detection limit, decision limit and detection capability). 
This analytical assay is applied in the Belgian monitoring programme for residues of classical 
anthelmintic veterinary drugs in raw farm cow’s milk. 
 
Keywords: food analysis, milk, validation, anthelmintics, benzimidazoles, levamisole 
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4.1  Introduction 
  4.1.1  Usage of anthelmintic veterinary drugs 
Within the group of antiparasitic drugs, anthelmintic products are widely used in veterinary 
medicine in cattle. Anthelmintics are used prophylactically and curatively to treat acute and 
chronic infections.1 The anthelmintic drugs involved in this chapter, have unique wide-spectrum 
properties against parasitic helminths.2 Control treatments reduce worm burdens, enhance 
productivity and substantially reduce the build-up of infective worm larvae on the pasture or 
eggs in the environment. Gross et al.3 reported a mean increased milk production of 0.63 kg/day 
due to an effective anthelmintic treatment. 
A lot of antiparasitic immunity is already achieved through treatment of young cattle. 
Nevertheless, in wet periods, the medication of dairy cows with endoparasiticides can also be 
necessary for protecting or treating the animals mainly against gastrointestinal nematodes, 
lungworms and liver flukes. Most forms of parasitic gastroenteritis in ruminants tend to occur in 
the second half of the summer.1 Most infection pressure of lungworms arises in summer or early 
autumn. 
 
 4.1.2  Chemical properties of anthelmintic compounds 
The veterinary drug substances involved in this study are the synthetic compounds 
thiabendazole (TB), oxfendazole (OF), oxibendazole (OB), albendazole (AB), fenbendazole 
(FB), triclabendazole (TC), flubendazole (FL), mebendazole (ME), levamisole (LE) and febantel 
(FE). TB, OF, OB, AB, FB, TC, FL and ME belong to the group of benzimidazole (BZ) 
anthelmintics. FL, a BZ substance very similar to most of the target compounds (TB, OF, OB, 
AB, FB, TC, LE and FE), was used to verify the specificity of the developed analytical method. 
ME was used as internal standard (IS). LE is an imidazothiazole substance defined as the        
L-isomer of the drug preparation tetramisole, a racemic mixture of D- and L-forms.4 FE is a   
pro-benzimidazole drug, which is closely related to the benzimidazoles and it converts in the 
host to both FB and OF (paragraph 4.1.4). 
The chemical structures of the examined anthelmintic compounds are shown in Figure 4.1. The 
benzimidazole compounds have a “benzimidazole” nucleus and most substances contain a 
“carbamate (-NHCOOCH3) type” functional group.5 
General chemical properties of the analytes and the heat stability of levamisole are described in 
paragraph 3.1.1 of Chapter 3. 
The heat stability of oxfendazole in water, in cooking oil and in incurred residues in cattle liver 
was investigated by Rose et al.6 Some evidence of instability was found in boiling water after    
3 h. This degradation was associated with the formation of an amine product formed by 
hydrolysis of the functional carbamate group on the OF molecule. In oil heated at 150 and 
180°C, the half-live of OF was 15 and 6 min, respectively. In tissue, OF residues were present 
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as an equilibrium between the parent compound and its oxidation (OF sulphone) and reduction 
products (FB). Heating did not destroy residues in incurred tissue, but it affected the equilibrium 
point. OF in fortified samples were found stable during six weeks at frozen storage. Frozen 
storage of incurred tissue resulted in a decrease of residues already after four weeks. 
 
 4.1.3  Toxicity 
Several toxicological effects of benzimidazoles and levamisole were described in paragraph 
3.1.2 in Chapter 3. 
BZs appear to be characterised by very low toxicity in mammals.5 Nevertheless, the extractable 
residues (parent drug and/or free metabolites) are chemical species with defined toxic potential 
for which safety margins may be defined.2 Mutagenic activity and mainly teratogenicity are 
reported as the most harmful toxicological problems. Oxfendazole and albendazole are known 
to be teratogenic and an eventually applied dose in early pregnancy should be limited and not 
greater than therapeutic level.4 In many cases, teratogenic metabolites have been identified in 
animal products as milk, eggs and meat.2 
Mammalian toxicity of levamisole is greater than with the BZs although, in normal usage, toxic 
effects are seldom observed.4 However, LE has also found clinical application as human 
anthelmintic medicine and in the treatment of cancer.8,9 
 
 4.1.4  Metabolism 
Benzimidazole anthelmintics and their primary metabolites appear to deplete from tissues 
relatively rapidly.2 No prolonged or unusual drug or metabolite retention in any tissue has been 
reported among the examined compounds. Biliary secretion of metabolites and conjugates does 
occur with BZs. BZ anthelmintics are extensively metabolised by mammals following oral 
administration. The parent drug is usually short-lived. Metabolites, rather than the parent drug, 
often dominate in blood, bile, tissues and urine. These free, primary metabolites are usually the 
products of normal oxidative or hydrolytic processes and are more soluble than the parent drug. 
However, a small amount of BZ metabolites becomes bound in relatively non-extractable form 
to endogenous macromolecules.  
Carbamate hydrolysis is a major metabolic route for several BZ carbamates. The resulting          
2-aminobenzimidazoles, which are often additionally metabolised in the 5-substituent as for FB 
and OF, are readily eliminated in the urine. In the case of AB, the 2-aminosulphone metabolite 
is the longest residing free metabolite in tissue.The alkyl groups of the 5-substituents of AB are 
subject to metabolic oxidation, which leads to alcohol metabolites. Oxidation in the benzene ring 
of the 5-substituent to produce phenols is an important metabolic process for FB and OF. 
The metabolism of TB has been studied in several animal species including cattle.10,11 The 
major metabolic steps were hydroxylation of the benzimidazole ring at the 5-position to form     
5-hydroxythiabendazole and subsequent conjugation to the glucuronide and sulphate. 
Chapter 4: Liquid chromatographic-electrospray tandem mass spectrometric multiresidue method 
 for anthelmintics in milk 
 
88
 
Metabolism of AB was studied by several research workers.12,13,14 Primary oxidation of the 
sulphide group of AB leads rapidly to albendazole sulphoxide (AB-SO). AB-SO is slowly 
metabolised to albendazole sulphone (AB-SO2), which is formed as a 2-step oxidation product. 
Albendazole 2-aminosulphone (NH2-AB-SO2) is formed by deacetylation of the carbamate group 
of AB-SO2 to an amine. Fletournis et al.13 have performed a depletion study for AB with milk 
cows treated with the recommended dose. AB could not be detected (LOD = 7 µg/l). The 
residue concentration of AB-SO is highest at 12 h (658 µg/l) after dosing and declines below     
3 µg/l at 36 h. AB-SO2 attains its highest level more slowly (705 µg/l at 24 h) and also 
disappears more slowly (< 5 µg/l at 72 h). The residue concentration of NH2-AB-SO2 is highest 
at 36 h after dosing (110 µg/l). It slowly disappears at 108 h after dosing.  
Other research workers have described the occurrence of metabolites of FB.15,16,17 After oral 
administration, FB is absorbed from the intestine and is rapidly metabolised to fenbendazole 
sulphoxide, a metabolite also defined as OF, which is an active anthelmintic drug. Afterwards, 
OF is oxidised to fenbendazole sulphone (FB-SO2). Fletournis et al.13 have also performed a 
depletion study for FB with milk cows treated with the recommended dose. FB was measured 
until the 48 h milking after application of a concentration of 10 µg/l. It seems that FB is readily 
oxidised to OF, because residue values of 196 µg/l were measured at 12 h after dosing. A 
maximum value of 248 µg/l was obtained 24 h after dosing which was declines below 3 µg/l at 
60 h. FB-SO2 appears more slowly, reaching a peak at 48 h after dosing and declines below     
5 µg/l at 84 h after dosing. 
Pro-drugs as FE, lead to active benzimidazoles by hydrolytic or cyclisation processes.2 They are 
converted either chemically or metabolically to the biologically active BZ soon after 
administration. FE is converted either directly to FB or to OF, which is obtained via febantel 
sulphoxide (FE-SO) as an intermediate. The complex metabolic pathway of FE is described by 
Rose.18 The structures and relationship of 11 compounds known to be part of the metabolic 
pathway of OF are illustrated in Figure 4.2. Several metabolites and breakdown products were 
identified in tissue. There was also evidence of an unstable equilibrium between OF, 
oxfendazole sulphone and FB in incurred tissue. Both FE and FE-SO were found to be unstable 
as they converted to FB during the extraction and clean-up procedure. Because of their mode of 
action, residues of these compounds are unlikely to be found in animal tissue. 
The metabolism of levamisole is discussed in Chapter 8 dealing with the depletion study of 
levamisole in milk. 
 
 4.1.5  Objectives 
If the recommended withdrawal times after anthelmintic treatment of dairy cows are not 
respected or if unauthorised substances are administered, the residue concentration in milk can 
be very high.19 Because a number of anthelmintic compounds have been shown to cause 
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teratogenic and embryotoxic effects in some species, MRL values were laid down by the EC to 
protect the consumer against potential toxic residues.20 
 
Figure 4.2  Metabolic pathway of oxfendazole18 
 
 
A lot of chromatographic methods exist for the residue analysis of one of more anthelmintics in 
a variety of animal products. UV, UV diode array or fluorescence detection were the most 
commonly used detection techniques.12,13,15,16,17,18,21,22,23 However, detection based on the 
chemical structure of the compound with mass spectrometry (MS) provides mass-related data 
which become desirable for confirmation in residue analysis. A lot of mass spectrometric 
detection methods for anthelmintic residues have already been described.8,24,25,26,27,28,29,30,31,32 
Several methods used a rather old ionisation mechanism or only single MS. Wilson et al.24 have 
described a multiresidue assay for confirmation of BZ anthelmintics in several animal tissues by 
gas chromatography with selected-ion monitoring electron impact mass spectrometry. Facino et 
al.25 have discussed the application of collisionally activated decomposition mass-analysed ion 
kinetic energy spectrometry in the electron impact mode for BZ residues in sheep milk. A 
hyphenated technique comprising of an on-line HPLC-GC-tandem ion trap mass spectrometer 
operating in the chemical ionisation and electron impact mode for the determination of LE in 
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milk is presented by Chappell et al.8 Blanchflower et al.26 have developed a method for the 
determination of FB and OF in liver and muscle tissues using single liquid chromatography-
mass spectrometry (LC-MS) with thermospray ionisation. The same analytical technique for the 
determination of LE in animal tissues was proposed by Cannavan et al.27 Balizs28 described the 
determination of several BZ residues in eggs and animal tissues using liquid chromatography 
and tandem mass spectrometry (LC-MS/MS) with electrospray ionisation (ESI). Cherlet et al.29 
presented a quantitative LC-MS/MS method with atmospheric pressure chemical ionisation 
(APCI) for the analysis of porcine tissues on residues of LE. De Baere et al.30 compared a 
HPLC-UV assay and a LC-MS/MS (ESI) procedure for the quantitative determination of LE in 
animal plasma. The LC-MS/MS method was considered as the superior method due to the 
possibility of a high sample throughput, the excellent specificity and the low analytical limits. 
To our knowledge, no LC-MS/MS method with ESI for the simultaneous determination of 
residues of benzimidazoles, febantel and levamisole in milk was published. The objective of this 
study was to develop such an analytical procedure for the multiresidue detection and 
quantitative determination of the benzimidazoles TB, OF, OB, AB, FB, TC, the                       
pro-benzimidazole FE and the imidazothiazole LE. Because levamisole and triclabendazole are 
not licensed for lactating dairy cows, a method with low decision limits was needed. An internal 
performance limit (IPL) of 1 µg/l was chosen. The MRL values for TB, OF, OB, AB, FB and FE 
are 100, 10, 50 (provisionally), 100, 10 and 10 µg/kg, respectively. A fast and relatively simple 
sample preparation procedure was required to obtain a method suitable for routine analysis in a 
monitoring programme to detect residues of anthelmintic veterinary drugs in raw farm cow’s 
milk. 
 
4.2  Experimental 
 4.2.1  Reagents and chemicals 
Analytical standard material of TB, OB, AB, FB, LE-hydrochloride and the internal standard ME, 
were purchased from Sigma (St. Louis, MO, USA). Standard material of OF, FE, TC and FL 
were kindly provided by Merial (Toulouse, France), Bayer (Leverkusen, Germany), Novartis 
(Munchwilen, Switzerland) and Janssen Animal Health (Beerse, Belgium), respectively. 
Dimethyl sulphoxide (HPLC grade), ethyl acetate (HPLC grade) and formic acid (analytical 
grade) were from Panreac (Barcelona, Spain). Acetonitrile and methanol of HPLC gradient 
grade and sodium hydroxide of analytical grade were obtained from Merck (Darmstadt, 
Germany). Water was purified with a Maxima LC 113 Ultra-pure water purification system (Elga, 
Bucks, UK) to HPLC grade. Blank milk samples were received from the Department of Animal 
Nutrition and Husbandry, Section cattle and pig husbandry (DVV-CLO, Merelbeke, Belgium). 
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 4.2.2  Standard solutions 
The analytes were dissolved in 10 ml of dimethyl sulphoxide. Stock solutions of 0.1 and          
0.2 mg/ml were prepared by dilution with methanol. The stock solutions were stored refrigerated 
at 5°C and replaced every two months. The working standard solutions were prepared 
immediately before use by dilution with mobile phase consisting of water containing 0.1% formic 
acid and acetonitrile (50/50, v/v). Tuning of the mass spectrometer and acquisition of the 
analyte identification spectra were performed with standard solutions of 1 µg/ml. During the 
validation procedure, the IS was spiked using a solution of 1 and 5 µg/ml for fortification to a 
final milk sample concentration of 10 and 100 µg/l, respectively. The anthelmintic analytes were 
fortified using a standard solution of 0.1, 1 and 5 µg/ml for matrix concentrations up to 2.5 µg/l, 
between 2.5 and 50 µg/l and above 50 µg/l, respectively. 
 
 4.2.3  Apparatus 
A shaker (Bühler, Hechingen, Germany), a RC-5B Sorvall centrifuge (DuPont Instruments, 
Wilmington, DE, USA) and a vortex mixer (Scientific Industries, Bohemia, NY, USA) were used 
during the sample preparation. A high-performance liquid chromatograph combined with a mass 
spectrometer already applied for previous research studies31,32,33 in our laboratory was used. 
The LC-MS/MS system consisted of a LC system (Kontron, Biotech Instruments, Milan, Italy) 
with a type 325 ternary pump system, a vacuum degasser and a type 465 autosampler, coupled 
with a Quattro LCZ tandem quadrupole mass spectrometer (Micromass, Altrincham, UK) 
provided with a “z”-spray electrospray ion interface. The mass spectrometer was fully controlled 
by MASSLYNX software version 3.3. A model 11 syringe pump of Harvard Apparatus (Holliston, 
MA, USA) connected to the interface, was very useful for tuning purposes. 
 
 4.2.4  Sample preparation 
Five ml of milk sample was transferred into a centrifuge tube of 50 ml. The sample was spiked 
with the compounds and/or the IS. After standing for 30 min, the milk sample was made alkaline 
with 100 µl of a 10 M sodium hydroxide solution. The extraction of the analytes was performed 
with 15 ml of ethyl acetate on a shaker (amplitude: 30 mm, frequency: 90 per min) for 5 min. 
The extract was centrifuged (5000 rpm, 10 min) and the supernatant was removed using a 
pipette and was transferred into a graduated tube. The organic fraction was evaporated to 
dryness under a stream of nitrogen in a water bath at 50°C. The dry residue was dissolved in 
600 µl of mobile phase consisting of 0.1% aqueous formic acid/acetonitrile (50/50, v/v) while 
vortex mixing. The mixture was heated at 50°C in a waterbath for 5 min. After vortex mixing and 
after cooling down to room temperature, the mixture was made up to 1 ml with mobile phase 
and was homogenised by vortex mixing. The cleaned sample extract was filtered through a    
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0.2 µm polytetrafluorethylene (PTFE) Chromafil filter (Macherey-Nagel, Düren, Germany) into 
an autosampler vial. 
 
 4.2.5  Liquid chromatography 
The LC separation of the anthelmintic analytes was performed on a reversed-phase column and 
was based on a previously developed procedure for the analysis of sheep liver for residues of 
mebendazole.32 The LC runs were carried out at room temperature on an Alltima C18 column 
(Alltech, Deerfield, IL, USA), 5 µm, 150 x 2.1 mm i.d. protected by an Alltima C18 guard cartridge 
of 7.5 x 2.1 mm i.d. The mobile phase consisted of water containing 0.1% formic acid              
(to increase the ionisation intensity) (A) and pure acetonitrile (B). Gradient elution was applied: 
A-B (65:35) (0 min), A-B (65:35) to (50:50) (0-0.1 min), A-B (50:50) to (25:75) (0.2-3 min), A-B 
(25:75) (4-5 min), A-B (25:75) to (50:50) (6-7 min), A-B (50:50) to (65:35) (8-15 min) and A-B 
(65:35) (16-25 min). The mobile phase flow rate and the injection volume were 0.25 ml/min and 
20 µl, respectively. 
 
 4.2.6  Mass spectrometry 
The analytes were detected and identified with a tandem quadrupole mass spectrometer 
without splitting the LC eluent. Atmospheric pressure electrospray ionisation in the positive 
mode (ESI+) was applied. The nitrogen gas flows were set at 80 and at 600 l/h for nebulising the 
LC eluent and for drying the solvents, respectively. The source block and solvent desolvation 
temperatures were 130 and 250°C, respectively. The parent molecular ions were fragmented in 
the collision cell with argon gas. 
The analytes were detected by tandem MS using the multiple reaction monitoring (MRM) 
function of two transitions, each from the molecular precursor ion to two different product ions. 
The mass spectrometer was tuned while optimising the specific cone voltage and the specific 
collision energy to maximise the ion current of the three diagnostic ions of each drug compound. 
The ESI+ mode leads to addition of a H-atom to the ions so that protonated pseudo-molecular 
positive ions are formed. The optimisation of the transition of the precursor ion, which was the 
molecular parent ion, to the two most abundant product ions was performed by infusion of a 
standard solution of 1 µg/ml using a syringe pump. 
Quantification was obtained by internal calibration. The data of the samples generated by MRM 
of the transition from the precursor ion into the most abundant product ion were evaluated by an 
internal standard procedure based on matrix calibration curves. The quantitative results were 
calculated automatically by MASSLYNX software version 3.3 of the mass spectrometer. The 
calibration curves were always calculated using the best fit of two replicated determinations per 
concentration level. The calibration curves were obtained using at least five concentration 
points, including the zero level. The response factors (Y values) (response factor = peak area 
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ratio of sample and IS multiplied by the concentration of the IS) were plotted against the 
concentrations (X values). 
 
 4.2.7  Validation procedure 
 4.2.7.1  Introduction 
The validation of the proposed LC-MS/MS method was based on the revised requirements for 
detecting residues of veterinary drug substances in animal products defined by the EC in the 
Draft Commission Decision SANCO/1805/2000.34 Several supplementary validation parameters 
were also evaluated. 
The examined validation parameters for the analytical assay were linearity, specificity, stability, 
recovery, precision (repeatability and within-laboratory reproducibility) and analytical limits (limit 
of detection, decision limit and detection capability). During the validation procedure, blank milk 
samples were fortified with a standard solution of a mixture of the anthelmintic compounds, 
unless otherwise stipulated. The IS was added with a separate standard solution. 
The method was validated at two residue levels. To evaluate the usefulness of the quantitative 
method for the unauthorised substances levamisole and triclabendazole at residue 
concentrations as low as possible, the validation was performed at the IPL (1 µg/l) 
concentration. Moreover, the method can also be used in depletion studies to quantify low 
residue concentrations. On the other hand, the method was also validated on MRL level which 
is very important to make the right decisions for the licensed substances for statutory testing 
purposes. 
 
 4.2.7.2  Liquid chromatographic-mass spectrometric analysis 
The specific criteria for LC separation and MS detection were verified during the whole 
validation procedure. Concerning the chromatographic separation, the difference between the 
relative retention time (RRT) of the analytes in the validation sample and those of the matrix 
calibration standards was measured. Concerning the ion recognition, each diagnostic ion was 
measured when it had a signal-to-noise (S/N) ratio of at least 3/1. Furthermore, the difference of 
the relative intensities of the detected ions (RI), expressed as a percentage of the peak area of 
the most intense ion in the validation samples and those of the matrix calibration standards, was 
evaluated. 
 
 4.2.7.3  Linearity 
The linearity of the response of the LC-MS/MS system was checked by repeatedly analysing 
standard solutions of a mixture of the anthelmintics at concentrations of 0, 1, 5, 25, 100 and  
500 µg/l. 
The linearity of the LC-MS/MS assay was demonstrated using blank milk samples spiked with 
the analytes at concentrations of 0, 1, 5, 25, 100 and 500 µg/l. 
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 4.2.7.4  Specificity 
To evaluate the specificity, potential endogenous interfering material during the LC separation 
was measured by analysing 20 blank milk samples. Potential hindered identification and 
quantification was detected by addition of flubendazole, a substance very similar to most of the 
target compounds. Hindered identification was checked by analysing blank milk samples 
separately spiked at MRL concentration for the authorised substances and at 10 µg/l for LE, TC 
and FL. Interferences on the quantification were evaluated by comparing the peak areas of 
blank samples spiked at 100 µg/l respectively with a mixture of 
FL+LE+TB+OF+OB+AB+FB+FE+TC and with a mixture of LE+TB+OF+OB+AB+FB+FE+TC. 
 
 4.2.7.5  Stability 
The stability of fortified samples was tested by repeatedly analysing a spiked milk sample during 
three months at 2-week time intervals. The samples were fortified at MRL concentration for the 
authorised compounds and at 10 µg/l for LE and TC and were stored frozen at -18°C until 
investigation. The regression data and measured residue values were compared with those 
obtained for a freshly fortified milk sample.  
Furthermore, the stability of a frozen (-18°C) incurred milk sample containing LE residues, was 
measured for 4.5 months. 
 
 4.2.7.6  Recovery 
Because no certified reference material of the anthelmintic substances exists, the analyte 
extraction recovery instead of the trueness was determined. The recovery was evaluated at two 
concentration levels. In a first series of analyses, blank milk samples spiked at concentrations of 
1.0 IPL (1.0 µg/l), 1.5 IPL (1.5 µg/l) and 2.0 IPL (2.0 µg/l) were analysed. This validation 
parameter was also calculated at MRL level with blank milk samples spiked with the authorised 
compounds at their respective MRL concentration. To obtain the recovery efficiency, the IS was 
added after the clean-up procedure and six replicates at each level were analysed. 
 
 4.2.7.7  Precision 
To verify the precision of the method, the repeatability and the within-laboratory reproducibility 
were determined. As described for the recovery, these validation parameters were also 
measured at the two concentration levels. The repeatability was calculated by analysing six 
replicates on three different days. The within-laboratory reproducibility was performed by two 
operators on five different days, using own standard solutions. To obtain six values, one value 
of the repeatability data was also taken into account. 
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 4.2.7.8  Analytical limits 
The limits of detection (LODs) were calculated as the apparent residue content corresponding 
to the value of the mean plus three times the standard deviation (s) obtained for at least 20 
representative blank sample determinations. If only noise was obtained, technical LODs were 
calculated as those concentrations which yield a S/N ratio of 3/1. 
Besides the more commonly used LOD, the new concept of decision limit (CCα) was also 
studied. The CCα values of the presented method are defined as the mean values of the 
obtained concentrations by determining blank milk samples spiked at MRL (authorised 
compounds) or IPL (authorised and unauthorised compounds, 1 µg/l) level plus 1.64 times the 
corresponding standard deviations (s). This validation parameter was calculated for the 
examined substances with already obtained values of the calibration curves calculated for the 
investigation of repeatability, recovery, within-laboratory reproducibility and stability. The 
analytical limits obtained for the authorised compounds at IPL concentration can also be defined 
as LOD values calculated according to the criterion for measuring of CCα values. 
The detection capability (CCβ) values were calculated as the sum of the respective CCα value 
plus 1.64 times the s value obtained on the measured concentration values by determining 20 
blank milk samples spiked at the respective analytical limits obtained at MRL and at IPL level. 
The analytical limits obtained for the authorised compounds at IPL concentration can also be 
defined as LOQ values calculated according to the criterion for measuring of CCβ values. 
 
4.3  Results and discussion 
 4.3.1  Mass spectrometry 
Deuterated analytical standards of the anthelmintics involved in this study are not available. 
Therefore, mebendazole, a BZ compound very similar with most of the examined analytes, was 
used as IS. ME is authorised for use in food animals, but not for lactating dairy cows. The 
presented method is therefore only applicable for milk samples. It is practically impossible to 
find ME residues in milk samples. Furthermore, the tandem MS detection technique has a very 
high sensitivity and specificity. Any ME residue in unknown samples will immediately be 
detected and can be compensated for after double analysis. 
A summary of the monitored protonated ions and the optimised MS operating parameters 
obtained for the examined anthelmintics is given in Table 4.1. Identification and confirmation of 
a violative sample for one of more anthelmintic residues is only proven by detection of their 
three diagnostic ions above the detection limit. 
The specific mass spectra for each analyte are presented in Figure 4.3. The full scan mass 
spectrum (a) shows the molecular precursor ion. The product ions obtained by fragmentation of 
the molecular ion are presented in the fragmentation mass scan of the precursor ion (b). 
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The fragmentation pathway from the compound molecules into the fragment diagnostic ions, 
can be explaned as follows. The most abundant protonated fragment ion for LE with m/z 91.1 is 
induced by fragmentation of the protonated molecular ion to C6H5 CH–. The product ion with 
m/z 123.1 can be explained by splitting off the fragment –NCSCH2CH2N– from the LE molecule. 
The consecutive loss of –CN and –CS from the molecular structure of TB gives rise to the 
fragments with m/z 175.2 and m/z 131.1. The two product ions with m/z 175.2 and m/z 159.1 of 
OF originate from consecutive losses of –SOC6H5 and –OCH3. 
 
Table 4.1  Summary of the protonated diagnostic ions and the MS operating parameters 
    Analyte Precursor ion (m/z) 
Product ions 
(m/z) 
Cone voltage 
(V) 
Collision energy
(eV) 
Levamisole 205.0+ 123.1+a, 91.1+ 40 29 
Thiabendazole 202.0+ 175.2+a, 131.1+ 45 28 
Oxfendazole 316.2+ 191.2+a, 159.1+ 40 22 
Oxibendazole 250.1+ 176.2+a, 218.2+ 35 23 
Albendazole 266.2+ 191.2+a, 234.3+ 35 27 
Fenbendazole 300.1+ 268.2+a, 159.0+ 40 28 
Febantel 447.4+ 383.4+a, 415.3+ 25 15 
Triclabendazole 359.0+ 274.1+a, 344.2+ 40 30 
Flubendazole 314.3+ 282.1+a, 123.0+ 29 40 
Internal standard 
(Mebendazole) 296.5
+ 264.4+a, 105.0+ 35 25 
a most abundant product ion  
The loss of –OCH3 from the molecular structures of OB, AB, FB, FE, FL and the IS results in 
product ions with m/z 218.2, 234.3, 268.2, 415.3, 282.2 and 264.4, respectively. The fragment 
with m/z 105.0 from IS originates from fragmentation into –COC6H5. The remaining product ion 
with m/z 123.0 for FL originates from fragmentation into –COC6H4F. The loss of –CH2CH2CH3 
from the product ion with m/z 218.2 of OB results in a second fragment with m/z 176.2. The 
second fragment of AB with m/z 191.2 is obtained by loss of –CONH from the main product ion 
with m/z 234.3. A second loss of –OCH3 from the product ion of FE with m/z 415.3 results in the 
remaining fragment with m/z 383.4. The fragment with m/z 159.0 for FB originates from the loss 
of –SC6H5 from the fragment with m/z 268.2. The derivatives of TC with m/z 344.2 and           
m/z 274.1 can be explained by the consecutive loss of –CH3 and 2 Cl-atoms, respectively. 
For the confirmation of the drug compounds involved in this study and belonging to the drug 
substances of group B, veterinary drugs and contaminants of Annex I of Council Directive 
96/23/EC, at least three identification points (IPs) have to be obtained using MS detection.34 The 
detection of the analytes in standard solutions and spiked milk samples in this study was 
performed with the transitions of the molecular precursor ion (M+H)+ to the two most abundant 
product ions. These two studied MRM transitions represent 4 IPs because the precursor ion 
accounts for 1 IP and its transition product earns 1.5 IPs. 
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4.3.2  Liquid chromatographic-mass spectrometric analysis 
A relatively simple, very fast, very sensitive and reliable quantitative multiresidue method for the 
simultaneous detection of LE, TB, OF, OB, AB, FB, FE and TC at residue concentrations lower 
than 1 µg/l was developed. The method was based on the principles of a presented method 
(Chapter 6) for the determination of mebendazole and its metabolites in sheep liver.32 
Mebendazole belongs to the same anthelmintic benzimidazole group as the examined 
compounds. The analytical procedure was optimised for analysis of milk samples. Preliminary 
experiments modifying the analyte extraction and the sample clean-up procedures indicated 
that defatting of the sample extract with n-hexane can be omitted. Furthermore, a slightly higher 
response for some of the substances was obtained without this supplementary sample 
preparation step. 
Netobimin and albendazole sulphoxide, two other authorised benzimidazole anthelmintics,20 
were also involved in this study. However, the discussed determination procedure, which is very 
useful for the examined compounds, was not successful for these substances. A new 
separation method has to be developed. Probably, the sample extraction and/or the MS 
ionisation mode should have to be changed. 
Compared with the described HPLC-DAD method19 in Chapter 3, this LC-MS/MS method is 
much faster, the scope of anthelmintic compounds is broader and specific mass spectra are 
obtained to allow unambigously identification of the presence of an analyte. Because of the high 
selectivity of tandem MS applied in the MRM mode resulting from the decrease in chemical 
noise, very high S/N ratios and very low LODs for the analytes of interest are obtained in spite 
of the very simple sample clean-up.35 
The mobile phase composition used for the determination of mebendazole and its two major 
metabolites in sheep liver and the developed gradient programme was successful for the        
LC separation of the eight analytes and the IS in this study. To increase the sensitivity, 20 µl 
instead of 10 µl of cleaned sample extract was injected in the LC-MS/MS apparatus. To shorten 
the run time, the mobile phase flow rate of 0.20 ml/min, which is recommended for a column 
with an i.d. of 2.1 mm, was increased to 0.25 ml/min.  
Identification and quantitative determination of the eight target compounds, flubendazole and 
the internal standard were carried out by MRM. Two transitions from precursor ion to product 
ions are measured. An example of a chromatogram of a blank milk sample fortified at 1 µg/l for 
each compound of a mixture of the anthelmintic analytes and at 10 µg/l for the IS is shown in 
Figure 4.4. The chromatogram shows two peaks per compound, one peak per transition from 
precursor ion to product ion. All compounds eluted within 11 min. As can be seen in the 
chromatogram, levamisole and thiabendazole are not chromatographically separated. However, 
LC separation of these compounds was not needed because of the powerful separation 
capacity of tandem MS in the MRM mode. Mosely et al.35 reported that the mass spectrometer 
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is used for the bulk of the separation process and that the LC is serving mainly as an automated 
sample injection technique. 
During the LC-MS/MS run in the presented method, the initial mobile phase composition was 
already obtained after a run time of 15 min. The column had to be equilibrated for a further      
10 min. The total run time was 25 min which means that 38 cleaned samples can be 
determinated per night. The sample preparation was more time consuming and was the      
time-limiting step. Twenty-four samples could be prepared during a 7-h working day per 
operator. Because the proven stability for spiked samples, prepared samples could be collected 
and stored refrigerated or deep frozen until determination during the validation study (see 
paragraph 4.3.3.4). 
 
 4.3.3  Validation study 
 4.3.3.1  Liquid chromatographic-mass spectrometric analysis 
The specific criteria on relative retention time and on ion ratio were examined for all the samples 
analysed for the validation study. The values of RRT and of RI obtained for all samples 
measured to evaluate the validation parameters, were in agreement with the EU criteria.34 As an 
example, the values of a sample spiked at 1 µg/l and of a matrix calibration sample spiked at    
1 µg/l to evaluate the repeatability, are given. The RRT values in the spiked sample were 0.31, 
0.31, 0.49, 0.51, 1.00, 1.27, 1.69 and 1.86 for LE, TB, OF, OB, AB, FB, FE and TC, 
respectively. These values are within the tolerance ranges of ± 2.5% obtained with the values of 
the calibration samples, which are 0.31±0.01, 0.31±0.01, 0,49±0.01, 0.51±0.01, 1.00±0.02, 
1.27±0.03, 1.69±0.04 and 1.86±0.05 for LE, TB, OF, OB, AB, FB, FE and TC, respectively. The 
values for the RI in the spiked sample were 31, 96, 81, 83, 80, 77, 84, 94 and 22% for LE, TB, 
OF, OB, AB, FB, FE, TC and the IS, respectively. These values are within the allowed ranges 
obtained for the calibration sample. These ranges are 27±25, 99±20, 92±20, 87±20, 81±20, 
79±20, 81±20, 90±20 and 22±25% for LE, TB, OF, OB, AB, FB, FE, TC and the IS, respectively. 
 
  4.3.3.2  Linearity 
The instrumental response was linear for the eight anthelmintic analytes in the concentration 
range 0-500 µg/l obtained by six-point standard calibration. The slope and the intercept values 
for the standard regression lines of LE, TB, OF, OB, AB, FB, FE, TC were 0.33 and -0.002, 1.44 
and 20.71, 0.21 and 0.002, 0.66 and -0.0002, 0.46 and 0.35, 0.82 and 0.20, 0.11 and 0.08, 1.21 
and 0.03, respectively. Because of the rather broad concentration range, a better fit for the low 
concentrations was obtained with a weighting factor of 1/y² calculated automatically by the 
MASSLYNX software. 
The linearity of the whole LC-MS/MS assay was demonstrated by six-point matrix calibration 
analysis for all compounds in a residue concentration range of 0 to 500 µg/l. The obtained linear 
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regression parameters slope and intercept for LE, TB, OF, OB, AB, FB, FE, TC were 0.19 and   
-0.0001, 0.66 and 0.017, 0.14 and 0.00005, 0.83 and 0.014, 0.43 and 0.0069, 0.67 and 0.0043, 
0.82 and 0.0041, 0.24 and 0.0026, respectively. Again, to increase the fit for the low residue 
concentrations, weighted least square regression was applied with a weighting factor of 1/y². 
 
 4.3.3.3  Specificity 
No interferences of endogenous material above a S/N ratio of 3/1 for all the analytes could be 
detected by analysing 20 blank milk samples. False positive or false negative results might be 
generated due to hindered identification. The absence of potential interference due to a similar 
substance belonging to the same chemical drug class as the examined analytes was 
demonstrated. No false positive or false negative results were obtained by analysing blank milk 
samples, separately spiked at MRL concentration with the licensed compounds and at 10 µg/l 
for LE, TC and FL. The quantification was not influenced by the presence of flubendazole in the 
samples. The differences on the peak areas between the samples with and without FL were 
very small and within the normal ranges of repeated analysis. Clearly, tandem mass 
spectrometry is a very powerful analytical technique showing a very high specificity. The 
identification and confirmation potentials of the LC-MS/MS technique are superior in comparison 
with the more traditional HPLC-DAD technique applied in our previous determination methods.19 
 
 4.3.3.4  Stability 
The stability of fortified milk samples, stored at -18°C, was tested by repeatedly determining the 
spiked milk samples at 2-week time intervals. The regression data and calculated concentration 
values were comparable with those obtained for freshly spiked milk samples during an 
observation period of three months. For practical reasons, this observed stability for fortified 
samples is important. The numerous samples to be analysed can be collected, stored and 
analysed in the most efficient way. The demonstrated instability of an incurred milk sample 
indicated that laboratories have to be careful with the conservation of real samples for testing 
purposes of anthelmintic residues for a long period of time. A decrease of 30% of the residue 
concentration of levamisole after three months storage at -18°C was observed in a violative milk 
sample of the Belgian monitoring programme. During subsequent storage under frozen 
conditions, the levamisole residue concentration decreased from 183.8 to 128.8 µg/l. The 
residue concentration stabilised the next 1.5 months of measurement. 
 
 4.3.3.5  Recovery 
The results of the sample extraction efficiency analyses are summarised in Table 4.2. The 
overall recovery values ranged from 89.6 to 102.0%. The obtained recovery values are in 
agreement with the requirements34 which are correlated with the concentration. The variabilities 
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on the overall recoveries, expressed as sr values, were acceptable and varied from 5.4 to 
11.6%. The obtained variabilities are in agreement with the criteria of the Horwitz equation34    
(sr = 2(1-0.5logC), where “C” represents the residue concentration expressed as a power of 10). 
The presented extraction recoveries are higher than those of our previous HPLC-DAD 
method.19 The supplementary clean-up during the sample preparation probably unfavourably 
influenced the analyte recovery. The extraction efficiency is probably also higher when the milk 
sample is firstly made alkaline. In spite of the very simple sample preparation, Facino et al.25 
reported somewhat lower recoveries (80 to 90%), probably due to the not fully optimised 
extraction procedure or to the choise of extraction solvents (mixture of diethylether/n-hexane). 
Chappell et al.8 used a more intensive solid phase extraction sample clean-up for the 
determination of LE in milk. The obtained recovery was acceptable and reached 82.6%. 
 
 4.3.3.6  Precision 
The precision of the method was determined by means of the repeatability and the            
within-laboratory reproducibility. 
The repeatability was evaluated at IPL and at MRL levels. The results of the repeatability study 
performed at IPL and at MRL levels, are summarised in Tables 4.3 and 4.4, respectively. The 
tables present mean values of measured residue concentrations and the variability on these 
values expressed as sr values. Almost all these mean values fell within the ranges stipulated by 
the EU criteria,34 except for a few very small deviations. Following the validation criteria, the 
repeatability or within-day precision expressed as sr values for analyses carried out under 
repeatability conditions would have to be between half and two thirds of these values according 
to the Horwitz equation. The repeatability of the presented confirmatory method is acceptable. 
All calculated sr values were within the allowed range. Moreover, the overall precision values 
were lower than half of the Horwitz values. The overall precision ranged from 5.2% for the 
determination of albendazole at 100 µg/l to 21.7% for the determination of thiabendazole at       
1 µg/l. 
An overview of the within-laboratory reproducibility results of the determinations at IPL and MRL 
levels are given in Tables 4.5 and 4.6, respectively. The analyses were performed on 5 different 
days and by two analysts with their own standard solutions. A sixth value for each concentration 
was obtained from data of the repeatability study. The method studied showed a good within-
laboratory reproducibility. The allowed ranges for the mean concentration values of this 
validation parameter are equal to those of the repeatability.34 This criterium was fulfilled for all 
the calculated mean values at the found concentration levels. The variability for the within-
laboratory reproducibility is allowed to be higher than for the repeatability and the sr values 
should be lower than the values of the Horwitz equation correlated with the concentration 
level.34 The values in Tables 4.5 and 4.6 are much lower than these limits. The within-laboratory 
reproducibility, expressed as sr value of the mean determined residue concentrations ranged 
Chapter 4:  Liquid chromatographic-electrospray tandem mass spectrometric multiresidue method 
 for anthelmintics in milk 
104
 
  
Ta
bl
e 
4.
3 
 R
ep
ea
ta
bi
lit
y 
re
su
lts
 fo
r t
he
 d
et
er
m
in
at
io
n 
of
 a
nt
he
lm
in
tic
 re
si
du
es
 in
 m
ilk
 s
am
pl
es
 s
pi
ke
d 
at
 1
.0
, 1
.5
 a
nd
 2
.0
 IP
L 
 
co
nc
en
tra
tio
n 
(=
 1
.0
, 1
.5
 a
nd
 2
.0
 µ
g/
l) 
(m
ea
n 
(µ
g/
l),
 s
r (
%
), 
n 
= 
6 
fo
r e
ac
h 
co
nc
en
tra
tio
n)
 
   
  L
E 
   
 T
B 
   
 O
F 
   
 O
B 
   
 A
B 
   
 F
B 
   
 F
E 
   
 T
C
 
Sp
ik
ed
 
le
ve
l 
(µ
g/
l) 
M
ea
n 
  s
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
ea
n
  s
r
M
ea
n
  s
r
M
ea
n
  s
r
M
ea
n
  s
r
M
ea
n
  s
r
M
ea
n
  s
r
M
ea
n
  s
r 
W
ith
in
-d
ay
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
ay
 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.
0
1.
1
17
.1
1.
1
16
.4
0.
9
11
.9
0.
9
10
.8
0.
9
6.
2
0.
8
12
.6
1.
0
15
.9
0.
9
9.
8
1.
5
1.
5
8.
6
1.
4
7.
9
1.
5
12
.1
1.
4
3.
5
1.
3
10
.3
1.
3
10
.2
1.
4
16
.3
1.
2
14
.4
2.
0
2.
1
2.
4
2.
1
7.
0
1.
9
9.
0
1.
9
5.
6
1.
9
3.
5
1.
7
5.
9
1.
6
6.
3
1.
4
8.
9
D
ay
2
1.
0
0.
9
19
.0
0.
8
24
.7
1.
0
9.
6
0.
9
14
.2
0.
8
7.
5
1.
0
5.
8
1.
1
7.
9
1.
0
5.
3
1.
5
1.
6
10
.1
1.
4
12
.4
1.
5
10
.1
1.
4
2.
8
1.
2
8.
8
1.
4
11
.0
1.
5
9.
9
1.
3
6.
0
2.
0
2.
1
10
.6
2.
0
9.
8
1.
9
14
.7
2.
0
6.
3
1.
8
5.
4
1.
7
7.
4
1.
7
13
.2
1.
4
11
.2
D
ay
3
1.
0
1.
0
13
.6
0.
8
18
.5
0.
8
28
.5
0.
9
11
.7
1.
0
10
.7
1.
0
12
.5
1.
1
8.
4
1.
0
10
.0
1.
5
1.
6
8.
7
1.
3
11
.4
1.
1
8.
7
1.
3
9.
3
1.
4
5.
5
1.
4
6.
3
1.
5
11
.8
1.
5
10
.0
2.
0
1.
8
6.
8
1.
6
3.
9
1.
6
13
.8
1.
7
4.
0
1.
9
8.
4
1.
8
4.
7
1.
9
3.
1
1.
8
10
.9
Be
tw
ee
n-
da
y 
O
ve
ra
ll 
(n
 =
 1
8)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.
0 
 
1.
0
18
.2
0.
9
21
.7
0.
9
18
.9
0.
9
11
.9
0.
9
11
.5
1.
0
15
.3
1.
0
11
.0
0.
9
9.
4
1.
5
1.
5
9.
1
1.
4
10
.8
1.
4
16
.0
1.
4
6.
1
1.
3
9.
0
1.
3
10
.3
1.
5
12
.2
1.
4
13
.8
2.
0
2.
0
10
.2
1.
9
13
.9
1.
8
14
.5
1.
9
8.
8
1.
9
6.
1
1.
7
7.
0
1.
7
12
.2
1.
6
16
.0
 
 
LE
: l
ev
am
is
ol
e 
 T
B:
 th
ia
be
nd
az
ol
e 
 O
F:
 o
xf
en
da
zo
le
  O
B:
  o
xi
be
nd
az
ol
e 
 A
B:
 a
lb
en
da
zo
le
  F
B:
 fe
nb
en
da
zo
le
  F
E:
 fe
ba
nt
el
  T
C
: t
ric
la
be
nd
az
ol
e 
Chapter 4:  Liquid chromatographic-electrospray tandem mass spectrometric multiresidue method 
 for anthelmintics in milk 
105
 
  
 
 
 
 
Ta
bl
e 
4.
4 
  R
ep
ea
ta
bi
lit
y 
re
su
lts
 fo
r t
he
 d
et
er
m
in
at
io
n 
of
 a
nt
he
lm
in
tic
 re
si
du
es
 in
 m
ilk
 s
am
pl
es
 s
pi
ke
d 
at
 0
.5
, 1
.0
 a
nd
 1
.5
 M
R
L 
co
nc
en
tra
tio
n 
 
 
(m
ea
n 
(µ
g/
l),
 s
r (
%
), 
n 
= 
6 
fo
r e
ac
h 
co
nc
en
tra
tio
n)
 W
ith
in
-d
ay
 
 
Be
tw
ee
n-
da
y 
D
ay
 1
 
 
D
ay
 2
 
 
D
ay
 3
 
 
O
ve
ra
ll 
(n
 =
 1
8)
 
   
  A
na
ly
te
 
  S
pi
ke
d 
   
  l
ev
el
 
   
 (µ
g/
l) 
M
ea
n 
s r
 
 
 
 
 
 
 
 
 
M
ea
n
s r
M
ea
n
s r
M
ea
n
s r
 
 
   
  5
0
   
  4
1.
8 
6.
9
   
   
46
.4
 9
.8
 
 4
8.
9
2.
8
 4
5.
7
9.
4
TB
 
   
10
0
   
  8
3.
6 
3.
0
   
   
91
.8
12
.3
 
 9
7.
3
1.
0
 9
0.
9
9.
4
 
   
15
0
 
   
13
3.
4 
6.
0
   
 1
45
.0
 5
.0
 
15
7.
4
6.
2
14
5.
3
8.
8
   
 
 
   
   
 5
   
   
5.
4 
7.
1
   
   
  4
.6
 7
.8
 
   
4.
9
4.
0
   
5.
0
9.
1
O
F 
   
  1
0
   
   
9.
0 
9.
6
   
   
  9
.7
 8
.5
 
 1
0.
1
7.
7
   
9.
6
9.
5
 
   
  1
5
 
   
 1
5.
1 
3.
5
   
   
15
.3
 8
.5
 
 1
5.
2
5.
3
 1
5.
2
5.
8
 
 
   
  2
5
   
 2
2.
0 
3.
5
   
   
24
.7
 1
.6
 
 2
5.
1
2.
7
 2
4.
0
6.
3
O
B 
   
  5
0
   
 4
2.
8 
3.
1
   
   
49
.0
 5
.9
 
 4
9.
9
2.
9
 4
7.
2
8.
0
 
   
  7
5
 
   
 6
6.
9 
3.
9
   
   
77
.2
 4
.5
 
 7
8.
9
3.
8
 7
4.
3
8.
3
 
 
   
  5
0
   
 4
4.
3 
7.
1
   
   
48
.3
 4
.9
 
 5
2.
0
3.
0
 4
8.
2
8.
2
AB
 
   
10
0
   
 9
3.
9 
2.
2
   
   
96
.4
 6
.4
 
10
2.
0
1.
3
 9
7.
4
5.
2
 
   
15
0
 
  1
43
.8
 
2.
8
   
 1
51
.3
 4
.4
 
16
1.
8
4.
5
15
2.
3
6.
3
  
 
 
   
   
 5
   
  5
.5
 
5.
1
   
   
  5
.4
 8
.1
 
   
5.
8
5.
0
   
5.
5
6.
8
FB
 
   
  1
0
   
10
.7
 
4.
1
   
   
10
.3
 8
.2
 
 1
1.
1
2.
4
 1
0.
7
6.
0
 
   
  1
5
 
   
16
.1
 
5.
1
   
   
16
.6
 4
.8
 
 1
6.
8
4.
1
 1
6.
5
4.
7
 
 
   
   
 5
   
  4
.8
 
5.
6
   
   
 4
.5
 8
.0
 
   
5.
0
5.
6
   
4.
8
7.
5
FE
 
   
  1
0
   
  9
.8
 
5.
9
   
   
 8
.9
10
.5
 
   
9.
9
3.
1
   
9.
5
8.
3
 
   
  1
5 
   
 1
5.
0 
5.
1 
 
   
   
14
.7
 
  8
.0
 
 
  1
6.
5 
6.
9 
 
  1
5.
4 
8.
3 
 
TB
: t
hi
ab
en
da
zo
le
   
O
F:
 o
xf
en
da
zo
le
   
O
B:
  o
xi
be
nd
az
ol
e 
  A
B:
 a
lb
en
da
zo
le
   
FB
: f
en
be
nd
az
ol
e 
  F
E:
 fe
ba
nt
el
Chapter 4:  Liquid chromatographic-electrospray tandem mass spectrometric multiresidue method 
 for anthelmintics in milk 
106
 
 
Table 4.5 Within-laboratory reproducibility for determination of anthelmintics residues in 
 milk samples spiked at 1.0, 1.5 and 2.0 IPL concentration (mean (µg/l), sr (%) 
 n = 6 for each concentration) 
  LE   TB    OF   OB Spiked 
level 
(µg/l) Mean sr Mean sr Mean sr Mean sr 
1.0 1.0 11.4 0.9 14.7 0.9 15.2 1.0 10.2 
1.5 1.5   6.5 1.4   9.0 1.5 21.8 1.5   8.8 
2.0 2.0   4.6 1.9 12.6 1.7   7.0 2.0   8.8 
    AB    FB    FE    TC Spiked 
level 
(µg/l) Mean sr Mean sr Mean sr Mean sr 
1.0 1.0 1.0 1.1 13.0 1.1 19.2 1.1 13.8 
1.5 1.5 6.6 1.5 10.0 1.6   5.5 1.6   7.1 
2.0 2.0 5.6 2.0 14.8 1.9 27.2 2.0 25.4 
 LE: levamisole  TB: thiabendazole  OF: oxfendazole  OB:  oxibendazole 
 AB: albendazole  FB: fenbendazole  FE: febantel  TC: triclabendazole 
 
Table 4.6 Within-laboratory reproducibility for determination of anthelmintic residues in 
 milk samples spiked at 0.5, 1.0 and 1.5 MRL concentration (mean (µg/l), sr (%) 
 n = 6 for each concentration) 
      Analyte  Spiked  level 
    (µg/l) 
    Mean       sr      Analyte 
Spiked 
level  
    (µg/l) 
   Mean       sr 
      50     49.2    6.5       50    51.3     3.4 
Thiabendazole    100     99.7    7.4  Albendazole    100  101.0     1.9 
    150   159.3    9.9     150  151.8     3.7 
        5       4.8    7.8        5      5.5   12.1 
Oxfendazole      10     10.1    4.5  Fenbendazole     10    10.8   10.6 
      15     14.5  18.9      15    16.4     7.0 
      25     25.0    5.3        5      5.2     9.0 
Oxibendazole      50     49.9    8.5  Febantel     10    10.7   11.3 
      75     77.8  12.7      15    16.3     3.5 
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from 1.0% for the determination of albendazole at 1.0 µg/l to 27.2% for the determination of 
febantel at 2.0 µg/l. As expected, this range was somewhat higher than the range obtained for 
the repeatability. 
 
 4.3.3.7  Analytical limits 
The development and the full optimisation of this LC-MS/MS method to obtain low detection 
limits was one of the objectives of this study. An IPL level of 1 µg/l was chosen to be able to 
detect low residue concentrations for the monitoring of anthelmintic residues in raw farm milk, 
especially because two unauthorised substances (levamisole and triclabendazole) are involved. 
As already expected from the study of the specificity, no endogenous interfering matrix material 
could be measured for any compound to calculate the LOD values while analysing 20 blank milk 
samples. Technical LOD values were estimated as those concentrations which yielded a S/N 
ratio of 3/1 by replicated analysis of blank milk samples spiked at a concentration series of 1.0, 
1.5, 3.0 and 5.0 µg/l. The sensitivity of the multiresidue confirmation method was very high and 
all compounds could be detected at a residue concentration lower than 1 µg/l. The measured 
LOD values (MRL values within brackets expressed in µg/kg) for LE, TB, OF, OB, AB, FB, FE 
and TC were 0.5 (0), 0.1 (100), 0.6 (10), 0.1 (50), 0.3 (100), 0.1 (10), 0.1 (10) and 0.6 (0) µg/l, 
respectively. As expected, these LOD values are much lower than those obtained in the 
previously presented HPLC-DAD methods.19 The performance of the discussed LC-MS/MS 
method is also better than these of existing methods. Macri et al.36 obtained a LOD of 10 µg/kg 
with their multiresidue HPLC-DAD method. LODs in the range of 0.6-2.8 µg/kg were obtained 
with the LC-MS method reported by Facino et al.25 Branchflower et al.26  reported a LOD of 50 
and 100 µg/kg for LC-MS analysis of liver tissue for FB and OF, respectively. Chapell et al.8 
demonstrated a comparable detection limit (0.5 µg/kg) for LE in milk by a procedure with online 
LC-GC including an ion trap multimass spectrometry detector. However, their method is very 
complex and can only determine levamisole.  
The decision limit values were calculated for the licensed drug substances as well as for the 
unauthorised compounds levamisole and triclabendazole. The analytical limit values for the 
MRL compounds were also calculated at IPL level and can also be defined as detection limit 
values. The analytical limit values at IPL level were calculated with concentration values already 
obtained for blank milk samples spiked at 1.0 µg/l for calculating the calibrations curves for the 
evaluation of the recovery, the repeatability and the within-laboratory reproducibility. The CCα 
values at MRL level for the licensed compounds were calculated with values already obtained 
for the determination of the recovery, the repeatability, the within-laboratory reproducibility and 
the stability. The calculated mean values plus 1.64 times the corresponding standard deviation 
equals the analytical limit (CCα and LOD values). These analytical limit values are summarised 
in Table 4.7. Obviously, the highest percentile deviation on the target concentration was 
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obtained for the analyses at IPL level. The highest value of 1.3 µg/l should be taken into 
account for decisions concerning the residues of febantel and triclabendazole. The highest 
percentile deviation (12%) at MRL level was also observed for the determination of febantel. 
The obtained CCα value was 11.2 µg/l. The decision limit should be handled as a very useful 
tool for the laboratory in order to make the right decision concerning a violative sample. The 
LOD values obtained with this criterion are somewhat higher (> 1 µg/l) than the detection limits 
obtained with the S/N ratio criterion. Therefore, LODs of different methods have to be 
interpreted in view of the used criterion. 
The detection capabilities were obtained by analysing 20 blank milk samples spiked at IPL or at 
MRL level for the unauthorised and authorised substances, respectively. The respective 
decision limit values plus 1.64 times the corresponding standard deviations equals the detection 
capabilities. Applying this criterion for the MRL compounds at IPL level leads to analytical limits 
which can be defined as limits of quantification. The CCβ and LOQ values are also given in 
Table 4.7. 
 
Table 4.7  Analytical limit values (CCα, CCβ, LOD and LOQ in µg/l) for the determination 
  of anthelmintic residues in milk at IPL and MRL concentrations 
Levamisole Thiabendazole Oxfendazole Oxibendazole      Spiked 
 concentration 
CCα CCβ LOD LOQ LOD LOQ LOD LOQ 
IPL 
(1.0 µg/l) 
1.2 1.4 1.1 1.2 1.1 1.3 1.1 1.2 
  CCα CCβ CCα CCβ CCα CCβ 
MRL - 105.8 118.2 10.5 12.1 52.6 58.9 
Albendazole Fenbendazole Febantel Triclabendazole 
     Spiked 
concentration LOD LOQ LOD LOQ LOD LOQ CCα CCβ 
IPL 
(1.0 µg/l) 
1.1 1.2 1.1 1.3 1.3 1.3 1.3 1.4 
 CCα CCβ CCα CCβ CCα CCβ  
MRL 104.6 110.5 10.9 12.1 11.2 12.9 - 
  - Decision limit: CCα (or LOD) = mean value of spiked milk samples + 1. 64 s  
 - Detection capability: CCβ (or LOQ) = CCα + 1.64 s (n = 20) 
 - n = 9 for IPL level and n = 12 for MRL level 
 
4.4  Conclusions 
A simple, very fast and specific LC-MS/MS confirmatory multiresidue method has been 
developed for the simultaneous, quantitative determination of levamisole, thiabendazole, 
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oxfendazole, oxibendazole, albendazole, fenbendazole, febantel and triclabendazole in milk at 
residue levels around 1 µg/l. The presented method is also suitable to quantify residues of 
anthelmintics at MRL level, providing the laboratory with a powerful tool to make decisions in 
violations for statutory testing purposes. The reliability of the liquid chromatographic-mass 
spectrometric procedure was proven by fulfilling all validation criteria of the final version of the 
European Commission Decision concerning analytical methods for detecting substances and 
residues thereof in live animals and animal products according to Council Directive 96/23/EC.34 
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Abstract: 
 
The optimisation of a quantitative LC-MS/MS method for the determination of residues of 
flubendazole and of its hydrolysed and reduced metabolites in eggs and poultry muscle is 
described. The benzimidazole components were extracted twice from the two matrices with ethyl 
acetate after the sample mixtures had been make alkaline. The collected organic supernatant 
fractions were concentrated by evaporation using vacuum and afterwards defatted with n-hexane. 
The LC separation was performed on a reversed-phase C18 column with gradient elution using a 
mobile phase containing ammonium acetate and acetonitrile. The analytes were detected after 
atmospheric pressure electrospray ionisation on a tandem quadrupole mass spectrometer in 
MS/MS mode. The MS/MS transition of the molecular precursor ion to the most abundant product 
ion of each analyte was measured. The overall extraction recovery values for flubendazole, the 
hydrolysed metabolite and the reduced metabolite in eggs (fortification levels 200, 400 and 800 
µg/kg) and in muscle tissue (fortification levels 25, 50 and 100 µg/kg) were respectively 77, 78 
and 80% and 92, 95 and 90%. The trueness (fortification level of 400 and 50 µg/kg, respectively 
for eggs and muscle tissue), expressed as a percentage of the added values for these 
compounds, was respectively 89, 100 and 86% and 110, 110 and 98%. The presented MS 
detection method operating in the MS/MS mode is very selective and has low detection limits. 
The limits of detection for flubendazole and its hydrolysed and reduced metabolites in egg and 
muscle tissue were respectively 0.19, 0.29 and 1.14 µg/kg and 0.14, 0.75 and 0.31 µg/kg. The 
limits of quantification were respectively 1, 1 and 2 µg/kg and 1, 1 and 1 µg/kg. 
 
Keywords: flubendazole, metabolites, residues, poultry, LC-MS/MS 
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5.1  Introduction 
 5.1.1  Properties of flubendazole and its metabolites 
Flubendazole (FL) is a broad-spectrum benzimidazole (BZ) anthelmintic, which is effective 
against endoparasites such as gastrointestinal roundworms, gapeworms and tapeworms.1 This 
antiparasitic drug is widely used in the veterinary medicine of poultry. 
Benzimidazole anthelmintics are extensively metabolised following oral administration.2 The 
major metabolites arising after treatment of poultry species with flubendazole are the hydrolysed 
(HFL) and the reduced compound (RFL), which are formed by hydrolytic and reduction 
reactions, respectively.3,4 
The molecular structures of FL, its two metabolites and the internal standard which will be used 
for the analytical method, are presented in Figure 5.1. 
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Figure 5.1  Chemical structures of flubendazole, its metabolites and the internal standard 
 
The BZ compounds, shown in Figure 5.1, have a common central “benzimidazole” nucleus and, 
except for HFL, contain a “carbamate (-NHCOOCH3) type” functional group each.5 
Flubendazole is the p-fluor analogue of mebendazole, another anthelmintic drug compound 
which is widely used for treatment of sheep. 
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Some general properties of the BZ analytes are described in paragraph 3.1.1 in Chapter 3. 
 
 5.1.2  Toxicity 
Short term studies suggest that benzimidazoles are efficacious for parasitic control while 
demonstrating a great margin of safety in mammals, including humans.2 
Thienpont et al.6 described the biological and pharmacological properties of flubendazole in 
seven animal species. Toxicity studies were performed in various laboratory animals. The LD50 
value in acute toxicity tests was above 2560 mg/kg for all animal species. In chronic toxicity 
studies with rats and dogs, no side-effects were observed, neither clinically nor 
histopathologically. The teratological results for rat and rabbit were normal, as well as the     
peri- and postnatal effects and fertility experiments in rats. The teratogenicity of flubendazole in 
rats was studied in detail by Yoshimura.7 The highest administered dose (160 mg/kg) was 
embryocidal and resulted in a significant increase in the fetal resorption rate. There was a  
dose-dependent decrease in fetal body weight which was significant at a dose of 40 mg/kg or 
more. The 40 and 160 mg/kg doses induced significant fetal (gross, skeletal and internal) 
malformations. 
Benzimidazole anthelmintic residues are of little human health concern. Toxicological data 
include studies on metabolism, carcinogenicity, genotoxicity, effects on reproduction and 
teratogenicity. For consumers of edible muscle tissues, drug residues covalently bound in tissue 
should not present significantly toxicological risks.2 However, the extractable residues (parent 
drug and/or free metabolites) are chemical compounds with defined toxic potential. 
 
 5.1.3  Objectives 
Administration of flubendazole to poultry species can result in the presence of residues of the 
parent flubendazole compound and its hydrolysed and reduced metabolites in eggs and in 
muscle tissues. By Council Regulation EEC/2377/90 and updates,8 the EC sets the MRLs for 
the sum of FL+HFL as marker residue in eggs and in poultry muscle tissue at 400 and 50 µg/kg, 
respectively. 
Only a few chromatographic methods for the determination of residues of flubendazole in eggs 
and/or muscle tissue have been published.3,4,9,10 Some depletion studies of flubendazole with 
laying hens and excretion data for residues in eggs are available.3,4 Balizs4 reported the 
determination of residues of different benzimidazoles in several animal tissues and eggs using 
liquid chromatography and tandem mass spectrometry (LC-MS/MS). A practical application of 
the assay has been described for incurred egg material of laying hens treated with 
flubendazole. The residue depletion curves in egg yolk as well as in egg white were drawn.   
Kan et al.3 studied the residue formation in eggs and the metabolism in laying hens after     
long-term low-level dose (carry-over dose) and normal dose level exposure of hens treated with 
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flubendazole via the feed. The residue concentrations of flubendazole and its two major 
metabolites in egg yolk and in egg white were quantified with a HPLC-UV method. Marti et al.9 
described a multiresidue HPLC-UV method for the determination of eight BZ anthelmintics in 
meat samples. For verification of violative samples, the drug substances were derivatised for 
detection by GC-MS in the electron-impact or chemical ionisation mode. The simultaneous 
determination of flubendazole, triclabendazole and metabolites of triclabendazole in milk, 
muscle tissue and liver samples by HPLC-UV was published by Takeba et al.10  
To our knowledge, no depletion studies with residue formation data in poultry muscle tissue 
after administration of flubendazole are reported in the open literature. 
The objective of this study was to optimise a sensitive and quantitative LC-MS/MS method for 
the simultaneous determination of residues of FL, of HFL and of RFL in eggs and in muscle 
tissue of poultry species. The developed method is applied in depletion studies (Chapter 9) with 
turkeys and with guinea fowls which were orally treated with flubendazole. The residues 
concentrations of FL, HFL and RFL were monitored in muscle and in liver tissues. 
 
5.2  Materials and methods 
 5.2.1  Reagents 
Analytical standard material of FL, HFL, RFL and IS was kindly provided by the manufacturer 
Janssen Animal Health (Beerse, Belgium). Acetonitrile (HPLC grade), methanol (HPLC grade) 
and acetic acid (100%) of analytical grade were from Merck (Darmstadt, Germany). Dimethyl 
sulphoxide (HPLC grade), ethyl acetate (HPLC grade), ammonium acetate (analytical grade), 
and 0.1 N sodium hydroxide (analytical grade) were purchased from Panreac (Barcelona, 
Spain). n-Hexane (analytical grade) was from BDH (Poole, UK). All water used was of HPLC 
grade and was purified by a Maxima LC 113 Ultra-pure water purification system (Elga, Bucks, 
UK). 
 
 5.2.2  Standard solutions 
The standard material was dissolved in dimethyl sulphoxide at a concentration of 0.3125 mg/ml. 
These solutions were further diluted with methanol to stock standard solutions of 0.1 mg/ml. The 
stock standard solutions were stored refrigerated at 5°C and were replaced every two months. 
The working standard solutions were diluted with methanol and prepared immediately before 
use. Standard solutions of 1 µg/ml in ammonium acetate and acetonitrile (30/70, v/v) were used 
for tuning the mass spectrometer and for acquisition of the analyte identification mass spectra. 
 
 5.2.3  Instrumentation 
The muscle tissue samples were minced and ground with a Knifetec sample mill (Tecator, 
Höganäs, Sweden). The ground muscle tissue samples and the egg samples were 
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homogenised with an Unimix homogeniser (Haagen and Rinau, Bremen, Germany). A shaker 
(Bühler, Hechingen, Germany), a RC-5B Sorvall centrifuge (DuPont Instruments, Wilmington, 
DE, USA) and a vortex mixer (Scientific Industries, Bohemia, NY, USA) were used during the 
sample preparation. The LC-MS/MS system consisted of a LC system (Kontron, Biotech 
Instruments, Milan, Italy) with a 325 ternary pump system, a vacuum degasser, a                   
465 autosampler and a 433 UV detector, coupled with a quattro LCZ tandem quadrupole mass 
spectrometer (Micromass, Altrincham, Cheshire, UK) with “z”-spray electrode and electrospray 
ion interface. The mass spectrometer was fully controlled by MASSLYNX software version 3.3. 
A model 11 syringe pump (Harvard Apparatus, Holliston, MA, USA) was connected to the 
interface for tuning purposes. The LC separations were carried out on a reversed-phase column 
Alltima C18 (Alltech, Deerfield, IL, USA), 5  µm, 150 x 2.1 mm i.d., in combination with an Alltima 
C18 guard cartridge of 7.5 x 2.1 mm i.d. 
 
 5.2.4  Sample Preparation 
  5.2.4.1  Muscle and liver tissue 
One gram of ground muscle or liver tissue sample was weighed into a 50 ml beaker. If 
necessary, FL, HFL, RFL, and/or IS solutions were added. After standing for 30 min, the mixture 
was homogenised in 10 ml of water for 30 s. The mixture was made alkaline with 5 ml of        
0.1 N sodium hydroxide. The analytes were extracted with 20 ml of ethyl acetate in centrifuge 
tubes of 50 ml on a shaker (amplitude: 30 mm, frequency: 90 per min) for 10 min. After 
centrifugation (5 min, 5000 rpm), the supernatant was transferred into a sidearm flask. The 
extraction procedure was repeated once on the lower layer with 10 ml of ethyl acetate. The 
collected organic fractions were evaporated to 4-5 ml in a water bath at 60°C using vacuum. 
The residual fraction was transferred into a graduated tube and was evaporated to dryness 
under a stream of nitrogen. The residue was dissolved with 600 µl of methanol. After mixing, the 
mixture was heated at 60°C in a water bath during 5 min. The mixture was defatted with 2 ml of 
n-hexane. After standing for 5 min, the upper hexane layer was removed. If necessary, for 
recovery experiments, the IS was added at this stage. The solution was made up to 1 ml with 
methanol and was heated at 60°C in a water bath for 2 min. After mixing, the mixture was 
filtered through a 0.2 µm polytetrafluorethylene (PTFE) Chromafil filter (Macherey-Nagel, Düren, 
Germany) into an autosampler vial. 
 
 5.2.4.2  Egg 
One gram of mixed whole egg sample was weighed into a centrifuge tube. If necessary FL, 
HFL, RFL and/or IS solutions were added. After standing for 30 min, the mixture was made 
alkaline with 1 ml of 0.1 N sodium hydroxide. The following steps were identical to those applied 
for the extraction and clean-up of muscle and liver samples described in paragraph 5.2.4.1. 
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 5.2.5  Liquid chromatographic-mass spectrometric method 
The LC separation of flubendazole, its metabolites and the IS was carried out on a       
reversed-phase column with a buffer solution. The mobile phase consisted of pure acetonitrile 
(B) and a buffer solution (A) containing 0.04 M ammonium acetate adjusted to a pH of 5.2 with a 
few microlitres of acetic acid (100%). Gradient elution was applied and the elution programme 
consisted of 50A:50B (0 min), 50A:50B to 25A:75B (1-3 min), 25A:75B (4-5 min), 25A:75B to 
50A:50B (6-7 min) and 50A:50B (8-15 min). The mobile phase flow rate was 0.25 ml/min and 
the injection volume was 10 µl. 
The analytes were detected and identified with a tandem quadrupole mass spectrometer. An 
incorporated split device was set to a split ratio of 1:1. Atmospheric pressure electrospray 
ionisation in the positive mode (ESI+) was applied. The molecular precursor ions were 
fragmented in the collision cell with argon. FL, HFL, RFL and IS were determined with tandem 
mass spectrometry (MS/MS) by the multiple reaction monitoring (MRM) function. One transition 
from precursor ion to product ion, was measured. Cone voltage and collision energy were tuned 
to optimise the transition from the molecular precursor ion to the most abundant product ion. 
 
 5.2.6  Method of data calculation 
The measured residue data of the samples by MRM of one transition are evaluated by an 
internal standard procedure based on calibration curves. Quantification is conducted by internal 
calibration following the formula: 
 
CS (µg/kg) = [(areaS X CIS (µg/kg) / areaIS – intercept) / slope] X 1/CF 
 
were C: concentration  s: sample  IS: internal standard  CF: concentration factor 
 
The results were calculated automatically by the MASSLYNX software version 3.3 of the mass 
spectrometer. 
 
 5.2.7  Validation of the analytical method 
  5.2.7.1  Introduction 
The validation of the analytical procedure was based on the EC guidelines for determination 
methods of veterinary drug residues.11 The validation procedure was carried out completely for 
egg and muscle tissue matrices. Breast muscle tissue of broiler chickens was used as validation 
matrix for muscle tissue. 
The IS was spiked or added with a working standard solution of 1 µg/ml. For determination of 
the linearity, the analytical limits and the repeatability, the IS was spiked to concentrations of 
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100, 10 and 100 µg/l or µg/kg, respectively. The IS concentrations used for the recovery and the 
trueness experiments, are summarised in paragraph 5.2.8. 
 
 5.2.7.2  Linearity 
The linearity of the LC-MS/MS response was checked by analysing three series standard 
solutions of a mixture of FL, HFL and RFL at concentrations of 0.5, 1, 5, 25, 100, 500, 600 and 
800 µg/l. 
Matrix calibration curves were obtained by analysing three series of spiked egg and muscle 
tissue samples with a mixture of FL, HFL and RFL at concentrations of 0.5, 1, 5, 25, 100, 500, 
600 and 800 µg/kg. The curves were calculated using the linear least squares regression 
analyses of the peak area to concentration ratios.  
The variation on the linearity is expressed as the relative standard deviation (sr) of the slope of 
the curves. 
 
 5.2.7.3  Recovery 
The extraction efficiency for the BZ analytes was determined for 10 blank samples fortified at 
three concentration levels, namely, 0.5 MRL, 1.0 MRL and 2.0 MRL. For determination of the 
recovery, the IS was not extracted but added just before injection on the LC column. The 
recovery values were calculated with calibration curves especially drawn during the 
determination of this validation parameter for muscle tissue samples and egg samples. These 
samples were spiked at concentrations of 10, 25, 50, 100 and 200 µg/kg, and of 100, 200, 400, 
800 and 1000 µg/kg, respectively. 
 
 5.2.7.4  Analytical limits 
The detection limits (LODs) were calculated as the apparent concentration corresponding to the 
value of the mean plus three times the standard deviation (s) obtained for at least 20 
representative blank sample determinations. If only noise was obtained, a technical LOD was 
calculated as those concentrations that yield a signal-to-noise (S/N) ratio of 3/1. 
The quantification limits (LOQs) were defined as the lowest concentration of the analytes for 
which the method is validated with an accuracy and precision that fall within the ranges 
recommended by the EC.11 
 
 5.2.7.5  Trueness 
The trueness was calculated as the closeness between the mean measured residue value and 
the fortified concentration. This validation parameter was determined by analysing 10 blank 
samples spiked with the analytes at MRL level. The trueness values were calculated using 
calibration curves obtained with spiked concentrations of 25, 50 and 100 µg/kg for muscle tissue 
and of 200, 400 and 800 µg/kg for eggs, respectively. The trueness is expressed as the 
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percentual agreement between the mean measured value and the added concentration. This 
validation parameter gives the measured concentrations after compensation for recovery which 
is incorporated in the calibration curves. 
 
 5.2.7.6  Repeatability 
The accuracy of the LC-MS/MS method was evaluated by determination of the repeatability or 
the within-day precision of the assay. The repeatability of the assay for eggs was studied by 
repeatedly analysing a blank egg sample, spiked at 100 µg/kg with a fortification solution 
containing the three analytes. The repeatability of the assay for muscle tissue was verified by 
repetitively analysing an incurred turkey breast muscle tissue sample taken during the 
administration period of the depletion study described in Chapter 9. The repeatability was 
expressed as sr value. 
 
 5.2.8  Sample fortification procedure for the determination of 
  recovery and trueness 
 5.2.8.1  Recovery 
For the recovery experiments, the standard solutions of the target analytes and of the IS were 
added after the n-hexane removal during the sample preparation of fortified blank egg samples 
and fortified blank muscle tissue samples. 
To fortify egg samples at 200, 400 and 800 µg/kg (IS at 400 µg/kg), 40, 80 and 160 µl of a 
standard solution of 5000 µg/l of a mixture of the compounds were added, respectively. To 
determine the calibration curves (concentration levels of 100, 200, 400, 800 and 1000 µg/kg), 
100 µl of a standard solution of 1000 µg/l and 40, 80, 160 and 200 µl of a solution of 5000 µg/l, 
respectively, were used. 
To fortify muscle tissue samples at 25, 50 and 100 µg/kg (IS at 100 µg/kg), 25, 50 and 100 µl of 
a standard solution of 1000 µg/l, respectively, were added. The calibration curves (10, 25, 50, 
100 and 200 µg/kg) with this matrix were made with 100 µl of a standard solution of 100 µg/l 
and 25, 50, 100 and 200 µl of a solution of 1000 µg/l, respectively. 
 
 5.2.8.2  Trueness 
To determine the trueness, equal volumes and spiking concentrations of standard solutions as 
described for the evaluation of the recovery were used. The standard solutions were added to 
the blank samples into the centrifuge tube at the beginning of the extraction step. 
The egg samples were spiked at 400 µg/kg with the target analytes and with the IS. Calibration 
was done with matrix curves made with concentrations of 200, 400 and 800 µg/kg. The muscle 
tissue samples were fortified at 50 µg/kg with the target analytes and at 100 µg/kg with the IS. 
The concentrations fortified for the calibration curves were 25, 50 and 100 µg/kg. 
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5.3  Results and discussion 
 5.3.1  Analytical method 
A relatively simple, fast and reliable method was developed for the quantitative determination of 
residues of flubendazole and its metabolites in eggs and poultry muscle tissue. 
Because of good results in previous research work on benzimidazole drugs in milk, ethyl 
acetate was also used as extraction reagent in this study.12 Preliminary experiments as well as 
the experience of Issar et al.13 have indicated that the alkaline conditions of the sample mixture 
have a great influence on the extraction recovery of the weak basic benzimidazole compounds. 
Sodium hydroxide was added to the sample to make the sample mixture alkaline. Interfering 
residual fat particles were removed with n-hexane. The sample preparation and clean-up 
procedures applied in the presented procedure are comparable with those reported by          
Kan et al.3 and Balizs4. 
Identification and determination of FL, its metabolites and the IS was carried out by tandem MS 
operating in the MRM mode. The mass spectrometer was previously tuned and optimised for 
maximum ion response of each analyte by infusion of a standard solution of 1 µg/ml with a 
syringe pump. A summary of the diagnostic ions obtained for the examined compounds and the 
optimised MS operating parameters are given in Table 5.1. 
 
Table 5.1  Summary of the diagnostic ions and MS operating parameters 
Analyte Precursor ion (m/z) 
     Product ions 
            (m/z) 
Cone voltage
(V) 
Collision energy 
(eV) 
    FL 314.1+a 282.0+a, 122.7+  40 25 
    HFL 256.1+a 122.9+a  50 30 
    RFL 316.2+a 284.1+a, 238.4+, 159.9+ 45 25 
    IS 330.3+a 297.9+a, 138.5+ 50 25 
a ions used for MRM detection     FL: flubendazole 
HFL and RFL: hydrolysed and reduced metabolites of flubendazole     IS: internal standard 
 
The ions indicated in Table 5.1 are protonated. The detection of the analytes in standard 
solutions and in spiked samples was performed by measuring the transition of the precursor 
(parent) ion (M+H)+ to the most abundant product ion (indicated in Table 5.1). Preliminary tests 
indicated that the ratio of the intensity of the different product ions was constant. For unknown 
samples out of control and monitoring programmes for example, a supplementary transition in 
the MRM mode has to be measured for the confirmation of a violative sample. The specific 
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mass spectra for each examined compound are presented in Figure 5.2. The full scan mass 
spectrum (a) and the fragmentation mass scan (b) of the precursor ion of each analyte are 
given. 
The LC separation of the analytes was obtained by gradient elution with 0.04 M ammonium 
acetate, adjusted to a pH of 5.2 and acetonitrile. Several LC methods using a mobile phase 
containing ammonium acetate are published.3,4,14 Previous work showed that methanol did not 
sufficiently separate the analytes. First of all, a gradient elution programme was optimised for 
the separation of FL, HFL and the IS. Increasing the flow rate from 0.20 to 0.25 ml/min 
decreases the total LC run time to 15 min. The preliminary analyte detection was performed by 
UV absorption at a wavelength of 254 nm. Afterwards, the reduced metabolite was also 
involved in this study. RFL could be determined with the same LC procedure. For further 
experiments, only MS detection was applied. As illustrated in Figure 5.3, the two metabolites are 
not chromatographically separated. However, this LC separation is not necessary because of 
the powerful separation capacity of the mass spectrometer operating in the MRM mode. 
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 Figure 5.3  Chromatogram of a blank muscle tissue sample spiked with a mixture of 
 flubendazole and its metabolites at 1 µg/kg and with the IS at 10 µg/kg 
 
Figure 5.3 shows a chromatogram of a blank muscle tissue sample spiked with a mixture of the 
analyte compounds at a concentration of 1 µg/kg and with the IS at a concentration of 10 µg/kg. 
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 5.3.2  Validation of the analytical method 
 5.3.2.1  Linearity 
The LC-MS/MS response was linear in the concentration range of 0.5 to 800 µg/l obtained with 
eight calibration points (0.5, 1, 5, 25, 100, 500, 600 and 800 µg/l). Three series of standard 
solutions were measured. Very stable linearity relationships were obtained for the three 
examined analytes. The sr values of the slope of the standard curves for FL, HFL and RFL were 
3.6, 1.8 and 1.0%, respectively. 
The results of the regression analysis of the calibration data obtained by analysing spiked egg 
and muscle tissue samples are summarised in Table 5.2. The linearity of the eight-point (0.5, 1, 
5, 25, 100, 500, 600 and 800 µg/l) matrix calibration curves was proven in the concentration 
range 0.5 to 800 µg/kg. The sr values of the slope of the three different curves were very low 
and were below 6% for each of the target compounds. 
 
 5.3.2.2  Extraction recovery efficiency 
Table 5.3 reports the mean extraction recovery values obtained for egg and muscle tissue 
samples spiked with a mixture of the analytes. The recovery values ranged from 77 to 95% and 
were higher for muscle tissue than for eggs. The overall extraction recovery values for FL, HFL 
and RFL in eggs and muscle were 77, 78 and 80%, and 92, 95 and 90%, respectively. The 
values for eggs are slightly lower than those obtained by Kan et al.3 These authors reported 
mean values of respectively 80, 82 and 89% for these compounds. Balizs4 obtained a mean 
recovery value of 72% for FL in eggs. The reported recovery value of 92% for FL in muscle 
tissue with the presented method is somewhat higher than that obtained by Takeba et al.10 
(86%). Even lower recoveries of 73 and 50% for FL in muscle tissue were published by Marti et 
al.9 and Balizs,4 respectively. 
 
 5.3.2.3  Analytical limits 
In contrast with the preliminary results reported in our earlier short publication,15 final detection 
limit values were determined more in detail by analysing series of 24 blank egg and 23 blank 
muscle tissue samples. The calculated LOD values are summarised in Table 5.4. For the 
hydrolysed metabolite in the two matrices, only noise was measured. Therefore, a technical 
LOD with fortified samples was calculated as that concentration which yields a S/N of 3. These 
results illustrate the extreme sensitivity of the presented LC-MS/MS method. Except for RFL in 
egg, all analytes can be detected at a residue level lower than 1 µg/kg. The obtained detection 
limits are lower than those reported Kan et al.3 These authors obtained LODs of 7, 12 and       
28 µg/kg for HFL, FL and RFL in whole egg, respectively. Less sensitivity was demonstrated by 
the methods of Balizs,4 Marti et al.9 and Takeba et al.10 These research workers reported 
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detection limit values for FL of 32 µg/kg in eggs, 50 µg/kg in muscle tissue and also 50 µg/kg in 
muscle tissue, respectively. 
 
 Table 5.4  Detection limits (LOD) (µg/kg) for the determination of 
  flubendazole and its metabolites in eggs and muscle tissue 
 
Compound 
 
 
Egg 
 
Muscle tissue 
 
              FL 
 
 
0.19 
 
0.14 
 
              HFL 
 
 
  0.29a 
 
  0.75a 
 
              RFL 
 
 
1.14 
 
0.31 
 a technical LOD with S/N = 3          FL: flubendazole 
 HFL and RFL: hydrolysed and reduced metabolites of flubendazole 
  
An overview of the quantification limit values is given in Table 5.5. Very low LOQs of 1.0 to     
2.0 µg/kg were obtained with the described LC-MS/MS method. With exception for RFL in eggs     
(2 µg/kg), the method was validated with an accuracy and precision that fall within the ranges 
recommended by the EC11 for samples spiked with the analytes in eggs and muscle tissue 
samples at a concentration of 1.0 µg/kg. 
 
 5.3.2.4  Trueness 
The calculated trueness values for muscle tissue samples are expressed as the percentual 
agreement between the mean measured concentration (n = 10) and the fortification 
concentration of 50 µg/kg (MRL). These values (sr (%) in parentheses) for FL, HFL and RFL 
were 110 (10.1), 110 (4.9) and 98% (7.1), respectively. The corresponding values obtained with 
blank egg samples (n = 10) fortified at a concentration of 400 µg/kg (MRL) were 89 (5.6),       
100 (8.7) and 86% (6.9), respectively. 
 
 5.3.2.5  Repeatability 
A summary of the within-day precision or repeatability results of the method is given in Table 
5.6. For most of the analytes, the repeatability, expressed as sr value, was not higher than 10%. 
The repeatability of the assay was least favorable for the HFL compound measured in the 
incurred turkey breast muscle sample at a residue concentration of 243 µg/kg. A repeatability of 
13.4% was obtained. 
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Table 5.6  Repeatability results for the determination of flubendazole and its metabolites in eggs 
  at 100 µg/kg and of incurred turkey breast muscle tissue [(sr (%)) mean value (µg/kg)] 
 
Analyte 
 
 
Egg 
 
Muscle tissue 
 
         FL 
 
 
           7.0 (83.6) 
 
            8.7 (61.6) 
 
         HFL 
 
 
         10.5 (86.8) 
 
          13.4 (243.1) 
 
         RFL 
 
 
           7.2 (95.5) 
 
           not detected 
n = 10 
 FL: flubendazole     HFL and RFL: hydrolysed and reduced metabolites of flubendazole 
 
5.4  Conclusions 
A relatively fast, sensitive and very selective LC-MS/MS method for the determination of 
flubendazole and its hydrolysed and reduced metabolites in eggs and poultry muscle tissue is 
described. Due to the relatively intensive sample preparation and the very classic equipment 
required, it was not possible to determine more than 16 muscle tissue samples or 32 egg 
samples per day per analyst. 
Because of the lack of screening methods for these group of drug substances, the method can 
be proposed for screening purposes in monitoring programmes for poultry products. Regarding 
the new EC rules for residues analysis, one supplementary transition in the MRM mode has to 
be measured to make the presented method suitable for confirmation purposes of violative 
samples in surveillance programmes. 
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Abstract: 
 
A quantitative liquid chromatographic-electrospray tandem mass spectrometric method for the 
determination of residues of mebendazole and its hydrolysed and reduced metabolites in 
sheep muscle and liver tissues has been developed. The benzimidazole substances were 
extracted twice with ethyl acetate after the sample mixture had been made alkaline. After 
centrifugation, the collected organic fractions were concentrated by evaporation using a 
vacuum evaporator and defatted with n-hexane. The LC separation was performed on a 
reversed-phase C18 column with gradient elution using a mobile phase consisting of water 
containing 0.1% formic acid and acetonitrile. 
Using a very selective tandem quadrupole mass spectrometer, the presented drug residue 
analysis method has low detection limits. The analytes were detected in multiple reaction 
monitoring mode after atmospheric pressure electrospray ionisation. The MS/MS transitions 
of the molecular precursor ion to the two most abundant product ions of each component 
were measured. The confirmatory method was validated according to the revised                
EU requirements. The evaluated validation parameters were stability, specificity, recovery, 
precision (repeatability and within-laboratory reproducibility) and analytical limits (decision 
limit, detection limit and quantification limit). Mebendazole-derived residues could be detected 
in sheep tissues at concentrations lower than 2 µg/kg. The validation limit or the internal 
performance limit was set at 10 and 50 µg/kg for muscle and liver tissue, respectively. The 
obtained overall recovery was higher than 90% for the three analytes. The relative standard 
deviation on the repeatability ranged from 5 to 11%. The range for the within-laboratory 
reproducibility was between 2 and 17%. The decision limits for mebendazole, the hydrolysed 
and the reduced metabolites in liver tissue were 445.9, 466.5 and 463.4 µg/kg, respectively. 
The limits of quantification for these substances were 60.0, 86.1 and 90.9 µg/kg, respectively. 
The decision limit values obtained for mebendazole, the hydrolysed and the reduced 
metabolite in muscle tissue were 72.5, 69.2 and 69.8 µg/kg, respectively. The quantification 
limits for these substances were 13.1, 15.2 and 15.8 µg/kg, respectively. 
To be suitable for analysis in a depletion study, the LC-MS/MS method was also optimised for 
the analysis of kidney and back fat tissues. 
 
Keywords: drug residue analysis, mebendazole, sheep tissues, LC-MS/MS, method validation 
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6.1  Introduction 
 6.1.1  Properties of mebendazole and its metabolites 
Mebendazole (ME) is a benzimidazole (BZ) antiparasitic substance widely used in veterinary 
drug products. This pharmaceutical compound is an orally active broad-spectrum anthelmintic 
which is effective against numerous species of nematodes and cestodes of the gastrointestinal 
tract of animals.1 ME is frequently used for sheep and goats against major gastrointestinal 
nematodes, lung nematodes and tapeworms.1,2,3,4,5 ME is known to be absorbed from the 
gastrointestinal tract and to be intensively metabolised in sheep.1 The major metabolic 
compound measured in sheep tissues and fluids after administration of mebendazole, is 
hydroxymebendazole. This reduced or alcoholic metabolite (RME) is formed by carbonyl 
reduction of the ketone group (Figure 6.1).1,6,7 The hydrolysed metabolite or aminomebendazole 
(HME) arises by hydrolysis of the carbamate group of the mebendazole molecule (Figure 6.1).6  
The chemical structures of the benzimidazole (BZ) compounds involved in this study are 
presented in Figure 6.1. All shown compounds have a “benzimidazole” nucleus. With exception 
for the hydrolysed metabolite, the substances have a “carbamate (-NHCOOCH3) type” 
functional group. Flubendazole (FL), an anthelmintic drug compound developed as the             
p-fluoro-derivative of mebendazole,8 was used as internal standard in this analytical method. 
The specificity of the assay was verified with oxfendazole (OF). 
Several general chemical properties of the BZ compounds were already given in         
paragraph 3.1.1 in Chapter 3. 
 
 6.1.2  Toxicity 
Concerning teratogenic toxicity, a great deal of information is available on embryopathic effects 
of benzimidazoles in rat.6 Embryolethal and teratogenic effects have been described for 
mebendazole. Teratogenicity occurs at fairly low dosages compared with acute toxicity to adult 
animals. Mebendazole is reported to be nonteratogenic at the therapeutic dosage in sheep. The 
hydroxymebendazole metabolite is more embryotoxic than mebendazole itself in rat. 
From the standpoint of public safety, the toxicological evaluation of benzimidazole residues is of 
considerable importance. Bound residues do not present a hazard for the consumer. The 
extractable residues are chemicals with defined toxic potential for which safety margins may be 
set. 
 
 6.1.3  Objectives 
Residues of the parent mebendazole substance and its reduced and hydrolysed metabolites in 
foodstuffs might occur after treatment of food-producing animals with mebendazole, especially 
when the recommended withdrawal period is not respected. 
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Figure 6.1  Molecular structures of the examined benzimidazole compounds 
 
To monitor the safety of food products, validated methods for the determination of 
mebendazole-derived residues in edible tissues of animals are needed. Several analytical 
methods for mebendazole-derived residues are developed and described in the literature. Most 
of them use HPLC.9,10,11,12 Steenbaar et al.9 developed a HPLC-DAD determination method for 
residues of ME in eel muscle tissue. The method was extended for the metabolites RME and 
HME and was published by Hajee et al.10 Al-Kurdi et al.11 presented a HPLC-UV method for the 
determination of residues of ME and HME in human pharmaceutical dosage formulations. A 
rapid and selective HPLC-UV assay for the simultaneous quantitative determination of ME and 
analogous compound in whole blood is described by Ramanathan et al.12 
Only a few methods for residues of mebendazole using liquid chromatography-mass 
spectrometry (LC-MS) are available.3,13 A collisional spectroscopy procedure for simultaneous 
detection of five widely employed BZ anthelmintics including ME in sheep milk was developed 
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by Facino et al.3 The milk samples were adjusted to an alkaline pH of 10 and the residues were 
extracted twice with trichloro methane. The combined organic phases were evaporated to 
dryness and the residues were dissolved in methanol before analysis. The determination 
involves injection of the extracts into the LC-MS system and selection and collision of the most 
abundant ion (molecular ion of fragment ion) obtained under electron impact ionisation. Balizs13 
published a more actual multiresidue liquid chromatographic-tandem mass spectrometric     
(LC-MS/MS) method with electrospray ionisation for benzimidazoles including ME in several 
animal tissues. The analytes were extracted twice out of the alkaline made tissue samples with 
ethyl acetate. The collected organic phases were evaporated to dryness. The dried residue was 
defatted with n-hexane and ethanol. The ethanol-acid layer was evaporated and dissolved in a 
mixture consisting of ammonium acetate and methanol. A solid phase extraction (SPE) was 
performed. The analytes were eluted from the SPE columns with a mixture consisting of 
methanol and ethyl acetate (20/80, v/v). The dried residue was dissolved in the LC mobile 
phase consisting of acetonitrile and 0.01 M ammonium acetate containing 0.5% acetic acid 
(60/40, v/v). The metabolites of ME were not involved in this method.  
To protect the consumer, the EC has established MRLs by Council Regulation EEC/2377/90 
and amendments14 for mebendazole-derived residues in sheep tissues. The MRL value for the 
sum of residues of ME+RME+HME in liver tissue is set at 400 µg/kg. The MRL value for these 
residues in muscle, kidney and back fat tissues is established at 60 µg/kg. 
The present study deals with the development of confirmatory assays with LC-MS/MS for the 
quantitative determination of residues of mebendazole, its reduced and its hydrolysed 
metabolites in muscle, liver, kidney and back fat tissues of sheep. The method is validated for 
liver and muscle tissues matrices according to the revised EC rules for drug residue analysis.15 
The analytical study was performed in two parts. Firstly, the method was developed for liver 
tissues. Afterwards, the analytical procedure was performed for muscle tissue and was 
optimised for the analysis of kidney and back fat tissues. 
The developed methods were used in a depletion study for the quantification of mebendazole-
derived residues in tissues of orally treated sheep. This depletion study is reported in      
Chapter 10. 
 
6.2  Experimental 
 6.2.1  Reagents and chemicals 
Analytical standard material of ME, HME, RME and the internal standard (IS) FL was 
generously donated by Janssen Animal Health (Beerse, Belgium). OF was kindly supplied by 
Merial (Toulouse, France). Acetonitrile and methanol were of HPLC grade and from Merck 
(Darmstadt, Germany). Dimethyl sulphoxide (HPLC grade), ethyl acetate (HPLC grade),            
1 M sodium hydroxide (analytical grade), 0.1 M sodium hydroxide (analytical grade) and formic 
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acid (analytical grade) were purchased from Panreac (Barcelona, Spain). n-Hexane (analytical 
grade) was from BDH (Poole, Dorset, UK). All water used was of HPLC grade and purified by a 
Maxima LC 113 Ultra-pure water purification system (Elga, Bucks, UK). 
 
 6.2.2  Standard solutions 
Analytical standard material of the analytes was dissolved in dimethyl sulphoxide at a 
concentration of 0.3125 mg/ml and further diluted with methanol to stock standard solutions of 
0.1 mg/ml. The stock standard solutions were stored refrigerated at 5°C and used for up to two 
months. The working standard solutions were made immediately before use by dilution with 
mobile phase consisting of acetonitrile and water, containing 0.1% formic acid (50/50, v/v). 
Standard solutions of 1 µg/ml were used for tuning the mass spectrometer and for acquisition of 
identification mass spectra of the analytes. 
 
 6.2.3  Apparatus 
The slightly thawed muscle, liver, kidney and back fat tissue samples were minced and ground 
with a Knifetec sample mill (Tecator, Höganäs, Sweden). The ground tissues were 
homogenised with an Unimix homogeniser (Haagen and Rinau, Bremen, Germany). A shaker 
(Bühler, Hechingen, Germany), a RC-5B Sorvall centrifuge (DuPont Instruments, Wilmington, 
DE, USA) and a vacuum evaporator (Büchi, Flawil, Switzerland) were used during the sample 
pretreatment. The LC-MS/MS instrument already used for previous analytical studies in our 
laboratory was utilised.16,17 The LC-MS/MS apparatus consisted of a LC-system (Kontron, 
Biotech Instruments, Milan, Italy) combined with a Quattro LCZ tandem quadrupole mass 
spectrometer (Micromass, Altrincham, Cheshire, UK) provided with a “z”-spray electrode and an 
electrospray ion interface. The LC-system consisted of a 325 ternary pump system, a vacuum 
degasser and a 465 autosampler. The mass spectrometer and the data acquisition were fully 
controlled by the MASSLYNX software version 3.3. The tuning experiments were performed 
with a Model 11 syringe pump (Harvard Apparatus, Holliston, MA, USA) which was connected 
to the interface. The LC separations were performed on an Alltima C18 reversed-phase column 
(Alltech, Deerfield, IL, USA), 5 µm, 150 x 2.1 mm i.d., protected with an Alltima C18 guard 
cartridge of 7.5 x 2.1 mm i.d. 
 
 6.2.4  Sample preparation 
 6.2.4.1  Liver tissue 
One gram of ground sheep liver sample was weighed into a centrifuge tube of 50 ml. If 
necessary, ME, HME, RME, OF and/or IS solutions were fortified at this stage. The spiked 
samples were left for 30 min. The sample was made alkaline with 1 ml of 0.1 M sodium 
hydroxide and was vortex mixed. The analytes were extracted with 20 ml of ethyl acetate on a 
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shaker (amplitude: 30 mm, frequency: 90 per min) for 10 min. After centrifugation (5 min,     
5000 rpm), the supernatant was transferred into a side-arm flask. The extraction procedure was 
repeated once on the centrifugate with 10 ml of ethyl acetate. The collected organic fractions 
were evaporated to 4-5 ml in a water bath at 60°C using vacuum. The residual fraction was 
transferred into a graduated tube. The flask was rinsed with 2 ml of ethyl acetate. The remaining 
extract was evaporated to dryness under a stream of nitrogen in a water bath at 60°C. The 
residue was dissolved in 600 µl of methanol and was vortex mixed. The mixture was heated at 
60°C in a water bath during 5 min. After vortex mixing, the mixture was defatted with 2 ml of     
n-hexane while swirling. After standing for 5 min, the upper hexane layer was removed and the 
tube was placed during 2 min in a water bath heated at 60°C. For the recovery experiments, the 
IS was added after the extraction, at this stage. The solution was vortex mixed and made up to 
1 ml with methanol while vortex mixing. The cleaned extract was filtered through a 0.2 µm 
polytetrafluorethylene (PTFE) Chromafil filter (Macherey-Nagel, Düren, Germany) into an 
autosampler vial. 
 
 6.2.4.2  Muscle and kidney tissue 
One gram of ground sheep muscle or kidney tissue sample was weighed into a beaker of 50 ml. 
If necessary, the analyte and/or IS solutions were spiked at this stage. The fortified samples 
were left for 30 min. The tissue was homogenised (8000 rpm, 15 s) in 10 ml of water. The 
sample was made alkaline with 1 ml of 1 M sodium hydroxide. The sample mixture was 
transferred into a centrifuge tube of 50 ml and the beaker was rinsed with 20 ml of ethyl acetate. 
The extraction was activated on a shaker (amplitude: 30 mm, frequency: 90 per min) for 10 min. 
After separation by centrifugation (5000 rpm) during 5 min, the supernatant was transferred into 
an evaporation tube. The extraction procedure was repeated once on the centrifugate with 10 
ml of ethyl acetate. The collected organic fractions were evaporated to 2-4 ml with the vacuum 
evaporator (260±10 X 102 N/m2, 60°C, 200 rpm). The residual fraction was quantitatively 
transferred into a graduated tube. The evaporation tube was rinsed with 2 ml of ethyl acetate. 
The remaining extract was evaporated to dryness under a stream of nitrogen in a water bath at 
60°C. The residue was dissolved in 600 µl of mobile phase consisting of acetonitrile and water 
containing 0.1% formic acid (50/50, v/v), and was vortex mixed. The mixture was heated at 
60°C in a water bath during 5 min. After vortex mixing, the mixture was defatted with 2 ml of     
n-hexane while swirling. After standing for 5 min, the upper hexane layer was removed and the 
tube was placed in a water bath at 60°C during 2 min. For the recovery experiments, the IS was 
added after the extraction at this stage. The solution was vortex mixed and made up to 1 ml with 
mobile phase and homogenised by vortex mixing. The cleaned extract was filtered through a 
0.2 µm regenerated cellulose (RC) Chromafil filter (Macherey-Nagel, Düren, Germany) into an 
autosampler vial. 
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 6.2.4.3  Back fat tissue 
One gram of ground back fat tissue sample was weighed into a centrifuge tube of 50 ml. If 
necessary, analyte and/or IS solutions were added at this stage. The fortified samples were left 
for 30 min. Ten ml of water was added and the sample mixture was made alkaline with 1 ml of  
1 M sodium hydroxide while swirling. The tubes were placed in a water bath at 60°C for 10 min 
while swirling regularly. Twenty ml of ethyl acetate as extraction reagent was added. The 
extraction was performed on a shaker (amplitude: 30 mm, frequency: 90 per min) for 10 min. 
After centrifugation (5000 rpm) during 10 min, the supernatant was transferred into an 
evaporation tube. The extraction procedure was repeated with 10 ml of ethyl acetate on the 
centrifugate which had been heated before in a water bath at 60°C during 5 min. The next steps 
were identical to those of the sample preparation procedure of muscle or kidney tissue 
described in paragraph 6.2.4.2. 
 
 6.2.5  Liquid chromatography 
The LC separation of mebendazole and its metabolites was performed on a reversed-phase 
column at room temperature. The mobile phase consisted of pure acetonitrile (B) and water 
containing 0.1% formic acid (to increase the ionisation intensity) (A). Gradient elution was 
applied to improve the separation capacity and to decrease the retention times of the analytes. 
The gradient programme consisted of 65A:35B (0 min), 65A:35B to 50A:50B (0-0.1 min), 
50A:50B to 25A:75B (0.2-3 min), 25A:75B (4-5 min), 25A:75B to 50A:50B (6-7 min), 50A:50B to 
65A:35B (8-15 min) and 65A:35B (16-25 min). The mobile phase flow rate was 0.25 ml/min. An 
injection volume of 10 µl of cleaned liver tissue sample extract was injected into the LC system. 
To increase the sensitivity of the method, the injection volume was increased to 30 µl for the 
other tissue samples. 
 
 6.2.6  Mass spectrometry 
The benzimidazole analytes were detected and identified with a tandem quadrupole mass 
spectrometer. The compounds were ionised by atmospheric pressure electrospray ionisation in 
the positive ion mode (ESI+). The LC eluent flow of 0.25 ml/min was sprayed into the mass 
spectrometer interface without splitting. Nitrogen gas flows of 80 and 600 l/h for nebulising the 
LC eluent and for drying the solvents respectively, were used. The source block and solvent 
desolvation temperatures were set at 130 and 250°C, respectively. Fragmentation of the 
precursor ions in product ions was obtained in the collision cell with argon gas. 
The analytes were detected by tandem MS using the multiple reaction monitoring (MRM) 
function of two transitions. The specific cone voltage and collision energy for each compound 
were optimised to maximise the ion current of the three induced ions, one precursor (parent) ion 
and two product (fragment) ions. Protonated positive ions are formed by ESI+ due to addition of 
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a H-atom to the ions. The transition of the precursor ion, the molecular parent ion, to the two 
most abundant fragment ions was optimised by means of infusion of separate standard 
solutions of 1 µg/ml using a syringe pump. Identification and confirmation of one or more 
analytes in a violative sample is proven by detection of these three diagnostic ions above the 
detection limit (signal-to-noise (S/N) ratio of at least 3/1). 
 
 6.2.7  Method of quantification 
The MRM-generated data of the transition from the precursor ion to the most abundant product 
ion were evaluated by an internal standard procedure based on matrix calibration curves. 
Quantification was conducted by internal calibration. The results were calculated automatically 
by the MASSLYNX software version 3.3 of the mass spectrometer. The calibration curves were 
always drawn using the best fit of two replicated determinations per concentration point. The 
calibration curves were obtained using at least five concentration points, including the zero 
level. The response factors (Y-values) (response factor = peak area ratio of sample and IS 
multiplied by the concentration of the IS) were plotted against the concentration levels             
(X-values). 
 
 6.2.8  Validation procedure 
 6.2.8.1  Introduction 
The main lines of the revised EC requirements for detecting residues of veterinary drug 
substances in animal products15 were applied as guide for the validation of the presented 
method. The validation was performed completely for liver and muscle tissue matrices. 
During the validation procedure for muscle and liver tissues, the IS was added using a solution 
with concentration of 1 µg/ml. Standard solutions of a mixture of ME, HME and RME were 
always used to fortify the samples, unless indicated otherwise. Blank muscle tissue samples 
were spiked using a mixed standard solution of 0.1 and 1 µg/ml for matrix concentrations up to 
25 µg/kg and above 25 µg/kg, respectively. Blank liver tissue samples were spiked using a 
mixed standard solution of 1 and 2 µg/ml for matrix concentrations of 50 to 250 µg/kg and above 
250 µg/kg, respectively. 
The validation parameters evaluated for the entire analytical assay were the stability, the 
specificity, the recovery, the precision (repeatability and within-laboratory reproducibility) and 
the analytical limits (decision limit, detection limit and quantification limit). 
During the validation of the analytical methods, the rules for validation of methods applicable for 
depletion studies by companies which are developing veterinary drugs, were taken into account. 
The EC requirements prescribe validation at concentration levels of 0.5 MRL, 1.0 MRL and    
1.5 MRL for each analyte.15 For the validation study of sheep tissues, this prescription can not 
be followed because the MRL for muscle and liver tissue is set at 60 and 400 µg/kg, 
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respectively,  for the sum of residues of ME+HME+RME. The revised European criteria guide 
shows a hiatus for this kind of veterinary drugs with an established MRL for marker residues 
consisting of the sum of parent drug and its metabolites or analogous compounds. To estimate 
useful tolerance levels and validation values in this case, the levels of 60 and 400 µg/kg have to 
be divided between the examined analytes ME, HME and RME. A validation limit or an internal 
performance limit (IPL) of 10 and 50 µg/kg for muscle and liver tissue, respectively, was chosen. 
The two higher concentration levels were chosen at 20 and 60 µg/kg, 100 and 400 µg/kg for 
muscle and liver tissue, respectively, so that a broad validated concentration range was 
obtained. 
 
 6.2.8.2  Liquid chromatographic-mass spectrometric analysis 
The specific criteria for liquid chromatographic separation and mass spectrometric detection 
were checked during the whole validation procedure. Firstly, there is the retention time criterion 
for the LC analysis. The difference between the ratio of the retention time of the analytes in the 
validation samples to that of the IS, i.e. the relative retention time (RRT) of the analytes, and 
that of the matrix calibration standards was measured. Secondly, two parameters related to the 
MS detection have to be evaluated. Concerning the ion recognition, each diagnostic ion was 
measured when it had a S/N of at least 3/1. Furthermore, the difference of the relative 
intensities of the detected ions (RI), expressed as a percentage of the integrated area of the 
most intense ion, in the validation samples and these of the matrix calibration standards, was 
evaluated. 
 
 6.2.8.3  Stability 
The stability of refrigerated standard solutions was verified by determinations at two week 
intervals. Standard mixtures of ME+HME+RME at concentration ranges of 0, 50, 100, 250 and 
500 µg/l were prepared. The regression data and calculated values were compared with those 
obtained for freshly made solutions. 
 
 6.2.8.4  Specificity 
To evaluate the specificity, potential endogenous interferences were checked by analysing 20 
blank muscle and 20 blank liver tissue samples from different origin. Hindered identification by 
the multiresidue method was detected by analysing blank muscle and blank liver tissue samples 
spiked at 10 and 50 µg/kg, respectively, separately with HME, RME and OF, a benzimidazole 
substance very similar to the target compounds. Interferences on the quantification were 
evaluated by comparing the integrated peak areas of muscle and liver tissue samples spiked at 
10 and 50 µg/kg, respectively, with a mixture of OF+ME+HME+RME and a mixture of 
ME+HME+RME. 
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 6.2.8.5  Recovery 
Because no certified reference material of the examined compounds exists, the recovery 
efficiency instead of the trueness was determined. This validation parameter was calculated at 
the validation concentrations of 10, 20 and 60 µg/kg for muscle tissue, and of 50, 100 and 400 
µg/kg for liver tissue. Blank samples were fortified with mixed standard solutions and six 
replicates at each concentration were analysed. To be able to calculate the recovery, the IS was 
added after the extraction and the clean-up of the analytes, at the end of the sample preparation 
procedure. 
 
 6.2.8.6  Precision 
The precision was evaluated by determining the repeatability and the within-laboratory 
reproducibility. The repeatability was determined with a comparable procedure as was used for 
the evaluation of the recovery. Evidently, the IS was now spiked at the beginning of the sample 
preparation, before the clean-up procedure. To evaluate the within-laboratory reproducibility, for 
each concentration, the analyses were performed on five different days, with different mixed 
standard solutions and by two operators. To obtain six values, one value out of the repeatability 
data was taken. The precision is expressed as the relative standard deviation (sr value) 
calculated with the results of the repeatedly analysed samples. 
 
 6.2.8.7  Analytical limits 
The decision limit (CCα) is the concentration, above which it can be decided with a statistical 
certainty of 1-α that the identified residue content is truly above 60 and 400 µg/kg, the MRL 
values for sheep muscle and liver tissue, respectively. The decision limits of the described 
determination method for mebendazole and its metabolites are defined as the mean values of 
the calculated concentrations by determining blank tissue samples spiked at the respective MRL 
values with the analytes plus 1.64 times the corresponding standard deviations. Since this 
validation parameter was calculated with values already obtained for the determination of the 
repeatability and the within-laboratory reproducibility, no supplementary analyses had to be 
performed. 
To determine the detection limit (LOD), the criterion for calculation of the decision limit (CCα) 
was also used. The analyses were performed at the chosen IPL values of 10 and 50 µg/kg for 
muscle and liver tissue, respectively. The LOD of the presented analytical method for 
mebendazole and its metabolites was defined as the mean values of the calculated 
concentrations by determining spiked muscle and liver tissue samples plus 1.64 times the 
corresponding standard deviations. No supplementary analyses had to be performed. This 
validation parameter was calculated with already obtained values of calibration curves made for 
the determination of some other validation parameters. 
Chapter 6:  Determination of residues of mebendazole and its metabolites in sheep tissues by 
 liquid chromatography-tandem mass spectrometry 
 
144
 
To calculate the limit of quantification (LOQ), the criterion for determination of the detection 
capability (CCβ) was used. The LOQ values were calculated as the respective LOD values plus 
1.64 times the corresponding standard deviations of the measured concentrations by analysis of 
20 blank muscle and tissue samples spiked at the respective LOD values with the analytes. 
 
6.3  Results and discussion 
 6.3.1  Mass spectrometric detection 
Deuterated analytical standards of mebendazole and its metabolites are not available. 
Flubendazole was used as internal standard. FL is another benzimidazole substance which is 
very similar to mebendazole and which is only licensed for use in poultry species and in pig, but 
not for sheep. The described methods are only suitable for determination of residues in sheep 
tissues, which in practice are very unlikely to contain flubendazole residues. Furthermore, the 
MS/MS detection technique, based on the structure related principle, is a very powerful tool with 
a high separation capacity, a high specificity and a high sensitivity. Residues of flubendazole in 
unknown incurred samples will be detected immediately and can be compensated for. 
The identification and the determination of the examined anthelmintic compounds were 
performed by MRM. Two transitions from the molecular precursor ion (M+H)+ to the two most 
abundant product ions were measured. For the confirmation of the analytes involved in this 
study and belonging to substances of group B, veterinary drugs and contaminants of Annex I of 
Council Directive 96/23/EC, at least three identification points (IPs) have to be obtained when 
MS detection is applied.15 With the two involved MRM transitions, four IPs were obtained 
because the precursor ion accounts for 1 IP and its transition products earns 1.5 IPs. 
The mass spectrometer was tuned by infusion of individual standard solutions of each 
compound at a concentration of 1 µg/ml. The monitored cations and the MS operating 
parameters optimised for the procedure for liver as well as for muscle tissue, are given in Table 
6.1. The indicated ions are protonated. The specific mass spectra of each compound are 
presented in Figure 6.2. The full scan mass spectrum (a) shows the precursor (parent) ion. The 
product ions obtained by fragmentation of the precursor ion are presented in the MS/MS scan 
(b). 
An explanation for the fragmentation pathway of the precursor ions into the various product ions 
is given. The loss of –OCH3 from the analyte molecules gives rise to the fragments with         
m/z 264.4, 266.5 and 282.5 for ME, RME and the IS, respectively. The fragment with m/z 105.0 
for ME and HME originates from the loss of C6H5CO–. The fragment with m/z 95.1 from HME is 
obtained by loss of C6H5CO– and of –NHCNH2. The fragment with m/z 160.3 from RME can be 
explained by consecutive splitting off the fragments C6H5COH– and –OCH3. The fragments with 
m/z 191.3 and 159.2 for OF originates from the consecutive losses of C6H5SO– and of both 
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C6H5SO– and –OCH3, respectively. Fragmentation of the IS into –COC6H4F results in the 
remaining fragment with m/z 123.1. 
 
Table 6.1  Summary of diagnostic ions and MS operating parameters 
Analyte 
Precursor ion 
(m/z) 
Product ions 
(m/z) 
Cone voltage 
(V) 
Collision energy
(eV) 
  ME 296.4+ 264.4+a, 105.0+ 35b/35c 25b/30c 
  HME 238.3+ 105.0+a, 95.1+ 45b/48c 30b/33c 
  RME 298.5+ 266.5+a, 160.3+ 40b/40c 25b/34c 
  OF 316.5+ 191.3+a, 159.2+ 35b/40c 25b/22c 
  FL (IS) 314.5+ 282.5+a, 123.1+ 40b/40c 23b/29c 
a most abundant fragment ion     b liver tissue procedure     c muscle tissue procedure 
OF: oxfendazole     FL (IS): flubendazole (internal standard)  
ME: mebendazole    HME and RME: hydrolysed and reduced metabolites of mebendazole 
 
 6.3.2  Liquid chromatographic-mass spectrometric analysis 
Relatively simple, sensitive and reliable confirmatory assays using LC-MS/MS for the 
quantitative determination of residues of mebendazole and its metabolites in sheep liver, 
muscle, kidney and back fat tissues were developed. The presented methods were based on a 
formerly described method for the residues of flubendazole and relevant metabolites.16 
During the sample preparation of liver tissue, homogenisation was not necessary because of its 
relatively soft matrix. The sample preparation procedure for the other sheep tissues was based 
on the procedure used for the liver tissue. Previous recovery tests indicated that the relatively 
firm muscle tissue had to be homogenised in water to obtain a better extraction of the analytes. 
This sample preparation is based on the method described by Balizs.13 Preliminary laboratory 
tests indicated that the optimised sample preparation for muscle tissue could also be used for 
kidney tissue. With respect to the back fat tissue, the efficiency of the analyte extraction was 
improved when the moistened sample was heated before the first extraction and when the 
centrifugate was heated before the second extraction. For this tissue, the centrifugation time 
also had to be increased from 5 to 10 min to reach a sharp separation in the centrifuge tube.
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During sample preparation of muscle, kidney and back fat tissues, a multitube vacuum 
evaporator was used for the concentration of the sample extracts. This allowed a better 
reproducibility and increased capacity as compared to a separate evaporation as used in the 
previous research studies for sheep liver tissue and for flubendazole-derived residues in poultry 
tissues and eggs.16 The sample preparation is similar to that reported by Balizs.13 
Problems with unstability of the ammonium acetate buffer obtained in the previous method16 
were avoided by changing the mobile phase. A new LC separation method was developed. A 
very good LC-MS/MS separation was obtained with a mobile phase consisting of acetonitrile 
and water containing 0.1% formic acid to increase the ionisation intensity. A specifically 
developed gradient was applied. The chromatographic separation procedure developed 
previously for mebendazole-derived residues in sheep liver tissue was satisfactory and an 
identical mobile phase and gradiënt programme were used during the study of the other sheep 
matrices. To increase the detection limit, the cleaned sample volume injected into the            
LC-MS/MS apparatus was increased to 30 µl. 
The described method was validated for liver tissue in the limited concentration range of 50 to 
400 µg/kg. However, the presented LC-MS/MS method was able to detect mebendazole and its 
metabolites at residue concentrations even lower than 1 µg/kg. 
The described LC-MS/MS method was validated for muscle tissue at a IPL of 10 µg/kg. 
However, as can be estimated from the chromatogram in Figure 6.3, the presented method is 
able to detect mebendazole-derived residues at concentrations even lower than 2 µg/kg. The 
analyte response intensity is also depending on the cleanliness of the sampling cone and of the 
baffle plate of the mass spectrometer. Figure 6.3 presents an example of a chromatogram of a 
blank muscle tissue sample spiked with a mixture of ME, RME and HME at a concentration of 
10 µg/kg for each compound and with the IS at 50 µg/kg. Each measured transition from 
precursor ion to product ion delivers one peak so that two peaks per analyte are shown in the 
figure. The compounds were already eluted after 6.1 min. The column had to be conditioned 
further and the total run time was 25 min. HME and RME eluted approximately at the same 
retention time and were not separated chromatographically. However, because of the powerful 
separation capacity of the mass spectrometer in MRM mode based on the molecular mass,    
LC separation is not required and the specificity of LC-MS/MS analysis is very high (Figure 6.4). 
Thirty eight prepared samples could be determined per night. The sample preparation was more 
time consuming. Sixteen samples could be prepared during a 7-h working day. Because the 
stability of the sample extracts, the vials were collected and stored refrigerated until 
determination. 
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 Figure 6.3  Chromatogram of a blank muscle tissue sample spiked with a mixture of 
 mebendazole and its metabolites (10 µg/kg) and with the IS (50 µg/kg) 
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 6.3.3  Validation study 
 6.3.3.1  Liquid chromatographic-mass spectrometric analysis 
The quality of the chromatographic separation and of the mass spectrometric detection was 
examined by evaluating the specific criteria on RRT and RI for all the samples analysed during 
the validation study for liver and muscle tissues. For all the samples used to calculate the 
validation parameters, the values for RRT and for RI were conform with the European 
requirements.14 Using liver tissue as an example, the values for a sample spiked at 50 µg/kg 
and for a matrix calibration sample spiked at 50 µg/kg to evaluate the repeatability, are given. 
The values for the RRT in the spiked samples were 0.87, 0.41 and 0.40 for ME, HME and RME, 
respectively. These values were within the tolerance ranges of ±2.5% obtained with the values 
in the calibration samples namely 0.88±0.02, 0.42±0.01 and 0.41±0.01 for ME, HME and RME, 
respectively. The values for the RI in the spiked samples were 23, 14, 5 and 11% for ME, HME, 
RME and IS, respectively. These values fulfilled the allowed ranges obtained with the values of 
the calibration samples. These ranges were 23±25%, 14±30%, 5±50% and 11±30% for ME, 
HME, RME and IS, respectively. 
As an example for muscle tissue, the values of a sample spiked at 10 µg/kg and for a matrix 
calibration sample spiked at 5 µg/kg to evaluate the within-laboratory reproducibility, are 
reported. The values for the RRT in the spiked sample were 0.88, 0.36 and 0.37 for ME, HME 
and RME, respectively. These values were within the tolerance ranges of ±2.5% obtained with 
the values in the calibration samples, namely 0.88±0.02, 0.35±0.01 and 0.36±0.01 for ME, HME 
and RME, respectively. The RI values in the spiked sample were 47, 22, 41 and 44% for MEB, 
HME, RME and IS, respectively. These values were very close to those obtained for the 
calibration sample and are between the allowed ranges. These ranges were 47±25%, 22±25%, 
42±25% and 44±25% for ME, HME, RME and IS, respectively. 
 
 6.3.3.2  Stability 
Using standard analyte solutions, the linearity of the LC-MS/MS response was proven with five 
calibration points in the concentration range of 0 to 500 µg/l. The regression data and measured 
concentrations for the refrigerated standard solution were compared with those obtained for 
freshly made solutions at two week intervals. With the results obtained, it can be concluded that 
the stability of standard solutions of mebendazole and its metabolites was proven during the 
test period of two months. The values measured in the reference standard solution were very 
close to those of the freshly made standard solutions. 
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 6.3.3.3  Specificity 
The specificity of the described analytical assays for sheep liver and muscle tissues was 
proven. In none of the 20 blank liver and muscle tissue samples from different origin, 
endogenous interfering matrix material above the detection limit (S/N ≥ 3/1) could be detected. 
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 Figure 6.4   Chromatogram of a blank liver tissue sample spiked with the hydrolysed 
 metabolite of mebendazole at a concentration of 50 µg/kg 
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False positive or false negative results might be generated for mebendazole and its metabolites 
due to hindered identification. Therefore, oxfendazole, a substance with a benzimidazole 
structure very similar to the target compounds, was used. Blank samples were spiked 
separately with oxfendazole, the hydrolysed and the reduced metabolite of mebendazole and 
were analysed by the multiresidue method. OF eluted at 2.8 min. No false positive or false 
negative results were obtained. An example of the high specificity of LC-MS/MS analysis 
operating in MRM mode is demonstrated in Figure 6.4. Figure 6.4 presents a chromatogram of 
a blank liver tissue sample spiked with HME at 50 µg/kg and analysed with the multiresidue 
method for ME, RME and HME. Unless the fact that HME eluted at approximately the same 
retention time (2.1 min) as RME (2.2 min), no interference in the retention window of RME was 
measured. As expected, only noise could be detected in the retention window of ME. Because 
of the structure related detection, MS/MS detection is a very powerful tool with a high separation 
capacity and a high specificity. Also, the quantification of mebendazole and its metabolites was 
not influenced by the presence of oxfendazole in the samples. The differences in the peak 
areas between the samples with and without oxfendazole were very small and within the normal 
ranges for repeated analyses.  
 
 6.3.3.4  Recovery 
 Table 6.2 reports the mean recovery values obtained for blank liver and muscle tissue samples 
spiked with a mixture of the analytes. The recovery efficiency for the analytes in the sheep 
tissues was high. The recovery was somewhat higher for muscle tissue. The overall recovery 
values for ME, HME and RME in liver and muscle tissues were 92, 94 and 91%, and 93, 96 and 
96%, respectively. These values were within the permitted range of 80 to 110%. The variabilities 
on these recovery values were low and the relative standard deviations (sr values) ranged 
respectively from 8.3 to 10.9% and from 5.0 to 6.9% for the three substances in liver and 
muscle tissues at the different fortified concentrations. The variability was in agreement with the 
criteria on the Horwitz equation (sr = 2(1-0.5 logC), where C is the concentration expressed as a 
power of 10 (e.g. 1 µg/kg = 10-9)). The obtained sr values for liver tissue were lower than the 
maximum allowed values of 16.7, 15.1 and 12.2%, respectively for the residue concentrations of 
50, 100 and 400 µg/kg. The obtained sr values for muscle tissue were much lower than the 
maximum allowed values of 21.3, 19.2 and 16.3%, respectively for residue concentrations of 10, 
20 and 60 µg/kg.  
 The reported recovery values were much higher than those obtained by Balizs.13 This author 
obtained a recovery value of only 50% for ME in pig muscle. The recovery was probably 
negatively influenced by the supplementary sample clean-up. Hajee and Haagsma10 reported 
comparable recovery efficiencies for RME (92%), slighty lower values for ME (90%) and much 
lower values for HME (74%) in eel muscle tissue. Some 20 to 30% (obtained recovery values 
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 between 62 and 83%) lower values were reported by Steenbaar et al.9 for ME for the same 
muscle tissue. However, probably because of the intensive clean-up procedure, the variability 
was very low and the sr values were not more than 5%. Excellent analyte extraction efficiency 
(100 to 101%) was obtained by Al-Kurdi et al.11 for ME and HME in pharmaceutical dosage 
forms. 
 
 6.3.3.5  Precision 
 The precision of the method was evaluated by means of the repeatability and the within-
laboratory reproducibility. The precision of the method is described as the variability on 
measured mean residue concentrations of spiked samples and is expressed as sr values. The 
repeatability results are summarised in Table 6.3. The repeatability or within-day precision for 
analyses performed under repeatability conditions would have to be between half and two-thirds 
of the values according to the Horwitz equation.15 These allowed maximum values for the 
variability are 16.7, 15.1 and 12.2% for spiked concentrations of 50, 100 and 400 µg/kg in liver 
tissue, respectively. The repeatability of the determination of mebendazole-derived residues in 
liver tissue was good and ranged from 5.3 to 10.0%. The obtained mean concentrations were 
very close to the fortified concentrations. The allowed ranges for these mean values are 40 to 
55, 80 to 110 and 320 to 440 µg/kg for spiked concentrations of 50, 100 and 400 µg/kg, 
respectively. For muscle tissue, the allowed maximum sr values are 21.3, 19.2 and 16.3% for 
residue concentrations of 10, 20 and 60 µg/kg, respectively. A small deviation on the criteria for 
RME was observed. The obtained variability for the determination at a concentration level of   
20 µg/kg was 23.0% and somewhat higher than the upper limit value of 19.2%. The calculated 
mean values were close to the spiked concentrations. The permitted ranges for these mean 
values were 8 to 11, 16 to 22 and 48 to 66 µg/kg for fortified concentrations of 10, 20 and        
60 µg/kg, respectively. The method published by Hajee and Haagsma10 was more precise, 
giving a highest within-day repeatability of 4.8% in eel muscle tissue. Al-Kurdi11 reported a 
repeatability of 1.4% for the determination of ME in a synthetic matrix used for suspension 
formulation. 
 The analyses for the determination of the within-laboratory reproducibility were performed on 
different days, with different standard solutions and by two analysts. The results are presented 
in Table 6.4. The method showed an acceptable within-laboratory reproducibility. The variability 
on the obtained mean values is allowed to be higher than for the repeatability.15 The values 
should be lower than the values of the Horwitz equation which are 25.1, 22.6 and 18.3% for the 
spiked concentrations of 50, 100 and 400 µg/kg in liver tissue, respectively. The variability 
shown on these mean values was relatively high and the sr values ranged from 2.9 to 17.8%. 
The allowed ranges for the mean values obtained for determination of the within-laboratory 
reproducibility are equal as those for the repeatability and were fulfilled for the method used for 
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 liver and muscle tissue. The variability values on the measured mean concentrations in the 
spiked muscle tissue samples have to be lower than 32, 28.8 and 24.4% for concentrations of 
10, 20 and 60 µg/kg, respectively. The obtained within-laboratory reproducibility ranged from 6.2 
to 21.5% for HME obtained at concentrations of 10 and 20 µg/kg, respectively. 
 
 6.3.3.6  Analytical limits 
 The decision limits were calculated with already measured residue concentrations for blank 
muscle and liver tissue samples spiked at 60 and 400 µg/kg, respectively, for the determination 
of the validation parameters repeatability and the within-laboratory reproducibility. The mean 
values plus 1.64 times the corresponding standard deviations equals the decision limits. These 
CCα values of the analytical method for mebendazole, the hydrolysed and the reduced 
metabolites in muscle and liver tissues were 72.5, 69.2 and 69.8 µg/kg, and 445.9, 466.5 and 
463.4 µg/kg, respectively. 
The detection limits were calculated with the criterion for determination of CCα with data already 
obtained during the validation study for blank samples spiked at the respective IPL 
concentration for muscle and liver tissue of 10 and 50 µg/kg. The LOD values calculated as 
mean measured values plus 1.64 times the corresponding standard deviations for the 
determination of mebendazole, the hydrolysed and the reduced metabolites in muscle tissue 
were 11.0, 12.4 and 13.2 µg/kg, respectively. The LODs of the method for determination of ME, 
HME and RME in sheep liver tissue were 56.6, 61.8 and 64.2 µg/kg. 
The limits of quantification were obtained by analysing 20 blank muscle and liver tissue samples 
spiked at the respective LOD values for the three analytes. The respective LOD value plus   
1.64 times the measured corresponding standard deviation of the residue determinations equals 
the LOQ. The obtained LOQ values for the determination method for ME, HME and RME in 
muscle and liver tissues were 13.1, 15.2 and 15.8 µg/kg, and 60.0, 86.1 and 90.9 µg/kg, 
respectively. 
 
6.4  Conclusions 
The LC-MS/MS assays described in this chapter provide relatively simple, fast, sensitive, very 
specific and reliable procedures for the quantitative determination of residues of mebendazole, 
its hydrolysed and reduced metabolites in sheep muscle, liver, kidney and back fat tissues. The 
confirmatory methods for muscle and liver tissues are validated in accordance with the main 
lines of the revised EC requirements for detecting residues of veterinary drug substances in 
animal products. Validation at 0.5, 1.0 and 1.5 MRL was not applicable because the EC 
established the MRL values for the sum of ME+HME+RME. The rules for validation of methods 
needed for depletion studies to be performed by veterinary drugs companies, were taken into 
account. The lowest possible detection limits were not studied. All examined validation 
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parameters in liver tissue fulfilled the requirements with respect to the tolerance levels. Except 
for one small deviation for the repeatabilty of the RME determination, the examined validation 
parameters fulfilled the requirements for muscle tissue. 
 The presented determination methods were used to analyse sheep tissues for mebendazole-
derived residues in a depletion study. This depletion study is reported in Chapter 10. 
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Abstract: 
 
Residues of tetracycline antibiotics in eggs and broiler muscle tissue were determined during 
and after oral administration of medicated feed. Medicated feed containing 840 mg of 
oxytetracycline per kg was provided to laying hens for seven successive days. Two days after 
the administration was ceased, the mean oxytetracycline residue value in eggs was already 
lower than the MRL level (200 µg/kg) and reached 118 µg/kg. Broiler chickens were supplied 
with medicated feed containing 480 mg of tetracycline per kg for seven successive days. Four 
days after the administration was stopped, the mean tetracycline residue value in breast 
muscle tissue declined below the MRL value and was 86 µg/kg. 
 
Keywords: tetracycline residues, eggs, chicken muscle tissue, HPLC 
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7.1  Introduction 
 7.1.1  Usage of tetracyclines for laying hens and broilers 
Tetracycline antibiotics (TCA’s) are broad-spectrum antibacterial compounds, widely used in the 
prevention and treatment of diseases of food-producing animals. The commonly used TCA 
drugs in veterinary medicine are tetracycline (TC), oxytetracycline (OTC), chlortetracycline 
(CTC) and doxycycline (DC). Among the antibiotics, TCA’s are most used in poultry husbandry 
because of their broad antibacterial spectra.1 However, since the incidence of resistant strains is 
very high, these antibiotics are prescribed less than in the past. Administration of tetracycline 
antibiotics results in healthier and faster-growing animals.2 TCA’s have been used to minimise 
poultry diseases such as chronic respiratory disease, blue comb and infectious sinusitis. Control 
of infectious synovitus, infectious coryza and fowl typhoid are also described.3 TCA’s will also 
act against some pathogenic agents unaffected by other antibiotics e.g. rickettsiae and certain 
large viruses belonging to the psittacosis group in animals.4 Kan5 reported that due to there 
cost-effectiveness and in spite of the increasing resistance, these drugs are still widely used in 
the poultry industry mostly as prophylactic agents for broiler chickens to prevent general 
infections and, in particular, respiratory diseases. The infection pressure on laying hens is much 
lower and for these poultry species, TCA’s are only useful for therapeutic purposes. 
OTC is the commonest intramuscularly administered TCA.4 CTC should not be administered 
intramuscularly because of severe tissue irritation and destruction. DC is more completely 
absorbed and is more slowly excreted than most other TCA’s. It has longer duration of action 
with attendant advantages of a smaller required dose and a less frequently administered 
maintenance dose. DC is useful as therapeutic agent in psittacine birds because of the 
favorable pharmacokinetic parameters to achieve high systemic concentration for longer periods 
than the more traditional CTC and OTC. Croubels et al.6 described DC as a broad-spectrum 
antibiotic which is widely used in the treatment of respiratory tract infections in various species. 
DC is widely used because of its advantageous pharmacokinetic properties.4,7 These include a 
better bioavailability from the gastrointestinal tract, a stronger lipophilic character and a higher 
affinity for tissues. However, the higher lipid solubility of DC may result in higher and more 
persistent residue amounts in edible tissues.3,7 
 
 7.1.2  Metabolism of tetracyclines 
Rational use of an antimicrobial drug in the treatment of an infectious disease, caused by a 
bacterial agent, requires knowledge not only of the susceptibility of the pathogen to the drug but 
also of its concentration in the body fluids of the treated animal.8 Tetracycline antibiotics are 
metabolised to various degrees.4 The most frequently identified substance in urine, faeces and 
tissues is the parent TCA. As much as 30% will be excreted unchanged in the faeces. TCA’s 
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are reversibly bound to plasma proteins and are widely distributed in the body. They are 
removed from the blood by the liver and high concentrations can be found in the bile. 
Most of the data documented in the literature deal with the epimerisation of TCA’s. Several 
publications describe metabolites obtained after isomerisation of the parent molecule. As 
example for all TCA’s, the chemical structure and full scan MS spectra of the 4-epimer and the 
6-isomer of CTC are presented in Figure 7.1.9 The full scan MS spectra were obtained by 
 
 
 Figure 7.1  Chemical structures and full scan MS spectra of chlortetracycline (a) 
     4-epi-chlortetracycline (b) and 6-iso-chlortetracycline (c)9 
 
atmospheric pressure chemical ionisation. CTC, 4-epi-chlortetracycline (4-epi-CTC) and           
6-isochlortetracycline (6-ICTC) show ions with the same m/z, but these analytes could be 
separated chromatographically. 
After administration of TC and CTC to animals, these parent substances and their metabolites, 
4-epi-tetracycline (4-epi-TC) and 4-epi-chlortetracycline (4-epi-CTC) are excreted.10 
Isochlortetracycline (ICTC) and 4-epi-isochlortetracycline (4-epi-ICTC) are not known as major 
mammalian CTC metabolites, but CTC is known to be degraded to its isomers under alkaline 
conditions. This might be the reason for the degradation of CTC to isochlortetracycline and its  
4-epimer in slurry. The degradation products of CTC have no antimicrobial activity. 
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Zurhelle et al.11 described the metabolites of OTC, TC and CTC and their distribution in egg 
white, egg yolk and hen plasma in feeding studies with either OTC, TC or CTC. These authors 
concluded that any residue besides the parent compounds in egg and plasma samples must 
have its origin from the in vivo metabolisation. The epimerisation rates of OTC, TC and CTC 
were constant during the whole medication period. The residue concentrations for TCA’s in egg 
yolk are higher than in egg white. 4-epi-tetracycline (4-epi-TC) and N-demethyltetracycline were 
detected as metabolites of TC in egg yolk and plasma. Metabolism of OTC resulted in              
4-epi-oxytetracycline and N-demethyloxytetracycline in these matrices. Twenty one to 24% of 
the OTC was epimerised in egg yolk. The epimerisation rate for TC was 41-50% in egg yolk and  
22-26% in egg white. N-demethylation rates for OTC and TC were 7-8 and 18-21%, 
respectively, in egg yolk. 6-ICTC, 4-epi-CTC, 4-epi-ICTC and N-demethylisochlortetracycline 
were detected as metabolites of CTC. The obtained ratios of epimerisation and N-demethylation 
in eggs did not change during the medication period. The epimerisation rates for ICTC (55-57%) 
and CTC (41-45%) in yolk were constant during the medication period. The epimerisation rate 
for ICTC in egg white was 22%.  
Croubels et al.7 described a liquid chromatographic separation method for DC and                   
4-epi-doxycycline (4-epi-DC) in a tissue depletion study for DC in turkeys. The metabolite         
4-epi-DC is an antibacterially inactive epimer of DC which is spontaneously formed in an acidic 
medium at a pH between 2 and 6. These authors concluded that probably the degradation 
compound was partially formed in vivo and to a lesser extent during sample preparation. 
However, additional studies are necessary to confirm this hypothesis. Moreover, a 4-epi-DC 
peak was detected in both incurred turkey liver and muscle tissues, though to a lesser extent in 
the latter. 
Kennedy et al.9 reported that the reversible epimerisation of CTC to 4-epi-CTC also can occur 
under mild acidic conditions. These authors also studied the metabolism of chlortetracycline in 
eggs of laying hens fed with a therapeutic dose and with a subtherapeutic dose (feed 
contamination level). They reported that residues of 6-ICTC plus 4-epi-6-isochlortetracycline 
rapidly accumulate to concentrations equivalent to more than twice the current MRL value of 
200 µg/kg. Residues of these metabolites were also detected after treatment with the low-level 
dose. It was unlikely to obtain mean residue concentrations in excess of 200 µg/kg. These 
authors could not explane whether these metabolite compounds are formed as a result of either 
metabolism or of chemical degradation. 
Capolongo et al.12 reported a depletion study of turkeys treated with OTC via drinking water. At 
the first day after the end of treatment, 4-epi-OTC was detected at very low concentrations       
(< 26 µg/kg) in muscle tissue, in liver tissue after 1 and 3 days of the withdrawal period and in 
kidney tissue at all sampling times until 5 days of the withdrawal period. 
A residue study of DC and 4-epi-DC in pigs medicated via drinking water was reported by 
Croubels et al.6 Comparable residue concentrations for DC and its metabolite 4-epi-DC were 
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measured in kidney 3 days after cessation of the medication. However, the detected response 
in liver tissue was much higher for the metabolite. 
The marker residues of the MRLs for TC, OTC and CTC are set as the sum of the parent 
compound plus its 4-epi derivative. 
 
7.1.3  Distribution of tetracycline residues in eggs 
A large number of studies on drug residues in eggs and edible poultry tissues have been 
published.13 Since the experimental designs widely varied, it is difficult to compare the obtained 
results. In general, the results show that the clearance times vary from a few days in edible 
tissues to 1 or 2 months in eggs. There is a close correlation between the physiological 
development of eggs and the length of time in which drug residues are found in egg white and 
yolk. Recent results indicate that the developing egg yolk serves as an important storage depot 
for chemical residues. 
Kan and Petz14 reported the distribution of residues of veterinary drugs between yolk and white 
in eggs in detail. When drug substances reach the bloodstream, they are distributed over the 
whole body. In the laying hen, this includes the ovary with growing follicles and the oviduct, 
where the egg white is formed and secreted. The amount of residues of drug substances or 
their metabolites in each tissue depends on their physicochemical characteristics. Due to the 
physiological processes of egg formation, the pharmacokinetics of drug residues in egg yolk 
and white show the following common features. Drug residues first occur in egg white, at least if 
the drug is distributed towards that compartment. Residues in egg white are a reflection of the 
plasma concentrations and will therefore show a constant concentration over time when plasma 
levels are constant. The time needed to achieve a constant concentration in egg white is 
generally 2-3 days. Residues in yolk reflect the plasma concentrations during the 10 days of 
their rapid growth. Residues of drugs in yolk generally require exposure for 8-10 days to reach a 
constant concentration. Disappearance of drugs from white and yolk heavily depends on the 
plasma concentrations of the drug tested. Drugs that rapidly clear from the body also disappear 
from egg white in 2-3 days after cessation of exposure. Disappearance of drugs from yolk 
generally takes 10 days. 
Traditionally, the rather lipid-soluble drugs are expected to yield residues only in the fat-rich 
yolk. However, the rather lipid-soluble DC drug showed higher residues in white than in yolk 
during long-term administration. Yoshimura et al.3 also made this conclusion. In spite of 
similarities in structure between DC and OTC, DC was deposited in higher concentrations and 
lasted in eggs for a longer period. This characteristic was considered to be due to its greater 
lipophilicity, closely correlated with oral absorption and tissue penetration. 
Several research workers reported that residue concentrations of TC, OTC or CTC in egg yolk 
are higher than in egg white.1,11,15,16 
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Donoghue17 described mechanisms regulating drug and pesticide residue uptake by egg yolk 
and developed predictive models. This author reviewed the physiology of egg yolk formation 
and its relation to residue incursion. Models were developed to understand and to quantify 
residue patterns. Magnetic resonance imaging was used to detect residue incorporation into 
eggs. The results obtained support the hypothesis that residues are sequestered in developing 
pre-ovulatory egg yolks and that they can be contained in laid eggs for weeks after the 
withdrawal period of the drug. The model is very useful for predicting residues in laid eggs 
following a hen’s exposure to chemicals with short half-lives, such as many veterinary or 
production drugs used by the poultry industry. 
Another publication of Donoghue and Myers18 was conducted to visualise incorporation and 
potential compartmentalisation of drug residues in developing egg yolks. Following dosing of 
hens, high-resolution magnetic resonance images of drug residues in eggs indicate that drugs 
can be incorporated and compartmentalised into ring structures within individual developing egg 
yolks. The significant human food safety implications are that sequestered drug residues may 
be stored and released later to contaminate eggs for days to weeks after dosing.  
Donoghue and Hairston19 studied the OTC transfer into egg yolk or albumen (egg white protein) 
of laying hens fed with the approved doses of OTC (50 and 200 g OTC per 1000 kg) for breeder 
hens and broilers. Residues of OTC were not detectable during the predosing, dosing or 
withdrawal period in egg yolks. OTC residues were detectable (100 to 120 µg/kg) however, in 
egg albumen during the fifth day of treatment and the first day of the withdrawal period. These 
data indicate that illegal or unintentional dosage of laying hens with feed medicated at doses 
allowed for breeder hens or broilers should not necessarily cause detectable residue 
concentrations of OTC in eggs. 
 
 7.1.4  Objectives 
The widespread use of tetracycline antibiotic veterinary drugs in the poultry industry may also 
cause residues in eggs, muscle tissue and other foodstuffs of poultry origin. Some drug 
residues or its metabolites may be deposited in eggs, as well as in muscle tissue.16 After 
metabolism, some antibiotics are excreted while others are stored in the tissues. The residue 
concentrations could be particularly high in foodstuffs if the recommended withdrawal times are 
not respected. The MRL values set by the EC20 for TC, OTC and CTC in eggs are 200 µg/kg, 
measured for the marker residue consisting of the sum of parent drug plus its 4-epimer 
metabolite compound. DC is not allowed by the EU for laying hens. The MRLs in muscle tissue 
of broiler chickens for TC, OTC, CTC and DC are 100 µg/kg. The marker residue for TC, OTC, 
CTC also is the sum of the parent plus its 4-epimer. 
Meridith et al.2 studied the depletion of chlortetracycline in eggs after oral treatment of laying 
hens with medicated feed. Roudaut et al.15 studied the excretion of tetracycline and 
chlortetracycline in eggs after oral medication of laying hens either through drinking water and 
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feed. Yoshimura et al.3 described the depletion of doxycycline in eggs after medication of laying 
hens via drinking water for seven consecutive days. Kennedy et al.9 reported the metabolism of 
chlortetracycline with drug accumulation and excretion results in eggs after oral treatment of 
laying hens with medicated feed. Zurhelle et al.11 performed depletion studies of tetracycline 
and doxycycline after oral treatment of laying hens via medicated feed. The parent drug 
residues and the metabolites were measured in eggs and plasma.  
To our knowledge, available depletion data for oxytetracycline in eggs after oral administration 
with medicated feed are rather scarce or old.1,2,3,11,16 Meridith et al.2 administered oxytetracycline 
to laying hens with feed containing 1000 mg of OTC per kg feed mixture. However, the residue 
concentrations in the eggs were measured by a microbiogical inhibition method. The effects of 
egg cooking processes as poaching and scrambling on the drug residues in the eggs were 
observed. Roudaut et al.1 described the kinetics of oxytetracycline elimination into eggs after 
oral administration through either drinking water or feed (300 and 600 mg of OTC per kg feed 
for seven successive days) and after intramuscular injections. However, the residues were also 
assayed by a microbiological agar diffusion method. Other residue studies of oxytetracycline in 
eggs after medication of laying hens via drinking water were reported by Yoshimura et al.3 and 
Omija et al.16 Also, these authors used microbiological inhibitor assays for their drug residue 
determinations. A more specific approach was applied by Zurhelle et al.11 by using HPLC-UV for 
investigating the occurence and distribution of residues of oxytetracycline in egg white and egg 
yolk. These research workers treated laying hens orally with feed medicated with OTC at 750 
and 3000 mg per kg. However, the study mainly focused on the metabolism and the occurence 
of metabolites of OTC in eggs. The depletion data were not reported in detail. 
Meridith et al.2 also reported chlortetracycline and oxytetracycline residues in liver, breast and 
thigh tissues of broiler chickens after oral administration of the drug substances via medicated 
feed. Black21 studied the pharmacodynamics of oxytetracycline in broiler chickens. The birds 
were orally, intramuscularly or subcutaneously treated and the disposition of oxytetracycline in 
tissues was measured. Croubels et al.7 determined the depletion of doxycycline in liver and 
muscle tissues of turkeys treated with medicated drinking water. The depletion of 
oxytetracycline in muscle, liver and kidney tissues of turkeys administered with OTC via 
medicated drinking water, was described by Capolongo et al.12  
No recent depletion data about tetracycline in chicken muscle tissue could be found in the open 
literature. Anadon et al.8 described the pharmacokinetics of tetracycline by means of plasma 
levels and biliary excretion in broiler chickens after intravenous administration. 
The objective of this study was to follow the disposition and distribution of residues of 
oxytetracycline in eggs and of tetracycline in chicken breast muscle tissue during and after oral 
medication of laying hens and broiler chickens, respectively. The animal treatments were 
performed at the Department of Animal Nutrition and Husbandry, Section Small Stock 
Husbandry (DVV-CLO, Merelbeke, Belgium). The residue analyses were carried out at the 
Chapter 7:  Depletion of tetracyclines in eggs and broiler muscle tissue 
 
169
 
Department of Animal Product Quality and Transformation Technology (DVK-CLO, Melle, 
Belgium). 
 
7.2  Materials and methods 
 7.2.1  Veterinary drug products 
Virginiamycine was supplemented as feed antibiotic in the feed rations of laying hens and of 
broiler chickens by means of StafacR (Smith-Kline, Rixensart, Belgium). The broiler chickens 
were vaccinated against Newcastle disease with Hitchner spray (Intervet, Boxmeer, The 
Netherlands) and against infectious bronchitis with H120 spray also purchased from Intervet. 
The vaccination against Newcastle disease was repeated with La Sota (Clone 30) delivered by 
Intervet. The oxytetracycline medicated feed for the laying hens contained OTC-hydrochloride 
obtained from VMD (Arendonk, Belgium). The prescribed withdrawal time after treatment of 
laying hens with this veterinary drug product is 14 days. The tetracycline medicated feed for the 
broiler chickens was prepared with TC-hydrochloride received from Wolfs-Kela & Eurovet 
(Heusden-Zolder, Belgium). The recommended withdrawal time for broiler chickens medicated 
with this veterinary drug product is seven days. 
 
 7.2.2  Animal treatments 
 7.2.2.1  Laying hens 
Twenty 64-week-old laying hens of the Isa Warren strain were used in the trials. Average egg 
production was about 75%. The hens were fed a mash ration containing 11.71 MJ AMEn/kg 
(apparent metabolisable energy, corrected for N-retention = 0) and 16.8% crude protein (CP). 
The diet contained 110 mg of StafacR per kg. Feed and drinking water were provided ad libitum. 
The hens were caged individually one week before the start of the medication. During this 
observation period, a few eggs were taken as blank control samples. Oxytetracycline was 
supplemented at a therapeutic level of 840 mg per kg diet. The medicated feed was supplied for 
seven consecutive days. The individual feed consumption was determined during this 
administration period. During the experimental period, eggs were collected twice a day at 8 a.m. 
and 3 p.m. The eggs were refrigerated until determination of the OTC residues. As stipulated by 
EU legislation concerning antibiotic residue studies, ten eggs per day were analysed. 
 
 7.2.2.2  Broiler chickens 
Day-old male and female broilers (Ross ‘208’, 75 of each gender) were obtained from a 
commercial hatchery. They were reared separately under infra-red bulbs. The broiler chickens 
received a diet containing 12.6 MJ AMEn/kg and 22% CP. Their ration also contained StafacR at 
a concentration of 40 mg/kg. Feed and drinking water were provided at libitum. The broilers 
were vaccinated the first day of age against Newcastle disease (Hitchner spray) and bronchitis 
Chapter 7:  Depletion of tetracyclines in eggs and broiler muscle tissue 
 
170
 
(H120 spray). At 16 days of age the vaccination against Newcastle disease was repeated with 
La Sota (Clone 30). At 19 days of age, during the observation period and when a vaccination 
reaction was no longer expected, some birds were sacrified, after stunning, by cervical 
dislocation. The breast muscle tissue was removed for investigation as blank control muscle 
tissue. Tetracycline was supplemented at a therapeutic dose level of 480 mg per kg diet. The 
broilers were provided with the medicated feed for seven consecutive days. Following EU 
legislation concerning antibiotic depletion studies, the breast muscle tissue of six broiler 
chickens was investigated daily. During the experimental period, three males and three females 
were weighed individually and slaughtered. These birds were taken ad random. The breast 
muscle tissue samples were refrigerated until investigation. The feed consumption per gender 
was determined during the observation time and the administration period. 
 
7.2.3  Analysis of medicated feed 
The concentrations of oxytetracycline and tetracycline in the medicated feeds were determined 
in the State Analysis Laboratory at Tervuren (Belgium). 
 
 7.2.4  Drug residue analysis 
The residue concentrations of oxytetracycline in the egg samples and of tetracycline in the 
breast muscle tissue samples of the broiler chickens were determined with the quantitative 
HPLC-DAD method described in Chapter 2. 
 
7.3  Results and discussion 
 7.3.1  Disposition of oxytetracycline in eggs 
The OTC residue values in eggs during (day 0 until day 7) and after (day 8 until day 17) 
medication of the laying hens are shown in Figure 7.2. Medicated feed was supplemented on 
day 0 and was changed for a normal feed ration on day 7. Each data point of the excretion 
curve represents the mean OTC residue concentration of ten eggs of ten different hens. To 
have ten eggs daily during the whole experimental period, 14 laying hens in total were needed 
for this investigation. The ranges of the residue concentrations of the individual eggs are 
indicated in Figure 7.2. The individual variation was high, especially during the medication 
period. As example, the OTC residue values ranged from 92 to 418 µg/kg on day 7. This 
fluctuation is mainly caused by physiological differences, but is also influenced by variations in 
feed intake and in egg weight. The mean residue values of each data point are also 
summarised in the inset-table in the figure. 
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The feed intakes observed during the administration period and the mean egg weights are 
summarised in Table 7.1. The daily feed intake ranged from 97.1 to 132.1 g. The mean egg 
weights varied from 57.8 to 71.8 g. 
 
 Table 7.1   Feed intakes and main egg weights of laying hens medicated orally 
 with 840 mg oxytetracycline per kg feed 
Hen 
Feed intake 
(g/day) 
Egg weight 
(g) 
               1            107.0 62.1 
               2            108.3 65.3 
               3            113.9 66.6 
               4            105.9 71.8 
               5            132.1 57.8 
               6            109.3 60.0 
               7              97.1 58.6 
               8            121.4 71.7 
               9            118.6 61.2 
             10            100.0 64.9 
             11            121.4 67.0 
             12            115.4 63.7 
             13            119.6 63.4 
             14            122.1 61.6 
 
After one day of administration, an OTC residue concentration of 38 µg/kg was already 
obtained. This rapid excretion could be expected because tetracyclines are readily absorbed to 
give peak blood plasma concentrations a few hours already after starting oral administration.4,21  
It took some five days before a plateau residue concentration in the eggs could be observed. 
On day 5, the OTC concentration reached a value near the MRL level (200 µg/kg). The residue 
values were fluctuating arround this level during the next two days of the administration period. 
On day 9, two days after ceasing of the administration, the residue value has already fallen 
below the MRL level. Afterwards, the residue level decreased slowly. This slow excretion can be 
explained by the persistence of tetracyclines in blood following absorption in contrast with other 
antibiotics which are eliminated more readily.4 Black2 obtained lower OTC residu concentrations 
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in tissues and noted a slower depletion after oral administration compared with intramuscular 
and subcutaneous medication. Also, Anadon et al.8 measured a slower excretion for tetracycline 
via the bile after oral medication. 
On day 17, ten days after ceasing the administration, a mean OTC residue concentration of    
26 µg/kg was obtained and the analyses were stopped because some of the ten individual 
figures approached the limit of quantification of 13 µg/kg. 
The presented results, to a certain extent, confirm published studies although they were not 
always conducted in similar conditions. Meredith et al.2 observed maximum OTC residue 
concentrations of 580 µg/kg in eggs of hens fed with medicated feed containing 1000 mg of 
OTC per kg. Roudaut et al.1 used a lower dose of 600 mg per kg of feed and measured a 
plateau level in OTC residue concentration of 250 µg/kg during day 6 and 7 of the medication. 
Zurhelle et al.11 reported a lower maximum OTC residue concentration of 120 µg/kg measured 
at day 14 after administration of medicated feed with 750 mg of OTC per kg feed.  
Yoshimura et al.3 compared the depletion of OTC and DC in eggs after medication of laying 
hens via drinking water at the recommended dosage for OTC of 0.5 g/l. The mean peak residue 
values were 5 times higher in yolk and more than 10 times higher in albumen for DC than for 
OTC. This depletion characteristic of DC is considered to be due to its greater lipophilicity, 
causing more efficient absorption and tissue penetration. 
Clearly, oxytetracycline does not accumulate very strongly and hence does not show high 
residue values in eggs. Huber4 reported that tetracyclines diffuse throughout the body and are 
found in highest concentrations in kidney, liver, spleen and lung. Tetracyclines also incorporate 
in chicken and turkey egg shells. Zurhelle et al.11 observed that only these shells of eggs 
sampled on the medication period showed a characteristic yellow fluorescence of the calcium-
tetracycline complex when irradiated with long-wave UV. 
Roudaut et al.1 calculated the total excretion of OTC into eggs. Between 0.015 and 0.020% of 
OTC supplied was recovered after oral administration and 0.22-0.24% after a intramuscular 
route. This means that the passage of OTC in egg was about 10 times higher by the latter route. 
Incomplete intestinal absorption in case of oral administration causes the lower disposition of 
OTC in eggs. TCA’s form complexes with bivalent ions such as Ca++ in the digestive tract, which 
markedly diminishes their absorption. Black21 reported that birds receiving the OTC drug orally 
tended to have considerably lower residue concentrations in their tissues. However, there was a 
tendency for residues to remain for a longer period of time. Oral administration of OTC 
apparently was a less efficient route. However, because of the savings in labour, the oral 
medication via feed or drinking water is the preferred route. A significantly greater quantity of 
drug appears to be required. Administration of antimicrobials to poultry via the drinking water is 
carried out widely in tropical countries, where the amount of drinking water consumed is 
considerably larger (350 ml per day per hen) than in moderate zone (200 ml per day per hen).1,3 
Even if the quantity of oxytetracycline ingested daily in the case of oral administration can not 
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be precisely determined, the holding conditions used in the described experiments offered the 
advantage of being very close to the practise in large breeding farms of laying hens. 
Some research workers studied the distribution of OTC residues between egg yolk and egg 
white.1,3,16 In all cases, it was in the egg yolk that OTC residues were present earlier after 
starting medication, that a higher maximum concentration was reached and that the clearance 
time was longer. Omija et al.16 confirmed that at higher dosages, OTC was found in the albumen 
and reached a maximum concentration faster in the albumen than in the yolk. The 
concentrations persisted for a longer period in the yolk. Clearly, the withdrawal period depends 
on the dosages of OTC administered. 
Although oxytetracycline residues are heat labile, the presence of antibiotic residues in eggs 
might cause some risks for the consumer’s health. OTC residues are totally destroyed by a 
thermal treatment at 100°C for 5 min, through formation of either inactive derivatives as            
4-epi-OTC and α- or β-apo-oxytetracycline. They are partially degraded by 60% or 80% whether 
the eggs are poached or scrambled.2,22 The temperature during cooking had the largest impact 
on the loss. 
 
 7.3.2  Disposition of tetracycline in breast muscle tissue of 
  broiler chickens 
The disposition of TC residues in breast muscle tissue of broilers during (day 0 until day 7) and 
after (day 8 until day 14) oral administration is presented in Figure 7.3. The shown excretion 
curve is drawn with mean values calculated with the residue values of six broilers, three males 
and three females. The mean residue values of each data point of these trials are also 
summarised in the inset-table in the figure. 
The range of the individual residue concentrations is indicated in Figure 7.3. The variability of 
the residue values during the medication period was high but somewhat lower than those 
obtained for the depletion of OTC in eggs. These residue fluctuations are mainly caused by 
physiological differences but also by variations in antibiotic intake and feed conversion. The 
observed mean daily feed intake during the medication period was 106.8 g for males and 88.1 g 
for females. The mean value and the relative standard deviation (sr value) of the broiler weights, 
obtained just before slaughter, are also presented in the inset-table in the figure. 
Following the oral administration, tetracycline is rapidly absorbed and efficiently distributed to 
breast muscle tissue of the broilers in the trials. On day 0, the birds were slaughtered only a few 
hours after supplying the medicated feed and the TC concentration already reached 41.7 µg/kg. 
Huber4 reported that following oral administration, TCA’s are readily absorbed from the stomach 
and the small intestine to give peak plasma concentrations in 2-4 h. Plasma concentrations of 
TC and OTC administered intramuscularly are detectable within 15 min, reach a peak within 1 h, 
maintain significant blood concentrations for about 12 h and decline to trace amounts 
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approximately 24 h after injection. Black21 was able to detect a measurable OTC peak              
(> 100 µg/l) in the blood serum of day-old chickens already 1.5 h after oral administration of a 
very low dosage of 5 mg per kg feed. This assessment is also in accordance with other 
published TCA depletion data. Anadon et al.8 measured a maximum TC plasma concentration 
of 690 µg/ml already 15 min after intravenous treatment of broiler chickens at a concentration of 
65 mg per kg body weight (BW). Capolongo et al.12 reported a mean maximum OTC residue 
concentration of 126 µg/kg in muscle tissue of turkeys already 1 day after cessation of the oral 
treatment of the birds via the drinking water with a varied dose of 57 to 103 mg/kg BW during 
three consecutive days. Croubels et al.7 found a similar rapid absorption for DC in turkey muscle 
tissue. However, these authors obtained much higher residue concentrations due to the higher 
lipid solubility of this antibiotic drug substance. A mean DC residue value above 2000 µg/kg was 
measured 12 h after last dosage of a medicated drinking water at a total daily dose of 25 mg/kg 
BW during four successive days.  
The obtained residue accumulation of TC in breast muscle tissue was very high. The applied 
therapeutical TC dosage level in the feed in the experiment (480 mg per kg) was also higher 
than the recommended dose of 50 to 450 mg OTC per kg reported by Black.21 On day 1, the  
TC residue concentration was already higher than 1000 µg/kg. A maximum TC concentration in 
the breast muscle tissue was found on day 2 and reached 1219 µg/kg. Meredith et al.2 reported 
a maximum OTC residue value of 1440 µg/kg in poultry muscle tissue after oral treatment of 
broilers with medicated feed containing 1000 mg of OTC per kg feed.  
A plateau residue concentration in the depletion curve in Figure 7.3 is already obtained after 
one day of medication which afterwards decreased until the end of the administration period. On 
day 7, a mean residue value of 694 µg/kg was obtained. This decreasing tendency is probably 
mainly caused by an increase of the feed conversion.  
The absorption of tetracycline in breast muscle tissue appears to be higher than the absorption 
of oxytetracycline in eggs. The maximum residue concentration for OTC in eggs was 210 µg/kg 
compared with a maximum TC residue concentration of 1219 µg/kg in muscle tissue. 
After the medication was stopped, the TC residue concentration decreased very rapidly. On day 
11, four days after the administration was stopped, the TC concentration was 86 µg/kg and 
declined below MRL level (100 µg/kg). Afterwards the residue concentration decreased slowly. 
On day 14, seven days after ceasing administration, a residue concentration of 39 µg/kg was 
still found. On day 15, the TC residue concentration of two samples was below the limit of 
quantification of 20.9 µg/kg. Anadon et al.8 and Black12 also obtained a slow elimination of 
tetracyclines after oral administration. Anadon et al.8 also observed a deep tissue sequestration 
of the TC drug and suggested a slow elimination process. Huber4 reported that TCA’s persist in 
blood following absorption in contrast with other antibiotics that are eliminated more rapidly. 
Black12 compared the depletion of OTC in tissues and serum of day-old and one-week-old 
broilers after either oral, intramuscular or subcutaneous administration of the birds. The birds 
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receiving the drug orally tended to have considerably lower concentrations of OTC in their 
tissues. However, this author observed a tendency for residues to remain for a longer period of 
time. 
Meredith et al.2 studied the difference in OTC depletion in several tissues of laying hens fed 
during 6 months with feed medicated with 1000 mg of OTC per kg feed. The greatest antibiotic 
residue concentration was measured in the liver (4050 µg/kg). The highest residue 
concentration in muscle tissue was generally found in dark meat taken from the thigh          
(1440 µg/kg) of the bird. The lowest residue concentration was measured in the breast muscle 
tissue (1200 µg/kg). 
As Meridith et al.2 have reported, adequate heat treatment of broiler chicken muscle tissue as 
well as of eggs before consumption will further minimise the tetracycline residue concentrations. 
The effect of a range of heating processes including microwaving, boiling, roasting, grilling, 
braising and frying on OTC residues in incurred animal tissues was also investigated by      
Rose et al.22 Substantial net reductions in OTC concentration of 35-94% were measured. 
Migration of residues from the tissue into the surrounding liquid or meat juices was observed 
during the different heating processes. 
 
7.4  Conclusions 
From the described depletion studies for OTC in eggs and for TC in broiler breast muscle tissue 
can be concluded that when the recommended withdrawal periods of 14 days for use of OTC 
for laying hens and seven days for use of TC for broiler chickens are respected, there is no risk 
for the public health. After these periods of time, the obtained residue concentrations were far 
below the MRL levels. However, the total elimination of tetracycline residues via eggs and via 
breast muscle tissue after oral administration takes several days. 
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Abstract: 
 
The disposition and distribution of levamisole in milk of dairy cows medicated with two doses 
was investigated. Cows were separately topically treated with a recommended dose of 10 mg 
for non-lactating cows and a higher dose of 20 mg of levamisole per kilogram body weight. 
Seven hours after administration of the recommended dose, a maximum residue value of    
1896 µg/l was measured in the milk. Seventy nine hours after the treatment, the mean 
levamisole concentration had declined to 21 and 83 µg/l for the low and the high dose, 
respectively. 
The highest obtained total excretion of levamisole via the milk was 0.55% of the dosed amount, 
measured after 76 hours of excretion with the cows administrated with the high dose. 
 
Keywords: anthelmintic drug residues, levamisole, milk, depletion 
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8.1  Introduction 
8.1.1  Usage of anthelmintics for dairy cows 
Anthelmintic drugs are widely used in the veterinary medicine for protecting or treating animals 
mainly against gastrointestinal nematodes and lungworms. The wide-spectrum anthelmintics 
currently available for cattle originate mainly from the chemical groups of benzimidazoles (BZs), 
tetramisoles (levamisole) and avermectins.1 The BZs are characterised by a very wide spectrum 
of activity and low mammalian toxicity. BZ efficiency increases as the exposure time of the 
nematode to a threshold level of the drug substance increases. Repeated administration of 
divided doses to prolong exposure and administration by the oral route may therefore enhance 
drug activity. BZs given orally are particularly effective in ruminants in which prolonged passage 
through the rumen and hence a reduced rate of absorption leads to a continued exposure of the 
parasite to the drug compound. For similar reasons, the most effective BZ are the less       
water-soluble compounds such as fenbendazole, oxfendazole and albendazole, which remain in 
solid form precipitates within the gut lumen for longer periods of time. When the BZ drug passes 
directly to the abomasums following oral administration, the time for passage through the 
gastrointestinal tract is reduced and efficiency is correspondingly decreased. Anthelmintic 
efficiency against adult and developing larval stages of the common gastrointestinal nematodes 
is high, but only the less soluble compounds which promote the maintenance of a treshold level 
of drug for a few days are effective against arrested larval stages and lungworms. 
Levamisole (LE) has a long history of use as a broad-spectrum anthelmintic which is effective 
against lungworms and gastrointestinal nematodes in large food-producing animals (cattle, 
sheep, pigs), poultry species and occasionally in wild animals.2 LE is used orally and 
parenterally mainly against lungworms and gastrointestinal nematodes. It is also effective by 
topical, dermal application of cattle as “pour-on” technique. In contrast to the BZs, the peak 
concentration of LE is more important since excretion is very rapid. More than 90% of the        
LE residues excrete within 24 hours.1 LE is readily absorbed independently of the route of 
administration and is rapidly excreted, predominantly via the urine. An increasing fraction of the 
portion of the dose remaining in the animal is bound to larger molecules forming non-extractable 
residues.2 The activity of LE against developing larvae and the adult forms of gut nematodes is 
high and the drug substance is also effective against arrested larvae of lungworms.1 Because of 
its broad and effective working spectrum, its short withdrawal time and its easy form of 
application, LE still remains the anthelmintic agent of choice for use in lactating dairy cows 
suspected of harbouring burdens of adult gastrointestinal nematodes. Most forms of parasitic 
gastroenteritis in ruminants tend to occur in the second half of the summer.3 Treatment of dairy 
cows in wet periods at the end of summer can be very useful to protect and to treat the animals 
against lungworms. 
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The effective therapeutic dose is best guaranteed when the drug is administered to cattle as a 
drench, paste or by injection.1 Administration in feed or drinking water may be labour saving but 
has some disadvantages. Because the cattle feed or drink individually there is no guarantee 
that a therapeutic dose will be obtained by each animal and subtherapeutic doses may promote 
the development of drug tolerance. Moreover, since depression of appetite is a common 
consequence of internal parasitism, the quantity of anthelmintic consumed may be sub-optimal. 
Where topical preparations of anthelmintics have been used, the activity, while good, has been 
generally less than that achieved following oral or parenteral administration. Unless the strong 
economic or management advantages of in-feed or topical application of cattle anthelmintics, 
the traditional route is to be preferred, particularly when the agents are being used 
therapeutically, rather than prophylactically. 
Resistance against thiabendazole and the other BZs has been recorded mainly from geographic 
areas where Haemonchus spp. predominate and the numbers of annual treatments are more 
numerous than in moderate zones such as Western Europe.1 This resistance or tolerance as it 
is frequently labeled, is sometimes incomplete and may be overcome by using higher dosage 
rates. Nematodes have sufficient genetic variation to develop resistance to several different 
anthelmintics at rates at least equal to that which develops to a single drug. On this basis, a 
good policy would be to alternate the anthelmintics used on farm provided that the alternation 
occurs between different generations or populations of worms and that the alternative drugs are 
from a different chemical group. 
The anthelmintic drugs are generally of very low toxicity to mammalian hosts but some BZ 
compounds such as albendazole and oxfendazole are known to be teratogenic.1 In general, BZ 
blood concentrations and excretion half-lives are longer in ruminants than in monogastric 
animals, but in either case BZs appear to be characterised by very low toxicity in mammals.4 
The mammalian toxicity of LE is greater than with the BZ although, in normal usage, toxic 
effects are seldom seen.1 
There is a considerable debate on the influence of gastrointestinal parasitism in limiting milk 
production in dairy cows. Positive evidence on increased milk yields following therapy with 
anthelmintics has come from various reports. Block et al.5 obtained an improved milk production 
of 4.8% and a reduced gastrointestinal worm burden after injecting of dairy cows with 
levamisole at calving. Spence et al.6 also reported an increase of 4.8% in milk production per 
lactation by treatment of artificially infected cows with broad-spectrum anthelmintics.          
Gross et al.7 reviewed the results of more than 80 experiments on gastrointestinal parasitism 
and the impact of anthelmintic treatment on milk production in dairy cattle. Their summary 
suggests that treatment with an anthelmintic drug produces an overall benefit of approximately 
0.6 kg milk per cow per day. 
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Figure 8.1  Metabolism of levamisole in cattle2 
 
Figure 8.2  Metabolites of levamisole in milk8
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 8.1.2  Metabolism of levamisole 
Levamisole is rapidly metabolised to a large number of metabolites.2 Studies based on both in 
vivo and in vitro in target species and laboratory animals indicate that the routes of metabolism 
of LE are qualitatively similar in most species. A study using 14C levamisole investigated the 
metabolism of LE in urine, plasma and liver in cattle. An extensive and rapid metabolism of LE 
was observed. Unchanged drug accounted for only 0.4-2.3% of the dosed amount in urine or 
faeces and less than 3% of the total residues in tissues. The main metabolites are shown in 
Figure 8.1. 
Paulson and Feil8 reported that there are two major routes of metabolism for levamisole. The 
first route includes the oxidation at the 2-position of the imidazothiazole ring (Figure 8.2) 
followed by oxidation to a carbonyl and hydrolysis to a thiohydantoic acid. The second route is 
the hydrolysis of the thiazoline ring to yield a mercapto-ethyl intermediate which forms the polar 
conjugate S-cysteinyl-glycine. These research workers also investigated and compared the 
disposition of 14C levamisole in lactating cows after oral and subcutaneous administration. The 
parent levamisole accounted for 14.1 and 10.5% of the 14C activity in milk collected 0-12 h after 
oral and subcutaneous dosing, respectively. The percentage of the total 14C activity present as 
14C levamisole declined in later collections to 1.7-1.8% of the total 14C residue in milk collected 
36-48 h after dosing. The proportion of total 14C residues present as 14C levamisole was similar 
in milk samples collected from the orally and subcutaneously dosed cows throughout the 48 h 
collection period. Metabolite ME (Figure 8.2), identified as dehydro-levamisole accounted for 
4.4-4.7% of the 14C activity in the 0-12 h milk. Some studies demonstrated that levamisole 
slowly decomposes under neutral and alkaline conditions to yield dehydro-levamisole.9 Thus it 
is possible that metabolite ME was an artifact and not a result of animal metabolism. The urine 
was the major route of elimination of 14C activity after both oral (82.9%) and subcutaneous 
(84.1%) dosing.8 Faecal excretions during the same time period were 10.6% and 9.1% of the 
administered dose, respectively. The parent drug was not found in the urine. The major          
14C labelled fraction isolated from urine was identified as 2-thio-3-(2-carboxymethyl)-5-
phenylimidazolidine (metabolite M4 in Figure 8.1). 
 
 8.1.3  Objectives 
Levamisole is still used for anthelmintic treatment of dairy cows. If farmers do not respect the 
recommended withdrawal times when using this drug substance for lactating dairy cows, the 
residue concentrations in the milk can be very high. Since several years, LE is not more 
approved for usage in lactating dairy cows.10 
Several depletion studies of benzimidazole anthelmintic compounds have been published 
recently.11,12,13,14,15,16 The distribution of albendazole and its major metabolites in ovine milk and 
milk products after single oral dose is presented by De Liguoro et al.11 Fenbendazole-related 
drug residues in milk from treated dairy cows were studied by Kappel and Barker.12 The 
Chapter 8:  Depletion of levamisole in milk  
 
187
 
depletion of albendazole metabolites from milk of sheep and goat was reported by Cinquina     
et al.13 The excretion of metabolites of albendazole in goat and sheep milk products and         
by-products is described by Longo et al.14 Fletournis et al.15 tested a rapid quantitative screening 
multiresidue HPLC-UV assay for tracing benzimidazoles and metabolites in milk of two cows 
respectively treated with an albendazole and a fenbendazole formulation. Barker and Kappel16 
investigated the drug residues in milk of cows treated with fenbendazole as a paste, drench or 
feed top-dressing. 
Reports of depletion studies of levamisole in dairy cows are scarce and most of the publications 
are rather old.17,18,19 Simkins et al.17 described the excretion of levamisole in milk from cows 
treated with various formulations. The rate of disappearance of LE in milk from cows given 
levamisole as drench, feed pellets, boluses and injections was determined. Each formulation 
was given as a single treatment to each of five cows at a dose equivalent to 8 mg of levamisole- 
hydrochloride per kg body weight (BW). The LE residues in the milk were measured by a gas 
chromatographic determination method until 72 h after treatment. Archambault et al.18 
performed a study on the plasma bioavailability after a cutaneous application of levamisole in 
cattle. The experiment was conducted in young animals which received successive doses of 10 
and 20 mg per kg BW at one-week interval. To compare the plasma concentrations with those 
obtained during a more conventional administration, the same animals were also administered 
an intramuscular injection of LE at a dose of 7.5 mg per kg BW. Dairy cows were cutaneously 
treated with levamisole at a dose of 10 mg per kg BW. Österdahl et al.19 reported a study of 
levamisole residues in milk from dairy cows suffering from lungworms. A single intramuscular 
dose of 7 mg levamisole-hydrochloride per kg BW was administered to a herd of 42 milking 
cows. 
Paulson and Feil8 investigated the disposition of 14C levamisole in the lactating dairy cow in 
detail. 14C levamisole was administered orally and subcutaneously to lactating cows at a dose of 
8 mg per kg BW. 14C labelled residues of levamisole and metabolites were measured in milk, 
blood, urine and faeces samples collected from 0 to 48 h after dosing. Tissues were collected 
and analysed 48 h after dosing. Cannavan et al.20 described the depletion of levamisole from 
muscle, liver and kidney tissues of sheep orally treated with a commercial drench containing 
levamisole at the recommended therapeutic dose of 7.5 mg per kg BW. 
Levamisole is normally administered to dairy cows in the hydrochloride form and by injection or 
orally.19 However, administration of LE to cattle by topical, dermal treatment as “pour-on” 
technique is another easy and very fast practise. To our knowledge, only Archambault et al.18 
reported a depletion study after topical administration in the open literature. 
The objective of the presented study was to perform depletion experiments for levamisole with 
lactating dairy cows treated topically at therapeutic dose levels. The evolution in levamisole 
residues was measured in the milk of successive milkings. The animal treatments were 
performed at the Department of Animal Nutrition and Husbandry, Section cattle and pig 
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husbandry (DVV-CLO, Merelbeke, Belgium). The residue analyses were carried out at the 
Department of Animal Product Quality and Transformation Technology (DVK-CLO, Melle, 
Belgium). 
 
8.2  Experimental 
 8.2.1  Treatment of the dairy cows 
Twenty lactating Holstein cows, divided into four groups of 5, were selected for the depletion 
studies. The cows were treated topically with levamisole (L-Ripercol pour-on, Janssen-Cilag, 
Beerse, Belgium) in two trials. In the first trial, the cows were treated with the recommended 
dose of 10 mg of levamisole per kg BW. The BW averaged 564±40 kg (mean±standard 
deviation (s)). Levamisole was administered to the four groups at different times. To obtain more 
data points shortly after treatment, group 1, 2, 3 and 4 were already treated, respectively 1, 3, 5 
and 7 h before the subsequent milking. The cows were milked twice a day. The first seven 
milkings after the administration were sampled for determination of LE residues. The samples 
were frozen and stored at -18 °C until investigation. 
Four weeks after the first trial, the same cows were treated with a double dose of 20 mg of 
levamisole per kg BW in a second trial in the same manner as in the first treatment. The 
average BW of the cows at the beginning of this second trial was 589±40 kg (mean±s). The milk 
samples were taken in the same way as in the first trial. 
A withdrawal time of 48 h for usage of L-Ripercol pour-on was prescribed for dairy cows. 
 
 8.2.2  Determination of levamisole residues in milk 
The quantitative HPLC-DAD determination method for residues of levamisole, described in 
Chapter 3, was applied on the milk samples collected during the depletion studies. If necessary, 
the milk samples were diluted with blank milk to decrease the residue concentration below 1000 
µg/l. 
 
8.3  Results and discussion 
 8.3.1  Depletion of levamisole in milk after treatment with the 
  recommended dose 
The depletion of levamisole in the milk after a single administration of the recommended dose of 
10 mg per kg BW is shown in Figure 8.3. The figure presents the data points of the mean LE 
concentrations of the different groups in function of time after administration. A simulated 
excretion curve is drawn. The mean values and the standard deviation values of the different 
groups are also indicated in the inset-table in Figure 8.3. In the blank milk samples, no 
levamisole could be detected. As expected from the literature,1 the levamisole anthelmintic 
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substance was very rapidly absorbed and was subsequently excreted in the milk. One h after 
dosing, a LE residue concentration of 488 µg/l could already be measured. This could be 
expected from reported residue values in blood samples. Archambault et al.18 measured a mean 
LE concentration of 334 µg/l in plasma samples of young animals already 1 h after a 
comparable treatment. Paulson and Feil8 obtained 1 h after dosing already a total 14C activity in 
blood samples of 1440 µg/l (oral dose) and 1570 µg/l (subcutaneous dose). Simkins17 also 
obtained a rapid absorption and excretion. The LE residue concentration in blood and urine 
peaked at 2 to 6 h after cattle were treated via a bolus formulation. Österdahl et al.19 obtained a 
maximum LE concentration of 2200 µg/l in milk after 1 h already. However, the cows in their 
trials were treated intramuscularly. Archambault et al.18 also found a significantly higher 
biodisponibility after intramuscular injection. A mean plasma concentration of 1063 µg/l was 
obtained for the young animals already 1 h after intramuscular treatment with a dose of 7.5 mg 
per kg BW. The lowest residue concentrations obtained by Österdahl et al.19 were found in the 
cows treated 7 h before milking probably due to the rapid metabolism of the drug. 
In the presented study, a highest LE residue concentration of 1896 µg/l was measured 7 h 
(group 4) after administration. Archambault et al.18 obtained comparable depletion results. 
These authors measured a residue concentration of 1100 µg/l at their first data point at 12 h 
after topical treatment of a dose of 10 mg per kg BW. 
The individual fluctuation of the residue concentrations within the groups was high and is 
probably caused by physiological differences. The most important differences between the 
individual cows are the biodisponibility and the rates and routes of metabolism and excretion of 
the parent drug and metabolites. The average daily milk yield of the 20 cows during the four 
days of the trial was 20.1±7.8 kg (mean±s). No relationship could be found between residue 
concentration and milk production. 
As reported by Armour1 also, the observed depletion of LE is very rapid. The mean residue 
concentration had decreased to 319 µg/l at 25 h after treatment. After the prescribed withdrawal 
period of 48 h, a residual LE concentration could still be observed. The mean LE concentration 
of the 4 groups of this milking was 88 µg/l. This concentration is still higher than the EC zero 
level, which was established recently. Paulson and Feil8 obtained approximately similar residue 
concentrations (60 µg/l) in the milk samples 36-48 h after the oral or subcutaneous 
administration. These researchers were able to distinguish the parent LE from its metabolites 
using 14C labelling. They remarked that only 1.7-1.8% of the total residue value was present as 
parent LE. In the presented depletion study, a HPLC-DAD technique was used and the identity 
of the LE peak was confirmed with an UV spectrum. In the last sampled milking, at 76 h after 
treatment, the LE residue concentration had declined to 21 µg/l. Archambault et al.18 was not 
able to measure a residue concentration above the detection limit (50 µg/l) at this time point. 
Österdahl et al.19 also reported a rapid residue decrease in the milk. A half-live of about 5 h was 
calculated. 
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The depletion pattern of levamisole in muscle tissue obtained by Cannavan et al.20 was 
comparable with that obtained in milk. A LE residue concentration of approximately 10 µg/kg 
was reported after a withdrawal of 2 days. 
The biodisponibility obtained by Archambault et al.18 after intramuscular injection of 7.5 mg per 
kg BW was significantly higher than that obtained after topical treatment with a dose of 10 mg 
per kg BW. However, the residue concentrations showed a good dose-reponse relation. With 
the topical dose of 20 mg, a significantly higher residue response in the plasma samples of 
young animals was already measured compared with the intramuscular treatment. As expected, 
the absorption and excretion in blood after topical treatment is somewhat slower, but the peak 
values were higher (2039 µg/l after 4 h compared with 1274 µg/l after 3 h for the topical and the 
intramuscular treatment, respectively). Simkins et al.17 reported that the ranges of LE residues 
in milk at 12 h after treatment are similar, which suggests that LE is rapidly absorbed for all 
formulations. LE-hydrochloride residues in milk averaged 50, 55, 58 and 32 µg/l at 12 h after the 
administration of levamisole drench, feed, bolus and injectable formulations. All formulations 
resulted in LE residues which were less than 10 µg/l after the 48 h milking. The residue 
concentration in muscle, fat, liver and kidney tissues had also fallen below the detection limit of 
10 µg/kg at 48 h after treatment. 
 
 8.3.2  Depletion of levamisole in milk after treatment with the 
  higher dose 
The depletion of levamisole after the topical treatment of the dairy cows with 20 mg per kg BW 
is shown in Figure 8.4. This figure presents the mean measured LE residue concentrations at 
each sampling point of the different groups of cows. A simulated depletion curve is drawn 
through the data points. The mean residue concentration values and the standard deviations 
are also given in the inset-table in this figure. No LE residues could be detected in the blank 
milk samples. The pattern of the depletion curve is comparable with that obtained in the first 
experiment with the recommended dose of 10 mg per kg BW. The residue values were 
approximately threefold those of the first trial. A residue concentration of 862 µg/l was already 
measured at 1 h after treatment. The highest obtained residue concentration averaged        
6027 µg/l and was measured as in the first trial, in the sample collected at 7 h after 
administration. Archambault et al.18 also obtained a threefold higher residue concentration  
(2039 µg/l at 4 h instead of 661 µg/l at 5 h after treatment) in the plasma samples of the young 
animals by doubling the topical treatment dose from 10 to 20 mg per kg BW. 
Again, the variability of the residue values in the different groups was high. The average daily 
milk yield during this trial was 20.9±9.0 kg. In this trial also, no relationship was found between 
residue concentration and milk yield. The residual levamisole concentration of the last milking, 
at 76 h after administration, had declined to 83 µg/l. 
 
Chapter 8:  Depletion of levamisole in milk  
 
192
 
 
 Ti
m
e 
af
te
r a
dm
in
is
tra
tio
n 
(h
)
0
20
40
60
80
LE concentration (µg/l)
0
10
00
20
00
30
00
40
00
50
00
60
00
LE
 c
on
ce
nt
ra
tio
n 
(µ
g/
l) 
Ti
m
e 
af
te
r  
ad
m
in
is
tra
tio
n 
(h
) 
M
ea
n 
s 
 
0 
 
0 
 
0 
 
1 
 
86
2 
 
67
4 
 
3 
 
36
00
 
 
14
95
 
 
5 
 
47
05
 
 
13
31
 
 
7 
 
60
27
 
 
21
68
 
 
15
.3
 
 
14
49
 
 
67
9 
 
17
.2
 
 
14
15
 
 
38
7 
 
19
.2
 
 
50
9 
 
23
0 
 
21
.3
 
 
86
3 
 
29
5 
 
25
 
 
62
5 
 
25
9 
 
27
 
 
56
3 
 
25
4 
 
29
 
 
22
1 
 
26
 
 
31
 
 
33
1 
 
82
 
 
39
.3
 
 
13
4 
 
49
 
 
41
.2
 
 
17
1 
 
43
 
 
43
.2
 
 
82
 
 
37
 
 
45
.3
 
 
13
4 
 
37
 
 
49
 
 
18
6 
 
14
9 
 
51
 
 
15
2 
 
82
 
 
53
 
 
11
8 
 
56
 
 
55
 
 
11
0 
 
31
 
 
63
.3
 
 
73
 
 
48
 
 
65
.2
 
 
11
3 
 
32
 
 
67
.2
 
 
61
 
 
69
 
 
69
.3
 
 
83
 
 
25
 
 
73
 
 
77
 
 
35
 
 
75
 
 
91
 
 
43
 
 
77
 
 
74
 
 
39
 
 
79
 
 
92
 
 
41
 
  
20
 m
g/
kg
 B
W
Fi
gu
re
 8
.4
  D
ep
le
tio
n 
of
 le
va
m
is
ol
e 
(L
E)
 a
fte
r t
op
ic
al
 tr
ea
tm
en
t o
f d
ai
ry
 c
ow
s 
w
ith
 a
 d
os
e 
of
 2
0 
m
g 
pe
r k
g 
bo
dy
 w
ei
gh
t 
 
Chapter 8:  Depletion of levamisole in milk  
 
193
 
 8.3.3  Total excretion of levamisole in milk 
The total excretion of the administered levamisole amount via the milk was estimated by means 
of the milk yields and the residue concentrations. The results for the different treated groups 
and the two applied doses are summarised in Table 8.1. The obtained total excretion of LE in 
the milk is very low and varied between 0.25 and 0.49% of the administered dose after 
treatment with the recommended dose. The highest mean excretion (0.49%) was found in group 
2, the group that was treated 3 h before the first milking. 
The percentual excretion of LE residues via the milk was not influenced by the route of 
administration. Österdahl et al.19 calculated a comparable total excretion of 0.3 to 0.7% after 
intramuscular administration. However, as expected, the highest excretion rates were found in 
the cows treated at 1 h before the first milking. The absorption of LE and the excretion in the 
milk was faster after intramuscular than after topical treatment. 
Paulson and Feil8 reported that milk collected from 0 to 48 h after dosing, accounted for 0.2% 
(oral dose) and 0.6% (subcutaneous dose) of the total 14C activity administered as                  
14C levamisole. These authors have shown that the urinary and the faecal excretion accounted 
for respectively 84% and 10% of the supplemented LE dose. No parent LE could be detected in 
the urine.  
In the trial with the dose of 20 mg per kg BW, the estimated total excretion after 76 h of 
depletion was highest and reached 0.55% of the dosed amount. This excretion was found in 
group 4, the group that was treated 7 h before the first milking. 
 
   Table 8.1  Total excretion of levamisole (% of administered amount) in milk after 
  topical administration 
Group Administered 
dose 
(mg/kg BW) 1 2 3 4 
10 0.25 0.49 0.37 0.38 
20 0.26 0.52 0.41 0.55 
 
8.4  Conclusions 
The absorption of levamisole in the animal body and the excretion of residues in the milk 
occurred very rapidly. However, the depletion studies indicate that, when a levamisole treatment 
is performed for lactating cows, a withdrawal period of 48 h is to short to obtain residue free 
milk. With the recommended dose of 10 mg per kg body weight, a levamisole residue 
concentration of 88 µg/l was measured after 48 h of withdrawal. 
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Abstract: 
 
Two separate depletion studies of avian species orally treated with medicated feed containing 
flubendazole were performed. Flubendazole was administered to turkeys and to guinea fowls in 
two doses. The concentrations of the flubendazole-derived residues in breast muscle, thigh 
muscle and liver tissues were determined by a liquid chromatographic-mass spectrometric 
method. 
A first pharmacokinetic study was performed with turkeys. Medicated feed containing 19.9 and 
29.6 mg per kg feed was provided in two trials for seven consecutive days. In the trial with the 
recommended dose of 19.9 mg/kg, one day after the end of the treatment, the mean sum of the 
residues of flubendazole plus hydrolysed metabolite in thigh and breast muscle tissues declined 
to around the MRL (50 µg/kg) and was 36.6 and 54.1 µg/kg, respectively. The corresponding 
values with the higher dose of 29.6 mg/kg were 101.7 and 119.7 µg/kg, respectively. 
In the second depletion study, guinea fowls were treated at doses of 56.2 and 86.1 mg per kg 
feed during seven successive days. The highest residue response was obtained for the reduced 
metabolite. With the therapeutic dose (56.2 mg/kg), the maximum mean residue concentrations 
obtained for this compound in breast muscle, thigh muscle and liver tissue were 287.6, 311.5 and 
1042.5 µg/kg, respectively. After 24 h of depletion, the sum of the residue concentrations of 
parent and metabolites in muscle tissue still exceeded 50 µg/kg. After eight days of depletion, 
flubendazole-derived residues at low concentrations could still be measured in both muscle and 
liver tissues. Generally, the disposition of residues in breast and thigh muscle tissues was 
comparable. 
The European Commission has not established a MRL for flubendazole in edible tissues of 
guinea fowl. In contrast, the existing MRLs for other bird species are expressed as the sum of 
parent flubendazole and its hydrolysed metabolites. It could be questionned whether the 
established MRLs could serve as a reference to evaluate the safety of flubendazole-derived 
residues in guinea fowl. A withdrawal period of three days will assure residue safety in the edible 
tissues of guinea fowl treated with flubendazole at therapeutic dose. 
 
Keywords:  flubendazole-derived residues, turkey and guinea fowl tissues, residue depletion 
 LC-MS/MS analysis 
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9.1  Introduction 
 9.1.1  Usage of flubendazole for poultry species 
Over the years, benzimidazole anthelmintics have provided unique broad-spectrum efficacy 
against parasitic helminths and have proved to be extraordinarily safe in practical use.1 In a 
variety of animal species, flubendazole has a broad-spectrum activity against nematodes, both 
adult and larval. This veterinary drug substance is widely used in the veterinary medicine of 
poultry. Flubendazole is very active against gastrointestinal roundworms, gapeworms and 
tapeworms in poultry (chickens, turkeys, geese) and game birds (pheasants and partridges), 
and also in minor species as guinea fowls.2 The tenicidal properties (activity against tapeworms) 
of flubendazole are limited compared with those of mebendazole.3 The introduction of a F-atom 
at the benzyl ring decreases the toxicity of flubendazole for cestodes compared with 
mebendazole. However, flubendazole differs from mebendazole by its better tolerance 
especially in those animal species showing higher sensitivity to mebendazole.4 Helminth 
infection is less a problem in poultry reared indoors because of their lack of contact with 
intermediate hosts.2 Breeding birds are treated before laying. Rearing birds are dosed three 
weeks after placing on infected ground, maintenance doses being given every six to eight 
weeks. 
Special attention was spent by Froyman and De Keyser5 to the safety of flubendazole with 
regard to egg production and reproductive performance. The medication of breeder chickens 
does not unfavourably affect egg production, fertility or hatchability. Vanparijs6 obtained a 100% 
worm elimination, no consistent change in egg-lay performance and a highly significant increase 
in hatchability after flubendazole medication of naturally infected geese. 
In France, the guinea fowl production reached 57000 tons in 1999, representing only 3% of the 
total poultry meat production; 36% are produced free-range.7 Also, in Belgium, guinea fowl 
production is marginally. Guinea fowls are still reared in management systems and housings 
were the animals are often kept on deep litter and have to be treated for parasitic infections.5 
 
 9.1.2  Metabolism of flubendazole 
Carbamate hydrolysis is a major metabolic route for several benzimidazole carbamates.1 The 
hydrolytic reaction of flubendazole (FL) results in its hydrolysed metabolite (HFL) or                  
2-aminoflubendazole (Figure 5.1 in Chapter 5). This metabolite is often additionally metabolised 
in the 5-substituent and is readily eliminated in the urine. The anthelmintic benzimidazoles 
containing 5-keto substituents, such as flubendazole, also undergo metabolic reduction of the 
carbonyl group to the corresponding alcohol compound. The flubendazole drug substance is 
reduced in the animal body to the reduced metabolite of flubendazole (RFL) or 
hydroxyflubendazole (Figure 5.1 in Chapter 5). 
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Benzimidazole (BZ) anthelmintics have an extremely limited water solubility.1 Metabolism 
(biotransformation) of the BZ drug substances decreases the lipid solubility of the compounds. 
The obtained metabolites are polar in nature and more water-soluble than the parent 
compound, and are readily excreted.8 Kan et al.9 found higher residue fractions for the parent 
flubendazole and its metabolites in the fatty egg yolk than in the egg white. Metabolites, rather 
than the parent drug, often dominate in blood, bile, tissues and urine. A small amount of 
benzimidazole metabolites is bound in relatively non-extractable form to endogenous 
macromolecules. The principles of the pharmacokinetics with disposition and fate of drugs in the 
animal body were explained in detail by Baggot.8 Before entering the systemic blood circulation, 
an orally administered drug must undergo three events: release from the dosage form, transport 
across the lipoid mucosal barrier and passage through the liver. In general, the kinetics of drug 
distribution in blood, organs and tissues depend on dose and route of administration, lipid 
solubility of the drug, extent of binding to plasma proteins and to extravascular tissue 
constituents and blood flow through organs and tissues. Differences in penetrating the capillary 
endothelium (influenced mainly by binding to plasma proteins) and in diffusing across biological 
cell membranes of the two metabolites of flubendazole, can be an explanation for the 
disposition and depletion of different metabolites in animals.  
Attention has to be spent on drug resistance. As microorganisms for antibiotics,10 the parasites 
in the enteric fauna may become drug resistant as a result of ingestion of minute amounts of 
antiparasitics. Armour11 reported that resistance or tolerance to BZs has been recorded in areas 
where the numbers of annual treatments are more numerous than in moderate zones such as 
Western Europe. This resistance is sometimes incomplete and may be overcome by using 
higher dosage rates. A good policy is to alternate the anthelmintics used on a farm, provided 
that the alternation occurs between different generations or populations of worms and that the 
alternative drugs are belonging to a different chemical group. 
 
 9.1.3  Objectives 
Treatment of poultry species with flubendazole could be accompanied with residues of the 
parent drug compound, its hydrolysed metabolite and its reduced metabolite in poultry 
foodstuffs.9,12 
The extractable residues of benzimidazole anthelmintics, parent drug and/or free metabolites 
are chemical molecules with defined toxic potential for which safety margins may be defined.1 
The risks from tissue-bound residues are less well defined. However, some theory suggests that 
they do not present a risk for the consumer. Some BZs are mutagenic, but the effect is marginal 
or low in mammals, even at high doses. Teratogenicity can be considered as a general property 
of these pharmacologic substances. In many cases, teratogenic metabolites have been 
identified and quantified in animal products as milk, eggs and meat. This means that acceptable 
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daily intake (ADI) values can be defined and that adequate safety margins can be established 
for the consumer. Research using radiolabeled drugs has shown that several metabolite 
residues are uncharacterised and persist in tissue much longer than the parent drug.13 The 
direct toxic effects for the consumer due to flubendazole-related residues in meat are negligible, 
because of the fact that the occuring residue concentrations are relatively low. The toxicity of 
flubendazole and its two metabolites are comparable. The toxicity of flubendazole still exists for 
its metabolites as long as the “carbamate” structure stays intact during the metabolism. The 
lethal dose (LD50) in acute toxicological tests for seven tested laboratory animals, namely rat, 
mouse, chicken, turkey, pig, dog and sheep reported by Thienpont et al.4 was at least          
2560 mg/kg. Besides the teratogenic properties, which were obtained at both administration 
doses of 40 and 160 mg/kg, Yoshimura14 observed supplementary significant embryocidal 
effects in rats after treatment with the highest dose of 160 mg/kg. 
The EU MRLs set by Council Regulation EEC/2377/90 and amendments for the sum of FL+HFL 
as marker residue in muscle tissue and liver tissue of the poultry species chicken, turkey, geese 
and game birds (pheasants and partridges) are 50 and 400 µg/kg, respectively.15 The 
prevention of drug residues in animal food products as meat, eggs and milk has to be a top 
priority in all activities involved in the food production chain.  
Depletion data of flubendazole-derived residues in laying hens after treatment are available in 
the literature.9,12 Kan et al.9 investigated the excretion of flubendazole and its hydrolysed and 
reduced metabolites in eggs of orally treated laying hens. Different medication doses were 
administered to the hens via the layer feeds. A therapeutic dose (27 mg per kg feed), a low 
dose (feed carry-over concentration) of 2.6 mg and an intermediate dose of 9.4 mg per kg feed 
were supplemented. Data on residue formation in eggs and metabolism in laying hens after 
long-term low-level exposure are not available in the literature. Carry-over of feed additives from 
former dosed batches to blank feed batches occurs during industrial feed manufacturing and 
transport. These research workers also measured the distribution of flubendazole-derived 
residues between egg yolk and egg white. Balizs12 measured the residue concentration of the 
parent compound flubendazole depleted in egg yolk and in egg white after oral treatment of 
laying hens via medicated feed containing a therapeutic dose of 30 mg per kg. Michiels et al.16 
reported the pharmacokinetics of flubendazole in animals (rats and dogs) and man. 
Flubendazole was given orally or by subcutaneous injection to the rats at a dose rate of 40 mg 
per kg body weight (BW). The dogs were treated intramuscularly with flubendazole once or 
repeatedly for five consecutive days at a dose concentration of either 2.5 or 25 mg per kg BW. 
To our knowledge, no depletion data for flubendazole in muscle tissue of poultry animals, game 
birds or minor species as guinea fowl are available in the open literature. Although not 
authorised by the EU and because of its very efficacious anthelmintic properties, flubendazole 
could be useful for treatment of guinea fowls. 
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The purpose of this study was to evaluate and to measure the disposition and distribution of 
residues of flubendazole, its hydrolysed and its reduced metabolites in edible tissues of turkeys 
and of guinea fowls during and after oral treatment of the animals via medicated feed. The thigh 
muscle, breast muscle and liver tissues of both avian species were analysed for the 
flubendazole-derived residues. The animal treatments and the collection of the target tissues 
were performed at the Department of Animal Nutrition and Husbandry, Section small stock 
husbandry (DVV-CLO, Merelbeke, Belgium). The residue analyses were carried out at the 
Department of Animal Product Quality and Transformation Technology (DVK-CLO, Melle, 
Belgium). 
 
9.2  Materials and methods 
 9.2.1  Veterinary medicinal products, reagents and 
 chemicals 
Coccidiosis was prevented by supplementation of the feed with 1 mg of diclazuril (Clinacox, 
Janssen Animal Health, Beerse, Belgium) per kg and with 120 mg of amprolium/ethopabaat 
(25/1.6, w/w) (Amprol plus, Merial, Lyon, France) per kg for the turkeys and the guinea fowls, 
respectively. These veterinary medicinal products were supplemented from day 1 onwards with 
a minimum withdrawal period of 5 days before slaughtering. Nifursol premix 2.5% (Duphar, 
Weesp, The Netherlands) at a dose of 75 mg per kg was supplemented to the feed in order to 
avoid histomoniasis for both animal species. The animals were treated from day 1 onwards with 
a withdrawal period of 14 days before slaughtering. 
The vaccination of the turkeys and the guinea fowls against Newcastle disease was performed 
with the living vaccine La Sota (ELD-50, Intervet, Boxmeer, The Netherlands). 
The flubendazole medication of the feed was performed with the commercial formulation 
Flubenol 5% (Janssen Animal Health, Beerse, Belgium). There is no withdrawal period 
prescribed before slaughtering and consuming edible tissues of poultry species treated with 
Flubenol 5%. 
With exception of formic acid, all reagents and chemicals used in the analytical methods for the 
quantification of the flubendazole-derived residues in the tissue samples are summarised in 
paragraph 5.2.1 in Chapter 5. Formic acid was of analytical grade and was obtained from 
Panreac (Barcelona, Spain). 
 
 9.2.2  Apparatus 
The commercial formulation of flubendazole was blended in the feed in 3 steps: a 2-step 
premixer (as a 1 and 5% premix in a Varimixer (Dehaeck, Ghent, Belgium) and a RM premixer 
(Quintijn, Zulte, Belgium), respectively) and the entire batch vertical mixer (Vrieco, Zelhem, The 
Chapter 9:  Disposition and distribution of residues of flubendazole and metabolites in edible 
 tissues of avian species 
 
203
 
Netherlands). Crude protein and crude fat were determined with a Kjeltec (Foss Tecator, 
Höganäs, Sweden) and a Soxhlet system (Gerhardt, Bonn, Germany), respectively. 
The apparatus used for the residue analysis of the tissue samples are described in Chapter 5. A 
supplementary vacuum evaporator of Büchi (Flawil, Switzerland) was used for the sample 
preparation of feed and tissue samples of the depletion study with the guinea fowls. 
 
 9.2.3  Animal treatments 
 9.2.3.1  Treatment of turkeys 
Day-old turkeys of the BUT 9 heavy medium strain (136 of each gender) were obtained from a 
commercial hatchery. They were reared separately until 8 weeks of age. Afterwards, males and 
females were allocated to three pens. The feeding program consisted of a phase-feeding 
system. Apparent metabolisable energy, nitrogen correction = 0 (AMEn), in MJ per kg and crude 
protein (CP) in percent in the feed for the day-old animals were 11.5 and 28.0, respectively. At 
4, 8 and 12 weeks of age, these composition parameters were respectively, 12.0 and 25.0, 12.2 
and 22.0, 12.5 and 19.0. Feed (in mash for the first period and in pellets for the subsequent 
periods) and water were available at libitum. The turkeys were vaccinated against Newcastle 
disease at days 1, 21 and 72. In two pens, the turkeys were fed medicated feed containing 
19.9±1.4 mg (mean±standard deviation (s)) and 29.6±1.4 mg of flubendazole per kg during 
weeks 13 and 15 of age for females and males, respectively. Feed intake and feed conversion 
rate were calculated for the respective periods. Three male and three female turkeys were 
weighed and slaughtered at different ages according to the flubendazole feeding schedule, just 
before the start, daily during the administration, and 2, 4 and 6 h and 1, 2, 5 and 7 days post 
administration. At each sampling time the same muscle group of breast and thigh and the liver 
were removed, frozen and stored at -18°C until investigation. 
 
 9.2.3.2  Treatment of guinea fowls 
One day-old guinea fowl chicks (136 of each gender) were purchased from a local commercial 
hatchery. They were reared separately until 6 weeks of age. Afterwards, males and females 
were allocated to three floor pens, needed for two administration doses and one control group. 
The feeding programme consisted of a phase feeding system. AMEn in MJ/kg and CP in % of 
the feed were respectively 11.8 and 22.4 for period 1 to 28 days of age and 12.4 and 20.9 for 
period 29 days to slaughter. Feed in mash form and water were available at libitum. In order to 
prevent coccidiosis and histomoniasis, the veterinary drugs were supplemented into the diets. 
The birds were vaccinated against Newcastle disease at day 1 and 21. In two pens, the healthy 
birds were fed medicated feed containing 56.2±4.7 mg (mean±s) or 86.1±1.6 mg of 
flubendazole per kg feed during week 9 of age for both females and males (a control diet 
without any flubendazole was fed to the control group). Three male and three female birds, 
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taken at random, were weighed and sacrificed at different time points according to the 
flubendazole feeding schedule, just before the start, daily during the administration period and 
2, 4 and 6 h and 1, 2, 5 and 8 days post administration. Each time point, the homogeneous 
muscle group of breast and thigh and the liver were collected separately and stored frozen at     
-35°C until investigation. 
 
 9.2.4  Growth performance and muscle composition of guinea 
 fowls 
The mean feed intake per pen was calculated separately for the observation, the administration 
and the depletion period. Just before slaughter, the body weight of the birds was noted. The 
crude protein and the crude fat content of some breast and thigh muscle samples were 
determined according to the technique of Kjeldahl (calculated as % N X 6.25) and Soxhlet 
(calculated as the petroleumether extract), respectively. 
 
9.2.5  Analysis of medicated feed samples 
 9.2.5.1  Medicated feed for turkeys 
The concentrations of flubendazole in the medicated feed prepared for the depletion study with 
the turkeys were determined in the State Analysis Laboratory at Tervuren (Belgium). 
 
 9.2.5.2  Medicated feed for guinea fowls 
The flubendazole content of the medicated feed material was measured on a homogeneous 
sample taken before supplementation as well as on the remainder after cessation of the 
administration. To determine the actual flubendazole dose, 1 g of ground medicated feed 
sample was weighed into a centrifuge tube of 50 ml. The FL and/or internal standard (IS) 
solutions were added at this stage. Ten ml of methanol was added and the mixture was 
homogenised by vortex mixing. The analyte extraction was performed on a shaker (amplitude: 
30 mm, frequency: 90/min) for 15 min. Afterwards, a clean-up of the sample mixture by 
centrifugation at 5000 rpm during 5 min was carried out. The organic upper layer was filtered 
through a 0.2 µm regenerated cellulose (RC) Chromafil filter (Macherey-Nagel, Düren, 
Germany) into an autosampler vial. Ten µl of filtrate was injected into the LC system and the 
flubendazole concentration was determined with the LC-MS/MS determination procedure 
described in the next section.  
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 9.2.6  Flubendazole-derived residue determination method 
 9.2.6.1  Tissue samples of turkeys 
The residue analysis of the edible tissue samples of the depletion study with the turkeys were 
performed with the LC-MS/MS method for muscle and liver tissue samples described in  
Chapter 5. For the incurred turkey tissue samples, the IS was spiked to a concentration of       
50 µg/kg. 
 
 9.2.6.2  Tissue samples of guinea fowls 
 9.2.6.2.1  Introduction 
The residue concentrations of the tissue samples of the depletion study with the guinea fowls 
were quantified with an optimised LC-MS/MS method. 
 
 9.2.6.2.2  Standard solutions 
Analytical standard material of the analytes were dissolved in 16 ml of dimethyl sulphoxide. The 
solutions were further diluted with methanol to stock standard solutions of 0.1 mg/ml which were 
stored refrigerated at 5°C and which were replaced every two months. A stock standard solution 
of 0.2 mg/ml flubendazole and the IS were prepared for the analyses of the medicated feed 
samples. The working standard solutions were made immediately before use by dilution with 
mobile phase consisting of 50/50 (v/v) acetonitrile and water containing 0.1% formic acid. 
Solutions of 1 µg/ml were used for tuning the mass spectrometer and for acquisition of the 
analyte identification spectra. During the preparation of matrix calibration samples, the analytes 
were spiked using a mixed standard solution of 0.01, 0.1, 1 and 5 µg/ml for concentrations up to 
1, 5, 100 and above 100 µg/kg, respectively. The IS was added to the calibration samples and 
to the incurred samples using a standard solution of 1 µg/ml. 
 
 9.2.6.2.3  Sample preparation 
 9.2.6.2.3.1  Breast and thigh muscle tissue 
One gram of ground guinea fowl muscle tissue sample was weighed into a beaker of 50 ml. The 
analyte and/or IS solutions were added at this stage. The spiked samples were left for 30 min. 
Ten ml of water was added and the tissue was homogenised for 15 s at 8000 rpm. The sample 
mixture was transferred quantitatively into a centrifuge tube of 50 ml. The beaker and the 
homogeniser rotor were rinsed twice with 10 ml of ethyl acetate, the extraction solvent. The 
rinse solutions were transferred into the tube. The mixture was made alkaline with 5 ml of       
0.1 M sodium hydroxide and a pH of approximately 11.3 was obtained. The extraction was 
activated on a shaker (amplitude: 30 mm, frequency: 90 per min) for 10 min. After separation by 
centrifugation at 5000 rpm for 5 min, the supernatant was transferred into an evaporation tube. 
The extraction procedure was repeated once on the centrifugate with 10 ml of ethyl acetate. 
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The collected organic fractions were evaporated to 2-4 ml with the vacuum evaporator 
((260±10) X 102 N/m2, 60°C, 200 rpm). The remainder was transferred quantitatively into a 
graduated tube. The evaporation tube was rinsed with 2 ml of ethyl acetate and the rinse 
solution was also transferred into the graduated tube. The remaining extract was evaporated to 
dryness under a stream of nitrogen in a water bath at 60°C. The residue was dissolved in 600 µl 
mobile phase consisting of acetonitrile and water containing 0.1% formic acid (50/50, v/v). The 
mixture was vortex mixed. The concentrated drug residue solution was heated at 60°C in a 
water bath for 5 min. After vortex mixing, the extract was defatted with 2 ml of n-hexane. After 
standing for 5 min, the hexane upper layer was removed and the tube was placed in a water 
bath at 60°C for 2 min. After cooling down to room temperature, the solution was made up to    
1 ml with mobile phase. The final residue solution was homogenised by vortex mixing and 
filtered through a 0.2 µm RC Chromafil filter into an autosampler vial. 
 
 9.2.6.2.3.2  Liver tissue 
One gram of ground guinea fowl liver tissue sample was weighed directly into a centrifuge tube 
of 50 ml. The analyte and/or IS solutions were added at this stage. The spiked samples were 
left for 30 min before the extraction of the benzimidazole compounds was performed.  
The next steps were identical to those of the sample pretreatment of muscle tissue as described 
in paragraph 9.2.6.2.3.1. 
 
 9.2.6.2.4  Liquid chromatographic–mass spectrometric analysis 
The liquid chromatographic separation and mass spectrometric detection (LC-MS/MS) of the 
flubendazole-derived residues were similar with the presented LC-MS/MS methods for 
determination of residues of anthelmintics in milk and of mebendazole-derived residues in 
sheep tissues, described in Chapters 4 and 6, respectively. 
The LC runs were performed at room temperature on a reversed-phase column with a mobile 
phase consisting of acetonitrile (B) and water containing 0.1% formic acid (to increase the 
ionisation intensity) (A). The elution gradient programme consisted of 65A:35B to 50A:50B      
(0-0.1 min), 50A:50B to 25A:75B (0.2-3 min), 25A:75B (4-5 min), 25A:75B to 50A:50B (6-7 min), 
50A:50B to 65A:35B (8-15 min) and 65A:35B (16-25 min). A volume of 30 µl of the cleaned 
sample extracts was injected into the LC apparatus. 
Atmospheric pressure electrospray ionisation in the positive ion mode (ESI+) was applied with 
the tandem quadrupole mass spectrometer. The LC eluent flow of 0.25 ml/min was sprayed 
directly into the mass spectrometer interface, without splitting. The analytes were detected by 
tandem mass spectrometry using the multiple reaction monitoring (MRM) function of two 
transitions. The optimisation of the transition of the molecular precursor ion to the two most 
abundant product ions was performed. 
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The generated data of the quantitative determinations by MRM of the transition from the 
precursor ion to the most abundant product ion were evaluated by an internal standard 
procedure based on matrix calibration curves and calculated automatically by the MASSLYNX 
software version 3.3. The calibration curves were obtained using at least five concentration 
points, including the zero level. They were calculated always using the best fit of two replicated 
determinations per concentration level. 
 
 9.2.6.2.5  Determination of the analytical limits 
The limits of detection (LODs) and limits of quantification (LOQs) were determined according to 
the EU requirements for drug residue analyses recently published by the EC.17 LOD and LOQ 
were calculated by performing a validation criterion for determination of the decision limit and 
the detection capability, respectively. 
The LOD values are defined as the mean values of the calculated concentrations by 
determining at least 20 blank tissue samples spiked at the internal performance limit (IPL) 
chosen at 1 µg/kg with the analytes plus 1.64 times the corresponding standard deviations. The 
LOD values for muscle tissue were determined with fortified blank guinea fowl breast muscle 
tissue samples. The LOD values for liver tissue were determined with spiked blank liver tissue 
samples. 
The LOQ values were calculated as the respective LOD values plus 1.64 times the 
corresponding standard deviations of the measured concentrations by determining at least 20 
blank breast muscle and liver tissue samples spiked at the respective LOD. 
 
9.3  Results 
 9.3.1  Rearing of the animals 
 9.3.1.1  Turkeys 
The turkeys were reared from 25 November 1999 until 16 March 2000. The experimental time 
could be divided into three successive periods. During the observation or acclimatisation period, 
some female and male turkeys were slaughtered and breast and thigh muscle tissue and the 
liver tissue were sampled for analysing as blank controls. The turkeys were treated with the 
medicated feed for seven consecutive days during the administration period. The trial schedule 
was made so that the last group of turkeys was slaughtered when these birds were 13 and 15 
weeks old for female and male, respectively, which is the normal practical rearing period for 
turkeys. After the anthelmintic treatment, the depletion of the residues was observed until seven 
days after cessation of the administration. 
During the animal trials, all turkeys were in good general health as indicated by the absence of 
any clinical sign. The growth results were in line with the target of BUT. The 12-week body 
weights were 12.7 and 7.6 kg for males and females, respectively. The corresponding feed 
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conversion rates were about 1.84 and 1.91 for males and females, respectively. The treatment 
with flubendazole did not influence daily feed intake and average values of 530 and 290 g per 
day were obtained for males and females, respectively. 
The mean body weights just before slaughter in the trial with the recommended dose of 19.9 mg 
per kg feed were 8.1 and 12.9 kg for females and males, respectively. The mean BWs in the 
depletion study with the medicated dose of 29.6 mg per kg feed were 8.1 and 12.5 kg 
respectively, for females and males. 
 
9.3.1.2  Guinea fowls 
The guinea fowls were reared from 21 January 2002 until 2 April 2002. The trial schedule was 
made so that the last group of eight guinea fowls were 10 weeks old at the time of slaughter, 
which is the normal practical rearing period for this avian species. Because the slaughter 
weights for females and males were supposed to be comparable, the trials for both genders 
were performed parallel. 
The animals were observed for one week before the birds were treated with the antiparasitic 
drug. During this acclimatisation period, two female and two male guinea fowls were 
slaughtered and breast and thigh muscle tissue and the liver tissue were sampled for analysing 
as blank controls. The medicated feeds were administered to the guinea fowls during seven 
 
Table 9.1  Mean feed intakes (g per bird per day) obtained per pen 
Birds Period 
Control 
group 
Dose 
56.2 mg/kg 
Dose 
86.1 mg/kg Mean 
    Acclimatisation 
158.4 
(n = 24) 
131.0 
(n = 52) 
135.5 
(n = 52) 141.6 
Females    Administration 
169.0 
(n = 22) 
144.3 
(n = 52) 
169.3 
(n = 52) 160.9 
    Depletion 
115.6 
(n = 15) 
128.2 
(n = 31) 
128.2 
(n = 31) 124.0 
      
    Acclimatisation 
135.7 
(n = 24) 
135.5 
(n = 52) 
130.0 
(n = 52) 133.7 
Males    Administration 
129.3 
(n = 22) 
160.1 
(n = 52) 
139.9 
(n = 52) 143.1 
    Depletion 
138.9 
(n = 15) 
113.8 
(n = 31) 
115.6 
(n = 31) 122.8 
n = maximum number of guinea fowls per pen 
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consecutive days. The excretion of flubendazole-derived residues was measured already during 
the treatment. The flubendazole contents of the remaining medicated feed materials were 
61.3±1.9 (mean±s) and 87.2±4.2 mg of flubendazole per kg feed for the recommended and the 
higher dose, respectively. After cessation of the administration, the depletion of the residues 
was observed for eight days. 
During the whole experimental period, the housing temperature could be kept relatively constant 
and ranged from 18.0 to 22.5°C. All guinea fowls were in good general health as indicated by 
the absence of any clinical sign. The mean feed intakes per pen obtained during the 
acclimatisation, the administration and the depletion period are summarised in Table 9.1. 
The feed intakes per animal varied from 115.6 to 169.3 g/day for females and from 113.8 to 
160.1 g/day for males. The increase in feed intake from observation to administration period 
during the rearing seemed normal for growing guinea fowls. The administration of flubendazole 
did not influence the daily feed intakes. 
Table 9.2 presents the mean body weights of the birds per pen obtained just before slaughter 
during the whole experimental period. 
Five remaining guinea fowls out of the trials of each gender were sampled to measure fat and 
crude protein composition of breast and thigh muscle tissue. For females and males, a same 
protein and fat content of 19.9 and 2.9% respectively, was measured in the homogenised and 
mixed breast muscle sample. The composition of thigh muscle was quite different. The protein 
and fat contents were 18.7 and 8.5% and 19.1 and 7.1% for females and males, respectively. 
 
 9.3.2  Depletion of residues of flubendazole and metabolites in 
  animal tissues 
 9.3.2.1  Depletion study with turkeys 
 9.3.2.1.1  Disposition and distribution of residues in tissues of 
 turkeys treated with the recommended dose 
The results of the depletion study with the recommended dose of 19.9 mg per kg feed are 
shown in Figure 9.1, which represents the mean FL and HFL residue values in breast and thigh 
muscle tissues of turkeys during and after the administration. In some breast and thigh muscle 
tissue samples, residues of the reduced metabolite of flubendazole could be detected in 
concentrations around the LOD. These residue values are not shown in Figure 9.1. 
In the blank muscle tissue samples, no flubendazole-derived residues could be detected. The 
shown residue values in Figure 9.1 are mean values obtained from six turkeys, three males and 
three females. The residue values of HFL were much higher than these of FL in both the thigh 
and breast muscle. Figure 9.1 shows a clear trend of higher residue concentration in thigh 
muscle. 
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After one day of treatment, the sum of the residue concentrations of FL plus HFL was already 
above the MRL value (50 µg/kg). The concentrations in thigh and breast muscle tissue were 
respectively, 304.8 and 266.6 µg/kg. Some liver tissue samples were also analysed at this time 
point and the residues were quantified with calibration curves obtained with spiked blank liver 
tissue samples. The residue response in liver tissue was very high and reached a concentration 
of 8304.6 µg/kg. 
A mainly steady state situation in residue concentration was obtained after four days of 
administration. The maximum concentration for the sum of residues of FL plus HFL in the thigh 
and breast muscle tissues were respectively, 742.8 and 561.1 µg/kg and were obtained after 
respectively, four and six days of treatment. The measured residue value in liver tissue after 
four days of administration was 10604.2 µg/kg. On day 7, just before the treatment was 
stopped, this residue value was 10275.7 µg/kg. 
The decline in residue concentration after cessation of the flubendazole administration is very 
rapid. After one day of withdrawal, the residue concentration already decreased to a level 
around the MRL value. To show clearly the decline of the residue concentration on the first day 
after the medication, a detailed inset-figure is given inside in Figure 9.1. As already mentioned, 
the drug residue excretion in breast muscle was somewhat slower. The sum of the residue 
concentrations of FL plus HFL in thigh and breast muscle tissue was respectively 36.6 and   
54.1 µg/kg. A residue concentration of 916.9 µg/kg was found in liver tissue. After five days of 
withdrawal, the flubendazole-derived residue depletion in muscle tissue was negligible and no 
residues could be detected anymore in the muscle tissue samples. 
The variability of the residue values of the six turkeys taken per sampling time was high and is 
probably caused by physiological differences. The most important differences between the 
individual turkeys are the biodisponibility and the rates and routes of metabolism and excretion 
of the parent drug and the metabolites. The variability of the residues in thigh muscle tissue per 
sampling time, expressed as relative standard deviation (sr), for FL and for HFL ranged (mean 
values in parentheses) from 15.3 to 81.5% (36.5) and from 12.1 to 74.3% (40.4), respectively. 
These ranges in breast muscle tissue were respectively 20.0 - 50.1% (32.8) and 18.9 - 72.7% 
(38.7). 
 
 9.3.2.1.2  Disposition and distribution of residues in tissues of 
 turkeys treated with the higher dose 
The results of the depletion study with turkeys treated with the higher dose of 29.6 mg per kg 
are shown in Figure 9.2. Again, the depletion curves are drawn with mean residue values for FL 
and HFL in thigh and breast muscle tissues of six turkeys, three females and three males. No 
residues could be detected in the blank muscle tissue samples. No relationship could be found 
between residue concentration and body weight. The same conclusions as for the first trial with 
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the recommended dose could be made. The shape of the depletion curves for the two trials 
were very similar. As expected, the residue concentrations of this trial with the higher dose were 
higher. The obtained residue concentrations for HFL were much higher than those for FL in both 
thigh and breast muscle tissues. Again, a clear trend of a higher residue concentration for both 
FL and HFL in thigh muscle tissue compared to the breast muscle tissue was observed. 
After one day of treatment, the sum of the residue concentrations for FL plus HFL in thigh and 
breast muscle tissue was respectively, 616.6 and 470.2 µg/kg. A residue concentration of 
14206.7 µg/kg was already measured in liver. The maximum concentrations for the marker 
residues of FL plus HFL in thigh and breast muscle tissues were respectively, 1104.3 and  
736.5 µg/kg and were obtained after five days of treatment. At this time, this residue value in 
liver tissue was 18127.0 µg/kg. After one day of withdrawal, the residue concentrations of FL 
plus HFL in thigh and breast muscle tissues had dropped to respectively, 101.7 and            
119.7 µg/kg. The residue value in liver had declined to 2333.9 µg/kg. The detail inset-figure in 
Figure 9.2 clearly shows the drop of the residue concentration the first withdrawal day. 
Generally, the depletion of the drug residues in breast muscle tissue was somewhat slower. 
Seven days after treatment of the turkeys, a low mean HFL residue concentration of 0.6 µg/kg 
could be detected in breast muscle tissue. 
The fluctuation on the individual residue values was high. The variability of the residues in thigh 
muscle tissue for one sampling time expressed as sr value respectively for FL and HFL ranged 
(mean values in parentheses) from 17.9 to 67.6% (39.5) and from 22.9 to 65.8% (40.2). These 
ranges in breast muscle tissue were, respectively, 11.0 - 56.7% (31.7) and 9.5 - 63.8% (35.9). 
 
 9.3.2.2  Depletion study with guinea fowls 
 9.3.2.2.1  Analytical method 
The monitored protonated ions and the optimised MS operating parameters for the 
determination method of FL, HFL, RFL and the IS are given in Table 9.3. 
The residue concentrations in the tissue samples were calculated using matrix calibration 
curves drawn with calibration points of 0, 1, 5, 25, 100, 250, 500 and 800 µg/kg. For each 
calibration point, two blank tissue samples were fortified and only the samples giving the best fit 
were used for the calibration curve. When residue concentrations above this range were 
expected in the incurred samples, these were diluted twice by weighing 0.5 g of tissue sample 
instead of 1 g. An example of a LC-MS/MS chromatogram of a breast muscle sample of a 
female guinea fowl sampled at day 3 of the administration period with the higher dose is shown 
in Figure 9.3. Chromatographic separation of the two metabolites was not needed. Because of 
the different m/z value, the two co-eluting compounds could be separated in the mass 
spectrometer. The analytes and the IS were eluted within 8 min. 
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Table 9.3  Summary of the diagnostic ions and the MS operating parameters 
Analyte 
Precursor ion 
(m/z) 
Product ions 
(m/z) 
Cone voltage 
(V) 
Collision energy
(eV) 
 
   FL 
 
314.4+ 
 
 
282.3+a, 123.1+ 
 
35 
 
30 
 
   HFL 
 
 
256.2+ 
 
 
122.7+a, 112.9+ 
 
45 
 
32 
 
   RFL 
 
 
316.4+ 
 
160.0+a, 284.4+ 
 
35 
 
35 
 
   IS 
 
 
330.3+ 
 
138.5+a, 298.3+ 
 
35 
 
30 
a most abundant product ion     FL: flubendazole  
HFL and RFL: hydrolysed and reduced metabolites of flubendazole 
IS: internal standard, methyl [5-(4-chlorobenzoyl)-1H-benzimidazole-2-yl] carbamate 
 
Fairly, the LC-MS/MS tissue residue quantification method is very selective, very specific and 
low detection limits can be obtained. The three benzimidazole compounds could be detected at 
residue concentrations between 1 and 3 µg/kg. The measured limits of detection and limits of 
quantification in muscle tissue were 1.9, 1.7 and 2.7 µg/kg and 4.5, 2.3 and 3.6 µg/kg for FL, 
HFL and RFL, respectively. These analytical limit values in liver tissue were 1.6, 1.1 and         
1.7 µg/kg and 2.6, 1.5 and 2.6 µg/kg, respectively. No endogenous interferences with residues 
of the medication with amprolium-ethopabaat, Nifursol and ELD-50 vaccine were observed. 
 
 9.3.2.2.2  Disposition and distribution of residues in edible 
  tissues 
 9.3.2.2.2.1  Introduction 
The results of the disposition and depletion of residues of flubendazole and metabolites in the 
guinea fowl tissues during and after the administration of flubendazole are shown in Figures 9.4, 
9.5, 9.6 and 9.7. The residue curves were drawn with mean residue values of six guinea fowls, 
as prescribed by European drug residue legislation. At each time point, three treated females, 
three treated males, one control untreated female and one control untreated male were 
sampled. All the control muscle and liver tissue samples were free of flubendazole-derived 
residues. 
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Figure 9.3  LC-MS/MS chromatogram of a breast muscle tissue sample of a female guinea fowl 
with residue concentrations of flubendazole (FL), the hydrolysed (HFL) and the 
reduced metabolite (RFL) of 154.3, 2.9 and 381.3 µg/kg, respectively. The internal 
standard (IS) was fortified at a concentration of 100 µg/kg. 
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 9.3.2.2.2.2  Disposition in muscle tissue 
 9.3.2.2.2.2.1  Trial with the therapeutic dose 
Figure 9.4 illustrates the residue concentration curves in breast and thigh muscle tissues during 
and after the administration with medicated feed at the therapeutic dose of 56.2 mg/kg. Residue 
values for FL and for RFL are given in Figure 9.4. The hydrolysed metabolite residues in the 
muscle tissues are omitted because the response of HFL was very low and varied around the 
detection limit. The MRL concentration of 50 µg/kg for muscle tissue in target poultry species is 
indicated in Figure 9.4 as reference. The disposition of flubendazole-derived drug residues in 
the muscle tissues starts very rapidly after the start of treatment. After oral administration of 
flubendazole, a large fraction of flubendazole was metabolised to the reduced metabolite. After 
one day of medication, considerable high residue concentrations for RFL and FL of 287.6 and 
97.0 µg/kg, respectively in breast muscle tissue and of 180.6 and 54.7 µg/kg, respectively in 
thigh tissue were already observed. A plateau residue concentration was then already obtained 
for both analytes and in both muscle tissues. This steady state concentration remained during 
the whole administration period. The difference in residue concentrations between the two types 
of muscle tissues for both FL and RFL was negligible. During the administration period, the 
residue concentration for RFL varied between 136.8 µg/kg (measured on day 6) and           
311.5 µg/kg (measured on day 3). This range for FL was between 28.7 µg/kg (measured on day 
4) and 113.7 µg/kg (measured on day 7, just before the administration was stopped). All these 
values were measured in thigh muscle tissues. The considerable decline in residue 
concentration of both compounds and in both muscle tissues from experimental days 3 until 5 
was surprising. 
The decline in residue concentration after cessation of medication was very rapidly. To clearly 
illustrate the decline of residue concentration on the first day after cessation of the 
administration, a detailed figure is given inside Figure 9.4. After one day of depletion, on 
experimental day 8, the marker residue concentration of the sum of FL plus HFL was already 
lower than 50 µg/kg. However, the highest residue concentration was still 80.6 µg/kg for RFL 
and 14.6 µg/kg for FL in thigh and breast muscle tissue, respectively. After eight days of 
depletion, on experimental day 15, the highest residual concentration for RFL was still          
13.5 µg/kg, observed in breast muscle tissue. No residues for FL could be detected in the 
analysed muscle tissues. 
During this depletion study, the variability on the residue values of the six individual animals per 
sampling time was high and is probably caused by physiological differences. Important 
differences between the individual animals are the biodisponibility and the rates and the routes 
of metabolism and excretion of the parent drug and its metabolites. The variability on the 
individual residues in thigh muscle tissue per sampling time expressed as relative standard 
deviation (sr) (mean values in parentheses) varied from 29.7 to 87.0% (46.8) and from 13.7 to 
Chapter 9: Disposition and distribution of residues of flubendazole and metabolites in edible 
 tissues of avian species 
 
218
 
 40
0
A
dm
in
is
tra
tio
n
D
ep
le
tio
nTi
m
e 
(d
ay
s)
0
2
4
6
8
10
12
14
Residue concentration (µg/kg)
0
10
0
20
0
30
0
FL
-th
ig
h 
FL
-b
re
as
t 
R
FL
-th
ig
h 
R
FL
-b
re
as
t 
Ti
m
e 
(d
ay
s)
7.
00
7.
10
7.
20
7.
30
7.
40
7.
50
7.
60
7.
70
7.
80
7.
90
8.
00
Residue concentration (µg/kg)
0
10
0
20
0
30
0
40
0
50
0
60
0
M
R
L 
- p
ou
ltr
y 
= 
FL
 +
 H
FL
 
Fi
gu
re
 9
.4
  D
is
po
si
tio
n 
of
 re
si
du
es
 o
f f
lu
be
nd
az
ol
e 
(F
L)
 a
nd
 it
s 
re
du
ce
d 
m
et
ab
ol
ite
 (R
FL
) i
n 
gu
in
ea
 fo
w
l b
re
as
t a
nd
 th
ig
h 
m
us
cl
e 
 
tis
su
es
 d
ur
in
g 
an
d 
af
te
r o
ra
l a
dm
in
is
tra
tio
n 
of
 5
6.
2 
m
g 
of
 fl
ub
en
da
zo
le
 p
er
 k
g 
fe
ed
 d
ur
in
g 
se
ve
n 
su
cc
es
si
ve
 d
ay
s 
Chapter 9:  Disposition and distribution of residues of flubendazole and metabolites in edible 
 tissues of avian species 
 
219
 
61.8% (31.8) for FL and RFL, respectively. These sr ranges for breast muscle tissue were    
19.1 - 63.1% (34.4) and 11.9 - 66.5% (35.0), respectively. 
 
 9.3.2.2.2.2.2  Trial with the higher dose 
The results of the depletion study for FL and RFL in the muscle tissues of the guinea fowls 
medicated at the higher dose of 86.1 mg per kg feed are presented in Figure 9.5. Nearly the 
same trends in depletion of residues could be observed as for the experiment with the 
therapeutic dose. Obviously, the measured residue concentrations were higher. During the 
administration of the veterinary drug, the steady-state concentration for RFL varied between 
263.3 µg/kg (measured on day 5) and 401.2 µg/kg (measured on day 1). Both values were 
measured in breast muscle tissue. The residue concentration for FL ranged between 58.5 µg/kg 
(measured in thigh muscle tissue on day 1) and 161.5 µg/kg (measured in breast muscle tissue 
on day 7, just before the administration was stopped). During this experiment, only a decline in 
residue concentration of RFL in breast muscle from day 1 until day 5 could be observed. The 
residue values for both FL and RFL and in both sampled muscle tissues were comparable. The 
residues of HFL were slightly higher than those obtained with the lower medication dose. The 
highest concentration reached 4.3 µg/kg and was obtained on day 7. The values for this 
metabolite were omitted also in Figure 9.5. As reference, the MRL concentration of 50 µg/kg for 
muscle tissue in target poultry species is indicated in the figure. 
Again, the decline of residue concentration after cessation of the administration is very rapidly. 
A detailed figure is given inside Figure 9.5, to show more clearly the decline tendency of residue 
concentration the first withdrawal day. On experimental day 8, after 24 h of depletion, the 
highest residue values measured for RFL and FL were 85.4 and 14.3 µg/kg, respectively. These 
residue values were obtained in thigh and breast muscle tissue, respectively. After eight days of 
depletion, a residue concentration of 18.1 µg/kg for RFL was obtained in breast muscle tissue. 
Residues of FL could be quantified in this kind of muscle tissue only and at a concentration of 
8.5 µg/kg. 
Again, the variation on the residue values of the individual guinea fowls was high. The variability 
on the individual residues in thigh muscle tissue per sampling time expressed as sr value varied 
(mean values in parentheses) from 21.0 to 63.4% (31.8) and from 10.2 to 51.0% (26.9) for FL 
and RFL, respectively. These sr ranges for breast muscle tissue were between 10.9 and 52.0% 
(29.5) and between 14.2 and 54.5% (34.2), respectively. 
 
 9.3.2.2.2.3  Disposition in liver tissue 
 9.3.2.2.2.3.1  Depletion of the reduced metabolite of flubendazole 
The highest residue response for the reduced metabolite of flubendazole was obtained in liver 
tissue. The disposition of residues of RFL in liver tissue of guinea fowls treated with the two 
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administration doses of 56.2 and 86.1 mg/kg is illustrated in Figure 9.6. The shape of the two 
residue curves are similar and comparable with the residue concentration curve obtained for this 
compound in the muscle tissues (Figures 9.4 and 9.5). The obtained residue values in liver 
tissue with the high treatment dose were about 1.5-fold higher of those obtained with the low 
administration dose. The values were about threefold and fourfold of those obtained in the 
muscle tissues with the low and the high dose, respectively. After one day of treatment, residue 
values of 855.2 and 1210.8 µg/kg were obtained for the low and high dose, respectively. During 
the administration period, the residue value varied between 472.5 and 1042.5 µg/kg and 
between 772.8 and 1694.5 µg/kg for the low and high dose, respectively. The same trend in 
decreasing of residues until experimental day 5 as observed in the muscle tissues could be 
observed, especially with the low dose. After the treatment was stopped, the depletion was very 
rapidly. As shown in detail in the inset-figure in Figure 9.6, within 24 h of depletion, the residue 
concentration decreased from 1042.5 to 282.9 µg/kg and from 1694.5 to 270.6 µg/kg for the low 
and the high dose, respectively. The MRL value of 400 µg/kg for the sum of residues of FL plus 
HFL in liver tissue in target bird species is indicated in Figure 9.6 as reference. The remaining 
residue concentrations obtained at the last sampling time after eight days of depletion were 24.8 
and 32.1 µg/kg for the low and the high dose, respectively. Also in liver tissue, the differences 
between the residue values of the individual guinea fowls were high. The variability per 
sampling time (mean values in parentheses) ranged from 13.7 to 69.5% (41.6) and from 8.9 to 
56.7% (27.9) for the low and the high dose, respectively. 
 
 9.3.2.2.2.3.2  Depletion of flubendazole and its hydrolysed metabolite 
The depletion results for FL and HFL in liver tissue with the two administered doses are shown 
in Figure 9.7. The residue values were considerably lower than those obtained for RFL. The 
residue concentrations for FL in liver tissue were slightly lower than those measured in the 
muscle tissue with both doses. A detectable response for HFL was observed in liver tissue. The 
values for HFL were lower than those obtained for FL. After one day of administration, the 
residue concentrations for FL were 45.5 and 59.3 µg/kg for the low and the high dose, 
respectively. The residue values for HFL were 10.2 and 17.0 µg/kg, respectively. During the 
whole antiparasitic treatment period, the residue values for FL ranged between 45.1 and    
107.5 µg/kg and between 59.3 and 156.1 µg/kg for the low and the high dose, respectively. 
These ranges for HFL were from 10.2 to 22.9 µg/kg and from 17.0 to 37.5 µg/kg, respectively. 
The decreasing trend of the residue concentrations until experimental day 5 could be observed 
again for both kinds of residues and for both doses. The rapid decline of the residue 
concentrations during the first depletion day, is illustrated in the inset-figure in Figure 9.7. After 
one day of depletion, the residue concentrations for FL were 16.8 and 23.8 µg/kg for the low 
and the high dose, respectively. These residue values for HFL were 11.3 and 13.9 µg/kg, 
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respectively. At the last sampling point, on experimental day 15, the residual drug 
concentrations for FL and HFL were 3.4 and 1.7 µg/kg and 4.7 µg/kg and below detection limit 
for the low and the high dose, respectively. The variability per sampling time (mean values in 
parentheses) for FL ranged from 21.9 to 86.5% (38.2) and from 18.5 to 45.2% (35.6). The         
sr values for HFL varied from 21.7 to 57.1% (33.1) and from 20.3 to 42.2% (32.9) for the low and 
the high dose, respectively. 
 
9.4  Discussion 
 9.4.1  Depletion study with turkeys 
The used LC-MS/MS analytical technique was very specific. No interference of residues of the 
other supplemented veterinary medicinal products diclazuril and Nifursol was obtained. 
During the administration period, no relationship was found between residue concentration and 
body weight. The effect of increasing body mass on residue level was probably compensated by 
the higher feed intake. 
To verify whether the differences in residue values between thigh and breast muscle tissue 
were statistically significant, a four-parameter Weibull function was fitted to both data series of 
the two trials with different administered dose. Comparing the confidence intervals of the 
estimated Weibull parameters showed a clear overlap and thus no significant difference for all 
cases. Nevertheless, when individual points of the breast-thigh series were compared with a     
t-test assuming homogenous variances, as validated by a Browne-Forsyth test, some 
measurement points proved to be significantly different. The majority of the individual points 
were not significantly different, which can be attributed to the substantial variance on the 
individual residue values of the six animals. Nevertheless, the higher fat content of thigh muscle 
can be an explanation for the supposed higher residue concentration. In the fat-rich egg yolk, 
higher flubendazole-derived residue concentrations were measured as compared to egg 
white.9,12 Another potential explanation could be the higher blood flow in the thigh, which is 
necessary for the mobility. Figure 9.1 shows a somewhat more rapid depletion of both analytes 
in thigh muscle, probably also due to the higher blood flow. 
The intensity of the metabolism of flubendazole to its hydrolysed metabolite, as observed with 
the residues in the tissues, was considerably high. The highest intensity was measured in liver 
tissue. In the trial with the recommended dose, the mean calculated percentual ratios of HFL in 
thigh and breast muscle to the total of FL plus HFL were respectively, 73 and 78%. This 
transformation value in liver tissue was 93%. The intensity of metabolism obtained with the 
higher dose was comparable. The calculated conversion values were 71, 75 and 95%, 
respectively in thigh muscle, breast muscle and liver tissue. 
The disposition and depletion obtained for flubendazole-derived residues in muscle tissue is 
higher than these published for eggs. Kan et al.9 obtained a mean value for the sum of residues 
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of FL plus HFL of 250 µg/kg in whole egg during a treatment of laying hens with feed medicated 
with a dose near the recommended dose. 
 
 9.4.2  Depletion study with guinea fowls 
An antiparasitic treatment of poultry species with flubendazole is strongly recommended by the 
oral route of administration. The applied veterinary medicinal product is prepared as a premix 
for medication of the feed diet. The presence of feed in the gastrointestinal tract enhanced the 
absorption of the drug. Michiels et al.16 also have reported higher plasma residue concentrations 
for FL in man when the medicinal product was supplemented directly after a meal. The 
increased absorption of flubendazole can be explained by the increased dissolution of the drug 
in the lipoid components of food and in bile acids. Hence, it is recommended to give systemic 
localised helmintics, such as flubendazole, during or after a meal. As prescribed for medication 
of game birds, a standard medicated feed with a dose of 60 mg of flubendazole per kg was 
supplemented to the guinea fowls. Compared with the used dose for turkeys, 1.5-fold higher 
flubendazole administration dose of 90 mg/kg as highest dose was applied for this depletion 
study with the guinea fowls. 
Compared with broiler chickens and turkeys, the growth rate of guinea fowls is much lower. 
Broiler chickens and turkeys show a higher gender related dimorphism than guinea fowls. The 
normal growth period for guinea fowls until slaughter takes ten weeks for a body weight of 2.0 to 
2.25 kg. Broiler chickens of 1.5 kg can be slaughtered already after a growth period of five 
weeks.18 Compared with males, females showed a higher feed intake. The mean feed intakes 
(Table 9.1) obtained for the three pens per gender in the acclimatisation, the administration and 
the depletion period were 141.6 and 133.7, 160.9 and 143.1, 124.0 and 122.8 g/day for females 
and males, respectively. This observation is opposite to the results for broiler chickens18 and 
certainly to those obtained for turkeys. During the medication period, the mean feed intakes 
were 88.1 and 106.8 g/day (for broilers) and 290 and 530 g/day (for turkeys) for females and 
males, respectively. 
The feed conversion is much lower for guinea fowls than for broiler chickens and turkeys. Baeza 
et al.7 and Sales et al.19 obtained higher BWs for the female guinea fowl birds than for the 
males. In the present study, rather heavy male birds were obtained. The effect of gender on 
body weight during the experimental period was assessed by an analysis of variance (ANOVA) 
of the data of Table 9.2. The difference on body weight between the two genders was not 
significant (P > 0.05) for most days, except for day 8 and 15. An almost significant difference   
(P = 0.055) was found at the sampling point day 7.08 (2 h after cessation of the drug 
administration at day 7). For these three cases, the male birds had a significant higher body 
weight than the female birds. The antiparasitic treatment of the guinea fowls at the two applied 
doses had no significant influence on the body weight (P > 0.05). As observed by Baeza et al.,7 
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males showed a higher feed conversion, compared with the females. Their feed intake was 
lower and in the presented study, male birds were obtained being at least as heavy as the 
female birds.  
Concerning the chemical composition of the guinea fowl body tissues, thigh muscle tissue had 
markedly higher fat contents than breast muscle tissue. The analysed fat contents in thigh 
muscle were 8.5 and 7.1% for females and males, respectively. A value of 2.9% in breast tissue 
was obtained for both genders. The same conclusions with respect to the influence of gender 
on protein and fat content of the guinea fowl body at the same age were made by Sales et al.,19 
in spite they had analysed the whole guinea fowl body after plucking. A higher fat content and a 
lower protein content for the female body, compared with the male body, was measured. The 
contents of protein and fat, which were close to the values obtained in the presented study were 
respectively, 16.8 and 6.6% and 17.1 and 5.9% for females and for males. 
The application of the sample pretreatment procedure, previously optimised for eggs and turkey 
tissues, confirmed the versatility of these extraction and clean-up procedure. Some 
improvements were implemented. A distinction in the sample preparation between muscle and 
liver samples was made. To shorten the sample preparation time, the homogenisation step of 
liver tissue in a small quantity of water could be omitted, because of the softness of this matrix.20 
The evaporation of the sample extracts was standardised by an automatic multitube vacuum 
evaporator. The LC separation was performed with a mobile phase consisting of acetonitrile and 
water containing 0.1% formic acid, which was successfully applied in analytical LC-MS/MS 
methods described in Chapters 4 and 6. The gradient applied gave a satisfactory LC-MS/MS 
separation and detection, avoiding problems with unstability of a mobile phase containing 
ammonium acetate. To increase the sensitivity of the determination method, the injection 
volume was increased from 10 to 30 µl. This modified LC-MS/MS method is relatively fast and 
very selective for the determination of flubendazole-derived residues in guinea fowl tissues. The 
determination method shows relatively low detection limits. The three drug compounds could be 
detected at residue concentrations lower than 3 µg/kg in muscle and liver tissues. 
The decline in residue concentration observed at the low dose, disappeared by treating the 
animals with a higher dose, probably due to an excessive drug uptake.  
Using TableCurve2D (SYSTAT software, Richmond, USA), it was determined that a four-
parameter linear polynomial function could best describe the different excretion curves (Figures 
9.4 and 9.5) overall. To verify whether the differences in depletion curves between thigh and 
breast muscle tissues were statistically significant, this function was fitted to all curves. 
Comparing the 95% confidence intervals of the estimated parameters showed clear overlap and 
thus no significant difference for all cases. 
Flubendazole is, in principle, not authorised for use in guinea fowl and its use is not supported 
by the veterinary medicinal product manufacturer. Nevertheless, flubendazole might be 
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employed by guinea fowl breeders in view of its effectiveness as documented in the literature. It 
is the objective of surveillance labs to monitor the residue safety of food. In the absence of 
MRLs for flubendazole in the edible tissues of guinea fowls, and with regard to the observed 
species difference in residue disposition between the guinea fowl and the other bird species, for 
which MRLs have been established, residue safety can only be guaranteed by recommending 
withdrawal periods which are sufficiently long for the elimination of the residues. The data on 
the depletion curves indicate that the residue concentrations do not longer decrease 
substantially after three days of withdrawal. A withdrawal period of three days will assure 
residue safety in the edible tissues of guinea fowls treated with flubendazole at a therapeutic 
dose during seven consecutive days. Instead of using the prescribed statistic calculation 
procedure, this withdrawal time was estimated as the time point where the mean concentration 
of all flubendazole-derived residues in all tissues were low and negligible and not longer 
decreasing substantially. 
 
 9.4.3  Species differences and similarities between turkeys 
 and guinea fowls 
Surprisingly, a large fraction of flubendazole was metabolised to its reduced metabolite in the 
guinea fowl body. Only small amounts were present as hydrolysed metabolite in the analysed 
tissues. This species difference between guinea fowl and turkey was unexpected. For the 
depletion study with turkeys, the residue concentrations found for RFL were around the 
detection limit and were negligibly. Kan et al.9 also reported higher residue concentrations for 
the hydrolysed than for the reduced metabolite in eggs. They measured whole eggs, egg white 
and egg yolk of laying hens treated orally with flubendazole. The maximum residue values for 
FL, HFL and RFL obtained in whole eggs were 140, 120 and 50 µg/kg respectively during the 
administration of medicated feed with a dose of 27 mg per kg feed.  
Delatour and Parish1 reported very important information about metabolisation and disposition 
of benzimidazole veterinary medicinal products. Unfortunately, for flubendazole, they reported 
no data on differences in excretion of the two metabolites in poultry species. Compared with the 
muscle tissues, RFL is excreted mainly by the liver into the bile of the guinea fowls. A relative 
molecular mass larger than 300 and the presence of polar groups appear to facilitate its biliary 
excretion.8 
The decline in residue concentration during the medication of guinea fowls with the low dose 
until day 5 (Figure 9.4) was also obtained in the depletion study with the turkeys during the 
administration of the lowest dose. A clear explanation for this phenomenon can not be given, 
but a residue dilution in the tissue of a faster growing bird with an increased body weight can be 
possible. The residue concentrations in muscle and liver tissues showed a good dose-response 
relation. The ratio of higher to lower dose is comparable with the ratio of the residue 
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concentrations obtained with these doses. Similar conclusions were made for the residue 
disposition with turkeys. However, Michiels et al.16 reported that the absorption of flubendazole 
was completely dose-independent for medication of man with much higher doses. The plasma 
residue values increased only 1.4-fold for a 20-fold higher dose. 
During the experiments with the turkeys as well as with the guinea fowls, complete depletion of 
all residues in each kind of tissue was difficult and would probably take a long time. The residue 
values declined very rapidly the first two days of depletion. Afterwards, only a very slow 
disappearance of the remaining drug residues was observed until the last data point. The avian 
birds in these trials were reared on the floor and recycling of drugs through faecal, dust or litter 
contamination could be a potential reason for this generally observed phenomenon.13 
 
9.5  Conclusions 
The results of the depletion study with turkeys demonstrated that there is no risk for the public 
health when a withdrawal period of one day is respected after treatment of flubendazole with the 
recommended dose. One day after cessation of the administration, the drug residue 
concentration of the sum of flubendazole and its hydrolysed metabolite in muscle tissue 
declined to or below MRL level. 
From the depletion study with the guinea fowls it can be concluded that a longer withdrawal time 
is needed. Residue safety in the edible tissues after treatment at therapeutic dose will be 
assured after a withdrawal period of three days. 
Species difference in flubendazole residue metabolism between turkey and guinea fowl was 
observed. In edible tissues of guinea fowl, a high residue concentration for the reduced 
metabolite of flubendazole could be detected. In tissues of turkey, a high response of the 
hydrolysed metabolite compound was observed. 
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Abstract: 
 
The disposition and distribution of mebendazole-derived residues in tissues of sheep was studied 
after a single oral treatment. 
The residues of mebendazole, its hydrolysed and its reduced metabolites were quantified in 
muscle, liver, kidney as well as back fat tissues by means of a liquid chromatographic-
electrospray tandem mass spectrometric method. 
After one day of excretion, the residue concentrations ranged from 21 to 7630 µg/kg. The highest 
residue concentrations were found in liver tissue. With exception of back fat tissue, the highest 
residue responses were always obtained for the reduced metabolite. The reduced metabolite in 
liver tissue and the hydrolysed metabolite in kidney tissue were found until 14 days after 
treatment. 
 
Keywords:  mebendazole-derived residues, sheep tissues, residue depletion, 
 LC-MS/MS analysis 
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10.1  Introduction 
 10.1.1  Usage of mebendazole for treatment of sheep 
Mebendazole is a benzimidazole, orally active broad-spectrum anthelmintic drug effective 
against numerous nematodes and cestodes of the gastrointestinal tract and against lung 
nematodes of different animals and humans.1,2 Mebendazole is the prototype of a series of 
broad-spectrum anthelmintics widely used in both animal and man.3 
Sheep is an animal species which is very susceptible to parasitic infections caused by 
helminths. These animals are often reared in circumstances (wet pastures) posing high parasitic 
risk. Bishop4 described mebendazole as a substance which is highly effective against 
gastrointestinal roundworms and tapeworms in sheep. Although adult tapeworms do not usually 
cause discernible disease, treatment is often necessary for public health purposes, to prevent 
disease due to larval stages in farm livestock and to minimise meat losses. Tapeworm infection 
is mostly seen in lambs during their first summer on pasture but rarely causes ill-effect, except 
perhaps for a marginal influence on growth. Infections often disappears spontaneously in the 
summer and are not common in older animals. Control of infection includes treatment in late 
spring or early summer and again in autumn. Prophylactical programmes in sheep are more 
complicated and often less satisfactory. The ewe acts as an extra source of infection to the lamb 
and the pre-lambing treatment is therefore necessary to eliminate the periparturient rise in 
faecal egg-counts. Additional treatment of lambs in spring may be necessary especially in a 
high-risk season due to climatic conditions. 
The pharmacokinetics of an anthelmintic drug and thus its efficacy may be affected by the level 
of infection. Bauer and Conraths5 reported the comparative efficacy of mebendazole and 
moxidectin (a macrocyclic lactone anthelmintic drug compound) against gastrointestinal 
nematodes in experimentally infected lambs. Pathological changes were therefore induced in 
the lambs by the inoculation of large doses of gastrointestinal nematode larvae. The 
mebendazole formulation was administered at the recommended therapeutic dose of 15 mg per 
kg body weight (BW). The nematode eggs were counted in individual collected faecal samples. 
The worm burdens were assessed in the gastrointestinal tracts of lambs euthanased seven 
days after treatment. The results of the trial demonstrate that mebendazole was highly effective 
against several adult gastrointestinal nematodes with an activity up to 100%. The failure to 
achieve a reduction of more than 76% against some species was most probably attributable to 
benzimidazole-resistance. 
Van der Westhuizen et al.6 described the anthelmintic efficacy of a mebendazole suspension 
against induced helminth infections in sheep and cattle. The mebendazole suspension was 
administered intraruminally via a stomach tube at a dosage rate of 15 mg of mebendazole per 
kg BW. Daily inoculations of larvae of various helminth parasites were given to the sheep over a 
period of several days. All animals were euthanased seven to 31 days after treatment. Several 
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gastrointestinal worms and lungworms and their stages were identified and the efficacy of the 
mebendazole treatment against each of the parasite species was calculated. The controlled 
efficacy of the mebendazole suspension obtained ranged from 79.8 to 100% against a wide 
variety of investigated larval and adult stages of sheep nematodes. 
Cavier and Notteghem7 performed a pharmacological study on the tenicidal properties (activity 
against tapeworms) of mebendazole and flubendazole. The tenicidal properties of the two 
compounds with similar molecular structure (flubendazole is the fluoro-substituted analogue of 
mebendazole) were comparatively studied on experimentally infested mice. Only mebendazole 
had sufficient activity warranting its therapeutical use against cestodes. 
 
 10.1.2  Metabolism of mebendazole 
Mebendazole (ME) is known to be absorbed from the gastrointestinal tract and to be intensively 
metabolised in sheep.1 The major metabolic reaction of mebendazole in sheep is the carbonyl 
reduction of the 5-keto group (Figure 6.1 in Chapter 6) to the corresponding alcohol compound 
hydroxymebendazole (RME).1,8 Hydrolysis of the “carbamate” group of ME to the resulting       
2-aminomebendazole (HME) (Figure 6.1 in Chapter 6) is the second metabolic pathway in 
sheep.9 The benzimidazole ring itself appears to be metabolically stable. The                        
2-aminobenzimidazoles of other benzimidazoles are often additionally metabolised in the         
5-substituent and are readily eliminated in the urine. No reported major metabolic pathway 
involving breakage of the benzimidazole ring system exists. Mebendazole metabolites appear to 
be extensively excreted in bile and this route is more important than urine. 
Also, HME is described by Al-Kurdi et al.10 as the main degradation impurity product of 
mebendazole in pharmaceutical dosage formulations such as tablets and suspensions, which 
are used in human medicine. HME was obtained in the laboratory by alkaline treatment of 
mebendazole. ME raw material was dissolved in 1 M sodium hydroxide solution, heated to 
boiling point under reflux cooling for 30 min, cooled down and neutralised with 1 N nitric acid. 
Delatour and Parish9 reported that in contrast with other benzimidazole anthelmintics as 
oxfendazole, albendazole and febantel, mebendazole appears to be nonteratogenic in sheep. 
Excellent toxicological correlation exists between rat and sheep with benzimidazoles. 
Compounds which are teratogenic in sheep are also teratogenic in rat. The reverse also 
appears to be true with the possible exception of mebendazole, which is reported to be 
nonteratogenic at the therapeutic dosage. However, embryolethal and teratogenic effects have 
been described for mebendazole in rats. The hydroxymebendazole metabolite is more 
embryotoxic than mebendazole itself. 
Mebendazole itself appears to be the active anthelmintic drug substance. The metabolites have 
very little anthelmintic activity.8,9 
Galtier and Alvinerie11 investigated the pharmacological basis for hepatic drug metabolism in 
sheep. The effect of experimental fascioliasis of sheep, proposed as a pathological model, on 
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the pharmacokinetics of various hepatic tracers and veterinary drugs, such as mebendazole, 
was investigated. The mean residence time of mebendazole was increased 1.5 to 2.7-fold when 
the lambs were treated 13-25 weeks post infection with consequences on the elimination of 
RME. The characteristic decrease in liver cytochrome could be responsible for most of the 
pharmacokinetic and pharmacodynamic changes observed in fluke-infected ruminants. A 
decrease of 59% in ME reduction was measured in liver microsomes prepared from 12-week 
infected sheep. The intermediate and late stages of fascioliasis (by weeks 8-25) were 
characterised by decreases (26 to 66%) in metabolism of ME to RME. 
A residue study of Iosifidou et al.12 clearly demonstrates that mebendazole given to European 
eel via the water is absorbed rapidly and is metabolised into its reduced and its hydrolysed 
metabolite. The hydrolysed metabolite proved to be the major metabolite of mebendazole in the 
eel. 
It was demonstrated that ME and its hydroxy metabolite (RME) constitute the residues of 
toxicological concern, because they were demonstrated to have embryotoxic potential.12 If the 
amino metabolite (HME) persists in edible parts of muscle tissues, it should be taken as the 
compound of interest for proving the animals treatment with mebendazole and estimating the 
withdrawal time for consumption of muscle tissue of the animal treated with mebendazole. 
 
 10.1.3  Objectives 
Blanchflower et al.13 measured residues in liver and muscle tissues after treatment of sheep 
with fenbendazole and oxfendazole. It can be expected that after treatment with mebendazole, 
a very similar anthelmintic drug compound, also residues remain in these tissues. 
Mebendazole-derived residues can still occur in food derived from sheep especially when the 
withdrawal time is not respected. To protect the consumer, the EC has established MRLs for 
residues of mebendazole and its two major metabolites in sheep tissues with as marker residue 
the sum of ME plus RME plus HME.14 The MRL value in liver tissue is set at 400 µg/kg. The 
MRL value for these residues in muscle, kidney and back fat tissues is established at 60 µg/kg. 
Several pharmacokinetic studies described the depletion of mebendazole-derived residues in 
plasma of sheep and goats.1,2,8,11 Galtier et al.1 described the pharmacokinetics of mebendazole 
in infected sheep after oral administration of mebendazole at 25 mg per kg BW. They reported 
the effect of Fasciola hepatica infestation on sheep plasma concentration of mebendazole and 
its reduced metabolite after administration to sheep before and after 4, 8, 13, 19 and 25 weeks 
of infection. The parent drug and especially its reduced metabolite were present in plasma of 
the animals. Behm et al.8 published residue concentrations of mebendazole and metabolites in 
sheep plasma at intervals up to 48 h after treatment of sheep with an intraruminal injection at 
dose rates of 12.5, 25, 50 and 100 mg per kg BW. Peak plasma concentrations occurred 
between 9 and 24 h for all dose rates and declined rapidly. Residues of the hydrolysed and 
reduced metabolite of mebendazole were detected and their concentrations exceeded that of 
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mebendazole at all dose rates. Galtier and Alvinerie11 determined the pharmacokinetics of 
mebendazole in sheep before and 4-25 weeks following a similar experimental fascioliasis.  
Age-related changes in hepatic drug metabolising activities of ewes were determined in foetal, 
neonatal, growing, pregnant and adult animals. After oral administration of mebendazole at     
25 mg per kg BW, the parent drug and especially its reduced metabolite were present in the 
animal plasma. The disposition kinetics of mebendazole in plasma, milk and ruminal fluid of 
goats were described by Pandey and Roy.2 Their experiment was designed to study the 
pharmacokinetics of mebendazole after single dose intravenous (5 mg per kg BW) and oral    
(40 mg per kg BW) administration in two separate groups of female goats. The plasma half-life, 
the total body clearance and the residue concentration of the parent drug in the experimental 
fluida was calculated. The highest residue response was obtained in the ruminal fluid and 
reached 40.1 µg/ml at 4 h after the single-dose oral administration. 
Facino et al.15 applied a liquid chromatographic-mass spectrometric analytical method to 
investigate the persistence of five benzimidazole anthelmintics, including mebendazole, in 
sheep milk. The healthy sheep, which were free of helminth parasites, were treated with a single 
oral therapeutic mebendazole dose of 25 mg per kg BW. Residues of mebendazole could be 
detected (detection limit of 2 µg/l) in the milk until 60 h after treatment. 
To our knowledge, no depletion data of mebendazole-derived residues in sheep tissues are 
available in the open literature. 
Michiels et al.3 investigated the pharmacokinetics of mebendazole and flubendazole in rats. 
Plasma mebendazole residue concentrations after oral and subcutaneous treatment at a dose 
rate of 40 mg per kg BW were about tenfold higher than those of flubendazole because of its 
better solubility. The comparative absorption experiment in rats suggested a marked strain 
difference with respect to the systemic absorption of oral mebendazole. Subcutaneous 
mebendazole appeared to be absorbed more gradually but at a similar rate for either strains. 
The extensive use of mebendazole in eel culture for anthelmintic treatment may lead to 
mebendazole-derived residues in eel tissues. Iosifidou et al.12 performed a residue study of 
mebendazole and its reduced and hydrolysed metabolites in liver, kidney, fat, skin and muscle 
tissue samples after batch treatment at a dose of 1 mg per l of water for 24 h. Liver and kidney 
were found to contain the highest concentrations of metabolites and fat contained the highest 
residue values of the parent compound. Skin contained higher residue concentrations for all 
three compounds, compared with muscle tissue. The hydrolysed metabolite could be detected 
(detection limit of 10 µg/kg) in the edible tissues (muscle and skin) sampled 14 days after the 
end of the treatment. 
The objective of this study was to investigate the depletion of the mebendazole-derived 
residues from tissues of sheep after a single oral treatment at 20 mg per kg body weight. The 
disposition and distribution of mebendazole and its hydrolysed and reduced metabolites was 
measured in thigh muscle, rib muscle, liver, kidney and back fat tissues. The incurred tissue 
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samples were received from Janssen Animal Health (Beerse, Belgium) who performed the 
sheep treatments. The residue analyses were carried out at the Department of Animal Product 
Quality and Transformation Technology (DVK-CLO, Melle, Belgium). 
 
10.2  Experimental 
 10.2.1  Treatment of sheep 
Eleven male, mixed Texel/Suffolk sheep of approximately 25 kg body weight were used in the 
depletion study performed by Janssen Animal Health. On day 0, ten sheep were treated with 
Ovitelmin at a single oral dose equivalent to 20 mg mebendazole per kg body weight. The 
sheep were weighed before the start of the experiment and samples were taken from the 
lightest and heaviest sheep at every time point. On day 1, two sheep were sacrificed using a 
captive bolt gun. After exsanguination, the liver, kidneys, 25 g of thigh muscle, 25 g of             
rib muscle and 25 g of back fat were collected in standard plastic bags, which were sealed, 
appropriately labeled and deep frozen. This procedure was repeated on days 7, 14, 21 and 28. 
The remaining, untreated sheep was sacrificed, sampled on day 28 and analysed as blank 
control. Samples were kept deep-frozen until needed for analysis. 
The recommended withdrawal period before slaughtering sheep after treatment with Ovitelmin 
is set at one week. 
 
 10.2.2  Determination of mebendazole-derived residues 
The incurred sheep tissue samples were analysed for residues of mebendazole and its 
hydrolysed and reduced metabolites with the quantitative liquid chromatographic-electrospray 
tandem mass spectrometric (LC-MS/MS) procedures described in Chapter 6. 
 
10.3  Results and discussion 
 10.3.1   Depletion of mebendazole-derived residues in sheep 
 tissues 
The applicability of the determination methods for mebendazole and its metabolites in tissues of 
sheep could be evaluated with the incurred samples of the limited depletion study. Samples of 
thigh muscle, rib muscle and the liver as well as the kidney and back fat were collected. The 
different kinds of samples were prepared by the different sample pretreatment procedures 
described in Chapter 6. 
The residue concentrations measured in the different tissue samples are summarised in     
Table 10.1. The values of the two sheep sampled at the same time point are given separately. 
The differences in the individual residue values between the sheep were high. It was therefore 
impractical to calculate mean values because the number of sheep involved in the trials was
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low. 
From the residue depletion results, it can be concluded that mebendazole was absorbed from 
the gastrointestinal tract very rapidly. ME metabolised mainly to the reduced metabolite and 
depleted in the tissues very rapidly. After one day of depletion, the residue concentrations 
ranged from 21 to 7630 µg/kg for ME in thigh muscle tissue and for RME in liver tissue, 
respectively. The highest residue response was found in liver tissue. Except for the back fat 
samples where the residue values for ME were higher, the highest residue values in the various 
tissues were measured for RME. No significant differences in residue response between thigh 
muscle tissue and rib muscle tissue were observed. The residue concentrations of the three 
compounds were comparable in each muscle tissue. Higher residue values were found for HME 
than for ME with maximum values of 119 and 67 µg/kg, respectively. The residue values for 
RME in the tissue samples varied between 585 and 1491 µg/kg. In kidney, liver and especially 
in back fat tissues, the concentrations for ME were higher than for HME. The maximum ME 
residue concentrations in kidney, liver and back fat tissue samples were 1160, 1628 and       
778 µg/kg, respectively. The maximum measured values for HME in these tissues were 237, 47 
and 28 µg/kg, respectively. 
Considerable residue concentrations were found only in the tissue samples taken after one day 
of depletion. From the tissues involved in this study, almost all residues disappeared during the 
first week of depletion. A rapid decrease of residue values occurs during this first week. Only a 
few residue values could still be measured at the second time point. Seven days after 
treatment, the sum of the residue values of ME plus RME plus HME in the various tissues had 
declined below the respective MRL values. Measurable residues of RME at a concentration of  
3 µg/kg were still found in liver samples until 14 days after treatment. 
From a practical point of view, detection limits (LODs) and quantification limits (LOQs) were 
used as analytical limits in order to be able to report more quantitative data for this depletion 
study with a limited number of samples. Decision limits and detection capabilities were of less 
practical use because higher minimum values for these analytical limits were obtained. The 
LOD and the LOQ for the various tissues in this depletion study were calculated as those 
concentrations that yield a signal-to-noise (S/N) ratio of at least 3/1 and 5/1, respectively. These 
analytical limit values were estimated as mean values at the calibration points of 1, 5 and        
10 µg/kg and are reported for the various tissues in Table 10.1. 
 
10.3.2  Discussion 
A comparable residue depletion pattern in sheep liver was obtained by Blanchflower et al.13 one 
day after oral treatment of fenbendazole and oxfendazole with the recommended therapeutic 
dose of 5 mg per kg BW. The mean residual concentrations of fenbendazole and oxfendazole 
were approximately 1050 and 2500 µg/kg, respectively. However, shown elimination rates of 
these compounds in the liver and muscle tissues were slower than that obtained with 
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mebendazole in this study. The half-lives of fenbendazole and oxfendazole in liver tissue were 
33.2 and 44.6 h, respectively. The residue concentrations of fenbendazole were much lower in 
muscle tissue than in liver tissue. A maximum concentration of 180 µg/kg was reached on     
day 2. On day 4, the concentrations had declined below the detection limit of the assay of 50 
µg/kg. However, the obtained residue response of fenbendazole was considerably higher than 
that obtained with mebendazole in the presented study. No oxfendazole was detected 
(detection limit of 100 µg/kg) in any of the muscle tissue samples tested. 
Good correlations between residue amounts in plasma samples found in the literature and the 
depletion results obtained in this study, especially for muscle and liver tissues, could be 
observed. The rapid absorption and distribution of mebendazole after oral treatment could be 
expected from the results of Galtier et al.1 After oral treatment of sheep with a dose of 25 mg 
per kg BW, ME and RME peaked, respectively, at 12 h (110 µg/l) and 11 h (930 µg/l) in the 
plasma of the sheep uninfested with fascioliasis. In animals treated 4 to 25 weeks postinfection, 
the observed maximum plasma concentrations were unchanged, whereas the corresponding 
times of plasma maxima obtained by week 14 were significantly increased by 256% for ME and 
154% for RME. Comparable results are published by Behm et al.8 They concluded in their study 
that mebendazole is absorbed rapidly into the blood in sheep and that it is quickly metabolised 
to the hydrolysed and the reduced metabolite. These research workers were able to measure 
ME residues in sheep plasma already 3 h after treatment with administration doses variing from 
12.5 to 100 mg per kg BW. They observed a peak concentration between 10 and 24 h of 
depletion. These research workers obtained a maximum residue concentration of 78 µg/l at 24 h 
after treatment by intraruminal injection of 25 mg per kg body weight. The total concentration of 
the two major metabolites were six- to eightfold higher than mebendazole itself, throughout the 
48 h after treatment. They obtained a peak concentration of 1600 µg/l estimated for the sum of 
the two metabolites between 9 and 24 h of excretion after treatment with a dose of 100 mg per 
kg BW. A more rapid and higher residue response for ME was obtained in plasma of goats by 
Pandey and Roy.2 After a single-dose oral administration of 40 mg per kg BW, ME appeared in 
plasma after 15 min. The maximum residue concentrations of 5.8 and 6.1 µl/ml were observed 
after 2 and 12 h of depletion. The mean plasma concentration of ME after intravenous 
administration of 5 mg per kg BW was 49.6 µg/ml obtained after 5 min. ME plasma 
concentration time profiles after intravenous and oral treatment, showed a secondary peak 
during the elimination phase, which led to the determination of additional redistribution 
(intravenous) and reabsorption (oral) components out of the usual elimination phases. A 
comparable residue response was obtained in the milk of the goats. The maximum ME residue 
concentration after the oral administration was 10.1 µg/ml obtained after 12 h of depletion. 
Residue values in milk could be detected (limit of detection of 0.1 µg/ml) until 120 h of depletion. 
From the results of Facino et al.15 can be concluded that the clearance of ME residues in milk is 
more rapid in sheep than in goat. These research workers could measure (detection limit of    
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2.0 µg/l) ME residues until 60 h of depletion after a single oral administration with a dose of     
25 mg per kg BW. 
The metabolism of mebendazole in eel, as reported by Iosifidou et al.,12 was quite different 
compared with that observed in sheep. The hydrolysed metabolite instead of the reduced one 
was the major metabolite of mebendazole measured in muscle tissue as well as in skin, kidney 
and fat tissues of eel. HME showed the highest residue concentration in each sample type from 
one day posttreatment and has the longest half-live. Elimination of ME and 
hydroxymebendazole from all tissues was comparable with exception for the skin tissue, which 
shows longer half-lives for ME and RME than the other tissues. The longest persistence of HME 
was obtained in skin and kidney tissues. The terminal elimination half-lives measured in skin 
and kidney tissue were 10.2 and 14.5 days. The residual concentrations measured 13 days 
after treatment were still approximately 1000 and 1300 µg/kg in skin and kidney tissue, 
respectively. 
 
10.4  Conclusions 
From the results of this depletion study can be concluded that the recommended withdrawal 
time for mebendazole administration to sheep of one week before slaughter is long enough. 
There is no risk for public health when the withdrawal period of one week before slaughtering of 
sheep is respected by the farmers and when sheep are not slaughtered during the first week 
after the mebendazole administration. The residue values in all tissues involved in this study 
declined below the respective MRL values seven days after the end of treatment. Only 
negligible mebendazole-derived residue concentrations were observed in rib muscle, kidney 
and liver tissues. Residues of the hydrolysed and the reduced metabolites of mebendazole 
could be detected, respectively in kidney and liver tissue, until 14 days of depletion. 
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General conclusions 
The main part of the experimental work of this doctoral thesis about residues of veterinary drugs 
considers the development of quantitative confirmatory analytical methods. 
The sample pretreatment procedure of the HPLC method with UV diode array detection for 
several anthelmintic residues in milk, was not fully optimised to obtain optimum analyte recovery 
(Chapter 3). A moderate extraction efficiency of about 70% can be reached with the described 
procedure. As proved for the LC-MS/MS method, alkaline conditions of the milk sample mixture 
seem necessary to improve the recovery substantially (Chapter 4). The extraction efficiency of 
the weak basic benzimidazole analytes was increased to at least 90% when the compounds 
were extracted in an alkaline sample matrix. 
The introduction of mass spectrometry as analytical tool in the residue analysis was very 
advantageous. The application of tandem mass spectrometric detection leads to very specific 
analyte detection. Although the sample clean-up was limited, reliable and accurate residue 
analysis could be performed and very low detection limits, even lower than 1 µg/kg, were 
reached. Because of the very easy sample preparation and the fast analyte determination, the 
LC-MS/MS methods are time and labour effective and very user friendly. Furthermore, in 
conformity with the recently published EC Decision 2002/657/EC, confirmatory methods for 
organic residues should provide information on the chemical structure of the analyte. Suitable 
confirmatory methods for residues of banned pharmacologically active substances for which no 
MRLs can be fixed need a liquid chromatographic method combined with infra red or mass 
spectrometric detection. UV diode array detection is acceptable as detection technique in HPLC 
methods for residues of authorised veterinary drugs. However, some limitations compared with 
mass spectrometry were discussed. Hence, HPLC methods are rather suitable for screening 
purposes. The LC-MS/MS analytical methods are very flexible. It is possible to change the 
parameters for the target substances within two hours. 
 
In the second part of this thesis, the developed analytical methods were applied to investigate 
the disposition and distribution of residues of veterinary drugs in milk, eggs and animal tissues. 
From the depletion results obtained for tetracyclines in eggs and broiler muscle tissues and for 
anthelmintics in milk, turkey, guinea fowl and sheep tissues, it can be expected that residues of 
these drug substances arise in food. In the past, less attention was paid to the potential 
occurrence of residues of anthelmintic drugs in food of animal origin. The residue analysis 
mainly focused on hormones and antibiotics.  
Anthelmintic drug substances are very rapidly absorbed, distributed and metabolised in the 
animal body after administration. Due to metabolisation, the administered compound will not 
always be the only target substance. Residues of the parent drug substances and metabolites 
are depleted in milk, eggs and animal tissues and shortly after administration, very high residue 
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amounts could be found. The anthelmintic veterinary medicinal products administered as topical 
or oral formulation, show a short efficacy time from one until a few days. The drug compounds 
do not persist in the animal body. A rapid decline in residue concentration in the animal tissues 
is observed after treatment. After treatment of healthy animals with the licensed veterinary 
medicinal products, all recommended withdrawal times were proved to be long enough to obtain 
safe animal products with residue concentrations below the MRL value. However, the total 
clearance of residues, as observed for flubendazole with the poultry species, takes several days 
probably because of recycling. 
Anthelmintic treatment of turkeys with flubendazole at the recommended therapeutic dose of 
19.9 mg per kg feed leads to residue amounts in muscle tissue up to 13-fold the MRL value 
during treatment. After 24 h of depletion, the residue concentration of the target residues 
declined to around the MRL level of 50 µg/kg. Therefore a withdrawal time of 24 h before 
slaughtering the target poultry species should be recommended. 
Species difference between turkey and guinea fowl in flubendazole metabolism was 
demonstrated. In turkeys, flubendazole was mainly converted to its hydrolysed metabolite while 
the reduced metabolite was the major metabolite depleted in tissues of guinea fowls. 
Consequently, it can be questionned whether the established MRLs for turkeys can serve as a 
reference to evaluate the safety of flubendazole-derived residues in guinea fowl. Flubendazole 
is not licensed for treatment of guinea fowl. Because of the higher potential toxicity of the 
reduced metabolite, it is strongly recommended to add this compound to the marker residues for 
this safety level. 
 
Besides the existing MRL concept, which is excluding as much as possible toxicological risks for 
public health, there is an arising consumer’s tendency for a zero tolerance. However, public 
health must be the priority in this ethical matter. 
 
Today’s consumers require the safest possible food in sufficient quantities at a reasonable 
price. Therefore, the precautionary principle has also been implemented in a systematic way as 
an approach to risk management. The ideal of zero risk concerning food safety does not exist. 
Because of communication problems on food safety issues, the consumer perception of food 
unsafety arised also. Surveillance and monitoring programmes should be harmonised in all EU 
member states and the results should be published in an uniform way, so that only those in 
excess of the MRL value and confirmed by validated confirmatory methods, are published. 
 
With this research study, a modest contribution for increasing the food safety is supplied. 
Several reliable and accurate analytical methods were developed which are suitable for routine 
quantitative determination of drug residues in food of animal origin in monitoring programmes or 
for surveillance analysis. The multiresidue LC-MS/MS method for anthelmintics in milk is 
currently used under accredited conditions for monitoring of Belgian farm milk. 
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Summary 
 
In the general introduction of this doctoral thesis, theoretical aspects and background 
information about residues of veterinary drugs in food are emphasised (Chapter 1). Residues of 
veterinary drugs not only originate from improper, illegal or off-label use of veterinary medicinal 
products. Small residue concentrations below MRL level can arise also after proper use of 
veterinary drugs. Otherwise, cross-contamination in feed mills is a recognised problem. Also 
environmental contamination may be a source of unwanted residues. Animal-to-animal transfer 
by recycling of veterinary drugs should not be neglected and can lead to very long clearance 
times, especially with eggs. Veterinary drug residue aspects are regulated in the European 
legislation. Recently, the EC Decision 2002/657/EC of 12 August 2002 implementing Council 
Directive 96/23/EC concerning the performance of analytical methods and the interpretation of 
results was published. This Decision established that the result of a residue analysis should be 
considered as non-compliant if the decision limit of the confirmatory method for the drug analyte 
would be exceeded. The most important disadvantage of existing chromatographic confirmatory 
methods showing low detection limits is that those are not suitable for routine analysis because 
of their very laborious and time consuming sample clean-up. Confirmatory methods have to be 
validated to demonstrate their reliability. The parameters which are thoroughly investigated for 
the presented quantitative confirmatory methods are: specificity, linearity, trueness, precision, 
recovery, analytical limits, stability and applicability/ruggedness. The relative retention times and 
the relative intensities of the measured precursor and product ions of the analytes were also 
monitored during the liquid chromatographic-mass spectrometric methods. 
 
The experimental part of this study deals with applied research work which recently has been 
published or which was submitted more briefly for publication in various scientific journals. The 
presented experimental work originates from the needs of the laboratory of the Department of 
Animal Product Quality and Transformation Technology (DVK-CLO, Melle, Belgium) which is 
involved in the screening of animal product samples for veterinary drug residues. There was a 
need for the ability to confirm samples suspected for antibiotics and to detect anthelmintic 
residues since no practical screening tests for these compounds were available until now. Most 
of the experimental work was focused on anthelmintic residues and the animal products under 
investigation were milk as well as eggs, poultry and sheep tissues. 
 
The experimental work of this doctoral thesis is divided in two separate parts. The development 
of chromatographic multiresidue confirmatory methods for the quantitative determination of 
tetracyclines and anthelmintics including metabolites is reported and discussed in the first part 
(Chapters 2, 3, 4, 5 and 6). A better insight into residue problems and the behaviour of drugs in 
the animal body is obtained via pharmacokinetic studies, which are described in the second part 
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(Chapters 7, 8, 9 and 10). The developed methods could be tested thoroughly with numerous 
incurred samples received from these depletion studies. 
 
Residues of tetracycline, oxytetracycline, chlortetracycline and doxycycline in eggs and poultry 
muscle tissue were determined by HPLC using UV diode array detection at 355 nm (Chapter 2). 
An acceptable separation of the analytes was obtained using ion-pair chromatography. Using 
this ion-pair technique, the sample clean-up could be kept to a minimum. The four tetracycline 
antibiotics could be detected in eggs and muscle tissue at limit concentrations ranging from    
2.2 to 27.3 µg/kg. Additional analyte confirmation was obtained through characteristic             
UV spectra of the diode array detector. 
The risks for human health due to residues of anthelmintics are rather limited. Nevertheless, 
also for these drug compounds MRL values were established by the European Commission and 
withdrawal times are recommended also. In the literature, teratogenicity is considered as the 
major potential risk. In addition to the well documented antibiotic resistance, precautions are 
also recommended to delay or to prevent the onset of resistance against anthelmintic drugs. 
Administration of the correct dose, usage of the minimum number of necessary treatments, 
rotation of the class of anthelmintics used annually and ensurance that animals would not 
infected with the resistant strains are effective policies for this goal. 
The determination of residues of anthelmintics in milk was investigated by two different 
detection techniques. Two separate HPLC methods were optimised for the determination of 
levamisole, fenbendazole, thiabendazole, albendazole and oxibendazole (Chapter 3). For these 
compounds extended with oxfendazole, febantel and triclabendazole, a multiresidue LC-MS/MS 
method was developed also (Chapter 4). Because of the quite different properties, levamisole 
had to be treated with a separate sample preparation procedure for the HPLC-DAD method. 
Satisfactory analyte separations and detection limits were obtained with ion-pair liquid 
chromatography and UV diode array detection at 225 nm for levamisole and at 295 nm for 
fenbendazole, thiabendazole, albendazole and oxibendazole. The previously used polymeric 
column with i.d. of 4.6 mm was changed for a reversed-phase C18 column with i.d. of 3.2 mm 
resulting in less pH-restrictions and higher analyte response values. The obtained detection 
limits varied from 0.5 to 3.8 µg/l. The introduction of mass spectrometry in the residue analysis 
was very advantageous. Much more specificity and lower detection limits were obtained using 
tandem mass spectrometry. The obtained specific mass spectra, showing the characteristic 
precursor and product ions, are very powerful analyte confirmation tools. Furthermore, 
compounds of the multiresidue methods do not have to be fully separated chromatographically 
because of the powerful separation capacity of tandem quadrupole mass spectrometer for 
compounds showing parent and product ions with different molecular mass. Because of the 
very specific detection principle, the sample clean-up could be omitted almost completely. The 
analytes were detected by positive electrospray ionisation. Further miniaturising of the            
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LC column was carried out. A reversed-phase C18 column with i.d. of 2.1 mm was used for all 
LC-MS/MS methods described in this thesis. 
The analytical method for the anthelmintics in milk has very low detection limits. Each 
compound could be detected at a residue concentration lower than 1 µg/l. The extraction 
recovery of the anthelmintics could be increased considerably to values of at least 90% by 
extracting the analytes in an alkaline milk matrix. The LC-MS/MS method was thoroughly 
elaborated. The validation was performed at two concentration levels. The reliability of the 
method was proven at MRL level as well as at an internal performance limit which was chosen 
at 1 µg/l. The decision limit and the detection capability, two analytical limits of the new 
validation concept, were determined also. For levamisole and triclabendazole, two unauthorised 
anthelmintic drugs for lactating dairy cows, a decision limit of respectively 1.2 and 1.3 µg/l was 
obtained. The method is also valid to quantify residues of the authorised anthelmintics at     
MRL level, providing the laboratory with a powerful tool to make decisions in violations for 
statutory testing purposes. 
A validated LC-MS/MS method is presented for the determination of flubendazole and its 
hydrolysed and reduced metabolites in eggs and in poultry muscle and liver tissues (Chapter 5). 
Flubendazole is the most frequently used anthelmintic drug in poultry species. The                  
LC separation of the analytes was performed with gradient elution with a mobile phase 
consisting of acetonitrile and ammonium acetate buffer. However, this ammonium acetate buffer 
is not stable, leads to blocking of tubings and hence to less robust analysis. Further optimisation 
in successive procedures indicated that this buffer could be omitted and changed succesfully for 
a mobile phase consisting of acetonitrile and water containing 0.1% formic acid to increase the 
analyte ionisation intensity. The limits of detection obtained for flubendazole, its hydrolysed and 
its reduced metabolite in egg and muscle tissue are 0.2, 0.3 and 1.1 µg/kg and 0.1, 0.8 and    
0.3 µg/kg, respectively. 
Sheep are one of the animal species who are most susceptible to parasitic infections caused by 
helminths. Sample preparation procedures and a LC-MS/MS determination method are 
developed for residues of mebendazole and its hydrolysed and reduced metabolites in muscle, 
liver, kidney and back fat tissues (Chapter 6). The method is validated for muscle and liver 
tissues at residue levels of 10, 20 and 60 µg/kg and 50, 100 and 400 µg/kg, respectively. The 
decision limits in muscle tissue for mebendazole, its hydrolysed and its reduced metabolite are 
72.5, 69.2 and 69.8 µg/kg, respectively. These analytical limit values in liver tissue are 445.9, 
466.5 and 463.4 µg/kg, respectively. However, mebendazole-derived residues can be detected 
in sheep tissues at concentrations lower than 2 µg/kg with the described method. 
 
The studies of dispositon, distribution and depletion of residues of tetracyclines and 
anthelmintics in eggs, milk and edible tissues of poultry species and sheep are described in the 
second part of this thesis. The amount of residues remaining in food are influenced by 
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pharmacokinetic processes as drug absorption, drug distribution and drug elimination 
(metabolism and excretion) out the animal body. The recommended withdrawal times have to 
be respected to ensure that the residue concentration in the animal product would be declined 
below the safety MRL level. 
The depletion of oxytetracycline in eggs is investigated during and after oral treatment of laying 
hens with a therapeutic dose of 840 mg per kg feed during seven successive days (Chapter 7). 
The absorption and disposition of oxytetracycline residues in eggs arised slowly. Five 
consecutive days of administration of medicated feed were needed to obtain a mean plateau 
residue concentration which was measured around the MRL level of 200 µg/kg. Two days after 
ceasing the administration, the residue concentration has fallen below the MRL level and was 
slowly declining during the successive withdrawal days. The disposition of tetracycline in muscle 
tissue is studied during and after oral administration of feed to broiler chickens medicated with 
tetracycline at a therapeutic dose of 480 mg per kg during seven successive days (Chapter 7). 
Tetracycline is very rapidly absorbed, efficiently distributed in the body of the broiler chicken and 
depleted in the muscle tissue. The residue amount of tetracycline accumulated in the muscle 
tissue was much higher than that of oxytetracycline in eggs. The plateau residue concentration 
of approximately 1200 µg/kg in muscle tissue was already obtained after one day of treatment. 
The residue concentration decreased very rapidly after the medication period and declined 
below MRL level the fourth day of the withdrawal period. 
Levamisole is a classic, imidazothiazole drug substance still frequently used for anthelmintic 
treatment of dairy cows. This anthelmintic drug is no more approved for usage in lactating dairy 
cows since several years. The depletion of levamisole in milk is investigated in dairy cows which 
were separately treated topically with the recommended dose of 10 mg for non-lactating cows 
and with a double dose of 20 mg per kg body weight (Chapter 8). Levamisole was very rapidly 
absorbed and subsequently excreted in the milk. Seven hours after dosing of the recommended 
amount, a maximum residue concentration of 1896 µg/l could already be measured.                  
A withdrawal time of 48 h is to short to obtain residue free milk. A levamisole residue 
concentration of 88 µg/l was still measured. 
The pharmacokinetics of flubendazole in avian species are investigated in two separate 
depletion studies with turkeys and guinea fowls treated orally with two doses (Chapter 9). 
Flubendazole is not licensed for usage of treatment of guinea fowls. Flubendazole was 
administered to the turkeys and guinea fowls with medicated feed at respective doses of 19.9 
and 29.6 mg and of 56.2 and 86.1 mg per kg feed during seven successive days. The 
disposition and distribution of flubendazole and its hydrolysed and reduced metabolites was 
measured in breast and thigh muscle tissues and in liver tissue. During the medication of the 
turkeys with the recommended dose, the residues accumulated in the tissues exceeded the 
MRL level which is established at 50 µg/kg for the sum of residues of flubendazole plus its 
hydrolysed metabolite in muscle tissues. A maximum mean residue concentration of           
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742.8 µg/kg was obtained in thigh muscle tissue after four days of treatment. Flubendazole was 
intensively metabolised to its hydrolysed metabolite and the residue concentration for the 
metabolite was approximately three- to fourfold that of the parent compound. The residue 
values for the reduced metabolite were negligible. The disposition of residues in thigh and 
breast muscle tissues was comparable. One day after treatment, the residue concentration 
already decreased to a level around the MRL. Nevertheless, since during treatment high 
residue concentrations are obtained it can be questionned if it would not be advisable to 
recommend a withdrawal time of 24 h after treatment and before slaughtering the animals. 
Species differences between turkeys and guinea fowls were observed. In contrast with the 
results obtained for turkeys, high residue concentrations for the reduced metabolite of 
flubendazole could be detected in edible tissues of guinea fowl. The disposition of residues in 
the muscle tissues of guinea fowl started even more rapidly than in the tissues of turkeys. After 
one day of treatment, a plateau residue level of approximately 400 µg/kg for the sum of residues 
of flubendazole plus the reduced metabolite was already obtained. After cessation of the 
administration, the decline of residue amount in the tissues was slower compared with the 
turkeys. Residue safety in the edible tissues after treatment with the therapeutic dose will be 
assured after a withdrawal period of three days. 
Despite the rapid decline in residue concentration just after cessation of the treatment, the total 
clearance of residues in tissues of turkeys as well as guinea fowls takes several days. Recycling 
of flubendazole-derived residues can be a potential cause for this observed phenomenon. 
The depletion of mebendazole-derived residues in tissues of sheep is investigated with a limited 
pharmacokinetic study with sheep orally treated with a single recommended dose equivalent to 
20 mg mebendazole per kg body weight (Chapter 10). The residues of mebendazole, its 
hydrolysed and its reduced metabolite were quantified in rib and thigh muscle, liver, kidney as 
well as back fat tissues at 1, 7, 14, 21 and 28 days after treatment. After one day of excretion, 
the residue concentrations ranged from 21 to 7630 µg/kg. With exception for back fat tissue 
samples, the highest residue response was always obtained for the reduced metabolite. There 
is no risk for public health when the withdrawal period of one week before slaughtering of sheep 
is respected. Only negligible amounts of mebendazole-derived residues were observed in rib 
muscle, kidney and liver tissues at this time point. The reduced metabolite in liver tissue and the 
hydrolysed metabolite in kidney tissue could be detected until 14 days of depletion. 
 
With this doctoral study, an additional contribution to the pool of analytical methods suitable for 
monitoring programmes or for confirmation purposes in residue surveillance analysis was made. 
The presented LC-MS/MS method for residues of anthelmintic drugs in milk is currently used 
under accredited conditions for monitoring of Belgian farm milk. 
 
 
 
 
 
 
 
 
 
 
 
 
Samenvatting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samenvatting 
 
257
 
 
Samenvatting 
 
In de algemene inleiding van dit doctoraal proefschrift worden de theorische aspecten en 
achtergrondinformatie over residuen van diergeneesmiddelen in levensmiddelen benadrukt 
(hoofdstuk 1). Residuen van diergeneesmiddelen zijn niet alleen afkomstig van 
onoordeelkundig, illegaal of buiten label gebruik van diergeneeskundige formuleringen. Ook 
door oordeelkundig gebruik van diergeneesmiddelen kunnen kleine restconcentraties beneden 
MRL waarde voorkomen. Kruiscontaminatie in mengvoederbedrijven is een ander gekend 
probleem. Ook contaminatie uit het milieu kan een bron zijn van ongewilde residuen. Het 
overbrengen van residuen van dier tot dier door recirculatie mag niet verwaarloosd worden en 
kan aanleiding geven tot heel lange uitscheidingstijden, en dit speciaal in eieren. De aspecten 
van residuen van diergeneesmiddelen zijn gereguleerd in de Europese wetgeving. Recentelijk 
werd de Beschikking 2002/657/EC van 12 augustus 2002 van de Europese Commissie 
gepubliceerd. Deze Beschikking implementeert Richtlijn 96/23/EG betreffende de prestaties van 
analysemethoden en de interpretatie van resultaten. Deze Beschikking bepaalt dat het resultaat 
van een residuanalyse voortaan als niet-conform wordt beschouwd als de beslissingsgrens van 
de bevestigingsmethode voor het analyt wordt overschreden. Het grootste nadeel van 
bestaande chromatografische bevestigingsmethoden met lage detectiegrenzen is dat deze niet 
geschikt zijn voor routinebepalingen omwille van de zeer arbeidsintensieve en tijdrovende 
staalopzuivering. Bevestigingsmethoden dienen gevalideerd te worden om hun 
betrouwbaarheid aan te tonen. De parameters die uitvoerig onderzocht werden voor de 
gepresenteerde kwantitatieve bevestigingsmethoden zijn: specificiteit, lineariteit, juistheid, 
precisie, recovery, analytische limieten, stabiliteit en toepasbaarheid/robuustheid. De relatieve 
retentietijden en de relatieve intensiteiten van de gemeten precursor- en productionen van de 
analyten werden opgevolgd bij de vloeistof chromatografische-massaspectrometrische 
methoden. 
 
Het experimenteel deel van deze studie handelt over toegepast onderzoekswerk dat recentelijk 
onder meer beknopte vorm werd gepubliceerd of werd ingediend voor publicatie in 
wetenschappelijke tijdschriften. Het gepresenteerde experimenteel werk kende zijn ontstaan in 
behoeften van het laboratorium van het Departement voor de Kwaliteit van dierlijke producten 
en transformatietechnologieën (CLO-DVK, Melle, België), betrokken bij de screening van 
dierlijke producten voor residuen van diergeneesmiddelen. Er was noodzaak aan bevestiging 
van verdachte stalen voor antibiotica en aan detectiemogelijkheden voor residuen van 
ontwormingsmiddelen wegens het ontbreken van praktische screeningstesten hiervoor. Het 
grootste deel van het onderzoekswerk was toegespitst op residuen van ontwormingsmiddelen 
en de bestudeerde levensmiddelen waren zowel melk als eieren, gevogelte- en 
schapenweefsels. 
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Het experimenteel werk van dit doctoraal proefschrift is onderverdeeld in twee afzonderlijke 
delen. De ontwikkeling van chromatografische multiresidu bevestigingsmethoden voor de 
kwantitatieve bepaling van tetracyclines en ontwormingsmiddelen met inbegrip van 
metabolieten wordt gerapporteerd en beschreven in het eerste deel (hoofdstuk 2, 3, 4, 5 en 6). 
Een beter inzicht in de residuproblematiek en het gedrag van geneesmiddelen in het dierlijk 
lichaam werd bekomen via farmacokinetische studies die beschreven zijn in het tweede deel 
(hoofdstuk 7, 8, 9 en 10). De ontwikkelde methoden konden uitvoerig worden getest met de 
veelvuldige praktijkstalen bekomen van de uitscheidingsstudies. 
 
Residuen van tetracycline, oxytetracycline, chloortetracycline en doxycycline in eieren en 
spierweefsel van gevogelte werden bepaald via HPLC met UV diode array detectie bij 355 nm 
(hoofdstuk 2). Een aanvaardbare scheiding van de analyten werd bekomen via ion-paar 
chromatografie. Door gebruik te maken van deze ion-paar techniek kon de staalopzuivering 
minimaal gehouden worden. De vier tetracycline antibiotica kunnen in eieren en spierweefsel 
gedetecteerd worden tot een limietconcentratie die varieert van 2.2 tot 27.3 µg/kg. 
Supplementaire analytbevestiging werd bekomen aan de hand van het karakteristieke            
UV spectrum via de diode array detector. 
De risico’s voor de volksgezondheid door residuen van ontwormingsmiddelen zijn eerder 
beperkt. Niettemin zijn door de Europese Commissie ook voor deze geneesmiddelen           
MRL waarden vastgelegd en worden hiervoor ook wachttijden aanbevolen. Teratogeniciteit 
wordt als het grootste potentiële risico aangehaald in de literatuur. Aanvullend aan de 
welomschreven antibioticaresistentie, worden ook voorzorgsmaatregelen aanbevolen voor het 
vertragen of voorkomen van het ontstaan van resistentie tegen ontwormingsmiddelen. Effectief 
zijn het toedienen van de correcte dosis, het strikt toepassen van het aantal noodzakelijke 
behandelingen, het jaarlijks veranderen van de gebruikte groep ontwormingsmiddelen en het 
verzekeren dat de kiemvrije dieren niet geïnfecteerd worden met resistente stammen. 
De bepaling van residuen van ontwormingsmiddelen in melk werd onderzocht via twee 
verschillende detectietechnieken. Twee separate HPLC methoden werden geoptimaliseerd voor 
de bepaling van levamisole, fenbendazole, thiabendazole, albendazole en oxibendazole 
(hoofdstuk 3). Voor deze componenten aangevuld met oxfendazole, febantel en triclabendazole 
werd ook een multiresidu LC-MS/MS methode ontwikkeld (hoofdstuk 4). Omwille van zijn 
afwijkende eigenschappen diende levamisole met een andere staalvoorbereidingsprocedure 
behandeld te worden in de HPLC-DAD methode. Voldoende analyt scheiding en aanvaardbare 
detectielimieten werden bekomen met ion-paar vloeistofchromatografie en UV diode array 
detectie bij 225 nm voor levamisole en bij 295 nm voor fenbendazole, thiabendazole, 
albendazole en oxibendazole. De voorheen gebruikte polymere kolom met i.d. van 4.6 mm werd 
vervangen door een omgekeerde fase C18 kolom met i.d. van 3.2 mm, wat resulteerde in minder 
pH beperkingen en hogere analyt responswaarden. De bekomen detectielimieten varieerden 
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van 0.5 tot 3.8 µg/l. De beschikbaarheid van massaspectrometrie voor de residuanalysen was 
zeer voordelig. Meer specificiteit en lagere detectiegrenzen werden bekomen via tandem 
massaspectrometrie. De bekomen specifieke massaspectra met de karakteristieke precursor- 
en productionen bieden een zeer krachtig analyt bevestigingsmedium. Bovendien dienen de 
componenten in de multiresidu methoden chromatografisch niet volledig gescheiden te zijn 
omwille van de krachtige scheidingscapaciteit van de tandem quadrupool massaspectrometer 
voor componenten met precursor- en productionen met verschillende moleculaire massa. 
Omwille van het zeer specifieke detectieprincipe kan de staalopzuivering bijna compleet 
achterwege gelaten worden. De analyten werden gedetecteerd via electrospray ionisatie in de 
positieve mode. Verdere miniaturisatie van de LC kolom werd doorgevoerd. Een omgekeerde 
fase C18 kolom met i.d. van 2.1 mm werd gebruikt voor iedere LC-MS/MS methode beschreven 
in deze thesis. 
De analysemethode voor ontwormingsmiddelen in melk is heel gevoelig en elke component kon 
gedetecteerd worden tot een residuconcentratie lager dan 1 µg/l. De terugvinding voor de 
ontwormingsmiddelen kon verhoogd worden tot 90% door de analyten te extraheren in een 
alkalische melk matrix. The LC-MS/MS methode werd grondig uitgewerkt. De validatie werd 
uitgevoerd op twee concentratie niveaus. De betrouwbaarheid van de methode was bewezen 
zowel op MRL niveau als op het niveau van een interne prestatielimiet welke op 1 µg/l werd 
vastgelegd. De beslissingsgrens en het detectievermogen, twee analytische limieten van het 
nieuwe validatieconcept, werden eveneens bepaald. Voor levamisole en triclabendazole, twee 
verboden ontwormingsmiddelen voor lacterende melkkoeien, werd een beslissingsgrens van 
respectievelijk 1.2 en 1.3 µg/l bekomen. De methode is ook geschikt voor het kwantificeren van 
residuen van toegelaten ontwormingsmiddelen op MRL niveau, waardoor het laboratorium 
voorzien wordt van een krachtig medium om beslissingen te nemen bij overtredingen 
vastgesteld bij officiële analysen. 
Een gevalideerde LC-MS/MS methode wordt voorgesteld voor de bepaling van flubendazole en 
de gehydrolyseerde en gereduceerde metabolieten in eieren en in spier- en leverweefsel van 
gevogelte (hoofdstuk 5). Flubendazole is het meest frekwent gebruikte ontwormingsmiddel bij 
pluimvee. De chromatografische scheiding van de analyten werd uitgevoerd met gradiëntelutie 
met een mobiele fase bestaande uit acetonitrile en ammoniumacetaat buffer. Deze 
ammoniumacetaat buffer is echter niet stabiel en geeft aanleiding tot blokkering van de tubings 
en tot een minder robuuste analysemethode. Verdere optimalisatie in de volgende procedures 
gaf aan dat het gebruik van deze buffer kon worden vermeden en dat deze met succes kon 
worden vervangen door een mobiele fase bestaande uit acetonitrile en water dat 0.1% 
mierenzuur bevat om de ionisatie-intensiteit te verhogen. De bekomen detectielimieten voor 
flubendazole, de gehydrolyseerde en de gereduceerde metabolieten in eieren en spierweefsel 
zijn respectievelijk 0.2, 0.3 en 1.1 µg/kg en 0.1, 0.8 en 0.3 µg/kg. 
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Schapen zijn één van de gevoeligste diersoorten voor parasietinfecties veroorzaakt door 
ingewandswormen. Staalvoorbereidingsprocedures en een LC-MS/MS bepalingsmethode zijn 
ontwikkeld voor residuen van mebendazole en de gehydrolyseerde en de gereduceerde 
metabolieten in spier-, lever-, nier- en vetweefsel (hoofdstuk 6). De methode is gevalideerd voor 
spier- en leverweefsel op respectievelijke residuniveaus van 10, 20 en 60 µg/kg en 50, 100 en 
400 µg/kg. De beslissingsgrenzen in spierweefsel voor mebendazole, de gehydrolyseerde en 
de gereduceerde metabolieten bedragen respectievelijk 72.5, 69.2 en 69.8 µg/kg. Deze 
analytische grenswaarden in leverweefsel zijn respectievelijk 445.9, 466.5 en 463.4 µg/kg. 
Residuen van mebendazole en metabolieten kunnen met de beschreven methode echter 
gedetecteerd worden tot concentraties lager dan 2 µg/kg. 
 
De distributie- en uitscheidingsstudies van residuen van tetracyclines en ontwormingsmiddelen 
in eieren, melk en eetbare weefsels van pluimvee en schapen zijn beschreven in het tweede 
deel van dit proefschrift. De hoeveelheid residuen in levensmiddelen wordt beïnvloed door 
farmacokinetische processen zoals absorptie, distributie van het geneesmiddel in en 
verwijdering uit (metabolisatie en uitscheiding) het dierlijk lichaam. De aanbevolen wachttijden 
dienen gerespecteerd te worden om te verzekeren dat de residuconcentratie in het dierlijk 
product is afgenomen tot beneden de veilige MRL waarde. 
De uitscheiding van oxytetracycline in eieren is onderzocht gedurende en na de orale 
behandeling van leghennen met een therapeutische dosis van 840 mg per kg voeder 
gedurende zeven opeenvolgende dagen (hoofdstuk 7). De absorptie en uitscheiding van 
oxytetracycline residuen in eieren geschiedde traag. Pas na vijf opeenvolgende 
behandelingsdagen werd een plateauwaarde in residuconcentratie bereikt welke ongeveer 
overeenkwam met het MRL niveau van 200 µg/kg. Twee dagen na stopzetting van de 
toediening daalde de residuconcentratie terug beneden het MRL niveau en daalde traag verder 
gedurende de volgende dagen van de wachtperiode. De uitscheiding van tetracycline in 
spierweefsel van braadkippen werd bestudeerd gedurende en na orale behandeling via voeder 
dat gemedicineerd werd met een therapeutische dosis van 480 mg per kg gedurende zeven 
opeenvolgende dagen (hoofdstuk 7). Tetracycline wordt zeer vlug geabsorbeerd, efficiënt 
verdeeld in het lichaam van de braadkip en vlug uitgescheiden in het spierweefsel. De 
geaccumuleerde tetracycline residuhoeveelheid in het spierweefsel is veel hoger dan dat van 
oxytetracycline in eieren. De plateau residuconcentratie van ongeveer 1200 µg/kg in het 
spierweefsel werd reeds bereikt na één dag behandeling. De residuconcentratie daalde zeer 
snel na de medicatieperiode en daalde onder het MRL niveau na de vierde dag in de 
wachtperiode. 
Levamisole is een klassiek imidazothiazole geneesmiddel bestanddeel dat nog frekwent wordt 
gebruikt voor ontworming van melkkoeien. Het ontwormingsmiddel is sedert enkel jaren niet 
meer toegelaten voor gebruik bij lacterend melkvee. De uitscheiding van levamisole in melk is 
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onderzocht met melkkoeien die behandeld werden via de “pour-on” techniek in twee 
verschillende periodes met de aanbevolen dosis van 10 mg voor niet-lacterende dieren en met 
een dubbele dosis van 20 mg per kg levend gewicht (hoofdstuk 8). Levamisole wordt zeer vlug 
opgenomen en snel uitgescheiden in de melk. Een maximale residuconcentratie van 1896 µg/l 
kon reeds worden gemeten zeven uur na toediening van de aanbevolen dosis. Een 
wachtperiode van 48 uur is te kort om residuvrije melk te bekomen. Er werd nog steeds een 
residuconcentratie van 88 µg/l gemeten. 
De farmacokinetische eigenschappen van flubendazole bij vogelachtigen zijn onderzocht in 
twee onderscheiden uitscheidingsstudies met kalkoenen en parelhoenders die oraal behandeld 
werden met de aanbevolen en met een hogere dosis (hoofdstuk 9). Flubendazole is niet 
geregistreerd voor behandeling van parelhoenders. Flubendazole werd toegediend aan de 
kalkoenen en aan de parelhoenders via gemedicineerd voeder met respectievelijke dosissen 
van 19.9 en 29.6 mg en van 56.2 en 86.1 mg per kg voeder en dit gedurende zeven 
opeenvolgende dagen. De verdeling en uitscheiding van flubendazole en van de 
gehydrolyseerde en gereduceerde metabolieten werd gemeten in borstspier-, in bilspier- en in 
leverweefsel. Gedurende de medicatie van de kalkoenen met de aanbevolen dosis overstegen 
de geaccumuleerde residuwaarden in de weefsels het MRL niveau dat vastgelegd is op          
50 µg/kg voor de som van de residuen van flubendazole plus de gehydrolyseerde metaboliet in 
spierweefsel. Een maximale gemiddelde residuconcentratie van 742.8 µg/kg werd bereikt in 
bilspierweefsel na vier dagen behandeling. Flubendazole metaboliseerde intensief en werd 
getransformeerd in de gehydrolyseerde metaboliet. De residuconcentratie voor de metaboliet 
was ongeveer 3 tot 4 maal deze van de ouder component. De residuwaarden voor de 
gereduceerde metaboliet waren verwaarloosbaar. De uitscheiding van residuen in bil- en 
borstspierweefsel zijn vergelijkbaar. Eén dag na de behandeling daalde de residuhoeveelheid 
tot het concentratieniveau van de MRL waarde. Niettegenstaande dit en omdat gedurende de 
behandeling hoge residuwaarden werden bekomen kan overwogen worden om een aanbevolen 
wachtperiode van 24 uur na behandeling te adviseren alvorens de kalkoenen te slachten. 
Soortverschillen tussen kalkoenen en parelhoenders werden vastgesteld. In tegenstelling tot de 
resultaten bekomen met de kalkoenen konden in de eetbare weefsels van de parelhoenders 
hoge residuconcentraties voor de gereduceerde metaboliet van flubendazole gedetecteerd 
worden. De uitscheiding van residuen in spierweefsels van parelhoenders startte nog sneller 
dan in de weefsels van de kalkoenen. Na één dag behandeling werd reeds een plateau 
residuwaarde van ongeveer 400 µg/kg voor de som van residuen van flubendazole en de 
gereduceerde metaboliet bekomen. De afname in residuhoeveelheid in de weefsels na 
stopzetting van de behandeling was trager dan bij de kalkoenen. Residuveiligheid in de eetbare 
weefsels na behandeling met de therapeutische dosis kan worden gegarandeerd na een 
wachtperiode van drie dagen. 
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Ondanks een snelle daling in residuconcentratie juist na stopzetting van de behandeling neemt 
de totale uitscheiding van residuen in weefsels van zowel kalkoenen als parelhoenders toch 
meerdere dagen in beslag. Recirculatie van residuen gestimuleerd door de grondhuisvesting, 
kan een mogelijke oorzaak zijn voor dit vastgesteld fenomeen. 
De uitscheiding van residuen afgeleid van mebendazole in schapenweefsels is onderzocht met 
een beperkte farmacokinetische studie met schapen die oraal behandeld werden met een 
enkelvoudige dosis equivalent met 20 mg mebendazole per kg levend gewicht (hoofdstuk 10). 
De residuen van mebendazole, de gehydrolyseerde en de gereduceerde metabolieten werden 
gekwantificeerd in ribspier-, bilspier-, lever-, nier- en vetweefsel en dit 1, 7, 14, 21 en 28 dagen 
na behandeling. Na één dag uitscheiding varieerden de residuconcentraties van 21 tot        
7630 µg/kg. Met uitzondering voor het vetweefsel werd steeds de hoogste residurespons 
bekomen voor de gereduceerde metaboliet. Er is geen gevaar voor de volksgezondheid indien 
de wachtperiode van één week na behandeling wordt gerespecteerd, alvorens de schapen 
worden geslacht. Enkel verwaarloosbare hoeveelheden residuen werden waargenomen in 
ribspier-, nier- en leverweefsel na één week uitscheiding. De gereduceerde metaboliet in 
leverweefsel en de gehydrolyseerde metaboliet in nierweefsel kon tot 14 dagen na behandeling 
nog worden gedetecteerd. 
 
Met deze doctoraatsstudie werd een aanvullende bijdrage geleverd aan de verzameling van 
geschikte analysemethoden voor monitoringsprogramma’s en voor bevestigingsdoeleinden in 
residucontrole analysen. De voorgestelde LC-MS/MS methode voor residuen van 
ontwormingsmiddelen in melk wordt momenteel onder geaccrediteerde omstandigheden 
gebruikt voor de monitoring van Belgische hoevemelk. 
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Annex: Curriculum vitae 
 
1  Personalia 
naam, voornaam :  DE RUYCK HENDRIK 
adres   :  Nazarethsesteenweg 36   9800   DEINZE 
tel.   :  0032 (0)9 380 14 18 
e-mail   :  h.deruyckdevolder@pi.be 
geboren  :  op 01/02/63 te Oudenaarde 
burgerlijke staat :  gehuwd, twee kinderen 
nationaliteit  :  Belg 
 
2  Loopbaan 
 2.1  Vanaf 16/01/89 
Wetenschappelijke Instelling van de Vlaamse Gemeenschap (voorheen Ministerie van 
Middenstand en Landbouw) 
Centrum voor Landbouwkundig Onderzoek - Gent (CLO) 
Departement Kwaliteit van dierlijke producten en transformatietechnologie (DVK) 
Brusselsesteenweg 370, 9090 MELLE 
tel. 0032 (0)9 272 30 31, fax. 0032 (0)9 272 30 01, e-mail: H.DeRuyck@clo.fgov.be 
 
-  functie: assistent 
 
-  hoofdtaken: 
 -  leiden van opeenvolgende onderzoeksprojecten: 
 -  kwaliteitsproblemen bij de bereiding van melkpoeder 
  -  ontwikkeling van speciale melkpoeders 
  -  toepassingsmogelijkheden van membraanfiltratietechnologie 
  -  toepassingsmogelijkheden van extrusietechnologie 
 -  huidige onderzoeksprojecten:  
-  ontwikkeling van chemische bevestigingsmethoden voor het bepalen van residuen 
van diergeneesmiddelen in dierlijke producten 
 -  uitscheidingsstudies van residuen van diergeneesmiddelen in dierlijke producten 
 -  dienstverlening in opeenvolgende taken: 
-  pilootfabriekverantwoordelijke voor technologisch proefwerk betreffende 
membraanfiltratie, indampen, drogen en extrusie van zuivelproducten, algemene 
levensmiddelen en diervoeder 
-  laboratoriumverantwoordelijke voor het fysico-chemisch laboratorium, 
geaccrediteerd volgens EN 45001 
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-  huidige dienstverlening: 
-  laboratoriumverantwoordelijke voor het laboratorium voor specifieke analysen van
 gedroogde zuivelproducten 
-  laboratoriumverantwoordelijke voor bepaling van residuen van klassieke 
antiparasitaire diergeneesmiddelen in melk in chromatografisch laboratorium 
geaccrediteerd volgens ISO/IEC 17025, monitoring van Belgische melk voor 
residuen van klassieke antiparasitaire diergeneesmiddelen in kader van het Fonds 
voor de Voedselveiligheid, bescherming van de Volksgezondheid en Leefmilieu in 
opdracht van het Federaal Agentschap voor de Veiligheid van de voedselketen 
(FAVV) 
 -  adjunct-milieucoördinator DVK 
-  neventaken: 
- begeleiding van thesisstudenten (zie paragraaf 7) 
- referee voor volgende wetenschappelijke tijdschriften: Food Additives and 
Contaminants, Analytica Chimica Acta, Journal of Pharmaceutical and Biomedical 
Analysis, Journal of Food Engineering en World Rabbit Science 
- geven van lessen in cursussen en presentatie van posters en lezingen op studiedagen 
en congressen 
- officiële melkpoederkeurder voor het FAVV 
 -  behandelen van aanbestedingen 
 
 2.2  Van 01/03/88 tot 31/12/88 
- assistent aan het Laboratorium voor levensmiddelentechnologie, -microbiologie en -chemie 
(diensthoofd: Prof. dr. ir. A. Huyghebaert) van de Faculteit Landbouwkundige 
Wetenschappen aan de Rijksuniversiteit Gent 
- IWONL-project "Studie van membraantechnieken bij de isolatie van melkeiwitpreparaten en 
van hun aanwending in gefermenteerde zuivelproducten" 
- assisteren bij laboratoriapractica 
- begeleiden van thesisstudent 
 
 2.3  Vanaf 01/08/87 tot 31/01/88 
- laboratoriumverantwoordelijke bij NV Clovis Matton, Avelgem 
- kwaliteitscontrole van land- en tuinbouwzaden en in vitro-bepaling van de voederwaarde 
van geënsileerde ruwvoeders 
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3  Studies 
- Universitaire studies van 1982 tot 1987 aan de Rijksuniversiteit Gent: 
  Ingenieur voor de Scheikunde en de Landbouwindustrieën 
 - specialisatie: technologie en bedrijfsleiding van landbouw- en voedingsnijverheden 
  - thesis: valorisatie van immunoglobulinen uit wei 
 - afgestudeerd met onderscheiding 
 
- Voorbereidend jaar in 1981 - 1982: 
- St. Amandusinstituut Gent 
- Bijzonder Wetenschappelijke klas 
 
- Middelbaar onderwijs van 1975 tot 1981: 
 - Vrij Landelijk Instituut Oudenaarde 
- Technisch onderwijs, A2 - Landbouw 
 
4  Publicaties  
- De Ruyck H. 
 Mogelijkheden van extrusie voor de zuivelindustrie. 
 De melk en wij, 1991, (1), 21-26 
 
- De Ruyck H. 
 Extrusietechnologie voor de ontwikkeling van nieuwe voedingsproducten. 
 Het Ingenieursblad, 1991, 60(3), 19-24 
 
- De Ruyck H. 
 Het voorkomen van white flecks bij instant volle melkpoeder. 
 Landbouwtijdschrift, 1991, 44(4), 751-761 
 
- De Ruyck H. en Traest P. 
 Membraanfiltratietechnieken in de zuivelindustrie. 
 Nijverheid-elektriciteit, december 1993, 29, 8-10 
 
- Maertens L., Luzi F. en De Ruyck H. 
Invloed van het extruderen van een zetmeelrijk en -arm voeder op de verteerbaarheid en 
het caecaal fermentatiepatroon van konijnen bij spenen en 3 weken na spenen. 
Bijdrage voor 20e studiedag van de Nederlandstalige voedingsonderzoekers, Katholieke 
Universiteit Leuven, Leuven, 7 april 1995 
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- De Ruyck H. 
 Modelling of the residence time distribution in a twin screw extruder. 
 Journal of Food Engineering, 1997, 32, 375-390 
 
- De Ruyck H., De Ridder H., Van Renterghem R. and Van Wambeke F. 
Validation of HPLC method of analysis of tetracycline residues in eggs and broiler meat and 
its application to a feeding trial. 
Food Additives and Contaminants, 1999, 16, 47-56 
 
- D’haese E., Nelis H.J., Reybroeck W. and De Ruyck H. 
 Evaluation of a modified enzymatic test for the detection of tetracyclines in milk. 
 Journal of Food Protection, 1999, 62, 632-636 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
 Confirmatory assay for the simultaneous detection of penicillins and cephalosporins in milk 
using LC/MS-MS, in: van Ginkel L.A. and Ruiter A. (Eds), Residues of veterinary drugs in 
food, Volume I, Proceedings of Euroresidue IV, 8-10 mei 2000, Veldhoven, RIVM, 
Bildhoven, Nederland, 333-338 
 
- De Ruyck H., De Ridder H., Van Renterghem R. and Daeseleire E. 
 Determination of flubendazole and metabolites in eggs and poultry meat with LC-MS/MS, 
in: van Ginkel L.A. and Ruiter A. (Eds), Residues of veterinary drugs in food, Volume II, 
Proceedings of Euroresidue IV, 8-10 mei 2000, Veldhoven, RIVM, Bildhoven, Nederland, 
962-968 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
 Confirmatory assay for the simultaneous detection of penicillins and cephalosporins in milk 
using liquid chromatography/tandem mass spectrometry. 
  Rapid Communications in Mass Spectrometry, 2000, 14, 1404-1409 
 
- De Ruyck H., Van Renterghem R., De Ridder H. and De Brabander D. 
Determination of anthelmintic residues in milk by high performance liquid chromatography. 
Food Control, 2000, 11, 165-173 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
 Rapid confirmatory assay for the simultaneous detection of ronidazole, metronidazole and 
dimetridazole in eggs using liquid chromatography-tandem mass spectrometry. 
The Analyst, communication, 2000, 125, 1533-1535 
 
 
Annex: Curriculum vitae 
 
269
 
- De Ruyck H., Daeseleire E., Grijspeerdt K., De Ridder H., Van Renterghem R. and 
Huyghebaert G. 
Determination of flubendazole and its metabolites in eggs and poultry muscle with liquid 
chromatography-tandem mass spectrometry. 
Journal of Agricultural and Food Chemistry, 2001, 49, 610-617 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
Rapid confirmatory assay for the simultaneous detection of ronidazole, metronidazole and 
dimetridazole in eggs using LC-MS/MS. 
Proceedings of Eurofoodchem XI, Biologically-active phytochemicals: analysis, metabolism, 
bioavailability and function, 26-28 september 2001, Norwich, Groot-Brittannië, 263-266 
 
- De Ruyck H., Daeseleire E., De Ridder H., Van Renterghem R. and Huyghebaert G. 
Determination of flubendazole and metabolites in eggs and poultry meat with LC-MS/MS, 
in: Laevens H., Geers R. and Vandenheede J. (Eds), Risk analysis and quality control of 
animal products, Proceedings of 9th Annual meeting of the Flemish society for veterinary 
epidemiology and economics (VEE), 25 oktober 2001, Melle, 71-73 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
Rapid confirmatory assay for the simultaneous detection of ronidazole, metronidazole and 
dimetridazole in eggs using LC-MS/MS, in: Laevens H., Geers R. and Vandenheede J. 
(Eds), Risk analysis and quality control of animal products, Proceedings of 9th Annual 
meeting of the Flemish society for veterinary epidemiology and economics (VEE),             
25 oktober 2001, Melle, 68-70 
 
- De Ruyck H., Daeseleire E. and De Ridder H. 
Development and validation of a liquid chromatography-electrospray tandem mass 
spectrometry method for mebendazole and its metabolites hydroxy-mebendazole and 
amino-mebendazole in liver of sheep. 
The Analyst, 2001, 126, 2144-2148 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
Development and validation of a liquid chromatography-electrospray tandem mass 
spectrometry method for anthelmintics in milk. 
Book of Abstracts of 7th International symposium on Hyphenated Techniques in 
Chromatography and hyphenated chromatographic analysers (HTC-7), 6-8 februari 2002, 
Brugge, 195-196 
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- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
 Development and validation of a liquid chromatographic-electrospray tandem mass 
spectrometric multiresidue method for anthelmintics in milk. 
 Journal of Chromatography A, 2002, 976, 181-194 
 
- Daeseleire E., Mortier L., De Ruyck H. and Geerts N. 
 Determination of flunixin and ketoprofen in milk by liquid chromatography-electrospray 
tandem mass spectrometry. 
 Abstract Book of the 4th International symposium on hormone and veterinary drug residue 
analysis, 4-7 juni 2002, Antwerpen, 63 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
 Development and validation of a liquid chromatography-electrospray tandem mass 
spectrometry method for anthelmintics in cow’s milk. 
 Abstract Book of the 4th International symposium on hormone and veterinary drug residue 
analysis, 4-7 juni 2002, Antwerpen, 68 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
Optimisation, validation and application of a liquid chromatography-electrospray tandem 
mass spectrometry method for mebendazole and its hydrolysed and reduced metabolites in 
sheep muscle. 
Abstract Book of the 4th International symposium on hormone and veterinary drug residue 
analysis, 4-7 juni 2002, Antwerpen, 69 
 
- De Ruyck H., Daeseleire E., Grijspeerdt K., De Ridder H., Van Renterghem R. and 
Huyghebaert G. 
 Distribution and depletion of flubendazole and its metabolites in edible tissues of guinea 
fowl. 
 British Poultry Science, 2002, submitted 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
Liquid chromatographic-electrospray tandem mass spectrometric method for the 
determination of mebendazole and its hydrolysed and reduced metabolites in sheep 
muscle. 
Analytica Chimica Acta, 2003, 483, 111-123 
 
- Daeseleire E., Mortier L., De Ruyck H. and Geerts N. 
 Determination of flunixin and ketoprofen in milk by liquid chromatography-tandem mass 
spectrometry. 
 Analytica Chimica Acta, 2003, accepted 
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5  Presentaties 
- The origin of white flecks of instant whole milk powder. 
 IDF-meeting workgroup E2, 15 maart 1990, Universiteit Gent, Gent 
 
- Bereiding van verstuivingsmelkpoeder voor de chocolade-industrie. 
 Comilac (Comelco), 21 februari 1991, Aalter 
 
- Toepassingsmogelijkheden van extrusie in de zuivel. 
 28e CTL zuivelstudiedag, 22 november 1991, Gent 
 
- Extrusion technology for the production of fish feed. 
 2nd commercial Inve aquaculture premix conference, 6 april 1995, Aalst 
 
 - Residuen van antiparasitaire middelen in melk en zuivelproducten. 
  Studienamiddag Merial, 22 juni 2000, Groot-Bijgaarden 
 
- Determination of anthelmintics in tissues of sheep with LC-MS/MS. 
Micromass 2001 New products Seminar and users event, 29 maart 2001, Gent  
 
- Uitscheiding van residuen van diergeneesmiddelen in eieren en gevogeltevlees. 
Studienamiddag van “the World’s Poultry Science Association” (WPSA): residuproblematiek 
in de pluimveevoeding, 30 april 2002, Melle 
 
6  Posterpresentaties 
- De Ruyck H., Daeseleire E., De Ridder H., Van Renterghem R. and Huyghebaert G. 
 Determination of flubendazole and metabolites in eggs and poultry meat with LC-MS/MS. 
 Euroresidue IV: Residues of veterinary drugs in food, 8-10 mei 2000, Veldhoven, Nederland 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
 Confirmatory assay for the simultaneous detection of penicillins and cephalosporins in milk 
using LC/MS-MS. 
Euroresidue IV: Residues of veterinary drugs in food, 8-10 mei 2000, Veldhoven, Nederland 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
Rapid confirmatory assay for the simultaneous detection of ronidazole, metronidazole and 
dimetridazole in eggs using LC-MS/MS. 
Eurofoodchem XI: Biologically-active phytochemicals, analysis, metabolism, bioavailability 
and function, 26-28 september 2001, Norwich, Groot-Brittannië 
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- De Ruyck H., Daeseleire E., De Ridder H., Van Renterghem R. and Huyghebaert G. 
 Determination of flubendazole and metabolites in eggs and poultry meat with LC-MS/MS. 
9th Annual meeting of the Flemish society for veterinary epidemiology and economics 
(VEE): Risk analysis and quality control of animal products, 25 oktober 2001, Melle 
 
- Daeseleire E., De Ruyck H. and Van Renterghem R. 
 Rapid confirmatory assay for the simultaneous detection of ronidazole, metronidazole and 
dimetridazole in eggs using LC-MS/MS. 
 9th Annual meeting of the Flemish society for veterinary epidemiology and economics 
(VEE): risk analysis and quality control of animal products, 25 oktober 2001, Melle 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
 Development and validation of a liquid chromatography-electrospray tandem mass 
spectrometry multiresidue method for anthelmintics in milk. 
 7th International symposium on Hyphenated Techniques in Chromatography and 
hyphenated chromatographic analysers (HTC-7), 6-8 februari 2002, Brugge 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
 Development and validation of a liquid chromatography-electrospray tandem mass 
spectrometry multiresidue method for anthelmintics in milk. 
 4th International symposium on hormone and veterinary drug residue analysis,                   
4-7 juni 2002, Antwerpen 
 
- De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
  Optimisation, validation and application of a liquid chromatography-electrospray tandem 
mass spectrometry method for mebendazole and its hydrolysed and reduced metabolites in 
sheep muscle. 
4th International symposium on hormone and veterinary drug residue analysis,                   
4-7 juni 2002, Antwerpen 
 
 - Daeseleire E., Mortier L., De Ruyck H. and Geerts N. 
  Determination of flunixin and ketoprofen in milk by liquid chromatography-electrospray 
tandem mass spectrometry. 
4th International symposium on hormone and veterinary drug residue analysis,                   
4-7 juni 2002, Antwerpen 
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 - De Ruyck H., Daeseleire E., De Ridder H. and Van Renterghem R. 
  Development and validation of a liquid chromatographic-electrospray tandem mass 
spectrometric multiresidue method for anthelmintics in milk. 
 Congrilait 2002: 26th IDF World Dairy Congress, Food Safety, Residues and Chemical 
Contaminants, 24-27 september 2002, Paris, Frankrijk 
 
7 Begeleiding van thesissen en eindwerken als promotor, 
copromotor of begeleider 
- Ir. Ketels P. 
 Verwijdering van micro-organismen door microfiltratie. 
Ingenieur voor de Scheikunde en de Landbouwindustrieën, Levensmiddelenchemie,            
-microbiologie en -technologie, Rijksuniversiteit Gent, 1987 - 1988 
 
- Ing. De Moor K. 
 Karakterisatie van white flecks bij instant volle melkpoeder. 
Industrieel Ingenieur Landbouw, optie Landbouw- en voedingsindustrieën, specialisatie 
Zuiveltechnologie, CTL Gent, 1989 - 1990 
 
- Ing. De Kinne L. 
 Bepaling van white flecks bij instant volle melkpoeder. 
Industrieel Ingenieur Landbouw, optie Landbouw- en voedingsindustrieën, specialisatie 
Zuiveltechnologie, CTL Gent, 1990 - 1991 
 
- Ir. Van Waeyenberge S. 
 Texturisatie van wei-eiwitten door verhittingsextrusie. 
Ingenieur voor de Scheikunde en de Landbouwindustrieën, Conserveringstechnologie, 
Katholieke Universiteit Leuven, 1992 - 1993 
 
- Rosseel C. 
 HPLC analyse van antibioticaresiduen in melk. 
Gegradueerde in Chemie, optie Chemie, Campus Hoger Technisch Instituut, Brugge,   
1996 - 1997 
 
- Verbeke K. 
 Bepaling van tetracyclineresiduen in eieren en kippenvlees via HPLC. 
Gegradueerde in Chemie, optie Chemie, Campus Hoger Technisch Instituut, Brugge,   
1997 - 1998 
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- Vermeire P. 
 Bepaling van residuen van anthelmintica in melk via HPLC. 
 Gegradueerde in Chemie, optie Chemie, Departement Technologie BME-CTL, Gent,
 1998 - 1999 
 
- Ing. Van Heghe A. 
Bepaling van residuen van anthelmintica in melk met HPLC. 
Industrieel Ingenieur in Landbouw en Biotechnologie, optie Landbouw- en 
voedingsindustrieën, specialisatie Zuiveltechnologie, CTL Gent, 1998 - 1999 
 
- De Roover K. 
 Uitscheiding van residuen van flubendazole en zijn metabolieten in parelhoenvlees. 
 Gegradueerde in Chemie, optie Chemie, Departement Technologie BME-CTL, Gent,
 2001 - 2002 
 
- Coudijzer V. 
Bepaling van albendazolsulfoxide en netobimin in melk met vloeistofchromatografie met 
massaspectrometrische detectie. 
 Gegradueerde in Chemie, optie Chemie, Departement Technologie BME-CTL, Gent,
 2002 - 2003 
 
8  Professionele lidmaatschappen 
- International Dairy Federation (IDF): 
- Standing Committee on Analytical Methods for Additives and Contaminants, Joint 
Action Team on Antimicrobials and other veterinary medicinal residues 
- Standing Committee on Dairy technology 
- Belgian Society for Mass Spectrometry (BSMS) 
- KVIV 
